Aarsvold, JN, 192(ab), 434(ab), 486(ab), 817(ab)
Ababneh, AA, 271(ab)
Abbey, H, 8(ab)
Abbruzzes, J, 263(ab), 1242(ab)
Abdel-Dayem, HA, 20(ab)
Abdel-Dayem, HM, 352(ab), 576(ab)
Abdel-Jalil, RJ, 1075(ab), 1078(ab)
Abdel-Rahman, M, 600(ab)
Abe, O, 802
Abe, T, 448(ab)
Abe, Y, 957(ab), 962(ab)
Aberion, D, 1122(ab)
Aberzanak, N, 964(ab)
Abi-Dargham, A, 57(ab), 60(ab), 396(ab)
Abitbol, C, 330(ab)
Abletshauser, C, 6(ab)
Aboul-Enein, FA, 749(ab)
Abou-Zied, M, 304(ab), 1221(ab)
Abreu, SH, 18N(1)
Abril, A, 971(ab)
Aburano, T, 489(ab), 766(ab), 1017, 1368(ab), 1425(ab), 1435(ab), 1447(ab)
Acampa, W, 742(ab)
Achtyes, ED, 295(ab)
Acker, P, 1043(ab), 1211(ab), 1340(ab)
Ackermann, R, 752
Acton, PD, 240(ab), 393(ab), 1002(ab), 1556
Adachi, I, 765(ab)
Adachi, Y, 999(ab)
Adam, LE, 481(ab), 485(ab), 1414(ab)
Adam, L-E, 1821
Adam, S, 1277(ab)
Adams, BK, 1429(ab)
Adjei, A, 1291(ab)
Adler, LP, 302(ab), 868(ab)
Adonai, N, 1185(ab)
Afriyie, MO, 165(ab), 494(ab), 596(ab)
Agafitei, RD, 831
Agarwal, A, 316(ab)
Agdeppa, ED, 241(ab), 242(ab)
Ageyeva, L, 260(ab)
Agnese, G, 116(ab), 781(ab)
Agostini, D, 290(ab), 299(ab), 1200(ab)
Aguadé-Bruix, S, 558, 1768
Agyeman, K, 200(ab)
Aharoni, D, 1129(ab)
Ahn, BC, 351(ab), 1394(ab)
Ahn, I-M, 497(ab)
Ahn, JY, 39(ab), 148(ab), 220(ab), 782, 938
Ahn, SH, 332(ab), 1158(ab)
Ahonen, A, 802(ab)
Ahrens, P, 334(ab)
Aichner, F, 949(ab)
Aide, N, 1200(ab)
Aigrain, Y, 329(ab)
Aihara, Y, 130
Ailland, J, 1391(ab)
Aizawa, T, 1407(ab)
Aizawa, Y, 707(ab), 708(ab), 729(ab)
Ajmi, S, 90(ab)
Akabani, G, 454(ab)
Akagi, H, 765(ab)
Akagi, N, 1215(ab)
Akakura, K, 1407(ab)
Akgün, I, 567
Akhurst, T, 239(ab), 1160(ab)
Akinboboye, O, 63, 194
Akincioglu, C, 507(ab)
Akita, Y, 982(ab)
Aktas, A, 1442(ab)
Alauddin, MM, 309(ab), 1160(ab), 1183(ab), 1682
Alavi, A, 4(ab), 118(ab), 122(ab), 161(ab), 269(ab, 273(ab), 275(ab), 477(ab), 481(ab), 482(ab), 485(ab), 498(ab), 541(ab), 578(ab), 583(ab), 968(ab), 993(ab), 994(ab), 1077(ab), 1146(ab), 1198(ab), 1233(ab), 1246(ab), 1257(ab), 1259(ab), 1280(ab), 1327(ab), 1414(ab), 1417(ab), 44, 1412, 1795
Alazraki, NP, 101(ab), 192(ab), 434(ab), 486(ab), 817(ab)
Albanis, E, 265(ab)
Albelda, SM, 1412
Albert, MS, 945(ab)
Albrecht, S, 232(ab)
Alderson, PO, 123(ab), 292
Aleksic, S, 1274
Alexander, C, 1128(ab)
Alexanderson, E, 737(ab)
Alexoff, D, 52(ab), 901(ab), 909(ab), 1120(ab)
Al-Haider, ZY, 1429(ab)
Ali, A, 455(ab), 582(ab), 1773
Ali, H, 1076(ab)
Ali, M, 392(ab)
Aliberti, G, 1329(ab)
Alkibay, T, 507(ab)
Allal, A, 1206(ab)
Allaoua, M, 232(ab), 840(ab), 1206(ab)
Allenberg, J, 325(ab)
Allman, KC, 534(le)
Almeida, OD, 170(ab), 202(ab), 710(ab)
Alnafisi, N, 118(ab), 1259(ab), 1414(ab), 1795
Alonso, G, 1219(ab)
Alonso, O, 577(ab), 1614
Alpert, NM, 794(ab), 896(ab), 918(ab), 1006(ab), 1007(ab), 1404(ab), 1420(ab)
Al-Saeed, T, 1449(ab)
Alston, KL, 454(ab), 1508
Al-Tailji, S, 1411(ab)
Altenvoerde, G, 1377(ab), 1378(ab)
Altmann, A, 317, 1155(ab)
Altuna, D, 545(ab)
Alvarez, C, 577(ab)
Al-Yasi, AR, 435(ab), 1225(ab)
Ambrose, J, 20(ab)
Amelsberg, A, 1291(ab)
Amendola, A, 476(ab), 1412(ab)
America, YG, 509(ab)
Amorim, BJ, 1016(ab), 1421(ab)
Amstel, D, 396(ab)
Anand, A, 61(ab)
Anderson, A, 803(ab)
Anderson, BO, 575(ab)
Anderson, CJ, 213, 529(le)
Anderson, JH, 309(ab)
Anderson, J, 11N(7)
Anderson, PM, 580(ab)
Anderson, T, 565(ab)
Ando, A, 1747
Andreeff, M, 1201(ab), 1320(ab)
Andriole, GL, 450(ab)
Angel, J, 1768
Angelberger, P, 1856
Angerstein, C, 252(ab), 587(ab), 1227(ab)
Anívarro, I, 1768
Annala, AJ, 280(ab)
Annoni, J-M, 864, 998(ab)
Anstett, F, 13(ab), 14(ab), 882(ab)
Antich, P, 1165(ab)
Antonescu, C, 333(ab), 1780
Antonini, A, 227(ab), 961(ab), 1591
Aoki, S, 750(ab)
Aomi, S, 1346
Apice, G, 102(ab)
Apostolidis, CH, 570(ab), 1309(ab)
Appledorn, CR, 1375
Aquino, SL, 128(ab)
Arahata, Y, 957(ab), 962(ab), 969(ab)
Arai, AE, 200(ab)
Aramburu, I, 180(ab)
Arano, Y, 529(le)
Araujo, LI, 1113(ab)
Archer, CN, 363(ab)
Areeda, J, 174(ab), 1630
Areeda, JS, 391(le)
Arens, HJ, 1143(ab)
Arens, S, 163(ab)
Argani, H, 324(ab)
Ariannejad, M, 586, 1139
Arienzo, S, 102(ab)
Arisaka, Y, 1244(ab), 1284(ab)
Armero, F, 505
Arora, V, 1165(ab)
Arram, S, 189(ab)
Arribeltz, G, 577(ab)
Arslan, N, 291(ab)
Arslandemir, C, 1269(ab), 1800
Asada, T, 1441
Asai, M, 736(ab)
Asano, K, 575
Asano, T, 985(ab)
Asano, Y, 736(ab)
Asenbaum, S, 974(ab)
Ashby, C, 56(ab), 901(ab), 1062(ab)
Ashino, H, 707(ab)
Askienasy, S, 1299(ab)
Asmuth, J, 128(ab)
Atavcý, S, 1003(ab)
Atehoefer, C, 591
Atsumi, H, 747(ab)
Aubier, M, 21
Audenaert, K, 361
Auditore-Hargreaves, K, 569(ab)
Augustine, AM, 1068(ab)
Augustine, S, 1519
Augustine, SC, 907
Aung, AM, 952(ab)
Aung, W, 38
Aurengo, A, 300
Auricchio, A, 240(ab)
Avril, N, 9, 298(ab), 306(ab)
Awasthi, V, 1086(ab)
Awh, OD, 1100(ab)
Axelrod, D, 576(ab)
Axworthy, DB, 567(ab), 569(ab)
Aykac, M, 365(ab)
Ayrosa, AMIb, 1108(ab)
Azad, M, 435(ab), 1225(ab)
Azad, N, 547(ab)
Azhdarinia, A, 97(ab), 263(ab), 311(ab), 1082(ab), 1099(ab)
Azure, MT, 258(ab)

Babich, JW, 55(ab), 267(ab), 898(ab), 1107(ab)
Bacharach, SL, 121(ab), 200(ab), 215(ab), 743(ab), 1316
Bachem, MG, 581(ab)
Backskai, BJ, 1060(ab)
Bader, J, 704(ab), 916(ab)
Bading, JR, 309(ab), 1682
Bae, SA, 392(ab), 420(ab), 1057(ab)
Bae, YT, 88(ab), 89(ab), 91(ab)
Baehre, M, 255(ab), 866(ab), 1277(ab), 1323(ab)
Baek, HJ, 1179(ab)
Baek, MY, 266(ab)
Baer, FM, 5(ab)
Baer, L, 1006(ab), 1007(ab)
Baez, L, 1133(ab)
Baghaei, H, 365(ab), 624
Baghestanian, M, 706(ab)
Bagnasco, M, 1198
Bahk, YW, 1416(ab), 1441(ab)
Bai, B, 855(ab)
Bai, C, 518(ab), 524(ab)
Baidoo, KE, 415(ab)
Bailey, J, 880(ab), 1209(ab)
Baio, SM, 1329(ab)
Baird, B, 527(ab)
Baird, WH, 833(ab)
Bajc, M, 1288
Bakale, G, 1222(ab)
Bakker, PF, 1265(ab)
Bakker, WH, 75(ab), 137(ab), 470(ab), 1159(ab), 1303(ab), 1841
Bakr, SA, 271(ab)
Bal, CS, 590(ab)
Balatoni, J, 239(ab), 1160(ab), 1161(ab)
Balcerzak, S, 1243(ab)
Baldwin, RM, 61(ab), 925(ab), 1013(ab)
Baldwin, SW, 556(ab), 557(ab), 1805
Ball, DL, 1596, 1605
Ball, K, 1243
Balleari, E, 116(ab)
Ballinger, JR, 149(ab), 1140(ab), 1169(ab), 1387(ab)
Balogh, A, 996(ab)
Balon, HR, 181(ab), 1134
Balter, HS, 788
Baltes, N, 1148(ab)
Baltuch, GH, 541(ab)
Balzarini, J, 95(ab)
Ban, K, 725(ab)
Bander, NH, 458(ab), 566(ab), 1021(ab), 1051(ab), 1223(ab), 1311(ab)
Bandhu, HK, 1050(ab)
Bandy, D, 756(ab)
Bangard, M, 600(ab), 1297(ab), 1298(ab), 1393(ab), 1395(ab)
Banik, N, 744
Barakos, JA, 132(ab)
Baranowska-Kortylewicz, J, 1068(ab), 1306(ab), 1519
Barbaras, LG, 1437(ab)
Barber, RW, 149(ab), 375(ab), 1140(ab)
Barbet, J, 146, 459(ab), 552(ab), 1313(ab)
Barbieri, A, 1219(ab)
Bardet, S, 290(ab), 299(ab)
Bardiès, M, 1030(ab), 146
Barendswaard, EC, 1251
Bares, R, 31(ab), 107(ab), 108(ab), 398(ab), 483(ab), 499(ab), 501(ab), 560(ab), 881(ab), 1010(ab), 1091, 1253(ab), 1408(ab)
Bar-Haim, N, 1017(ab)
Barkovics, M, 1426(ab)
Barlow, R, 435(ab)
Barnden, LR, 191(ab)
Barnes, WE, 547(ab)
Barnett, CA, 1773
Barnhart, TE, 54(ab), 930(ab), 934(ab), 1044(ab), 1118(ab)
Barolet, A, 353(ab)
Barone, P, 961(ab)
Barraclough, ED, 1113(ab)
Barre, L, 290(ab)
Barret, J, 472(ab), 474(ab), 1020(ab)
Barrett, JA, 412(ab), 1090(ab), 1307(ab)
Barrio, JR, 51(ab), 230(ab), 241(ab), 242(ab), 790(ab), 1023(ab), 1075(ab), 1078(ab), 1153(ab), 1185(ab), 96, 1225
Barron, B, 1242(ab)
Barros, A, 1228(ab)
Barros, N, 1228(ab)
Barrow, SA, 918(ab), 1125(ab)
Barrow, SB, 896(ab)
Bar-Sever, Z, 975(ab)
Bar-Shalom, R, 117(ab), 127(ab), 164(ab)

Bartenstein, P, 59(ab), 84(ab), 110(ab), 411(ab), 709(ab), 928(ab), 929(ab), 933(ab), 1202(ab)
Bartis, J, 474(ab), 1020(ab)
Bartlett, NL, 1115(ab)
Bartolomei, M, 134(ab), 1037(ab)
Bascom, DA, 133(ab)
Bass, L, 213, 795
Bateman, TM, 12(ab), 189(ab), 1424
Batra, SK, 1519
Battafarano, RJ, 291(ab)
Bauer, B, 902(ab)
Bauer, E, 96
Bauer, MJ, 955(ab)
Baum, RP, 37(ab), 223(ab), 561(ab), 1032(ab)
Baumann, E, 869(ab)
Baumer, M, 33
Baumert, B, 1235(ab)
Baumgartl, H, 456(ab)
Baumgartner, G, 1856
Baune, A, 804(ab)
Bax, JJ, 79
Bayram, E, 1121
Beanlands, RS, 171(ab), 359(ab), 1730
Beattie, B, 239(ab), 863(ab), 865(ab), 1160(ab)
Beauchesne, LM, 171(ab), 359(ab)
Beaudouin, V, 290(ab)
Becherer, A, 591(ab), 974(ab)
Becker, DP, 551(ab)
Becker, DW, 249(ab), 1053
Becker, G, 483(ab), 1408(ab)
Becker, GA, 1091
Becker, JA, 945(ab)
Becker, KF, 1309(ab), 1310(ab)
Becker, L, 14(ab)
Becker, M, 1206(ab)
Becker, W, 252(ab), 585(ab), 587(ab), 1022(ab), 1227(ab), 1377(ab), 1378(ab), 1384(ab)
Beekman, FJ, 204(ab), 528(ab), 832(ab), 856(ab)
Behr, TM, 160(ab), 252(ab), 585(ab), 587(ab), 1022(ab), 1148(ab), 1227(ab), 1354(ab)
Behrend, M, 598(ab)
Belanger, M-J, 803(ab)
Belasmy, J, 235(ab)
Belhocine, TZ, 312(ab), 1195(ab), 1241(ab)
Beljaars, L, 265(ab)
Bellemann, ME, 1265
Beller, GA, 1090(ab), 1388
Belmatoug, N, 21, 1403(ab)
Belzberg, AC, 1773
Ben, M, 577(ab)
Benali, H, 216(ab), 521(ab)
Benard, F, 154(ab), 719(ab), 1076(ab)
Benayoun, S, 845
Bencherif, B, 35(ab), 44(ab), 399(ab), 532(ab), 1281(ab)
Bencini, C, 1444(ab)
Bender, D, 795, 1673
Bender, H, 294(ab), 600(ab), 1297(ab), 1298(ab)
Bendriem, B, 213(ab)
Bengel, F, 6(ab), 7(ab), 505(ab), 712(ab), 727(ab), 732(ab), 757(ab)
Bengel, FM, 1011
Ben-Haim, S, 753(ab)
Bennett, M, 1165(ab)
Bennink, R, 1863
Bennink, RJ, 317(ab)
Bensadoun, H, 1200(ab)
Benti, R, 227(ab), 1261(ab), 1444(ab)
Bentourkia, M, 96(ab)
Bentz, M, 109(ab)
Berding, G, 538(ab), 544(ab)
Berenji, B, 373(ab)
Berenji, M, 284(ab)
Beresten, T, 260(ab)
Bergamini, C, 847(ab)
Berger, F, 204(ab), 281(ab), 283(ab), 288(ab)
Bergman, J, 1397, 1643
Bergman, S, 302(ab)
Bergmann, H, 150(ab)
Bergmann, R, 1320(ab)
Bergmann, S, 195(ab)
Bergmann, SR, 219(ab), 271(ab), 767(ab), 807(ab), 63, 194, 201, 1439(le)
Bergsneider, M, 374(ab), 551(ab), 992(ab)
Bergström, K, 802(ab)
Berkowitz, M, 104(ab)
Beriangieri, SU, 250(ab), 300(ab)
Berman, DS, 174(ab), 346(ab), 745(ab), 749(ab), 758(ab), 391(le), 528(le), 687, 831, 1424, 1630
Bernante, P, 1350(ab)
Bernard, BF, 1841
Bernard, G, 1371(ab)
Bernard, HF, 413(ab), 468(ab), 470(ab), 1303(ab)
Bernardo, M, 1001(ab)
Bernaski, EJ, 20(ab)
Bernd, L, 120(ab), 125(ab)
Berner, U, 1211(ab)
Berni, GF, 178(ab)
Bernison, CM, 1234(ab)
Berridge, MS, 36(ab), 155(ab), 1077
Berthier, V, 894(ab)
Berthold, T, 42(ab), 740(ab)
Besnard, JC, 1052(ab)
Bette, P, 1291(ab)
Bettman, L, 998
Beu, M, 209(ab), 1691
Beuthien-Baumann, B, 990(ab)
Beyer, G, 1309(ab)
Beyer, T, 129(ab), 210(ab), 211(ab), 369(ab)
Beyer, W, 71
Bhargava, KK, 165(ab), 494(ab)
Bhaskaran, S, 20(ab), 576(ab)
Bhatnagar, VB, 1098(ab)
Bhattacharya, A, 1050(ab), 1446(ab)
Bhattacharya, K, 966(ab)
Bialostozky, D, 737(ab)
Bianchi, P, 116(ab), 781(ab)
Bieber, T, 1232(ab)
Bieg, C, 1081(ab)
Biersack, HJ, 163(ab), 294(ab), 600(ab), 1232(ab), 1297(ab), 1298(ab), 1393(ab), 1395(ab), 744, 1295(br)
Biesma, B, 1254(ab)
Bigio, EH, 943(ab), 1131(le)
Bigner, D, 1508
Bigner, DD, 454(ab)
Bihl, G, 375(ab)
Bijster, M, 1159(ab), 1303(ab)
Billheimer, D, 559(ab)
Billotey, C, 848(ab)
Bilotti, MA, 165(ab)
Binnie, D, 1300(ab)
Binns, D, 1238
Binns, DS, 1158
Bird, NJ, 375(ab)
Birk, D, 721
Bischof Delaloye, A, 333(ab)
Bishayee, A, 253(ab), 254(ab)
Bishop, H, 563(ab), 1247(ab)
Bishop, HA, 960
Bishop, MC, 726
Biswal, S, 1406(ab)
Bitter, K, 1211(ab)
Bitzén, U, 1288
Biyi, A, 329(ab)
Bizais, Y, 1370(ab)
Bjornholm, B, 912(ab)
Blake, G, 371(ab), 1402(ab)
Blake, H, 426(ab)
Blanchet, C, 1418(ab)
Blankenberg, F, 168(ab), 169(ab), 313(ab), 479(ab), 1383(ab), 1406(ab), 309
Blankenberg, TA, 1383(ab)
Blasberg, R, 239(ab), 1160(ab), 1161(ab)
Blaufox, MD, 138, 279(ab), 1440(le), 1729
Blevis, I, 1214(ab)
Blinder, S, 172(ab)
Blocher, A, 1081(ab)
Block, S, 701(ab), 723(ab), 734(ab)
Bloomgarden, D, 1437(ab)
Blotta, A, 1470
Blumenfeld, H, 987(ab)
Blundell, H, 186(ab)
Böning, G, 871(ab)
Boaz, M, 783(ab)
Bobbert, C, 866(ab)
Boccalandro, F, 768(ab)
Boccardo, F, 781(ab)
Bocher, M, 932(ab), 1017(ab)
Bodei, L, 134(ab), 1037(ab)
Boecker, H, 929(ab), 933(ab)
Boeckxstaens, GE, 317(ab)
Boellaard, R, 425(ab), 808, 842(ab), 843(ab), 1622
Boening, G, 213(ab), 382(ab)
Boerman, O, 268(ab), 272(ab), 472(ab), 474(ab), 568(ab), 1020(ab), 1088(ab), 1373(ab), 1381(ab), 1389(ab), 117, 917, 1235, 1257, 1405
Boerner, AR, 1197(ab), 1296(ab), 1376(ab)
Boersma, E, 79
Boersma, HH, 177(ab), 1048(ab), 382
Bogdanov, AA, 286(ab)
Bogsrud, TV, 597(ab)
Bohuslavizki, KH, 71, 248(ab), 496(ab), 646, 886(ab), 1057, 1338
Bok, BD, 329(ab)
Bokde, A, 243(ab)
Bolch, WE, 81(ab), 1029(ab), 1030(ab), 1222
Bolton, DM, 300(ab)
Bom, HS, 256(ab), 409(ab), 480(ab), 1024(ab), 1045(ab)
Bomanji, J, 384(ab)
Bombardieri, E, 1329(ab)
Bonab, AA, 55(ab), 794(ab), 896(ab), 898(ab)
Bonafous, J, 141
Bondanelli, M, 1470
Bongers, V, 86(ab), 1203(ab)
Bonjer, HJ, 1353(ab)
Bonne, O, 932(ab), 1017(ab)
Bonnet, JP, 329(ab)
Bonnin, F, 329(ab)
Bonow, RO, 755(ab)
Bonte, FJ, 943(ab), 1059, 1131(le)
Bontemps, L, 221(ab)
Booij, J, 1863
Boon, P, 231(ab)
Boone, J, 1122(ab)
Boonstra, H, 472(ab), 474(ab), 1020(ab)
Booth, BJM, 1519
Borbély, K, 247(ab), 996(ab)
Borchardt, P, 1308(ab), 1311(ab)
Bordewyk, R, 1133(ab)
Borges-Neto, S, 343(ab), 871
Borgwardt, L, 142(ab), 145(ab)
Borkowski, J, 14(ab)
Borm, JJ, 348(ab), 509(ab)
Börner, AR, 598(ab), 752, 1174
Borras, X, 516(ab)
Bos, GM, 1048(ab)
Bos, R, 94(ab)
Bosch, FX, 1143(ab)
Bosch, J-A, 738
Bosnjakovic, V, 885(ab)
Bossuyt, A, 154, 401, 1171(ab), 1432(ab)
Both, S, 110(ab), 709(ab)
Bottet, P, 1200(ab)
Bottino, B, 1122(ab)
Bottlaender, M, 940(ab)
Botvinick, EH, 27(ab)
Boubaker, A, 333(ab), 1780
Boucharеb, Y, 1737
Boucher, L, 154(ab), 719(ab)
Bouchet, LG, 1029(ab), 1030(ab)
Bourguet, P, 1287(ab)
Bourke, B, 173(ab)
Bouvard, G, 290(ab), 299(ab), 1200(ab)
Bowers, GD, 558(ab)
Bowsher, JE, 363(ab), 526(ab), 888(ab)
Bozarth, J, 412(ab)
Bozkirli, I, 507(ab)
Braban, LE, 1255(ab)
Brackney, M, 878(ab)
Braden, B, 334(ab)
Bradley, LA, 995(ab)
Brambatti, JC, 183(ab)
Brandau, W, 467
Brandes, K, 570(ab)
Brandt, D, 160(ab), 1354(ab)
Brandt, J, 44(ab)
Brandt-Mainz, K, 496(ab)
Brandwein, J, 1072(ab)
Brasic, J, 533(ab), 537(ab)
Brasse, D, 524(ab)
Bräunlich, I, 467
Brautigam, P, 481(ab), 485(ab)
Braverman, LE, 1470
Bray, DM, 192(ab), 817(ab)
Breakefield, XO, 239(ab)
Brechbiel, MM, 1084(ab)
Brechbiel, MW, 567(ab), 1087(ab), 1288(ab), 1281
Bredow, J, 496(ab), 502(ab)
Breeman, WA, 75(ab), 413(ab), 468(ab), 470(ab), 1303(ab), 1304(ab), 1305(ab), 1841
Breen, WJ, 584(ab)
Breistol, K, 431(ab)
Breitz, HB, 81(ab), 492, 830(ab)
Brenner, W, 230, 475(ab), 1000(ab), 1391(ab), 1399(ab), 1413(ab), 1422(ab), 1545
Bressan, RA, 939(ab)
Brezovich, IA, 80(ab)
Brink, I, 591
Brinkbaeumer, K, 1210(ab)
Brinker, T, 544(ab)
Brioschi, M, 879(ab), 1268(ab)
Brittinger, G, 585(ab)
Britton, KE, 435(ab), 567, 816(ab), 825(ab), 1223(ab), 1225(ab), 1439(le)
Brix, G, 1038(ab), 1265
Brockmann, J, 84(ab), 110(ab), 1146(ab)
Broderick, F, 23N(1)
Brodie, J, 909(ab)
Brodie, JD, 52(ab), 56(ab)
Broft, A, 57(ab), 797(ab)
Bromer, MQ, 321(ab)
Bromhead, SE, 1392(ab)
Brooks, DJ, 538(ab), 544(ab), 933(ab)
Brown, DJ, 264(ab)
Brown, ML, 1317(ab)
Brown, RS, 92(ab), 1173(ab)
Brown, SD, 131(ab)
Brown, WD, 536(ab)
Brownell, A-L, 50(ab), 919(ab)
Bruch, H-P, 1323(ab)
Bruckbauer, T, 853(ab), 878(ab), 1286(ab)
Bruemmer, C, 475(ab), 1422(ab)
Brugere, S, 180(ab)
Bruin, NM, 869(ab)
Bruland, O, 431(ab)

Brümmer, C, 1545
Bruneus, M, 904(ab)
Brunken, RC, 3(ab)
Bruno, A, 227(ab), 1337(ab)
Bruyant, P, 849(ab)
Buchberger, R, 198(ab)
Buchert, R, 71, 646, 886(ab)
Buchholz, HG, 59(ab), 84(ab), 110(ab), 709(ab), 928(ab)
Buchmann, I, 109(ab), 457(ab), 721, 1294(ab)
Buchpiguel, C, 1228(ab), 1371(ab)
Buchwald, C, 297(ab)
Buck, A, 212(ab), 305(ab), 581(ab), 1071(ab), 1269(ab)
Buck, AC, 721
Buck, AK, 1800
Budach, W, 560(ab), 1253(ab)
Budinger, TF, 27(ab), 272, 859(ab)
Buell, U, 24(ab), 701(ab), 723(ab), 734(ab), 852(ab)
Buffoni, F, 116(ab), 781(ab)
Bugaj, JE, 469(ab), 470(ab), 1064(ab), 1303(ab)
Bugai, JL, 137(ab)
Buijs, W, 1020(ab), 382
Bülow, HP, 757(ab)
Bunjes, D, 457(ab), 1294(ab)
Bunker, SR, 132(ab)
Bunko, H, 596, 1457
Buoncompagni, A, 1151
Burchert, W, 259(ab), 990(ab), 1174
Burger, C, 42(ab), 125(ab), 130(ab), 212(ab), 248, 713, 788(ab), 801(ab), 1274(ab)
Burgman, P, 170
Burke, PA, 571(ab)
Burke, T, 1240(ab)
Burker, M, 147(ab), 896(ab), 1386(ab)
Burker, MA, 1107(ab), 1125(ab)
Burkhalter, W, 1351(ab)
Burkhart, F, 326
Burma, P, 1257
Burnham, CA, 208(ab)
Burns, HD, 1274
Burrows, RC, 913(ab)
Burton, J, 583(ab), 588(ab)
Busch, R, 1144
Buscombe, JR, 99(ab), 484(ab), 1188(ab), 1318(ab), 3, 1198
Bush, SA, 586(ab)
Bushnell, DL, 1264(ab)
Busutti, L, 1470
Büttner, C, 259(ab)
Buursma, A, 314(ab)
Buvat, I, 214(ab), 215(ab), 216(ab), 376(ab), 519(ab), 521(ab)
Buxton-Thomas, MS, 966(ab)
Byas-Smith, M, 911(ab)
Byrd, DR, 575(ab)
Byun, SS, 1065(ab), 1178(ab), 1181(ab)

Cacciabaudo, JM, 1050
Cachin, F, 90(ab)
Cadorette, J, 854(ab), 876(ab)
Cagliyan, F, 1352(ab)
Cai, G, M, 703(ab)
Cai, S, 1160(ab)
Cain, SA, 1088(ab)
Caldwell, CB, 366(ab), 760(ab)
Caldwell, JH, 70(ab)
Caligaris, F, 183(ab)
Callahan, RJ, 66(ab), 1125(ab)
Callans, LS, 578(ab)
Camacho, V, 516(ab)
Camargo, EE, 611, 1016(ab), 1111(ab), 1421(ab), 1448(ab)
Cameron, R, 1073(ab), 1249(ab)
Camici, PG, 264(ab)
Camp, VM, 558(ab)
Campion, L, 1229(ab)
Campisi, C, 781(ab)
Canales, K, 50(ab), 919(ab)
Canavese, G, 1198
Canclini, S, 179(ab)
Candell-Riera, J, 558, 1768
Canevari, S, 1697
Canizales, A, 1223(ab)
Cantez, S, 323(ab)
Cantilena, LR, 927(ab)
Cantor, SB, 321(ab)
Capello, A, 468(ab)
Caplin, ME, 99(ab), 1318(ab)
Capoccetti, F, 1212(ab)
Caprioli, R, 165(ab)
Capuano, SV, 905(ab)
Carbon, C, 1385(ab)
Carel, I, 515(ab), 754(ab), 770(ab)
Carey, JE, 975
Carey, MF, 282(ab)
Caride, VJ, 159(ab)
Carletto, M, 45(ab), 116(ab), 781(ab)
Carlos-Marquez, R, 570(ab)
Carmel, A, 267(ab)
Carney, J, 211(ab)
Caroline, DF, 321(ab)
Caron, J, 1030(ab)
Carone, M, 1121(ab)
Carpenter, R, 435(ab), 1225(ab)
Carpenter, T, 593(ab)
Carpinelli, A, 961(ab)
Carr, B, 1317(ab)
Carrasco, N, 987(le), 1346(ab)
Carrasquillo, JA, 121(ab), 567(ab), 1141(ab), 1316, 1359, 1538
Carrington, B, 1209(ab)
Carrió, I, 516(ab), 1062
Carroll, MJ, 816(ab), 825(ab), 1225(ab)
Carson, J, 200(ab), 743(ab)
Carson, RE, 243(ab), 395(ab), 786(ab), 1166(ab), 1316
Carter, EA, 147(ab), 1404(ab)
Carter, P, 909(ab)
Caruba, JF, 884(ab)
Carvalho, F, 1228(ab)
Casara, D, 1338(ab), 1350(ab)
Case, JA, 12(ab), 189(ab), 717(ab)
Caserta, B, 577(ab)
Casey, ME, 1286(ab)
Casperson, P, 745(ab)
Cassem, EH, 1006(ab)
Castagnola, F, 781(ab)
Castellani, M, 1337(ab)
Castell-Conesa, J, 558, 1768
Castiglioni, ML, 1219(ab)
Castilla, A, 1299(ab)
Castle, V, 143(ab)
Catafau, AM, 516(ab), 537(ab), 800(ab), 927(ab), 1001(ab), 259
Cavalieri, RR, 1326(ab)
Caveliers, V, 154, 1171(ab)
Cayre, A, 90(ab)
Ceballos-Baumann, AO, 929(ab), 933(ab)
Cebon, JS, 1288(ab)
Celegon, L, 345(ab)
Celler, A, 8(ab), 172(ab), 1704
Cerato, E, 459(ab)
Cesarman, G, 1034(ab)
Chae, SC, 351(ab)
Chajari, M, 290(ab), 299(ab)
Chalela, W, 183(ab)
Chalon, S, 419(ab), 1052(ab)
Chambless, M, 871
Chamorro, H, 180(ab)
Champier, J, 221(ab)
Chan, J, 250(ab)
Chan, T, 1288(ab)
Chan, WL, 21(ab)
Chandler, S, 133(ab), 862(ab)
Chang, AE, 307(ab)
Chang, C, 225(ab)
Chang, CP, 111(ab), 979(ab)
Chang, CW, 21(ab), 111(ab), 979(ab), 1154(ab)
Chang, DJ, 987(ab)
Chang, F, 261(ab)
Chang, FY, 491(ab)
Chang, HD, 735(ab)
Chang, K, 459(ab), 552(ab)
Chang, L, 402(ab), 1012(ab)
Chang, MC, 243(ab)
Chang, YS, 266(ab)
ChangLai, S-P, 17
Channing, MA, 243(ab)
Chao, I, 111(ab)
Chao, Y, 345
Chapman, JD, 337, 1653
Chapman, JT, 884(ab)
Chapman, S, 415(ab)
Chappard, C, 151(ab)
Chappell, SA, 280(ab)
Charlop, A, 85(ab)
Charnsangavej, C, 1074(ab), 1242(ab), 1530
Charon, Y, 867(ab)
Charron, M, 129(ab), 328(ab), 1321(ab), 1423(ab)
Chatal, JF, 146, 459(ab), 583(ab), 1229(ab), 1287(ab), 1313(ab)
Chatterjee, A, 797(ab)
Chatterjee, R, 392(ab)
Chatziioannou, A, 855(ab), 864(ab)
Chatziioannou, SN, 454
Chaudhuri, KR, 966(ab)
Chaudhuri, T, 745(ab), 1728(br)
Chee, IS, 991(ab)
Chehade, F, 1358(ab)
Chelikani, S, 889(ab)
Chen, CC, 1015(ab)
Chen, CH, 251(ab), 824(ab)
Chen, CP, 491(ab)
Chen, CY, 735(ab)
Chen, F-D, 345
Chen, J, 217(ab), 717(ab)
Chen, JC, 251(ab), 824(ab)
Chen, JQ, 416(ab), 417(ab), 1069(ab), 1070(ab), 1847
Chen, K, 756(ab)
Chen, LC, 358(ab)
Chen, M, 958(ab)
Chen, P, 1072(ab), 1073(ab)
Chen, S, 1290(ab), 967
Chen, SM, 1330(ab)
Chen, T, 1132(ab)
Chen, W, 225(ab)
Chen, WT, 201(ab), 202(ab)
Chen, YI, 50(ab), 919(ab)
Chen, ZP, 67(ab)
Cheng, KT, 1109(ab)
Cheng, Z, 416(ab), 417(ab), 1069(ab), 1070(ab), 1847
Chengazi, V, 986(le), 532(le), 1131(le)
Cheon, GJ, 15(ab), 16(ab), 17(ab), 19(ab), 39(ab), 220(ab), 347(ab), 738(ab), 748(ab), 1040(ab), 1177(ab), 695, 782, 938
Cheon, JH, 98(ab)
Cher, LM, 250(ab)
Cherng, SC, 735(ab)
Cherry, SR, 204(ab)
Cherstniakova, S, 927(ab)
Chesnay, E, 290(ab), 299(ab)
Chessa, F, 87(ab), 1328(ab)
Cheung, NK, 1308(ab)
Chi, DY, 1095(ab)
Chi, K-H, 345
Chicherio, C, 864, 998(ab)
Chierichetti, F, 198(ab), 345(ab)
Chin, B, 828(ab)
Chinen, LK, 469(ab), 1064(ab)
Chinn, PC, 1115(ab)
Chinol, M, 134(ab), 1037(ab), 1697
Chiocca, EA, 239(ab)
Chirakal, R, 1079(ab)
Chirala, RC, 1049(ab)
Chirala, SK, 326(ab), 327(ab), 1049(ab)
Chisin, R, 932(ab), 1017(ab), 1129(ab)
Chittenden, S, 78(ab), 822(ab)
Chiu, NT, 1015(ab)
Chiu, PF, 792(ab)
Chmielweski, GW, 287(ab)
Cho, IH, 354(ab)
Cho, J-H, 1103(ab)
Cho, KH, 409(ab)
Cho, S, 948(ab), 953(ab)
Choe, YS, 534(ab), 772(ab), 851(ab), 954(ab), 1065(ab), 1095(ab), 1178(ab), 1181(ab), 1187(ab), 1342(ab), 1400(ab)
Choi, C, 256(ab)
Choi, CW, 1047(ab), 1100(ab), 1158(ab), 1179(ab), 1180(ab), 1192(ab), 1273(ab)
Choi, JK, 1394(ab)
Choi, SR, 393(ab), 1556
Choi, TH, 1100(ab), 1158(ab)
Choi, Y, 534(ab), 772(ab), 851(ab), 954(ab), 1065(ab), 1095(ab), 1178(ab), 1181(ab), 1187(ab), 1342(ab), 1400(ab)
Chong, G, 1288(ab)
Chorianopoulos, EK, 473(ab)
Chou, C, 67(ab)
Chou, KL, 111(ab)
Chou, RL, 271(ab), 767(ab), 807(ab), 63, 201
Chou, S-L, 345
Choukèr, M, 236(ab), 237(ab)
Christian, BT, 878(ab), 1243(ab)
Christian, P, 882(ab)
Christian, PE, 368(ab), 944
Christians, MA, 161(ab), 477(ab)
Chu, J, 1205(ab)
Chu, LS, 21(ab), 251(ab), 358(ab), 452(ab), 453(ab), 491(ab), 979(ab)
Chu, V, 1322(ab)
Chu, YK, 21(ab), 453(ab), 979(ab)
Chugani, D, 141(ab)
Chui, CS, 1255(ab)
Chui, S, 545(ab)
Chun, KA, 354(ab), 1416(ab)
Chun, KJ, 320(ab)
Chun, KS, 1180(ab)
Chun, M, 1319(ab)
Chung, AJ, 534(ab)
Chung, H-W, 177(le)
Chung, J-K, 15(ab), 16(ab), 17(ab), 19(ab), 39(ab), 148(ab), 220(ab), 266(ab), 347(ab), 432(ab), 497(ab), 500(ab), 549(ab), 738(ab), 748(ab), 948(ab), 950(ab), 953(ab), 980(ab), 1040(ab), 1094(ab), 1103(ab), 1135(ab), 1142(ab), 1177(ab), 1182(ab), 1220(ab), 1245(ab), 695, 782, 938
Chung, SK, 1416(ab), 1441(ab)
Chung, YA, 1441(ab)
Cicchetti, F, 50(ab)
Cichon, G, 259(ab)
Cid, E, 768(ab)
Cinca, J, 516(ab)
Cinotti, L, 894(ab)
Ciprian, A, 355(ab), 1347(ab)
Cittanti, C, 355(ab), 1347(ab)
Civelek, AC, 594(ab), 595(ab), 1355(ab)
Civollani, S, 847(ab)
Claessens, RA, 1144(ab)
Clapp, K, 1292(ab)
Clark, JA, 935(ab)
Classe, JM, 1229(ab)
Clausen, M, 71, 248(ab), 646, 886(ab), 1338
Clermont, DA, 935(ab)
Clinthorne, N, 860(ab)
Clinthorne, NH, 206(ab), 383(ab), 887(ab)
Cloos, J, 1364
Clorius, JH, 325(ab)

Cluckie, A, 966(ab)
Coaguila, C, 158(ab), 511(ab), 515(ab), 754(ab), 770(ab)
Coan, PN, 258(ab)
Cocquyt, V, 1818
Cody, HS, III, 420
Coenen, HH, 209(ab), 752
Cohen, C, 434(ab)
Cohen, I, 346(ab), 831
Cohenpour, M, 33
Cohen-Solal, A, 504(ab)
Cokgor, I, 454(ab)
Colamussi, P, 355(ab), 1347(ab)
Colcher, D, 907, 1306(ab), 1519
Coleman, M, 441(ab), 443(ab), 583(ab)
Coleman, R, 455(ab)
Coleman, RE, 131(ab), 363(ab), 367(ab), 454(ab), 556(ab), 557(ab), 888(ab), IS, 11N(4), 871, 1132(le), 1805
Coles, D, 838(ab)
Colin, P, 1043
Coll, C, 180(ab)
Collier, BD, 1411(ab)
Collier, TL, 271(ab)
Collins, JM, 308(ab)
Collins, L, 1317(ab)
Colnot, DR, 1364
Colquhoun, SD, 110
Comans, EFI, 1139(ab)
Comerci, J, 1186(ab)
Comor, J, 1309(ab)
Comtat, C, 34(ab), 524(ab)
Conant, EF, 578(ab)
Connelly, CA, 110
Connolly, C, 243(ab)
Connolly, LP, 209
Conrad, B, 929(ab), 933(ab)
Conrad, EU, 1275(ab)
Constans, JM, 299(ab)
Constantinescu, A, 1165(ab)
Conti, A, 178(ab)
Conti, PS, 114(ab), 309(ab), 387(ab), 1160(ab), 1183(ab), 1194(ab), 1682
Converse, AK, 54(ab), 930(ab), 934(ab), 1118(ab)
Cook, G, 371(ab), 1402(ab)
Cook, MJ, 1158
Cooke, CD, 219(ab), 722(ab), 811(ab), 1185
Cooper, T, 57(ab)
Cooper, W, 545(ab)
Copello, F, 1412(ab)
Corbett, JR, 185(ab), 188(ab), 744(ab), 839(ab), 1639
Corbitt, B, 995(ab)
Cornel, JH, 79
Cornelius, EA, 139(ab), 593(ab)
Cornelius, S, 636
Correia, JA, 208(ab)
Correia, JMS, 1111(ab)
Corsi, M, 987(ab)
Corsino, A, 287(ab)
Corstens, FH, 268(ab), 272(ab), 472(ab), 474(ab), 568(ab), 1020(ab) 1088(ab), 1199(ab), 1279(ab), 1371(ab), 1381(ab),1389(ab), 117, 917, 1235, 1257, 1405
Corujo, YI, 1133(ab)
Cosgrove, GR, 1006(ab)
Costa, DC, 384(ab)
Costa, PA, 1228(ab)
Costanzo, EN, 178(ab)
Costes, N, 894(ab)
Côté, CM, 779(ab)
Cottens, T, 705(ab)
Cotter, A, 4(ab), 541(ab), 968(ab), 993(ab), 994(ab), 1113(ab)
Cottu, P, 87(ab)
Coulon, C, 932
Cousins, C, 149(ab)
Couturier, O, 1370(ab)
Crabb, AH, 533(ab)
Cremieux, AC, 1375(ab), 1385(ab)
Cremonesi, M, 134(ab), 1037(ab)
Crestani, B, 21
Crocker, AC, 412(ab)
Croissant, B, 398(ab)
Cronin, B, 371(ab), 1402(ab)
Cross, DJ, 548
Crouzel, C, 932
Cruz, NF, 1243
Cselényi, ZS, 419(ab), 900(ab), 907(ab), 1058(ab)
Cuccia, C, 179(ab)
Cui, RX, 67(ab)
Cullom, SJ, 12(ab), 189(ab)
Cumming, P, 59(ab)
Cunningham, VJ, 939(ab)
Cuocolo, A, 742(ab)
Curcio, M, 1311(ab)
Curtet, C, 146, 1229(ab)
Curtius, JM, 223(ab)
Cutler, PD, 213
Cwikla, JB, 3, 484(ab), 1188(ab)
Cyr, JE, 258(ab)
Czech, N, 475(ab), 1000(ab), 1399(ab), 1413(ab), 1422(ab), 1545
Czerniecki, BJ, 578(ab)
Czernin, J, IS, 30(ab), 225(ab), 277(ab), 301(ab), 440(ab), 461(ab), 464(ab), 546(ab), 562(ab), 586, 952(ab), 955(ab), 1130(ab), 1139, 1190(ab), 1249(ab), 1334
Czuczman, M, 583(ab)

Dabbs, KA, 54(ab), 930(ab), 934(ab), 1044(ab), 1118(ab)
Dabezies, L, 577(ab)
Dabiri Oskoie, S, 176(ab), 324(ab)
Dadachova, E, 987(le), 1346(ab), 1538
Dae, MW, 772, 891(ab)
Daenen, F, 1195(ab), 1241(ab)
Dafermou, A, 1347(ab)
Daftary, A, 550(ab)
Daftary, S, 139(ab)
Dagher, A, 933(ab)
D'Agnolo, A, 113(ab), 445(ab)
Dahlbom, M, 30(ab), 38(ab), 814(ab), 855(ab), 864(ab), 877(ab), 952(ab), 1023(ab), 1225
Dahlheimer, JL, 285(ab), 418(ab), 426(ab)
Dahlström, J, 835(ab)
Dahut, W, 1359
Dakhel, M, 220(ab), 576(ab)
Dakshinamurthy, KV, 326(ab), 327(ab)
Daldrup-Link, HE, 1272(ab)
Dalipaj, MA, 739(ab)
Dalrymple, GV, 1068(ab)
Dancey, JE, 1588(le)
Danforth, DN, 1316
Dang, LX, 484(ab)
Dann, EJ, 117(ab)
Dannals, RF, 146(ab), 533(ab), 537(ab), 1281(ab), 1274
Dansereau, RN, 1116(ab)
Daou, D, 11(ab), 21, 158(ab), 167(ab), 511(ab), 512(ab), 513(ab), 514(ab), 515(ab), 754(ab), 770(ab), 1043, 1331(ab), 1403(ab), 1451
Das, SK, 981(ab), 988(ab), 995(ab)
DaSilva, J, 711(ab), 899(ab)
Da Silva, AJ, 237, 772
D'Asseler, Y, 361, 1266(ab), 1396(ab)
Daube-Witherspoon, ME, 1821
Daum, S, 1170(ab)
Dave, PK, 484(ab)
David, A, 1470
Davids, E, 59(ab)
Davila-Roman, V, 196(ab)
Davis, I, 1288(ab)
Davis, ID, 300(ab)
Davis, JG, 905(ab)
Dawry, FP, 1879(le)
Dayeh, W, 1358(ab)
Dean, RT, 258(ab)
Dearnaley, DP, 822(ab), 1300(ab)
Dearstyne, E, 569(ab)
Debarsy, C, 1195(ab), 1241(ab)
de Beco, V, 463(ab), 487(ab)
Debnath, ML, 423(ab), 1060(ab)
De Bondt, P, 1(ab), 705(ab), 764(ab), 1396(ab)
DeBraal, L, 811(ab), 1185
de Bree, R, 1364
de Bruin, K, 1863
Debruyne, FM, 1199(ab)
Debus, J, 246(ab), 249(ab), 317, 1053
De Cesare, A, 1737
De Cicco, C, 433(ab), 573(ab)
Decker, RW, 445(ab)
De Clercq, D, 1396(ab)
Decoo, D, 43(ab)
Dede, F, 352(ab), 1352(ab)
Dedeoglu, A, 919(ab)
Defrise, M, 401, 524(ab)
Degen, K, 61(ab)
de Geus-Oei, LF, 1199(ab)
degli Uberti, EC, 1470
DeGrado, TR, 55, 556(ab), 557(ab), 1805
de Guevara, DL, 564
deGuzman, A, 1316(ab)
Dehdashti, F, 213, 291(ab), 450(ab)
Dei, S, 821(ab), 985(ab), 1434(ab)
DeJesus, OT, 53(ab), 54(ab), 536(ab), 897(ab)
de Jong, B, 798(ab)
de Jong, HW, 528(ab), 832(ab), 856(ab)
de Jong, IJ, 449(ab)
de Jong, M, 75(ab), 135(ab), 137(ab), 138(ab), 413(ab), 468(ab), 469(ab), 470(ab), 1159(ab), 1303(ab), 1841
de Jonge, WJ, 317(ab)
deKemp, RA, 171(ab), 359(ab), 1730
de Klerk, JM, 1265(ab), 1302(ab)
de la Brassinne, M, 1241(ab)
de Labriolle-Valey, C, 167(ab), 1299(ab)
de la Fuente-Fernandez, R, 29(ab)
Delahaye, N, 167(ab), 1451
Delaloye, AB, 1780
Delano, D, 196(ab), 360(ab)
de Latour, M, 141
Delavelle, J, 232(ab)
Delbot, T, 1331(ab)
Delforge, J, 894(ab)
Delgado, LB, 1614
Delmonte, M, 45(ab)
Delpassand, AS, 1530
Delpassand, E, 1240(ab)
De Lucchi, M, 116(ab)
Del Vecchio, C, 1444(ab)
De Man, B, 211(ab)
De Mey, S, 705(ab)
Dempsey, MF, 986(le)
Demuth, HU, 1148(ab)
Den, EI, 1216
Den, RB, 1216
DeNardo, GL, 81(ab), 571(ab), 1295(ab), 1324
DeNardo, SJ, 571(ab), 1295(ab), 1324
den Boer, J, 798(ab)
Deng, H, 904(ab)
Deng, WP, 1154(ab)
Dengler, R, 538(ab)
De Notaris, R, 227(ab), 961(ab)
Denton, G, 726
DePuey, EG, 14(ab), 219(ab), 1773
Der, MG, 395(ab)
Derdeyn, CP, 1195
de Ribaupierre, A, 998(ab), 864
de Ribaupierre, S, 998(ab), 864
de Rimini, ML, 102(ab)
Derlon, JM, 290(ab), 1200(ab)
De Sadeleer, C, 564
Desai, MY, 10(ab)
Desfachelles, G, 569(ab)
Desideri, A, 345(ab)
De Sutter, J, 1(ab), 705(ab), 764(ab)
Deterding, TA, 376
Detry, R, 462(ab)
Dettori, G, 87(ab)
Deutsch, G, 981(ab), 995(ab)
Devillers, A, 459(ab), 1287(ab)
DeVincentes, G, 868(ab)
Devinsky, O, 235(ab)
De Vos, F, 1056(ab), 1061(ab), 1818
Devous, MD, 545(ab), 548(ab), 1019(ab), 535, 1059
de Vries, EGE, 432, 579
Dewaraja, YK, 83(ab), 389(ab)
Dewey, S, 377(ab), 901(ab), 909(ab)
Dewey, SL, 52(ab), 56(ab), 424(ab)
De Winter, F, 764(ab), 1266(ab), 1343(ab), 1396(ab)
De Winter, H, 1343(ab)
De Winter, O, 1(ab), 705(ab), 764(ab)
de Wit, M, 881(ab)
De Wolf-Peeters, C, 446(ab)
Dey, D, 37(ab)
Dhaene, K, 1818
Dhawan, DK, 1050(ab)
Dhekne, RD, 454
D'Hemecourt, PA, 209
d'Herbomez, M, 993
Diamond, BA, 138
Díaz, MºC, 505
Di Bella, EVR, 944, 1704
Dick, DW, 54(ab), 930(ab), 934(ab), 1044(ab), 1118(ab)
Dick, S, 1144
Diederichs, CG, 721
Diehl, M, 334(ab), 496(ab),1129(ab), 1211(ab)
Diemel, GA, 1243
Dierckx, R, 1(ab), 41(ab), 43(ab), 229(ab), 231(ab), 705(ab), 1056(ab), 1061(ab), 1266(ab), 1343(ab), 1396(ab), 361, 1722, 1818
Dierickx, LO, 1171(ab), 1432(ab)
Dietlein, M, 496(ab), 1324(ab)
Dietz, A, 1143(ab)
Dietz, HG, 1424(ab)
Díez-Castro, MJ, 558
DiFilippo, FP, 379(ab), 892(ab)
Diggles, LE, 868(ab)
Dijkers, ECF, 1167(ab)
Di Lorenzo, C, 1423(ab)
Dilsizian, V, 200(ab), 743(ab)
Di Luzio, E, 1212(ab)
DiMaio, AA, 904(ab)
DiMeo, AJ, 890(ab)
Dimitrakopoulou-Strauss, A, 120(ab), 125(ab), 248, 465(ab), 713, 788(ab), 1274(ab)
Ding, L, 799(ab)
Ding, YA, 358(ab)
Ding, Y-S, 402(ab), 403(ab), 424(ab), 906(ab), 908(ab)
Dione, D, 173(ab)
Dionne, G, 1217(ab)
Dispenzieri, A, 580(ab)
Dittmann, H, 107(ab), 499(ab), 501(ab), 560(ab)
Divgi, CR, 1291(ab)
Dizendorf, E, 130(ab), 1235(ab)
Dodig, D, 1046(ab), 1335(ab)
Dodin, S, 1418(ab)
Doehner, H, 457(ab), 1294(ab)
Dogan, AS, 537(ab), 800(ab), 927(ab)
Dogar, M, 259(ab)
Dohan, O, 987(le), 1346(ab)
Dohmen, BM, 31(ab), 107(ab), 108(ab), 499(ab), 501(ab), 560(ab), 1010(ab), 1081(ab), 1253(ab)
Doi, H, 344(ab)
Doi, M, 543
Doi, R, 1174(ab), 1176(ab)
Doliba, N, 269(ab)

Doll, J, 1053, 1265
Dollé, F, 932
Domb, AR, 756(ab)
Dombret, MC, 21
Domingo, E, 1768
Domingues, C, 292
Dominguez, A, 1075(ab)
Donauer, N, 996(ab)
Dondi, M, 730(ab)
Donohoe, KJ, 1134, 1437(ab)
Donovan, PI, 594(ab), 595(ab), 1355(ab)
Dose, J, 9
dos Santos, A, 662
Doubrovin, M, 260(ab), 1160(ab), 1161(ab)
Doudet, DJ, 29(ab)
Dougall, P, 484(ab)
Dougherty, DD, 1006(ab), 1007(ab)
Dräger, E, 438(ab), 1231(ab)
Dragotakes, SC, 66(ab), 1125(ab)
Dragotakes, SD, 896(ab)
Dravet, F, 1229(ab)
Dreher, D, 443(ab)
Dresel, S, 58(ab), 144(ab), 288(ab), 1210(ab)
Drevets, WC, 63(ab)
Drew, PD, 1243
Dreyer, M, 142(ab)
Driedger, A, 140(ab)
Drocea, CW, 123(ab)
Droubi, N, 1358(ab)
Drubach, LA, 209
Drumm-Giuseppe, DL, 567(ab)
Drzezga, A, 47(ab), 224(ab), 548, 1018(ab)
Du, Y, 67(ab), 527(ab), 1312(ab)
Duan, J, 80(ab)
Duarte, PS, 44
Duboc, D, 1415(ab)
Dubois Randé, JL, 339(ab), 504(ab), 1737
Dubrovin, M, 239(ab)
Dudczak, R, 150(ab), 591(ab), 706(ab), 746(ab), 1134(ab), 1309, 1856
Dukat, VJ, 907
Dukoff, R, 903(ab)
Dulguerov, P, 1206(ab)
Dumarey, N, 1432(ab)
Dumont, A, 1299(ab)
Dumont, F, 43(ab), 1056(ab), 1061(ab), 361, 1722
Dumont, M, 779(ab), 1217(ab), 1418(ab)
Duncan, JR, 529(le)
Duncker, CM, 1344(ab)
Duncker, IM, 1344(ab)
Dunigan, K, 878(ab), 914(ab), 1243(ab)
Dunkelmann, S, 1270(ab)
Dunn, KE, 71(ab), 1123(ab)
Dunn, WL, 76(ab)
Dunnwald, LK, 85(ab), 303(ab), 575(ab)
Dupont, P, 95(ab), 446(ab)
Durack, LD, 584(ab), 586(ab)
Durbin, M, 838(ab)
Durie, BG, 113(ab)
Dutton, JA, 488(ab), 1392(ab)
Dwamena, BA, 176(br)
Dworkin, HJ, 287(ab), 826(le)
Dye, YC, 817(ab)
Dyer, V, 1359
Dyszlewski, ME, 426(ab)
Dzewas, B, 915(ab), 1144
Dziuk, K, 1269(ab), 1800

Early, M, 539(ab)
Eary, JF, 370(ab), 575(ab), 584(ab), 586(ab), 770, 813(ab), 1275(ab)
Eaton, MW, 715(ab)
Eckelman, WC, 243(ab), 395(ab), 535(ab), 936(ab), 1156(ab), 1166(ab), 1538
Eckerle, S, 1323(ab)
Eckerman, KF, 492, 1027(ab), 1029(ab)
Eckervogt, V, 1390(ab)
Edge, SB, 579(ab)
Edwards, D, 472(ab), 474(ab)
Edwards, DS, 412(ab), 1307(ab)
Edwards, R, 1186(ab)
Edwards, S, 1020(ab)
Eftychiou, N, 396(ab)
Ehrlich, LE, 366(ab), 760(ab)
Ehrlichmann, W, 1081(ab)
Ehsani, A, 196(ab), 360(ab)
Eich, K, 712(ab)
Eicken, A, 732(ab)
Eidelberg, D, 1591
Eigtved, A, 142(ab), 297(ab)
Eijkemans, MJ, 222
Eisa, M, 539(ab)
Eisbruch, A, 295(ab)
Eisenhut, M, 246(ab), 317, 428(ab), 1143(ab), 1157(ab)
Eisensehr, I, 236(ab), 237(ab)
Elayi, C, 504(ab)
Eldeiry, L, 4(ab), 498(ab)
El Fakhri, G, 300, 945(ab)
Elfving, B, 912(ab)
Elgazzar, AH, 1409(ab), 1411(ab), 1449(ab)
El-Haddad, ES, 99(ab)
Ell, PJ, 384(ab), 939(ab)
Ella, AL, 221(ab)
Ellis, GK, 85(ab)
Ellis, L, 1530
Ellison, D, 1223(ab)
Ellwood, J, 1025(ab)
Elnaas, S, 1223(ab)
Elsaid, M, 1409(ab), 1449(ab)
Elsinga, P, 314(ab), 712(ab)
Elstein, D, 1129(ab)
Elstrodt, J, 1144(ab)
Ely, T, 1053(ab)
Emerson, S, 1146(ab)
Emfietzoglou, D, 499
Emmannouilides, C, 440(ab), 1130(ab)
Emmett, L, 353(ab)
Emond, P, 419(ab), 1052(ab)
Emons, G, 1227(ab)
Emrich, D, 1341(ab)
Enayati, P, 342(ab)
Endo, K, 130, 1282(ab)
Endres, CJ, 532(ab), 927(ab)
Engel, A, 127(ab), 998
Engelbach, M, 84(ab)
Enk, A, 110(ab)
Enke, CA, 1068(ab), 1306(ab)
Epelbaum, R, 117(ab)
Epstein, S, 63
Erba, P, 45(ab), 781(ab)
Ercoli, LM, 228(ab), 230(ab), 546(ab)
Erdi, AK, 1255(ab)
Erdi, Y, 815(ab)
Erdi, YE, 1255(ab)
Erdil, TY, 1352(ab)
Erdmann, E, 5(ab)
Eriksson, F, 835(ab)
Erion, JL, 75(ab), 137(ab), 469(ab), 470(ab), 1064(ab), 1303(ab)
Eritja, R, 428(ab)
Erlandsson, K, 939(ab), 1563
Ernst, IR, 743(ab)
Ernst, N, 1101
Erwin, WD, 194(ab), 755(ab), 884(ab), 1124(ab), 1773
Eryilmaz, A, 323(ab)
Esaki, T, 936(ab)
Eschmann, SM, 107(ab), 560(ab), 1010(ab), 1253(ab)
Eshima, D, 376
Eshima, L, 376
Eskola, O, 1397, 1643
Esser, PD, 850(ab)
Esteves, F, 101(ab)
Estorch, M, 516(ab)
Etchebehere, ECsc, 1016(ab), 1421(ab), 1448(ab)
Etchepare, M, 551(ab)
Ethendy, A, 79
Ettinger, DS, 1281(ab)
Eubank, B, 40(ab)
Evangelista, E, 1438(ab)
Even-Sapir, E, 998
Everaert, H, 401, 726(ab), 1171(ab), 1432(ab)
Ewerbeck, V, 120(ab), 125(ab)
Ezquerra, NF, 811(ab), 1185
Ezuddin, SH, 362(ab)
Ezura, M, 543
Ezziddin, S, 600(ab), 1232(ab), 1297(ab), 1298(ab)

Faber, TL, 217(ab), 219(ab), 717(ab), 722(ab), 861(ab)
Fabinyi, G, 250(ab)
Fagioli, G, 730(ab)
Fagret, D, 1395
Fahey, FH, 1121
Fahrner, TJ, 285(ab)
Faintuch, BL, 1108(ab), 1110(ab), 1111(ab)
Faivre-Chauvet, A, 146, 459(ab), 1313(ab)
Fajman, WA, 486(ab)
Falay, O, 323(ab)
Falchi, A, 1263(ab), 1328(ab), 1348(ab)
Falen, SW, 846(ab)
Fan, H, 533(ab)
Fan, YM, 735(ab)
Fang, P, 67(ab)
Fang, W, 1166
Fanti, S, 730(ab), 847(ab), 1126(ab)
Faraggi, M, 11(ab), 21, 167(ab), 512(ab), 1043, 1375(ab), 1385(ab), 1403(ab), 1451
Farboud, B, 853(ab)
Farde, L, 419(ab), 900(ab), 907(ab), 1058(ab)
Faries, MB, 578(ab)
Farncombe, TH, 172(ab), 523(ab), 844(ab), 849(ab)
Faulhaber, PF, 155(ab), 751(ab), 1222(ab), 1226(ab)
Fawwaz, R, 123(ab)
Fazio, F, 879(ab), 961(ab), 1268(ab)
Fehr, M, 1237(ab)
Feiden, W, 916(ab)
Feifel, G, 1128(ab)
Feigin, A, 1591
Feiglin, DH, 510(ab), 893(ab), 1216(ab)
Feillel, V, 90(ab)
Feinendegen, LE, 17N(7), 26N(9)
Feldman, H-J, 1144
Felton, A, 1382(ab)
Feng, B, 193(ab)
Feng, D, 789(ab)
Feng, H-Q, 1673
Fernando, GP, 173(ab)
Ferrari, M, 433(ab), 1037(ab)
Ferreira, LCt, 1016(ab)
Ferri, P, 178(ab)
Ferriere, JP, 90(ab)
Ferrieri, R, 901(ab), 906(ab), 908(ab), 1062(ab), 1120(ab)
Fersis, N, 107(ab)
Fessler, JA, 389(ab), 839(ab)
Fettich, J, 484(ab)
Fettich-Selinger, M, 484(ab)
Feuereisl, R, 181(ab)
Fey, J, 420
Ficaro, EP, 185(ab), 188(ab), 548, 744(ab), 839(ab), 882(ab), 1639
Fiche, M, 1229(ab)
Fieber, S, 972(ab)
Fickling, HW, 713(ab)
Fig, LM, 1586(br), 1656
Figg, WD, 1359
Figulla, HR, 49
Filice, A, 355(ab), 1347(ab)
Filmont, JE, 301(ab), 440(ab), 461(ab), 464(ab), 1130(ab)
Filocamo, M, 476(ab), 1412(ab)
Fine, EJ, 1440(le)
Fink, U, 293(ab)
Finkelman Keeney, C, 968(ab), 1002(ab), 1113(ab)
Finley, BR, 853(ab)
Finn, R, 239(ab), 257(ab), 572(ab), 1161(ab)
Finn, RD, 863(ab), 875(ab), 1251, 1281
Fiore, JM, 443(ab)
Fiore, V, 198(ab)
Fiorenza, M, 1037(ab)
Fioretti, PM, 79
Fischer, KC, 450(ab)
Fischer, M, 1148(ab)
Fischer, S, 144(ab), 1032(ab), 1424(ab), 1101
Fischer, U, 1189(ab)
Fischman, AJ, 55(ab), 128(ab), 147(ab), 208(ab), 794(ab), 896(ab), 898(ab), 918(ab), 1006(ab), 1007(ab), 1107(ab), 1125(ab), 1386(ab), 1404(ab), 1420(ab)
Fischman, MW, 403(ab)
Fishbein, M, 277(ab)
Fisher, RS, 321(ab)
Fisher, SJ, 92(ab), 829(ab)
Fitschen, J, 1296(ab)
Fitzgerald, RH, 44
Fitzner, H, 1117(ab)
Flaxman, M, 149(ab)
Flint, A, 1173(ab)
Flores, J, 591(ab)
Flores-Torres, S, 241(ab)
Flotats, A, 516(ab)
Flower, M, 78(ab)
Flower, MA, 822(ab)
Flux, GD, 78(ab), 822(ab)
Fodstad, Ø, 431(ab)
Fogelman, I, 371(ab), 1402(ab)
Fogler, WE, 263(ab)
Folks, R, 12(ab), 722(ab), 1185
Foltin, RW, 403(ab)
Font, M, 1001(ab)
Ford, E, 124(ab)
Ford, PV, 391(le), 454
Forsback, S, 1397
Förster, GJ, 84(ab), 1202(ab)
Forster, J, 319(ab)
Forster, K, 933(ab)
Foster, B, 1149(ab)
Foster, N, 226(ab)
Fougeres, P, 869(ab)
Fouquet, B, 1217(ab)
Fourme, T, 511(ab), 513(ab), 514(ab), 515(ab), 754(ab), 770(ab), 1043
Fowler, J, 52(ab), 56(ab), 377(ab), 400(ab), 402(ab), 403(ab), 410(ab), 897(ab), 906(ab), 908(ab), 909(ab), 1009(ab), 1011(ab), 1012(ab), 14N(1)
Fox, PT, 32(ab)
Franc, B, 1464
France, M, 1317(ab)
Franceschi, D, 400(ab), 402(ab), 403(ab), 906(ab), 908(ab), 1009(ab), 1011(ab), 1012(ab)
Franchi Jr, GC, 1111(ab)
Francis, IR, 83(ab)
Frangos, S, 484(ab)
Frank, H, 741(ab)

Franke, WG, 82(ab), 478(ab), 502(ab), 990(ab), 1104(ab), 1201(ab), 1320(ab), 685(le)
Franken, P, 564
Franken, PH, 1171(ab)
Franken, PR, 726(ab), 401
Franks, S, 1068(ab)
Franssen, EJ, 425(ab)
Franzius, C, 917(ab), 1272(ab), 1390(ab)
Freas, MS, 379(ab)
Freedman, N, 121(ab), 932(ab), 1017(ab)
Freeman, LM, 320(ab)
Freeman, M, 353(ab)
Freeman, SD, 913(ab)
Freimanis, RI, 302(ab)
Freimuth, P, 1066(ab)
Freitas, JE, 984(br)
Frey, E, 865(ab), 882(ab)
Frey, EC, 23(ab), 190(ab), 203(ab), 527(ab), 832(ab), 833(ab), 836(ab), 846(ab)
Frey, P, 333(ab), 1780
Fricke, H, 538(ab), 1174
Friedel, G, 560(ab), 1253(ab)
Friedman, AH, 454(ab)
Friedman, HS, 454(ab), 1805
Friedman, JD, 346(ab), 749(ab), 758(ab), 687, 831
Friedman, NC, 547(ab)
Friedman, SL, 265(ab)
Friedrich, D, 1278(ab)
Frielink, C, 268(ab)
Fritzberg, AR, 567(ab)
Frodl, T, 58(ab)
Froissart, M, 151(ab)
Front, A, 753(ab)
Frost, JJ, 35(ab), 44(ab), 399(ab), 532(ab), 1162(ab), 1281(ab)
Frouin, F, 339(ab), 808(ab), 1415(ab), 1737
Frouin, V, 34(ab), 808(ab), 1415(ab), 1737
Fröberg, AC, 1353(ab)
Frölich, L, 951(ab)
Fu, ZL, 390(ab), 1092(ab)
Fueger, B, 591(ab), 1309, 1856
Fuerst, S, 306(ab)
Fujibayashi, Y, 124, 310(ab), 655, 920(ab), 938(ab), 1152(ab), 1156(ab)
Fujieda, K, 1425(ab)
Fujii, H, 72(ab), 1285(ab), 1407(ab), 989
Fujii, S, 1191(ab)
Fujimori, K, 1361(ab)
Fujimoto, H, 983(ab)
Fujimoto, T, 1397(ab)
Fujino, S, 336(ab), 1457
Fujita, M, 61(ab), 550(ab), 795(ab), 925(ab), 1013(ab), 124
Fujita, T, 982(ab), 1239(ab)
Fujiwara, S, 747(ab), 776(ab), 784(ab)
Fukuchi, K, 152(ab), 503(ab), 762(ab), 983(ab), 859
Fukuchi, M, 845(ab)
Fukuda, H, 922(ab), 1207(ab)
Fukuhara, R, 1446
Fukui, A, 747(ab), 776(ab), 784(ab), 820(ab)
Fukui, M, B, 133(ab)
Fukumitsu, N, 965(ab), 1439(ab)
Fukumoto, M, 1215(ab)
Fukunaga, K, 1138(ab), 1260(ab)
Fukunami, M, 736(ab)
Fukushima, K, 405(ab), 859
Fukuzawa, S, 508(ab)
Fulham, MJ, 789(ab)
Fullerton, C, 57(ab)
Funaki, M, 378(ab)
Funari, M, 1371(ab)
Fung, AF, 8(ab)
Furl, N, 545(ab)
Furuyama, H, 338(ab), 763(ab), 774(ab), 775(ab), 778(ab)
Fuseau, C, 932
Fussel, B, 539(ab)
Futatsubashi, M, 442(ab), 707, 1196(ab)

Gabbert, G, 545(ab)
Gabelmann, A, 1800
Gagne, GM, 893(ab), 1216(ab)
Gaitini, D, 117(ab), 127(ab), 998
Gales, B, 337(ab), 356(ab)
Gali, H, 1067(ab), 1149(ab)
Galimberti, V, 433(ab)
Gallini, C, 178(ab)
Galofré, P, 738
Galt, J, 12(ab), 189(ab), 192(ab), 217(ab), 717(ab)
Galvan, G, 424
Gambhir, SS, 1S, 96, 280(ab), 281(ab), 282(ab), 283(ab), 284(ab), 372(ab), 373(ab), 435(ab), 562(ab), 572(ab), 586, 827(ab), 924, 1075(ab), 1078(ab), 1153(ab), 1185(ab), 1190(ab), 1225, 1334, 1360(ab)
Ganatra, R, 186(ab)
Ganguli, SN, 366(ab), 760(ab)
Gangwar, PK, 1098(ab), 1314(ab)
Gansen, D, 1124(ab),1289(ab)
Gao, DW, 891(ab)
Gao, JH, 32(ab)
Gao, R, 1166
Garcez, A, 1228(ab)
Garcia, E, 189(ab)
Garcia, EV, 12(ab), 217(ab), 219(ab), 717(ab), 722(ab), 811(ab), 391(le), 1185
García, V, 505
Gardin, I, 1030(ab)
Gargari, H, 415(ab)
Garin, E, 1287(ab)
Garino, JP, 44, 477(ab)
Garmestani, K, 1084(ab), 1538
Garreau, L, 1052(ab)
Garrè, S, 116(ab)
Garza, V, 906(ab), 908(ab), 1062(ab), 1120(ab)
Gasparini, M, 227(ab), 1261(ab)
Gasto, C, 1014(ab)
Gatley, J, 403(ab)
Gatley, SJ, 53(ab), 400(ab), 402(ab), 897(ab), 904(ab), 908(ab), 1011(ab)
Gatti, M, 134(ab), 433(ab), 573(ab)
Gatti, R, 476(ab), 1412(ab)
Gattorno, M, 1151
Gaughan, JP, 321(ab)
Gautherot, E, 146
Gauthier-Koelesnikov, H, 1464
Gavaruzzi, G, 847(ab)
Gawish, A, 1449(ab)
Gay, O, 533(ab), 927(ab)
Gayed, IW, 768(ab)
Gazawi, A, 1358(ab)
Gbel, H, 1000(ab)
Gebbinck, JWK, 509
Geisinger, KR, 302(ab), 868(ab)
Gelbard, I, 396(ab)
Genel, M, 593(ab)
Génin, R, 11(ab), 1295(ab), 1375(ab), 1403(ab), 21, 1451
Genton, L, 864, 998(ab)
George, S, 186(ab)
Georgi, P, 1117(ab), 1189(ab)
Gerard, SK, 1326(ab), 1878(br)
Gerasimov, M, 52(ab), 56(ab), 377(ab), 424(ab), 901(ab), 909(ab), 1062(ab), 1120(ab)
Gerlach, J, 687, 758(ab), 1630
Germano, G, 174(ab), 346(ab), 391(le), 528(le), 687, 749(ab), 758(ab), 831, 1424, 1499, 1630
Gerundini, P, 153(ab), 227(ab), 1261(ab), 1337(ab), 1444(ab)
Gestin, J-F, 1313(ab), 146
Gewirtz, H, 87
Geworski, L, 438(ab), 439(ab), 881(ab), 1231(ab)
Gfrörer, W, 109(ab)
Ghazarossian, V, 168(ab)
Ghazzar, N, 1403(ab)
Ghesani, N, 122(ab), 273(ab), 328(ab), 481(ab), 482(ab), 1327(ab)
Ghezzi, C, 1395
Ghio, R, 116(ab)
Ghirlanda, P, 116(ab)
Gianolli, L, 879(ab), 1268(ab)
Gibson, RE, 1274
Gielen, J-L, 1241(ab)
Gieles, M, 528(ab)
Gielow, P, 259(ab)
Gifford, A, 56(ab), 400(ab), 403(ab), 1011(ab)
Gifford, AN, 53(ab), 897(ab), 904(ab)
Gifford, HC, 844(ab)
Giganti, M, 355(ab), 1347(ab)
Gigot, JF, 462(ab)
Gil, MC, 1101(ab)
Gilardi, MC, 879(ab)
Gilbert, C, 167(ab)
Gilbert, K, 234(ab)
Gildehaus, FJ, 237(ab), 1059(ab)
Gill, LM, 304(ab)
Gill, R, 60(ab)
Gilland, K, 865(ab)
Gillinov, M, 3(ab)
Gillispie, S, 522(ab)
Ginesu, F, 1263(ab)
Ginovart, N, 62(ab), 391(ab), 895(ab)
Giona, F, 476(ab), 1412(ab)
Gionfriddo, MA, 1109
Giordani, B, 226(ab)
Giorgetti, A, 476(ab), 1412(ab)
Giovacchini, G, 243(ab)
Gips, S, 753(ab)
Girard, P, 848(ab)
Girtler, N, 45(ab)
Giubbini, R, 179(ab)
Gjedde, A, 59(ab), 996(ab)
Glaser, M, 264(ab)
Glatting, G, 109(ab), 457(ab), 804(ab), 1038(ab), 1150(ab), 1294(ab), 1800
Glenn, TC, 992(ab)
Glennon, RA, 397(ab)
Glick, SJ, 883(ab), 1116
Glidden, DV, 1713
Glover, DK, 1090(ab), 1388
Gmeiner, P, 422(ab)
Gobar, LS, 907
Gobbo, CL, 961(ab)
Gockerman, J, 455(ab)
Goddu, SM, 162
Goedemans, W, 75(ab)
Goedicke, F, 1117(ab)
Goeke, BJ, 1148(ab)
Goel, A, 1519
Goergen, T, 701(ab)
Goerres, G, 42(ab), 130(ab), 212(ab), 1208(ab), 1237(ab)
Goetz, C, 972(ab)
Goin, J, 1588(le)
Goins, BA, 1163(ab), 1379(ab), 1380(ab), 446
Gökçora, N, 1003(ab)
Golan, H, 1419(ab)
Golanowski, LN, 739(ab)
Goldberger, J, 755(ab)
Goldenberg, DM, 79(ab), 459(ab), 552(ab), 583(ab), 588(ab), 976
Goldenberg, G, 929(ab)
Goldin, J, 356(ab)
Goldman, R, 1225
Goldsmith, S, 460(ab), 1293(ab)
Goldsmith, SJ, 441(ab), 443(ab), 458(ab), 566(ab), 1021(ab), 1051(ab), 1292(ab), 1134
Golish, SR, 372(ab), 924
Gomeza, J, 535(ab)
Gonen, M, 278(ab), 420
Gonzalez, J, 1032(ab)
Gonzalez, LR, 1421(ab)
Gonzalez, P, 180(ab)
Gonzalez, R, 330(ab)
Goodbody, AE, 154
Goodman, ER, 320(ab)
Goodman, MM, 558(ab), 911(ab), 1053(ab), 376
Goodman, SL, 326
Goodman, TM, 1173(ab)
Goodwin, DA, 670
Gopal, AK, 586(ab)
Gordon, D, 13(ab)
Gordon, EM, 1682
Gordon, I, 1426(ab)
Gordon, L, 1351(ab), 1128(br)
Gordon, SJ, 1223(ab)
Gore, JC, 889(ab)
Gorenberg, M, 18(ab), 490(ab)
Gorey, J, 397(ab), 401(ab), 903(ab)
Gorman, J, 60(ab)
Goshtasby, A, 799(ab)
Gosink, HJ, 255(ab)
Gossmann, A, 238(ab)
Gotthardt, M, 160(ab), 1148(ab), 1354(ab)
Gottschalk, A, 13N(6), 1729
Gottschalk, C, 550(ab), 987(ab)
Gottschild, D, 49
Gould, K, 1242(ab)
Gould, R, 20(ab)
Goulding, V, 62(ab)
Gournay, J, 1370(ab)
Gouze, V, 993
Govindan, SV, 967
Gracia, SC, 1133(ab)
Graeber, G, 564(ab)
Graf, R, 467
Graf, S, 741(ab), 746(ab), 189
Graham, MM, 257, 679, 973(ab)
Grahek, D, 463(ab), 487(ab)
Graichen, S, 951(ab)
Gralow, JR, 85(ab), 303(ab), 679
Grana, C, 134(ab)
Granowska, M, 1225(ab)
Grant, S, 434(ab)
Grant, SF, 192(ab), 817(ab)
Gratz, S, 585(ab), 917, 1022(ab), 1257, 1373(ab), 1381(ab)
Graves, S, 569(ab)
Green, AM, 312(ab)
Green, LA, 373(ab)
Green, MA, 427(ab)
Greer, KL, 888(ab)
Greer, P, 921(ab)
Greeson, TW, 14N(12)
Gregoire, M-C, 34(ab)
Gregory, SA, 455(ab), 582(ab)
Grénman, R, 1643
Grever, M, 1243(ab)
Grierson, J, 106(ab), 1184(ab)
Gries, P, 232(ab), 840(ab), 1206(ab)
Griesinger, F, 585(ab), 1227(ab)
Griffin, BP, 3(ab)
Griffiths, G, 552(ab), 568(ab), 967
Grillo-Lopez, AJ, 76(ab), 1115(ab), 1124(ab)
Grinwald, F, 163(ab), 334(ab), 951(ab), 1043(ab), 1211(ab), 1340(ab)
Groch, MW, 194(ab), 884(ab), 1773
Groen, HJM, 579
Groiselle, CJ, 883(ab)
Grönblad, M, 476
Grönroos, T, 1397, 1643
Gropler, RJ, 196(ab), 360(ab)
Grosev, D, 1046(ab), 1335(ab)
Groshar, D, 490(ab)
Gross, HJ, 581(ab)
Gross, MD, 1656
Grosu, AL, 915(ab), 978(ab), 1144
Groth, P, 1270(ab)

Grow, KL, 1121
Gruaz-Guyon, A, 146
Grubb, RL, Jr., 1195
Gruenwald, F, 496(ab)
Gründer, G, 59(ab), 928(ab)
Gruning, T, 478(ab), 502(ab), 1104(ab), 685(le)
Grünwald, F, 1129(le)
Gschwend, J, 451(ab)
Guan, YH, 970(ab), 1005(ab)
Guaraldi, MT, 258(ab)
Gücüyener, K, 1003(ab)
Guenther, I, 932
Guenther, R, 701(ab)
Guenthert, A, 1227(ab)
Guerrero, JL, 1404(ab)
Guhlke, S, 1297(ab), 1298(ab)
Guhlmann, C-A, 721
Guidalotti, P, 730(ab), 847(ab)
Guilloteau, D, 419(ab), 1052(ab)
Guleng, RJ, 597(ab)
Gulke, S, 600(ab)
Gullberg, GT, 26(ab), 193(ab), 518(ab), 1704
Gulluoglu, BM, 1352(ab)
Gulyás, B, 247(ab), 419(ab), 900(ab), 907(ab), 1058(ab)
Gunkel, O, 757(ab)
Gunn, RN, 939(ab)
Guo, D, 1476
Guo, N, 420(ab), 910(ab), 1057(ab)
Guo, S, 1166
Gupta, A, 233(ab)
Gupta, AK, 1314(ab)
Gupta, KK, 1098(ab)
Gupta, NC, 563(ab), 564(ab), 1247(ab), 1250(ab), 1256(ab)
Gupta, S, 261(ab), 414(ab), 494(ab), 553(ab), 1870
Gur, RC, 1002(ab)
Guralnik, L, 127(ab), 998
Gutierrez, F, 1001(ab)
Guy, MJ, 78(ab), 822(ab)
Gwechenberger, M, 746(ab)

Haaparanta, M, 1397
Haas, F, 818
Haberal, MEH, 1442(ab)
Haberkorn, U, 246(ab), 249(ab), 317, 325(ab), 428(ab), 1053, 1143(ab), 1155(ab), 1157(ab), 1265
Habraken, JBA, 1863
Hachamovitch, R, 1424
Hacker, M, 335(ab)
Hadas-Halpern, I, 1129(ab)
Haddad, M, 189
Hadfield, J, 1209(ab)
Haenggeli, CHA, 1206(ab)
Hagen, PJ, 393
Hahn, J, 1324(ab)
Hahn, K, 58(ab), 144(ab), 236(ab), 237(ab), 288(ab), 335(ab), 972(ab), 1059(ab), 1210(ab), 1424(ab)
Haidar, M, 1299(ab)
Haim, N, 117(ab)
Hajjar, G, 583(ab), 588(ab)
Halac, M, 567
Haley, RW, 943(ab), 1059
Halfter, H, 917(ab)
Halkar, RK, 101(ab), 192(ab), 486(ab), 817(ab)
Hall, C, 764
Hall, H, 1052(ab)
Halldin, C, 419(ab), 900(ab), 907(ab), 1052(ab), 1058(ab)
Hallett, W, 371(ab)
Halperin, N, 33
Ham, H, 564
Hamacher, K, 209(ab), 752, 27, 1216
Hamada, S, 752(ab), 769(ab)
Hamaguchi, S, 1282(ab)
Hamblen, SM, 841(ab)
Hamburg, S, 445(ab)
Hamill, JJ, 213(ab)
Hamilton, G, 1856
Hamlin, DK, 554(ab)
Hammami, H, 845
Hampel, H, 47(ab), 1018(ab)
Hamscho, N, 334(ab)
Han, G, 22(ab), 834(ab)
Han, L, 206(ab)
Han, SH, 1302(ab)
Han, YM, 1065(ab), 1178(ab), 1181(ab), 1342(ab)
Hanai, N, 1288(ab)
Handa, S, 725(ab)
Handrick, W, 990(ab)
Hanes, MA, 1380(ab)
Hannah, A, 250(ab), 1288(ab)
Hannequin, P, 848(ab)
Hanrahan, SM, 270(ab)
Hans, D, 864
Hanselmayer, G, 591(ab)
Hansen, H, 552(ab)
Hansen, HJ, 967
Hansen, HS, 297(ab)
Hansen, L, 1091(ab)
Hansen, SB, 795
Hapdey, S, 214(ab), 376(ab), 519(ab), 521(ab)
Haque, TL, 1087(ab)
Hara, T, 68(ab), 447(ab), 827(le), 1815
Harada, J, 965(ab)
Hardenbergh, PH, 888(ab)
Hardoff, R, 975(ab)
Harel, F, 11(ab), 167(ab), 512(ab), 1043, 1403(ab), 1451
Harer-Mouline, C, 1010(ab)
Hareyama, M, 1361(ab)
Hari, K, 235(ab)
Harkness, BA, 1121
Harmelink, MJ, 404(ab), 1008(ab)
Harper Mozley, LM, 541(ab), 968(ab), 1002(ab)
Harris, JC, 146(ab)
Harris, T, 545(ab)
Harris, TD, 1090(ab)
Harris, TS, 548(ab), 943(ab), 1059
Harrison, RL, 522(ab)
Harrop, R, 172(ab)
Harshbarger, T, 981(ab)
Hart, CL, 715(ab)
Hart, R, 171(ab), 359(ab)
Hartmann, IJC, 393
Hartmann, V, 1018(ab)
Hartner, W, 711(ab)
Harwood, S, 455(ab)
Hasebe, N, 766(ab), 1017
Hasegawa, BH, 205(ab), 891(ab), 237, 772, 1713
Hasegawa, S, 169(ab), 720(ab), 809(ab), 285
Hasegawa, Y, 976(ab), 1267(ab)
Hashikawa, K, 408(ab)
Hashimoto, A, 1757
Hashimoto, K, 394(ab)
Hashimoto, N, 982(ab)
Haslinger, B, 933(ab)
Hastings, DL, 880(ab), 1209(ab)
Hata, T, 721(ab)
Hatada, K, 752(ab), 769(ab)
Hatano, K, 957(ab), 962(ab), 969(ab)
Hattori, N, 551(ab), 992(ab)
Haubner, R, 326, 473(ab)
Haufe, S, 325(ab)
Hauser, M, 727(ab), 732(ab)
Hautmann, R, 451(ab)
Hawkins, RA, 237, 1713
Hay, RV, 1656
Hayama, K, 378(ab)
Hayashi, K, 1132(ab), 1369(ab), 1425(ab), 1428(ab)
Hayashida, K, 152(ab), 405(ab), 859, 983(ab)
Hayem, G, 1375(ab)
Hayes, DL, 1067(ab), 1149(ab)
Hayes, S, 745(ab)
Hayes, SW, 687
Hayes, W, 749(ab), 758(ab)
Haynes, PT, 337
Haynor, DR, 40(ab), 522(ab)
Hays, M, 670
Hazra, DK, 1098(ab), 1314(ab)
He, G, 1092(ab), 1322(ab)
Heřmanská, J, 1084
Hefft, S, 232(ab)
Heiba, S, 20(ab), 352(ab), 576(ab)
Heichel, T, 120(ab), 125(ab), 713
Heidelberg, TH, 42(ab)
Heidendal, GA, 177(ab), 312(ab), 1048(ab), 382
Heifetz, LJ, 445(ab)
Heikkinen, JO, 380(ab)
Heinz, A, 31(ab), 398(ab), 401(ab), 1010(ab)
Heinze, A, 1000(ab)
Heinze-Kuhn, K, 1000(ab)
Heiss, WD, 49(ab), 238(ab), 902(ab), 467
Heitmiller, RF, 1281(ab)
Helal, BO, 11(ab), 158(ab), 511(ab), 512(ab), 513(ab), 514(ab), 515(ab), 754(ab), 770(ab), 1043, 1331(ab), 1451, 1464
Held-Feindt, J, 248(ab), 1338
Helisch, A, 709(ab)
Heller, B, 565(ab)
Heller, KS, 596(ab)
Hellwigm, BJ, 893(ab), 1216(ab)
Hellwigm, D, 276(ab), 916(ab)
Heminway, S, 412(ab)
Hemler, PF, 1121
Hendel, RC, 194(ab), 1773
Henderson, BL, 322(ab)
Hendler, AL, 1073(ab)
Hendrikse, NH, 1167(ab)
Henkel, K, 1038(ab)
Henley, A, 369(ab)
Henriksen, G, 431(ab)
Henze, E, 248(ab), 475(ab), 1000(ab), 1391(ab), 1399(ab), 1413(ab), 1422(ab), 230, 1338, 1545
Henze, M, 246(ab), 249(ab), 317, 1053
Herbrik, S, 1341(ab)
Herbst, R, 263(ab), 1242(ab)
Herfarth, K, 246(ab)
Herholz, K, 49(ab), 902(ab)
Hermann, D, 398(ab)
Herment, A, 808(ab), 1737
Hermsdörfer, J, 929(ab)
Hernandez, G, 1034(ab)
Hernandez Pampaloni, M, 337(ab), 340(ab), 356(ab)
Heroes, M, 9(ab)
Herrero, P, 196(ab), 360(ab), 823(ab)
Herrlinger, U, 239(ab)
Herrmann, J, 1341(ab)
Herry, JY, 1287(ab)
Herscheid, JD, 425(ab)
Herschman, HR, 96, 280(ab), 1153(ab), 1185(ab), 1225
Herscovitch, P, 243(ab), 395(ab), 1166(ab)
Hershey, ED, 1388(ab)
Hertel, A, 1043(ab), 1340(ab)
Herz, M, 915(ab), 1170(ab)
Herzog, H, 752, 931(ab)
Hess, J, 727(ab), 732(ab)
Hesse, S, 199(ab), 1189(ab)
Hesselmann, V, 467
Hetzel, J, 1800
Hetzel, M, 1269(ab), 1800
Hichwa, RD, 64(ab), 935(ab)
Hickeson, M, 122(ab), 273(ab), 275(ab), 994(ab), 1321(ab), 1417(ab)
Hickey, K, 271(ab), 767(ab), 807(ab)
Hicks, RJ, 1158, 1238, 1596, 1605
Higashi, K, 977(ab), 1244(ab), 1284(ab), 1476, 1489
Higashi, T, 105(ab), 292(ab), 1172(ab), 1174(ab), 1176(ab), 1191(ab), 1239(ab), 1252(ab)
Higashioka, H, 976(ab)
Higgins, CJ, 716(ab)
Higley, D, 401(ab)
Hignette, C, 151(ab)
Higuchi, I, 289(ab)
Higuchi, T, 336(ab), 1191(ab), 1282(ab), 183, 1571
Hikosaka, K, 244(ab), 313(ab), 1175(ab), 1551
Hildinger, M, 240(ab)
Hilditch, TE, 986(le)
Hill, JC, 287(ab), 24N(12)
Hill, TC, 1437(ab)
Hillier, S, 1386(ab)
Hilson, AJW, 99(ab), 1318(ab), 3
Hilson, JB, 945(ab)
Hilton, J, 309(ab), 532(ab), 533(ab), 537(ab), 927(ab)
Hiltunen, J, 419(ab), 802(ab)
Hinnen, F, 932
Hino, I, 467(ab)
Hinrichs, SH, 1519
Hipp, P, 249(ab), 1053
Hirai, M, 1747
Hirai, T, 733(ab), 124
Hiraki, Y, 1427(ab)
Hirano, Y, 447(ab)
Hiraoka, M, 1252(ab)
Hirata, A, 736(ab)
Hirayama, H, 1747
Hironaka, F, 1228(ab), 1371(ab)
Hirono, O, 747(ab), 776(ab), 784(ab)
Hisada, K, 1579
Hittinger, L, 504(ab)
Hitzel, A, 167(ab), 1403(ab)
Hitzemann, R, 400(ab), 402(ab), 1012(ab)
Hliscs, R, 82(ab)
Hnatowich, DJ, 73(ab), 261(ab), 414(ab), 553(ab), 1083(ab), 1102(ab), 1660, 1870
Ho, S, 1587(le)
Ho, Y-J, 17
Hoecker, H, 701(ab)
Hoefnagel, CA, 436(ab), 574(ab), 826(le)
Hoegerle, S, 591
Hoejgaard, L, 142(ab), 145(ab)
Hoekstra, C, 112(ab), 1254(ab)
Hoekstra, OS, 94(ab), 112(ab), 1139(ab), 393
Hoffend, J, 1143(ab)
Hoffman, E, 855(ab), 864(ab), 877(ab)
Hoffman, EJ, 28(ab), 294(ab)
Hoffman, EW, 1288(ab), 1289(ab), 1291(ab)
Hoffman, JM, 376, 1132(le)
Hoffman, MA, 1136(ab), 1137(ab)
Hoffman, TJ, 1067(ab), 1149(ab), 1847
Hoffmann, B, 826(le)
Hofland, LJ, 1305(ab)
Hofmann, M, 598(ab), 1053, 1296(ab), 1376(ab)
Hofstra, L, 177(ab), 312(ab), 382, 1048(ab)
Hogg, A, 1596
Hoh, C, 814(ab)
Hoh, CK, 386(ab), 430(ab), 951
Hohenstein, MA, 907
Hoki, N, 736(ab)
Holden, JE, 29(ab), 536(ab)
Holdsworth, C, 855(ab), 864(ab), 877(ab)
Hollett, P, 156(ab)
Holloway, B, 3
Holm, S, 826(ab), 924(ab)
Holschneider, CH, 1193(ab)
Holt, DP, 423(ab), 1060(ab)
Holzmannhofer, J, 424

Honda, N, 821(ab), 985(ab), 1364(ab), 1434(ab)
Hondo, M, 1434(ab)
Honeychurch, J, 1312(ab)
Hong, JO, 791(ab)
Hong, JP, 1100(ab)
Hong, MK, 175(ab), 1142(ab)
Hong, SB, 853
Hong, SM, 1094(ab)
Hong, SW, 1180(ab)
Hopkins, W, 1288(ab), 1289(ab), 1291(ab)
Hori, M, 408(ab)
Horibe, K, 962(ab)
Horita, Y, 152(ab)
Horn, LC, 1189(ab)
Horne, T, 33, 1398(ab)
Hornick, C, 530(le)
Horstick, G, 709(ab)
Horvath, J, 1614
Hosaka, K, 48(ab), 922(ab)
Hosoi, S, 182(ab)
Hosokawa, M, 1175(ab), 1551
Hosokawa, R, 733(ab), 124
Hosono, M, 821(ab), 985(ab), 1364(ab), 1434(ab)
Hosotani, R, 1174(ab), 1176(ab)
Hotze, A, 744
Hou, C, 393(ab), 1556
Houle, S, 62(ab), 391(ab), 895(ab), 899(ab)
Hovanessian, L, 437(ab)
Hovda, DA, 551(ab), 992(ab)
Hove, JD, 924
Howden, N, 1186(ab)
Howell, LL, 911(ab)
Howell, RW, 253(ab), 254(ab), 162
Hsiao, I, 857(ab)
Hsiao, P, 1122(ab)
Hsieh, J-F, 17
Hsu, CH, 1330(ab)
Hsu, H, 1404(ab)
Hsu, PI, 1365(ab)
Hsueh, W, 340(ab)
Hu, P, 492(ab), 495(ab)
Hu, S, 1166
Hu, YC, 1255(ab)
Huang, CC, 387(ab)
Huang, CL, 792(ab)
Huang, GF, 423(ab)
Huang, LL, 944(ab)
Huang, SC, 51(ab), 228(ab), 230(ab), 241(ab), 242(ab), 374(ab), 551(ab), 787(ab), 790(ab), 992(ab)
Huang, WS, 735(ab), 956(ab), 1303
Huang, Y, 392(ab), 396(ab), 420(ab), 531(ab), 910(ab), 1057(ab)
Huang, Z, 1055(ab)
Huber, R, 1309(ab), 1310(ab)
Huberty, J, 237, 1713
Hubner, H, 422(ab)
Hubner, KF, 818(ab)
Hübner, GE, 744
Huemmer, CL, 53(ab)
Huesman, RH, 27(ab), 272
Huglo, D, 993, 1266(ab)
Huijgens, PC, 1139(ab)
Hulse, P, 1209(ab)
Humbert, M, 513(ab), 514(ab)
Humeres, P, 180(ab)
Hüfner, M, 587(ab), 1022(ab)
Humm, J, 124(ab), 257(ab), 1255(ab)
Humm, JL, 170, 1130(le), 1251, 1281
Hung, JC, 827(le), 1112(ab)
Hunt, J, 1027(ab)
Huo, L, 1092(ab)
Hurd, T, 579(ab)
Hurwitz, RA, 331(ab)
Husain, M, 353(ab), 1019(ab)
Hussain, SA, 546(ab)
Hussey, D, 62(ab), 391(ab), 895(ab)
Hustinx, R, 1195(ab), 1241(ab)
Hutchins, GD, 364(ab), 483, 1183, 1375
Hutchinson, R, 143(ab)
Huten, D, 1375(ab)
Hutton, I, 350(ab)
Hwang, D, 531(ab)
Hwang, DR, 60(ab), 392(ab), 396(ab), 420(ab), 910(ab)
Hwang, I, 1004(ab)
Hwang, KH, 1131(ab), 1204(ab), 1319(ab)
Hwang, KL, 1036(ab)
Hwang, SH, 534(ab)
Hwang, WS, 173(ab)
Hwang, Y, 271(ab)
Hyman, BT, 1060(ab)
Hyytinen, T, 476

Ibrahim, T, 7(ab)
Ichiba, F, 1410(ab)
Ichihara, K, 1407(ab)
Ichihara, T, 750(ab)
Ichikawa, A, 1282(ab)
Ichikawa, Y, 506(ab), 702(ab)
Ichimiya, T, 394(ab)
Ichise, M, 755, 801(ab)
Ide, M, 989, 1285(ab)
Ido, T, 315(ab), 1106(ab)
Iglesias, F, 505
Iguchi, Y, 965(ab)
Iida, H, 2(ab), 220(ab), 341(ab), 795(ab), 870(ab), 925(ab), 926(ab), 937(ab)
Iida, Y, 1054(ab), 1332(ab)
Iizuka, H, 977(ab)
Ijbema, T, 869(ab)
Ikeda, M, 1446
Ikeda, T, 72(ab)
Ikegami, H, 1346
Ikezoe, J, 182(ab), 407(ab), 820(ab), 1297, 1446
Ikezoe, MD, 947(ab)
Illidge, TM, 1312(ab)
Im, KC, 851(ab)
Imai, T, 1262(ab), 1410(ab), 1436(ab)
Imai, Y, 1262(ab), 1410(ab), 1436(ab)
Imaizumi, M, 408(ab)
Imakita, S, 859
Imamura, M, 105(ab), 292(ab), 1174(ab), 1176(ab)
Inagaki, K, 827(le)
Inagaki, M, 508(ab)
Inanir, S, 1352(ab)
Inenaga, T, 152(ab)
Infanger, M, 1278(ab)
Inglese, E, 730(ab)
Innis, R, 539(ab), 550(ab)
Innis, RB, 61(ab), 795(ab), 925(ab), 1013(ab)
Inoue, K, 1288(ab)
Inoue, M, 394(ab), 707(ab), 802
Inoue, S, 845(ab)
Inoue, T, 1282(ab)
Inoue, Y, 782(ab), 733, 802, 1005
Inubushi, M, 859
Iosilevsky, G, 998
Iozzo, P, 264(ab)
Irie, A, 1213(ab)
Irie, T, 873(ab), 942(ab)
Irngartinger, G, 1274(ab)
Irwin, AG, 99(ab)
Isacson, O, 50(ab)
Ishida, R, 38
Ishida, Y, 503(ab), 762(ab)
Ishii, K, 48(ab), 548, 806(ab), 922(ab)
Ishikawa, Y, 489(ab), 766(ab), 1017, 1368(ab), 1425(ab), 1435(ab), 1447(ab)
Ishimori, T, 105(ab), 292(ab), 1087(ab), 1172(ab), 1174(ab), 1176(ab), 1191(ab), 1239(ab), 1252(ab)
Ishiwata, K, 314(ab)
Ishizu, H, 1359(ab), 1362(ab), 1363(ab), 1367(ab)
Ishizu, K, 105(ab), 982(ab), 1239(ab)
Iskandrian, AE, 1424
Isobe, S, 1747
Isoda, Y, 805(ab)
Israel, O, 117(ab), 127(ab), 164(ab), 998
Ito, K, 957(ab), 962(ab), 969(ab)
Ito, M, 747(ab), 776(ab), 784(ab)
Ito, T, 1747
Ito, Y, 197(ab), 338(ab), 731(ab), 774(ab), 775(ab), 778(ab), 965(ab), 838
Itoh, K, 1484
Itoh, M, 315(ab), 1207(ab), 1397(ab)
Itoh, S, 344(ab), 989(ab)
Itoh, Y, 936(ab)
Itou, H, 946(ab)
Itti, E, 771(ab), 868(ab), 1438(ab), 845
Itti, R, 221(ab)
Ivancevic, V, 438(ab), 881(ab), 1231(ab), 1258(ab), 1374(ab)
Iverson, BC, 1112(ab)
Iwado, Y, 338(ab), 731(ab), 773(ab), 774(ab), 775(ab), 778(ab)
Iwai, K, 962(ab)
Iwamoto, S, 809(ab)
Iwanczyk, J, 28(ab), 363(ab)
Iwanochko, RM, 353(ab)
Iwasa, M, 999(ab)
Iwasaka, T, 752(ab), 769(ab)
Iwasaki, T, 845(ab)
Iwasaki, Toshiya, 130
Iwasaki, Tsutomu, 130
Iwata, K, 205(ab), 891(ab)
Iwata, M, 1332(ab)
Iwata, R, 1106(ab)
Iwata, Y, 1359(ab), 1362(ab), 1363(ab), 1367(ab)
Iyengar, S, 828(ab)
Iyer, M, 96, 280(ab), 281(ab), 282(ab), 283(ab), 284(ab), 1185(ab), 1225
Iyer, RV, 337
Izhaki, A, 783(ab)
Izumi, T, 169(ab), 285

Jackowski, M, 799(ab)
Jacob, J, 290(ab)
Jacobs, A, 238(ab), 239(ab), 467
Jacobs, M, 878(ab), 882(ab), 1243(ab)
Jacobson, DA, 907
Jadvar, H, 114(ab), 437(ab), 1194(ab)
Jager, GJ, 1279(ab)
Jager, PL, 759(ab), 432, 579
Jagoda, EM, 535(ab)
Jahn, M, 483(ab), 1091, 1408(ab)
James, JL, 77(ab), 1085(ab)
Jamriska, D, 1086(ab)
Jamsheed, HC, 27(ab)
Jan, H, 1223(ab), 1225(ab)
Jana, S, 352(ab), 576(ab)
Janacek, M, 877(ab)
Janecek, M, 28(ab), 855(ab), 864(ab)
Jang, HJ, 772(ab), 1187(ab), 1400(ab)
Jang, JJ, 1177(ab)
Jang, JS, 1004(ab), 1035(ab), 1039(ab), 1131(ab), 1204(ab)
Jang, S, 498(ab), 1198(ab), 1233(ab), 1417(ab), 1795!
Jangid, DR, 357(ab), 361(ab)
Jänicke, F, 9
Janssen, DM, 1048(ab)
Janssen, M, 472(ab), 474(ab), 1020(ab)
Janzen, I, 1375
Jarkas, N, 1053(ab)
Jaszczak, RJ, 363(ab), 526(ab), 529(ab), 718(ab), 888(ab)
Jatko, MK, 218(ab)
Jayne, M, 400(ab), 1011(ab)
Jen, CG, 735(ab)
Jenike, MA, 1006(ab), 1007(ab)
Jenkins, BG, 919(ab)
Jennings, D, 539(ab)
Jensen, M, 924(ab)
Jeon, DG, 1273(ab)
Jeon, T, 126(ab)
Jeon, TJ, 791(ab)
Jeong, H, 126(ab)
Jeong, HJ, 480(ab)
Jeong, JM, 266(ab), 432(ab), 500(ab), 1040(ab), 1094(ab), 1103(ab), 1142(ab), 1177(ab), 1182(ab)
Jiang, S, 317, 1155(ab)
Jian-hua, J, 1440(ab)
Jian-zhong, L, 1440(ab)
Jin, J, 703(ab)
Jirsa, L, 1084
Jisaki, F, 1476
Joaquim, A, 183(ab)
Jobst, B, 234(ab)
Jofre, J, 180(ab)
Joh, CW, 1035(ab), 1039(ab), 1131(ab), 1204(ab), 1319(ab)
Johansen, J, 297(ab)
John, EK, 1122(ab)
Johnson, G, 715(ab), 716(ab)
Johnson, JT, 133(ab)
Johnson, KA, 945(ab)
Johnson, MA, 469(ab)
Johnson, PW, 1312(ab)
Johnston, MV, 146(ab)
Johnston, T, 1240(ab)
Jones, AG, 267(ab)
Jones, D, 401(ab)
Jones, DW,397(ab), 903(ab)
Jones, LA, 93(ab)
Jones, S, 1077(ab)
Jonkhoff, AR, 1139(ab)
Jonson, B, 1288
Jonsson, BA, 1031(ab)
Jonsson, L, 1031(ab)
Jordan, R, 1184(ab)
Joseph, K, 160(ab), 1148(ab), 1354(ab)
Joski, P, 871
Joung, J, 207(ab)
Juarez, B, 340(ab)
Juhasz, C, 141(ab)
Julyan, PJ, 880(ab), 1209(ab)
Jung, H-W, 980(ab)
Jung, P, 335(ab)
Jung, SI, 1101(ab)
Jung, WS, 1158(ab)
Jungbluth, A, 1281
Jurcic, JG, 27
Jürgens, H, 1272(ab)
Juri, C, 577(ab)
Jurisson, SS, 416(ab), 417(ab), 1070(ab), 1847

Kääpä, E, 476
Kabasakal, L, 1614
Kachelriess, M, 211(ab)
Kachi, T, 957(ab), 962(ab), 969(ab)
Kacperek, A, 880(ab)
Kadalie, C, 110(ab)
Kadish, A, 755(ab)
Kadrmas, D, 368(ab), 944
Kaelicke, T, 163(ab)
Kaepplinger, S, 49
Kaestle, C, 238(ab)
Kagaya, Y, 1106(ab)
Kahn, D, 1264(ab)
Kairemo, KJA, 471(ab), 476
Kaiser, HJ, 24(ab), 852(ab)
Kaji, T, 1333(ab), 1334(ab)
Kajino, H, 1425(ab)
Kakiuchi, T, 1833
Kakuma, K, 989(ab)
Kakuta, K, 989(ab), 1430(ab)
Kalahasti, V, 3(ab)
Kalapparambath, TP, 596(ab)
Kalemkerian, G, 829(ab)
Kalender, WA, 211(ab)
Kalff, V, 191(ab), 1596, 1605
Kalifa, J, 850(ab)

Kalimi, SK, 263(ab), 311(ab)
Kalin, NH, 1118(ab)
Kalker, T, 305(ab)
Kallinowski, F, 325(ab)
Kalliokoski, K, 1643
Kallmes, D, 1388(ab)
Kam, BL, 137(ab)
Kambara, N, 733(ab)
Kamel, EM, 130(ab)
Kaminek, M, 181(ab)
Kaminski, M, 83(ab), 582(ab), 1292(ab), 1293(ab)
Kampen, AM, 230
Kampen, WU, 475(ab), 1000(ab), 1391(ab), 1399(ab), 1413(ab), 1422(ab), 230, 1545
Kamphuis, C, 856(ab)
Kamran, M, 219(ab), 1773
Kanakura, Y, 444(ab), 601
Kanamalla, U, 321(ab)
Kanayama, S, 1579
Kanazawa, S, 1427(ab)
Kanda, T, 130
Kanegae, K, 1551
Kaneko, K, 747(ab), 776(ab), 784(ab), 1132(ab)
Kaneko, S, 1447(ab)
Kaneta, T, 1106(ab)
Kang, DY, 761(ab), 1101(ab)
Kang, E, 549(ab)
Kang, HJ, 1035(ab)
Kang, SB, 1135(ab)
Kang, TA, 1321(ab)
Kang, WJ, 17(ab)
Kang, X, 346(ab), 831, 1630
Kanmaz, B, 484(ab), 567
Kanno, T, 442(ab), 1196(ab)
Kao, C-H, 17
Kao, CM, 831(ab)
Kao, PF, 542(ab)
Kaplan, MS, 522(ab)
Kappis, B, 411(ab)
Karabacak, NÝ, 1003(ab)
Karacay, H, 552(ab)
Karaman, R, 323(ab)
Karcher, K, 1038(ab)
Karitzky, J, 804(ab), 1038(ab)
Karlan, BY, 1193(ab)
Karlsson, P, 900(ab), 907(ab)
Kárný, M, 1084
Karonen, S-L, 471(ab), 476
Karp, JS, 1821
Kárpáti, E, 907
Kartheuser, A, 462(ab)
Kasagi, K, 1332(ab)
Kasahara, Y, 596
Kasanuki, H, 1346
Kashiba, A, 1368(ab)
Kashimada, A, 1364(ab), 1434(ab)
Kashimada, K, 821(ab), 985(ab)
Kashiwagi, T, 845(ab)
Kashmiri, SVS, 1528
Kassecker, S, 499(ab)
Kässmann, H, 424
Kat, S, 1357(ab)
Kataoka, J, 989(ab)
Kataoka, K, 733(ab), 124
Kato, T, 296(ab), 414, 448(ab), 922(ab), 957(ab), 962(ab), 969(ab), 1175(ab)
Kato-Azuma, M, 310(ab)
Katoh, C, 33(ab), 197(ab), 222(ab), 338(ab), 448(ab), 731(ab), 763(ab), 775(ab), 778(ab), 810(ab), 923(ab), 1333(ab), 1334(ab), 414, 838
Katoh, H, 130
Katoh, K, 344(ab)
Katsikis, PD, 479(ab)
Katsuda, S, 1476, 1489
Kaufman, DE, 208(ab)
Kaufmann, CC, 1227(ab)
Kaufmann, PA, 740(ab)
Kaufmann, R, 1043(ab), 1276(ab)
Kauppinen, TA, 802(ab)
Kavanagh, P, 174(ab)
Kavanagh, PB, 758(ab), 687, 1630
Kawaguchi, T, 1093(ab)
Kawakami, K, 115(ab)
Kawakami, T, 802
Kawamoto, S, 1087(ab)
Kawamura, K, 314(ab)
Kawamura, M, 344(ab)
Kawano, M, 183, 1571
Kawano, Y, 152(ab)
Kawashima, A, 1151(ab)
Kawasumi, Y, 957(ab), 962(ab), 969(ab)
Kawatsu, S, 969(ab)
Kaya, H, 1352(ab)
Kaznatcheev, E, 906(ab)
Ke, CY, 427(ab)
Ke, S, 1530
Keckler, MS, 1379(ab)
Kegeles, L, 57(ab), 392(ab), 420(ab), 421(ab), 531(ab)
Keidar, Z, 127(ab), 164(ab), 998
Keiding, S, 795, 1673
Keil, R, 376
Keilp, J, 60(ab)
Kelley, DE, 63(ab)
Kelly, MJ, 191(ab)
Kelsch, DN, 379(ab)
Kemerink, GJ, 382, 1048(ab)
Kemna, LJ, 931(ab)
Kemp, BJ, 841(ab), 882(ab)
Kemper, CA, 36(ab)
Kepe, V, 241(ab), 242(ab)
Kerenyi, L, 1274
Kernstine, KH, 1264(ab)
Kerr, K, 123(ab)
Kerrou, K, 151(ab), 463(ab), 487(ab)
Kessler, H, 326, 473(ab)
Kettner, BI, 1258(ab), 1374(ab)
Khalkhali, I, 868(ab)
Khan, SA, 61(ab)
Khandekar, S, 233(ab)
Khanna, P, 1098(ab)
Khaw, B, 711(ab)
Khaw, BA, 262(ab), 715(ab), 716(ab)
Khin, MM, 200(ab), 743(ab)
Kühn, T, 305(ab)
Khorsand, A, 189, 741(ab), 746(ab)
Kiat, H, 1205(ab)
Kibel, AS, 450(ab)
Kieboom, L, 9(ab)
Kiemeney, LA, 1199(ab)
Kiesewetter, DO, 535(ab), 936(ab), 1166(ab)
Kijewski, MF, 300, 385(ab), 945(ab)
Kikuchi, K, 407(ab), 766(ab), 1435(ab), 1447(ab), 1017
Kikuchi, MD, 947(ab)
Kikuchi, T, 407(ab), 1297, 1446
Killiany, R, 945(ab)
Kilts, CD, 376, 911(ab), 1053(ab)
Kim, BC, 409(ab)
Kim, BG, 1192(ab)
Kim, BK, 1177(ab)
Kim, BT, 534(ab), 772(ab), 851(ab), 954(ab), 1065(ab), 1095(ab), 1178(ab), 1181(ab), 1187(ab), 1245(ab), 1342(ab), 1400(ab)
Kim, CG, 97(ab), 1283(ab)
Kim, CK, 170(ab), 202(ab), 409(ab), 1230(ab)
Kim, CS, 549(ab)
Kim, DK, 761(ab), 1101(ab)
Kim, E, 1242(ab)
Kim, EE, 97(ab), 263(ab), 311(ab), 409(ab), 1028(ab), 1082(ab), 1099(ab), 1283(ab), 1368
Kim, EH, 1047(ab)
Kim, EN, 1416(ab), 1441(ab)
Kim, ER, 1441(ab)
Kim, GE, 406(ab)
Kim, H, 126(ab)
Kim, HJ, 791(ab), 1039(ab), 1394(ab)
Kim, HS, 1100(ab)
Kim, IJ, 88(ab), 89(ab), 91(ab), 157(ab), 599(ab), 1366(ab)
Kim, IS, 1441(ab)
Kim, JH, 1192(ab)
Kim, JJ, 175(ab)
Kim, JK, 266(ab)
Kim, JS, 98(ab), 406(ab)
Kim, J-W, 549(ab)
Kim, JY, 256(ab), 409(ab), 480(ab), 823(ab), 1024(ab), 1045(ab)
Kim, KB, 15(ab), 16(ab), 17(ab), 347(ab), 738(ab)
Kim, KH, 1039(ab)
Kim, KM, 220(ab), 795(ab), 925(ab), 926(ab), 937(ab)
Kim, M, 126(ab)
Kim, S, 225(ab), 1131(ab), 1204(ab)
Kim, SE, 534(ab), 772(ab), 851(ab), 954(ab), 1065(ab), 1095(ab), 1178(ab), 1181(ab), 1187(ab), 1342(ab), 1400(ab), 853
Kim, SH, 1416(ab), 1441(ab)
Kim, SJ, 88(ab), 89(ab), 91(ab), 157(ab), 599(ab), 1366(ab)
Kim, SK, 220(ab), 782, 938
Kim, SM, 409(ab), 480(ab)
Kim, SP, 868(ab)
Kim, SW, 1180(ab), 1220(ab)
Kim, W, 4(ab), 273(ab), 275(ab), 1198(ab), 1246(ab), 1259(ab), 1414(ab), 1417(ab), 1795
Kim, Y, 534(ab)
Kim, YJ, 354(ab), 432(ab), 1094(ab), 1103(ab)
Kim, YK, 16(ab), 17(ab), 88(ab), 89(ab), 91(ab), 157(ab), 497(ab), 599(ab), 738(ab), 748(ab), 950(ab), 980(ab), 1040(ab), 1135(ab), 1220(ab), 1366(ab)
Kim, YS, 157(ab)
Kimura, K, 859
Kinahan, PE, 129(ab), 133(ab), 211(ab), 524(ab), 862(ab)
Kinami, S, 466(ab)
King, MA, 23(ab), 523(ab), 837(ab), 844(ab), 849(ab)
King, P, 1120(ab)
Kinnunen, P, 471(ab)
Kino, S, 489(ab)
Kinscherf, R, 1157(ab)
Kinuya, K, 989(ab), 1430(ab)
Kinuya, S, 466(ab), 1147(ab), 1151(ab), 1430(ab), 596
Kirsch, B, 1338
Kirsch, CM, 276(ab), 704(ab), 916(ab), 1128(ab)
Kirven, D, 718(ab)
Kishi, H, 447(ab)
Kishibe, Y, 721(ab), 941(ab)
Kison, PV, 829(ab), 1173(ab)
Kisrieva, Z, 360(ab)
Kiss, B, 900(ab), 907(ab)
Kita, M, 1191(ab)
Kitabatake, A, 197(ab), 338(ab), 731(ab), 775(ab), 838
Kitada, T, 809(ab)
Kitagawa, K, 408(ab)
Kitagawa, Y, 72(ab)
Kitajima, M, 72(ab)
Kitamura, K, 809(ab)
Kitano, H, 184(ab)
Kitayama, H, 444(ab), 601
Kitsikis, AD, 359(ab)
Klain, M, 884
Klauss, V, 335(ab)
Klein, C, 7(ab)
Klein, GJ, 27(ab)
Klein, LJ, 1622
Kleinschmidt, J, 1155(ab)
Kletter, K, 741(ab), 746(ab), 974(ab)
Klinge, P, 544(ab)
Klipper, R, 446, 1163(ab), 1379(ab), 1380(ab)
Klok, RP, 509
Kluge, R, 199(ab), 1189(ab)
Klunk, WE, 423(ab), 1060(ab)
Knaapen, P, 842(ab)
Knable, MB, 903(ab)
Knackstedt, C, 734(ab)
Knapp, F, 82(ab)
Knapp, FF, Jr. (Russ), 1384
Knapp, WH, 259(ab), 538(ab), 544(ab), 598(ab), 1197(ab), 1296(ab), 1376(ab), 1174
Knesaurek, K, 170(ab), 710(ab), 1831
Knickmeier, M, 264(ab)
Knight, LC, 321(ab)
Knoll, P, 390(le), 826(le)
Knoop, BO, 1296(ab)
Knudsen, GM, 826(ab), 912(ab)
Kobayashi, H, 105(ab), 1087(ab), 1172(ab), 1346
Kobayashi, J, 33(ab), 923(ab)
Kobayashi, K, 596
Kobayashi, M, 442(ab)
Kobayashi, T, 314(ab), 466(ab)
Kober, A, 49
Koch, K, 723(ab)
Kochan, L, 60(ab)
Kocoshis, S, 1423(ab)
Kodama, M, 707(ab)
Kodoma, Y, 1244(ab), 1284(ab), 1476
Koeppe, RA, 829(ab), 1040
Koerber, C, 496(ab)
Koga, H, 1132(ab)
Kohanawa, M, 1175(ab), 1551
Kohli, T, 1184(ab)
Kohlmyer, S, 207(ab), 381(ab), 520(ab), 874(ab)
Köhn, H, 390(le), 826(le)
Kohno, M, 773(ab)
Kohno, S, 152(ab)
Kohya, T, 197(ab), 338(ab), 731(ab), 775(ab), 838
Koivunen, E, 471(ab)
Koizumi, K, 1407(ab)
Koizumi, M, 1407(ab)
Kokhanyuk, V, 1086(ab)
Kokubun, M, 1397(ab)
Kolar, ZI, 1144(ab)
Kolasinska, A, 484(ab), 1188(ab)
Kolbert, K, 875(ab), 27
Koller, E, 706(ab)
Koller, J, 424
Kolodny, GM, 1437(ab)
Kolsky, KL, 1086(ab)
Komuro, K, 731(ab), 838
Kondo, S, 845(ab)
Kondoh, T, 1428(ab)
Kondoh, Y, 937(ab)
Konietzko, N, 744
Konings, IR, 138(ab)
Konishi, J, 2(ab), 105(ab), 184(ab), 292(ab), 341(ab), 733(ab), 982(ab), 1087(ab), 1093(ab), 1172(ab), 1174(ab), 1176(ab), 1191(ab), 1239(ab), 1252(ab), 1332(ab), 124
Konishi, S, 1147(ab), 1151(ab)
Konno, H, 543
Koo, CW, 235(ab)
Koo, J-W, 549(ab)
Koo, J-Y, 851(ab)
Kooij, PP, 135(ab), 137(ab), 1841
Koole, M, 41(ab), 361
Koomaegi, R, 120(ab)
Koong, SS, 1342(ab)
Kopka, K, 917(ab), 1390(ab)
Koral, KF, 83(ab), 389(ab)
Korf, J, 43(ab)
Koriska, K, 390(le)
Körner, TH, 1372(ab)
Kortylewicz, ZP, 1068(ab)
Kosaka, N, 447(ab), 827(le)
Kossmann, T, 162(ab)

Kostakoglu, L, 441(ab), 443(ab), 455(ab), 458(ab), 1051(ab)
Kostarelos, K, 499
Kosuda, S, 1407(ab)
Kosugi, S, 987(le)
Kotagal, P, 233(ab)
Kotzerke, J, 451(ab), 457(ab), 721, 1294(ab)
Kovacs, AF, 1211(ab)
Kowalski, J, 249(ab), 1053
Kowalski, R, 196(ab)
Koyama, K, 1282(ab)
Kozikowski, AP, 55(ab)
Koziorowski, J, 1281
Kracht, L, 238(ab), 902(ab)
Kraeber-Bodere, F, 459(ab)
Kramer, E, 235(ab), 1224(ab)
Krammer, PH, 1157(ab)
Kranert, WT, 1043(ab), 1211(ab), 1340(ab)
Kratzsch, T, 951(ab)
Krause, T, 600(ab), 1393(ab)
Krausz, Y, 1017(ab), 1129(ab)
Kraut, EH, 1243(ab)
Kravchuk, VL, 1086(ab)
Krawczynska, EG, 722(ab), 811(ab), 1185
Krenning, BJ, 138(ab)
Krenning, EP, 75(ab), 135(ab), 137(ab), 413(ab), 468(ab), 470(ab), 1303(ab), 1304(ab), 1305(ab), 1353(ab), 222, 1134, 1841
Kreuzer, W, 826(le)
Krevsky, B, 321(ab)
Kridelka, F, 1195(ab)
Krieter, H, 1265
Krisch, B, 248(ab)
Krishnamurthy, GT, 493(ab)
Krishnamurthy, S, 493(ab)
Krisht, A, 1243
Kritzman, JN, 185(ab), 188(ab), 744(ab), 839(ab)
Kritzman, ML, 839(ab)
Kritzmann, J, 882(ab)
Krohn, KA, 40(ab), 70(ab), 106(ab), 370(ab), 679, 913(ab), 973(ab)
Krol, A, 510(ab), 893(ab), 1216(ab)
Krolicki, L, 1188(ab)
Kroll, S, 460(ab), 1292(ab), 1293(ab)
Kronauge, JF, 1107(ab)
Kronauge, JK, 267(ab)
Kronenberg, MW, 1437(br)
Kroon, BB, 574(ab)
Kroonenburgh, MV, 963(ab)
Kropp, J, 82(ab), 502(ab), 744, 1320(ab), 1384
Kross, B, 960
Kruber, S, 1148(ab)
Krug, B, 9(ab)
Krug, L, 278(ab)
Krüger, M, 646
Krynyckyi, BR, 170(ab), 202(ab), 710(ab), 1230(ab)
Kubik-Huch, RA, 1237(ab)
Kübler, W, 317
Kubo, A, 72(ab)
Kubo, N, 222(ab), 778(ab)
Kubo, S, 2(ab), 184(ab), 341(ab)
Kubo, T, 1789
Kubota, K, 733, 1207(ab), 1497
Kubota, T, 1789
Kudo, M, 596
Kuehn, A, 727(ab), 732(ab)
Kuehnel, G, 1189(ab)
Kuenig, G, 1591
Kugaya, A, 61(ab), 1013(ab)
Kuge, Y, 69(ab), 197(ab), 244(ab), 296(ab), 313(ab), 338(ab), 414, 448(ab), 731(ab), 763(ab), 775(ab), 778(ab), 780, 810(ab), 838, 1175(ab), 1325(ab), 1551
Kuhl, D, 226(ab), 548
Kuhn, W, 298(ab)
Kühnel, G, 1174
Kuikka, J, 802(ab)
Kuji, I, 458(ab), 1051(ab)
Kukis, DL, 1324
Kulinski, JA, 968(ab), 1002(ab), 1113(ab)
Kulkarni, M, 114(ab)
Kulkarni, PV, 1165(ab)
Kumagai, K, 736(ab)
Kumar, A, 590(ab)
Kumar, P, 1168(ab)
Kumar, S, 1098(ab)
Kung, HF, 240(ab), 392(ab), 393(ab), 1002(ab), 1556
Kung de Aburto, MA, 30(ab)
Kunkel, M, 1202(ab)
Kunstmann, S, 180(ab)
Kuo, J, 373(ab)
Kurdziel, KA, 121(ab), 1166(ab)
Kurihara, H, 752(ab), 769(ab)
Kurizaki, T, 1068(ab), 1306(ab)
Kuroda, K, 543
Kurtaran, A, 1134(ab), 1309
Kurz, A, 224(ab)
Kurz, B, 1391(ab)
Kusakabe, K, 1346
Kusewitt, DF, 138(ab)
Kusuoka, H, 720(ab)
Kutzner, J, 1202(ab)
Kuwabara, H, 533(ab), 793(ab)
Kuwabara, Y, 1132(ab)
Kuwert, T, 422(ab), 1345(ab), 1357(ab)
Kuyama, J, 946(ab), 1407(ab)
Kuzniecky, R, 988(ab)
Kuzuhara, S, 506(ab)
Kvols, LK, 138(ab)
Kwak, DH, 351(ab)
Kwee, SA, 226(ab)
Kwekkeboom, DJ, 135(ab), 137(ab)
Kweon, SU, 406(ab)
Kwon, AS, 256(ab), 1024(ab), 1045(ab)

Labbie, A, 330(ab)
Lacorte, LB, 122(ab), 273(ab), 275(ab), 1259(ab), 1280(ab), 1795
Laemmli, C, 840(ab)
Laffont, S, 1287(ab)
Laforest, R, 213, 655
Lago, G, 577(ab)
Lahaye, T, 1241(ab)
Lahoutte, T, 1171(ab), 1432(ab)
Lai, CP, 187(ab)
Lai, KH, 1365(ab)
Lai, L, 1311(ab)
Lai, LT, 1308(ab)
Laine, AF, 194, 201, 850(ab)
Laitinen, OM, 476
Lalush, DE, 190(ab)
Lalush, DS, 23(ab), 217(ab), 218(ab), 530(ab), 865(ab), 890(ab)
Lam, P, 139(ab)
Lam, PT, 349(ab)
Lamberts, SW, 222
Lambrecht, RM, 1105(ab)
Lambright, ES, 1412
Lamki, L, 1242(ab), 824(br)
Lammertsma, AA, 94(ab), 112(ab), 425(ab), 842(ab), 843(ab), 1139(ab), 1245(ab), 808, 1622
Lamonica, D, 76(ab), 583(ab), 1124(ab)
Lamonica, DM, 565(ab), 579(ab)
Lancaster, JL, 32(ab)
Lancaster, TL, 1226(ab)
Landis, T, 232(ab)
Landoni, C, 879(ab), 1268(ab)
Landvogt, C, 411(ab), 928(ab)
Landwehrmeyer, GB, 1038(ab)
Lang, L, 395(ab)
Lang, O, 181(ab), 1134
Lange, H, 496(ab), 499(ab), 501(ab)
Langen, K-J, 432, 752
Langenhoff, BS, 1279(ab)
Langer, J, 498(ab)
Langer, O, 900(ab)
Langston, JW, 51(ab)
Laniece, P, 867(ab)
Lantsberg, S, 1419(ab)
Lanuti, M, 1412
Lanzzeri, S, 788
Lapointe, D, 96(ab)
Lappalainen, AK, 476
Lapshina, EV, 1086(ab)
Lara, A, 1034(ab)
Larisch, R, 209(ab), 1691
Larsen, RH, 431(ab)
Larsen, T, 434(ab)
Larson, J, 54(ab), 930(ab), 934(ab)
Larson, SM, 124(ab), 201(ab), 239(ab), 257(ab), 278(ab), 572(ab), 815(ab), 863(ab), 875(ab), 1160(ab), 1236(ab), 1255(ab), 1291(ab), 1339(ab), 27, 420, 1130(le), 1251, 1281
Lartizien, C, 862(ab)
Laruelle, M, 57(ab), 60(ab), 392(ab), 396(ab), 420(ab), 421(ab), 531(ab), 797(ab), 910(ab), 1057(ab)
Lastoria, S, 102(ab)
Laszlovszky, I, 900(ab)
Lau, JWY, 1587(le)
Lauer, B, 757(ab)
Lautenschlager, N, 224(ab)
Lavenne, F, 894(ab)
Law, MP, 264(ab)
Lawhorn Crews, J, 108(ab)
Lawson, H, 57(ab)
Lawson, M, 756(ab)
Lawson, MA, 893
Laymon, C, 874(ab)
Laymon, CM, 522(ab)
Lazewatsky, JL, 412(ab)
Leahy, R, 855(ab), 864(ab)
Le Bars, D, 894(ab)
Lebellec, Y, 1375(ab)
Leblhuber, F, 949(ab)
Lebtahi, R, 11(ab), 21, 103(ab), 167(ab), 1043, 1299(ab), 1375(ab), 1385(ab), 1403(ab), 1451
Lecomte, R, 96(ab), 154(ab), 517(ab), 719(ab), 854(ab), 876(ab)
Lee, BC, 1095(ab)
Lee, CW, 175(ab)
Lee, DS, 15(ab), 16(ab), 17(ab), 19(ab), 39(ab), 148(ab), 220(ab), 266(ab), 347(ab), 432(ab), 497(ab), 500(ab), 549(ab), 738(ab), 748(ab), 948(ab), 950(ab), 953(ab), 980(ab), 1094(ab), 1103(ab), 1135(ab), 1142(ab)1177(ab), 1182(ab), 1220(ab), 1245(ab)
Lee, FT, 1288(ab), 1289(ab), 1291(ab), 764, 1281
Lee, HB, 138
Lee, HK, 98(ab), 175(ab), 406(ab), 1097(ab), 1114(ab), 1431(ab)
Lee, HW, 354(ab)
Lee, J, 126(ab), 351(ab), 1394(ab)
Lee, JD, 1039(ab)
Lee, JH, 175(ab)
Lee, J-K, 17
Lee, JS, 39(ab), 148(ab), 220(ab), 549(ab), 948(ab), 950(ab), 953(ab), 782, 938
Lee, KB, 351(ab), 1394(ab)
Lee, KH, 534(ab), 851(ab), 1040(ab), 1095(ab), 1192(ab), 1245(ab)
Lee, K-H, 772(ab), 954(ab), 1065(ab), 1178(ab), 1181(ab), 1187(ab), 1342(ab), 1400(ab)
Lee, KS, 397(ab), 903(ab)
Lee, KW, 991(ab)
Lee, MC, 15(ab), 16(ab), 17(ab), 19(ab), 39(ab), 148(ab), 220(ab), 266(ab), 347(ab), 432(ab), 497(ab), 500(ab), 549(ab), 738(ab), 748(ab), 948(ab), 950(ab), 953(ab), 980(ab), 1040(ab), 1094(ab), 1103(ab), 1135(ab), 1142(ab), 1177(ab), 1182(ab), 1220(ab), 1245(ab), 695, 782, 938
Lee, MK, 157(ab)
Lee, MM, 19(ab), 347(ab), 695
Lee, N-Y, 851(ab)
Lee, SC, 772(ab), 1365(ab)
Lee, SD, 491(ab), 1431(ab)
Lee, SJ, 266(ab), 1158(ab)
Lee, SS, 480(ab)
Lee, SW, 351(ab), 1394(ab)
Lee, SY, 1065(ab), 1416(ab)
Lee, TS, 1100(ab), 1158(ab)
Lee, WC, 792(ab)
Lee, WR, 772(ab)
Lee, YJ, 500(ab), 1142(ab), 1177(ab), 1182(ab)
Lee, YS, 432(ab), 1094(ab), 1103(ab)
Lee, Z, 36(ab), 155(ab), 1222(ab), 1226(ab), 1077
Leenders, KL, 1591
Leentjens, A, 963(ab)
Léger, G, 517(ab), 854(ab), 876(ab)
Le Guludec, D, 11(ab), 21, 103(ab), 167(ab), 512(ab), 1043, 1299(ab), 1375(ab), 1385(ab), 1403(ab), 1451
Lehmann, K, 1377(ab), 1378(ab), 1384(ab)
Lehmann, W, 1206(ab)
Lehner, B, 120(ab), 125(ab)
Lehnert, J, 7(ab)
Lehnert, T, 1274(ab), 713
Lehtiö, K, 1397, 1643
Lei, Y, 492(ab), 495(ab)
Leigh, BR, 76(ab), 1124(ab)
Leite, H, 1016(ab)
Lele, VR, 484(ab)
Lemaire, C, 894(ab)
Lenarczyk, M, 162
Leo, R, 1337(ab)
Leonard, J, 455(ab)
Leonard, JL, 1292(ab)
Leonard, JP, 441(ab), 443(ab), 583(ab)
Leonhardi, J, 223(ab)
Leopold, NA, 541(ab)
Lepage, MD, 854(ab), 876(ab)
Lepor, H, 1224(ab)
Lercher, M, 238(ab), 467
Le Rest, C, 384(ab), 1370(ab)
Leroux, JD, 854(ab), 876(ab)
Lesko, NM, 302(ab)
Lesse, L, 183(ab)
Lester, H, 932(ab), 1017(ab)
Leu, M, 1234(ab)
Leung, TWT, 1587(le)
Levenback, C, 1240(ab)
Levin, C, 386(ab), 855(ab), 864(ab), 877(ab)
Levine, EA, 302(ab)
Levy, AV, 410(ab)
Levy, M, 771(ab)
Lew, M, 437(ab)
Lewellen, TK, 40(ab), 207(ab), 381(ab), 520(ab), 522(ab), 874(ab)
Lewin, HC, 346(ab), 687, 749(ab), 758(ab), 831, 1424
Lewis, JS, 213, 655
Lewis, PJ, 234(ab), 986(ab)
Ley, A, 1870
Li, C, 968(ab), 1074(ab), 1530
Li, GQ, 1092(ab)
Li, H, 74(ab), 365(ab), 624
Li, HF, 1059(ab)
Li, J, 83(ab)
Li, L, 834(ab)
Li, MH, 1024(ab), 1045(ab)
Li, P, 1412
Li, PY, 119(ab)
Li, Q, 64(ab)
Li, S, 706(ab), 1134(ab)

Li, X, 834(ab), 857(ab)
Li, Y, 279(ab), 320(ab), 1346(ab), 1440(le)
Li, YQ, 1169(ab)
Li, Z, 77(ab), 1085(ab)
Liang, Z, 22(ab), 834(ab), 857(ab)
Liao, RP, 557(ab), 1805
Liao, SQ, 453(ab)
Libutti, SK, 121(ab), 1316
Licho, R, 844(ab)
Liem, IH, 177(ab), 382
Liepe, K, 82(ab)
Lieske, A, 1104(ab)
Li-Guang, C, 124
Lill, MC, 445(ab)
Lim, SJ, 1158(ab), 1180(ab)
Lim, SM, 1047(ab), 1100(ab), 1158(ab), 1179(ab), 1180(ab), 1192(ab), 1273(ab)
Lim, ST, 19(ab)
Lim, SW, 445(ab)
Lim, WB, 256(ab)
Lima, CSP, 1448(ab)
Lima, MCl, 1016(ab), 1421(ab), 1448(ab)
Lim-Joon, M, 1288(ab)
Lin, JC, 956(ab), 1303
Lin, JH, 390(ab)
Lin, J-W, 194, 201
Lin, KS, 415(ab)
Lin, P, 1205(ab)
Lin, SZ, 956(ab), 1303
Lin, WJ, 1036(ab), 1154(ab)
Lin, XT, 970(ab), 1005(ab)
Lin, Y, 569(ab)
Lin, YS, 67(ab)
Lin, ZY, 319(ab)
Linden, J, 1090(ab)
Line, BR, 819(ab)
Ling, CC, 170, 875(ab), 1653
Link, JM, 70(ab), 370(ab), 679
Link, T, 1168(ab)
Linke, D, 294(ab)
Linke, R, 236(ab), 237(ab), 1059(ab)
Links, J, 13(ab)
Links, JM, 14(ab), 35(ab), 309(ab), 9N(1)
Lionnet, M, 894(ab)
Lipowska, M, 1091(ab)
Lipsztein, J, 1027(ab)
Lipszyc, H, 265(ab), 1230(ab)
Lisbona, A, 1030(ab)
Lister-Jaes, J, 258(ab)
Liu, CB, 1083(ab)
Liu, CP, 780(ab)
Liu, F, 1092(ab)
Liu, FM, 122(ab), 273(ab), 477(ab), 565(ab), 1257(ab), 1280(ab)
Liu, G, 73(ab), 261(ab), 414(ab), 553(ab), 1102(ab)
Liu, GZ, 1092(ab)
Liu, HG, 988(ab)
Liu, J, 241(ab)
Liu, N, 261(ab), 553(ab), 1083(ab), 1102(ab), 1660
Liu, RS, 21(ab), 111(ab), 251(ab), 358(ab), 452(ab), 453(ab), 491(ab), 780(ab), 792(ab), 824(ab), 956(ab), 979(ab), 1036(ab), 1154(ab), 1330(ab), 1365(ab), 345, 1303
Liu, S, 412(ab), 472(ab), 474(ab), 1020(ab), 1307(ab)
Liu, X, 1026(ab), 1031(ab), 1166
Liu, Y, 365(ab), 1166
Liu, YC, 970(ab)
Liu, YH, 173(ab), 349(ab)
Liu, Z, 715(ab), 716(ab), 1288(ab)
Liu, ZJ, 1443(ab)
Livingston, RB, 85(ab), 303(ab)
Livni, E, 50(ab), 55(ab), 794(ab), 1386(ab)
Ljungberg, M, 389(ab), 528(ab), 835(ab), 1026(ab), 1031(ab), 1077, 1563
Llamas-Olier, A, 1614
Llaurado, JG, 282
Lóber, S, 422(ab)
LoBuglio, AF, 80(ab)
Lodge, MA, 525(ab)
Loening, AM, 827(ab)
Logan, J, 52(ab), 301(ab), 400(ab), 402(ab), 403(ab), 464(ab), 906(ab), 908(ab), 909(ab), 1011(ab)
Lohman, JW, 270(ab)
Lohmann, B, 1354(ab)
Lohmann, G, 1298(ab)
Lombardi, CA, 955(ab)
Lombardo, I, 60(ab), 392(ab), 396(ab), 421(ab)
Lomena, F, 1001(ab), 1014(ab)
Loncaric, S, 1046(ab), 1335(ab)
Longari, V, 153(ab)
Lonneux, M, 462(ab)
Loos, A, 1202(ab)
Lopez, H, 180(ab)
Lopresti, BJ, 905(ab)
Lorberboym, M, 783(ab)
Lorenz, E, 382(ab), 871(ab)
Lorenzo, A, 737(ab)
Lorke, DE, 646
Losman, M, 552(ab)
Lottmann, H, 329(ab)
Lotze, U, 49
Lou, C, 1322(ab)
Loussouarn, A, 146, 1313(ab)
Loutfi, I, 713(ab)
Love, C, 165(ab), 166(ab)
Loven, D, 975(ab)
Lövqvist, A, 1281
Lowe, G, 525(ab)
Lowe, J, 525(ab)
Lowe, VJ, 274(ab), 841(ab)
Löwenberg, B, 222
Loyo, M, 183(ab)
Lu, C, 225(ab), 408
Lu, CL, 491(ab)
Lu, CS, 542(ab), 543(ab), 562(ab), 952(ab), 955(ab), 967(ab)
Lu, H, 834(ab), 857(ab)
Lu, HK, 714(ab), 1164(ab), 1336(ab)
Lubic, SP, 670
Lubov, T, 18(ab)
Lucht, R, 1265
Lucignani, G, 961(ab)
Ludwig, C, 864, 998(ab)
Luetolf, UM, 1235(ab)
Lugtenburg, PJ, 222
Lui, D, 322(ab)
Luini, A, 433(ab), 573(ab)
Luison, E, 1697
Luk, P, 369(ab)
Luker, GD, 285(ab)
Luker, KE, 285(ab)
Lumenta, C, 978(ab), 1144
Luna, NR, 1034(ab)
Luo, J, 576(ab)
Luo, QY, 714(ab)
Lupetti, A, 788
Lupoglazoff, JM, 1415(ab)
Luurtsema, G, 425(ab)
Luxen, A, 894(ab)
Lyddane, C, 1161(ab)
Lyster, D, 172(ab)

Ma, D, 1311(ab)
Ma, Y, 395(ab)
Mabuchi, M, 197(ab), 222(ab), 338(ab), 414, 731(ab), 763(ab), 774(ab), 775(ab), 778(ab), 810(ab)
Macapinlac, H, 124(ab), 201(ab), 815(ab), 1236(ab), 1255(ab), 77
Maccauro, M, 1329(ab)
MacDonald, L, 28(ab)
MacDonald, LR, 363(ab)
MacGregor, D, 300(ab), 1288(ab)
MacGregor, R, 906(ab), 908(ab), 1062(ab), 1120(ab)
Machac, J, 170(ab), 201(ab), 202(ab), 265(ab), 710(ab), 1230(ab)
Machado, C, 588(ab)
Machida, K, 821(ab), 985(ab), 1364(ab), 1434(ab)
Machtens, S, 1197(ab)
Machulla, HJ, 107(ab), 108(ab), 398(ab), 483(ab), 1010(ab), 1081(ab), 1119(ab), 1168(ab), 1408(ab)
Machulla, H-J, 1091
Mäcke, HR, 1053
MacLennan, GT, 1222(ab), 1226(ab)
MacManus, MP, 1596, 1605
Madar, I, 35(ab), 44(ab), 399(ab), 532(ab), 1162(ab), 1281(ab)
Maddahi, J, 342(ab)
Madeddu, G, 87(ab), 1263(ab), 1328(ab), 1348(ab)
Madelmont, J-C, 141
Madras, BK, 794(ab), 896(ab), 898(ab)
Maecke, H, 134(ab), 136(ab), 1296(ab), 249(ab)
Maeda, H, 750(ab)
Maeda, M, 1196(ab)
Maehlum, G, 378(ab)
Maes, A, 44
Magata, Y, 2(ab), 184(ab), 310(ab), 341(ab), 1054(ab), 1093(ab), 1156(ab)
Mageras, G, 124(ab)
Maggio, S, 1263(ab)
Magnuson, D, 582(ab)
Mah, E, 1351(ab)
Mahlmann, B, 255(ab)
Mahmut, M, 317
Mahoney, DW, 1112(ab)
Maier, G, 483(ab), 1091, 1408(ab)
Mainolfi, C, 884
Majd, M, 878
Majewski, S, 960
Makhija, S, 1186(ab)
Makikawa, K, 720(ab)
Makino, N, 736(ab)
Makoto, N, 960(ab), 984(ab), 1271(ab)
Makriyannis, A, 904(ab)
Maksud, P, 300
Makuuchi, H, 1285(ab)
Makuuchi, M, 733
Malhi, H, 494(ab)
Mallett, RW, 567(ab), 569(ab)
Malmin, RE, 884(ab)
Maltz, JS, 859(ab)
Malveaux, E, 376
Malveaux, EJ, 558(ab)
Mamede, M, 2(ab), 292(ab), 341(ab), 1172(ab), 1191(ab)
Mamede, MH, 1087(ab), 1174(ab), 1176(ab), 1239(ab), 1252(ab)
Manabe, K, 773(ab)
Manalili, E, 1127(ab), 1136(ab), 1137(ab)
Manchanda, R, 258(ab)
Mandel, S, 498(ab), 1327(ab)
Mang'era, K, 553(ab)
Mangner, TJ, 108(ab), 308(ab)
Mankoff, DA, 85(ab), 303(ab), 370(ab), 575(ab), 679
Mann, JJ, 803(ab)
Mann, K, 398(ab), 1010(ab)
Manns, M, 259(ab)
Mannting, F, 10(ab)
Manocha, D, 23(ab)
Manoj, C, 123(ab)
Mantil, J, 878(ab), 914(ab), 1243(ab)
Manuel, MR, 1193(ab)
Mar, GY, 780(ab)
March, KL, 1375
Marchais, S, 1058(ab)
Marchandise, X, 993
Marcos, T, 1014(ab)
Mardirossian, G, 79(ab)
Marek, K, 539(ab)
Marengo, M, 730(ab), 847(ab)
Maresca, KP, 267(ab), 1107(ab)
Margouleff, D, 1025(ab)
Mari, C, 168(ab)
Mariani, G, 45(ab), 116(ab), 476(ab), 781(ab), 1151, 1198, 1412(ab)
Mariano-Goulart, D, 512(ab), 1043
Mariß, P, 1341(ab)
Maris, J, 1321(ab)
Marjamäki, P, 1397
Markert, U, 1323(ab)
Markham, J, 823(ab)
Marmor, A, 18(ab)
Marmuse, JP, 103(ab)
Marois, M, 1217(ab)
Marotta, G, 153(ab), 1444(ab)
Marquet, RL, 1304(ab)
Marry, JM, 829(ab)
Marsden, P, 371(ab), 1402(ab)
Marseille, DM, 546(ab)
Marshall, M, 267(ab)
Marshall, RC, 270(ab), 272, 1773
Marsland, B, 880(ab)
Martarello, L, 558(ab), 911(ab), 1053(ab)
Marteaux, C, 9(ab)
Martin, CC, 32(ab)
Martin, H, 457(ab)
Martin, JC, 516(ab)
Martin, W, 350(ab)
Martinelli, MA, 129(ab), 133(ab)
Martinez, D, 57(ab), 60(ab), 396(ab), 797(ab), 1057(ab)
Martinez, J, 577(ab)
Martins, PA, 1110(ab)
Maruno, H, 812(ab)
Maruoka, N, 920(ab), 938(ab)
Maruoka, S, 1106(ab)
Maruyama, K, 169(ab)
Marzilli, LG, 1091(ab)
Mas, J, 848(ab)
Mason, GF, 61(ab)
Masoodi, M, 1193(ab)
Massardo, T, 180(ab), 1614
Massuger, L, 472(ab), 474(ab), 1020(ab)
Mast, ST, 871
Mastrippolito, R, 867(ab)
Masud, M, 315(ab), 1397(ab)
Masuda, D, 733(ab)
Masuda, K, 1132(ab)
Masui, K, 805(ab)
Matano, S, 1430(ab)
Mateos, JJ, 1014(ab)
Matheja, P, 245(ab), 496(ab)
Matheoud, R, 153(ab), 1261(ab)
Mather, SJ, 1223(ab)
Matherly, J, 281(ab)
Mathews, D, 1165(ab), 1356(ab)
Mathews, WB, 1281(ab), 1274
Mathias, CJ, 427(ab)
Mathis, CA, 63(ab), 423(ab), 905(ab), 921(ab), 1060(ab)
Matschinsky, F, 269(ab)
Matsuda, H, 1441
Matsudaira, M, 1579
Matsui, M, 48(ab)
Matsui, T, 985(ab)
Matsumoto, K, 2(ab), 341(ab), 1239(ab)
Matsumoto, M, 408(ab)
Matsumoto, N, 749(ab), 758(ab), 687
Matsumoto, Y, 1213(ab)
Matsumura, K, 506(ab), 702(ab), 750(ab), 999(ab)
Matsunaga, N, 292
Matsunari, I, 336(ab), 818, 1457, 1579
Mattes, D, 40(ab), 520(ab)
Mattfeldt, T, 305(ab), 721
Matthay, KK, 237, 1713

Matthews, DC, 584(ab)
Matthews, JP, 1596, 1605
Matthies, A, 275(ab)
Mattmuller, S, 1121(ab)
Mattrey, RF, 951
Matzky, C, 1320(ab)
Maublant, J, 90(ab)
Maughan, RL, 1233(ab)
Maunda, KK, 1614
Maurea, S, 884
Maurer, AH, 321(ab)
Maurer, G, 741(ab)
Maurizis, J-C, 141
Mauro, VP, 280(ab)
Maus, S, 1146(ab)
Mausner, LF, 1086(ab)
Mawlawi, O, 57(ab), 60(ab), 396(ab), 531(ab), 797(ab)
Mayberg, HS, 1006(ab)
Mayer, E, 864, 998(ab)
Maynard, L, 400(ab), 1009(ab), 1011(ab)
Maza, S, 438(ab), 439(ab), 1231(ab)
Maziere, B, 940(ab)
Mazumdar, S, 63(ab)
McAndrew, PF, 445(ab)
McBride, W, 552(ab), 568(ab)
McCallum, RW, 319(ab)
McCarron, JA, 1058(ab)
McCarthy, DW, 213
McCarthy, T, 823(ab)
McCartney, WH, 846(ab)
McCaul, ME, 399(ab)
McConathy, J, 558(ab), 1053(ab)
McCook, B, 129(ab), 862(ab), 1186(ab), 1317(ab)
McCready, VR, 822(ab), 1300(ab)
McCusker, CD, 1107(ab)
McDade, M, 350(ab)
McDevitt, MR, 1308(ab), 1311(ab)
McDougall, IR, 589(ab)
McElroy, D, 204(ab), 855(ab)
McEwan, AJB, 1418
McGarry, J, 1068(ab)
McKenzie, AF, 1596, 1605
Mckenzie, J, 29(ab)
McLaughlin, K, 1264(ab)
McLendon, RE, 454(ab)
McManus, LM, 1379(ab)
McMenemin, RM, 986(le)
McMillin, C, 1382(ab)
McQuarrie, SA, 1418
Mearadji, A, 1305(ab)
Meares, CF, 670, 1324
Mechtersheimer, G, 713
Mecklenbeck, W, 1372(ab)
Medea, S, 198(ab), 345(ab)
Medvedec, M, 1046(ab), 1129(le), 1335(ab)
Meewes, C, 248(ab), 1338
Mehrke, G, 581(ab), 1071(ab)
Mehrotra, B, 1136(ab), 1137(ab)
Meier, D, 206(ab)
Meignan, M, 771(ab), 845, 1438(ab)
Meikle, SR, 789(ab)
Meinken, G, 77(ab), 1066(ab), 1085(ab)
Meir-Weil, Y, 932(ab)
Meisenzahl, E, 58(ab)
Meisetschläger, G, 978(ab)
Melamed, I, 1419(ab)
Melamde, M, 117(ab)
Mele, D, 355(ab)
Mele, F, 159(ab)
Meller, B, 255(ab)
Meller, J, 1378(ab), 1384(ab)
Meller, JJ, 1377(ab)
Meller, S, 78(ab)
Melnick, JR, 166(ab)
Meltzer, CC, 63(ab), 129(ab), 133(ab), 862(ab), 921(ab), 1186(ab)
Melzer, PC, 794(ab), 896(ab), 898(ab)
Menard, L, 867(ab)
Menda, Y, 1264(ab)
Meneghetti, C, 183(ab)
Mengatti, J, 1108(ab)
Mensink, HJ, 449(ab)
Menzel, C, 951(ab), 1211(ab), 1340(ab), 1395(ab)
Menzel, M, 9
Menzies, AR, 1392(ab)
Meoli, D, 173(ab)
Mercer, JR, 1418
Meredith, RF, 80(ab), 81(ab)
Merkin, V, 1419(ab)
Merlet, I, 894(ab)
Merlet, P, 339(ab), 504(ab), 808(ab), 1415(ab), 1464, 1737
Mestas, D, 90(ab)
Mester, J, 886(ab)
Meta, J, 301(ab), 461(ab), 464(ab), 562(ab), 586, 1139, 1190(ab)
Methe, BM, 1116(ab)
Metzler, SD, 526(ab)
Meucci, N, 227(ab)
Meyer, CG, 201(ab), 815(ab), 1236(ab)
Meyer, CR, 829(ab)
Meyer, J, 701(ab)
Meyer, JH, 62(ab), 391(ab), 755
Meyer, MA, 964(ab)
Meyer, VE, 1278(ab)
Meyrat, B, 333(ab), 1780
Mezi, S, 1212(ab)
Miao, Y, 1070(ab), 1847
Miao, ZX, 1092(ab)
Michalski, JM, 450(ab)
Michel, SC, 1237(ab)
Michigishi, T, 596, 1147(ab), 1151(ab), 1430(ab)
Mick, R, 578(ab)
Miederer, M, 1308(ab), 1309(ab)
Mielke, R, 49(ab)
Mier, W, 246(ab), 428(ab)
Mignon, M, 103(ab)
Miki, H, 407(ab), 1446
Miki, K, 733
Mikolajczyk, K, 788(ab)
Milan, E, 198(ab), 345(ab)
Milbrandt, J, 285(ab)
Miller, S, 1264(ab)
Miller, SD, 213(ab)
Miller, TR, 291(ab), 450(ab)
Mills, C, 576(ab)
Mimura, J, 769(ab)
Min, JJ, 500(ab), 980(ab), 1142(ab), 1182(ab), 1245(ab)
Minamihaba, O, 747(ab), 776(ab), 784(ab)
Minar, E, 706(ab)
Minato, K, 870(ab)
Mindlin, L, 33
Ming, ZG, 1218(ab)
Minn, H, 388(ab), 1397, 1643
Minoshima, S, 47(ab), 224(ab), 226(ab), 388(br), 548, 946(ab), 1018(ab), 1040
Miranda, R, 831
Mirick, GR, 1324
Mirzaei, S, 390(le), 826(le)
Mirzaitehrane, M, 20(ab), 352(ab)
Misaki, T, 987(le), 1332(ab)
Mishani, E, 932(ab)
Mishra, A, 1360(ab)
Missimer, J, 1591
Missorici, M, 558
Mitchell, P, 1291(ab)
Mitra, A, 292
Mittal, BR, 1050(ab), 1446(ab)
Miura, H, 575
Miwa, K, 466(ab)
Mixon, L, 13(ab), 14(ab)
Miyagawa, M, 182(ab)
Miyake, Y, 762(ab)
Miyamoto, S, 982(ab)
Miyamoto, T, 747(ab), 776(ab), 784(ab)
Miyaoka, RS, 207(ab), 381(ab)
Miyashita, T, 747(ab), 776(ab), 784(ab)
Miyatake, K, 503(ab), 762(ab)
Miyazaki, S, 765(ab)
Miyazoe, H, 1428(ab)
Miyoaka, R, 874(ab)
Mizohata, Y, 820(ab)
Mizusige, K, 773(ab)
Mizutani, H, 750(ab)
Moameni, A, 974(ab)
Mobilia, G, 198(ab)
Mochizuki, T, 182(ab), 313(ab), 407(ab), 1175(ab), 1297, 1551
Modarres, S, 345(ab)
Modesti, M, 1212(ab)
Moeller, HJ, 58(ab)
Moeller, JR, 1591
Moertl, D, 189
Mohammad, MH, 739(ab)
Mohammed, A, 246(ab), 428(ab), 1143(ab)
Mohr, V, 223(ab)
Mohsen, R, 588(ab)
Moisan, C, 1217(ab)
Moka, DC, 5(ab), 1324(ab)
Mokbel, K, 1225(ab)
Molina, IL, 1133(ab)
Molinet, R, 570(ab)
Möller, HJ, 47(ab), 1018(ab)
Möller, P, 109(ab)
Molls, M, 978(ab), 1144
Molter, JP, 1222(ab)
Molthoff, CF, 94(ab), 425(ab), 509
Momen, A, 401
Momose, M, 6(ab), 712(ab), 1346
Momose, T, 540(ab), 782(ab), 1005
Monden, M, 289(ab)
Monden, T, 997(ab)
Monetti, N, 730(ab), 1126(ab)
Monk, PN, 1088(ab)
Montane, B, 330(ab)
Montoya, J, 1057(ab)
Montravers, F, 463(ab), 487(ab)
Moody, R, 143(ab)
Moody, SB, 486(ab)
Moon, DH, 98(ab), 175(ab), 332(ab), 406(ab), 1097(ab), 1114(ab), 1431(ab)
Moore, SC, 300, 385(ab), 945(ab)
Moore, WH, 454
Mor, M, 117(ab), 127(ab), 164(ab)
Morales, R, 1614
Moray, GOK, 1442(ab)
Morcos, N, 1105(ab)
Moreau, S, 299(ab)
Morena, RA, 1115(ab)
Moresco, L, 1198
Moresco, RM, 961(ab)
Morganti, A, 1444(ab)
Mori, E, 48(ab)
Mori, T, 48(ab)
Mori, Y, 965(ab), 1439(ab)
Morikawa, H, 1096(ab)
Morin, J, 1217(ab)
Morita, K, 197(ab), 778(ab), 1325(ab), 1333(ab)
Morita, T, 827(le)
Morita, Y, 222(ab), 414, 838
Moritan, T, 782(ab), 1005
Moriwaka, H, 983(ab)
Morlote, M, 20(ab)
Morota, K, 1334(ab)
Morr, I, 317
Morris, G, 435(ab)
Morris, R, 1409(ab)
Mortazavi, J, 1042(ab)
Mortelmans, L, 95(ab), 446(ab), 1254(ab)
Moser, E, 591
Moser, HW, 146(ab)
Mosna-Firlejczyk, K, 1208(ab)
Mostbeck, A, 150(ab)
Motoishi, S, 596
Mountz, JM, 527(br), 981(ab), 988(ab), 995(ab)
Moussavian, B, 122(ab), 161(ab), 273(ab), 477(ab), 482(ab), 1259(ab)
Mouton, P, 309(ab)
Movsas, B, 337
Mozley, PD, 481(ab), 485(ab), 541(ab), 968(ab), 993(ab), 994(ab), 1002(ab), 1113(ab), 1327(ab), 1412
Mruck, S, 1345(ab)
Mudun, A, 323(ab)
Mueller, BA, 1401(ab)
Mueller, J, 136(ab)
Muenz, LR, 316(ab)
Muhle, C, 475(ab), 1000(ab), 1399(ab), 1413(ab), 1422(ab), 1545
Mukai, T, 2(ab), 184(ab), 341(ab), 1054(ab), 1093(ab), 1239(ab)
Mukherjee, J, 914(ab), 1121(ab)
Mulkens, PJM, 1232(ab)
Mullan, BP, 274(ab)
Mullani, NA, 263(ab), 1242(ab)
Muller, SH, 436(ab)
Müller, J, 439(ab)
Müller, MJ, 59(ab)
Müller, SP, 385(ab)
Muller-Gartner, HW, 209(ab), 1691
Müller-Mattheis, V, 752
Mulligan, RS, 939(ab)
Mundle, G, 1010(ab)
Munk, OL, 59(ab), 795, 1673
Munz, DL, 438(ab), 439(ab), 881(ab), 1101, 1231(ab), 1258(ab), 1374(ab)
Murakami, M, 1244(ab)
Murasaka, K, 989(ab)
Murase, K, 809(ab), 820(ab), 1446
Murase, P, 947(ab)
Murashima, S, 506(ab)
Murata, H, 873(ab), 942(ab)
Murata, T, 920(ab), 938(ab)
Murata, Y, 38
Murayama, H, 873(ab)
Murone, C, 1288(ab)
Murphey-Corb, M, 905(ab)
Murphy, M, 1158
Murphy, PH, 391(le)
Murphy, R, 1288(ab)
Murray, A, 726
Musachio, JL, 533(ab), 1281(ab)
Muto, P, 102(ab)
Mutty, C, 565(ab)
Muzi, M, 106(ab), 370(ab), 913(ab), 973(ab)
Muzic, RF, 36(ab), 379(ab)
Muzic, RF, Jr., 636, 1077
Muzik, O, 108(ab), 141(ab), 308(ab)
Myers, EN, 133(ab)
Myers, R, 905(ab)
Myslivecek, M, 181(ab)

Nabi, HA, 304(ab), 1221(ab)
Nacca, A, 1697
Nackaerts, K, 1254(ab)
Naddaf, S, 1411(ab)
Naeher, I, 1148(ab)
Nagai, R, 130, 782(ab), 1005
Nagamatsu, H, 1346
Nagamatsu, T, 315(ab)
Nagano-Saito, A, 957(ab), 962(ab), 969(ab)
Nagao, M, 177(le), 1446
Nagao, MD, 947(ab)
Nagaoka, M, 725(ab)
Nagashima, S, 1196(ab)
Nagata, Y, 1252(ab)
Nagatsu, K, 69(ab)
Nagayama, Y, 281(ab)
Nagle, CE, 9N(1)
Nahlawi, M, 755(ab)
Nahmias, C, 1079(ab)

Nährig, J, 298(ab)
Naidu, S, 146(ab)
Naik, V, 326(ab), 327(ab)
Nair, M, 713(ab)
Nakada, K, 92(ab), 414, 448(ab), 763(ab), 810(ab), 1175(ab), 1325(ab), 1333(ab), 1334(ab)
Nakagawa, H, 976(ab)
Nakagawa, M, 1132(ab)
Nakahara, T, 989
Nakajima, K, 183, 336(ab), 466(ab), 1457, 1571, 1579
Nakamoto, Y, 105(ab), 292(ab), 295(ab), 307(ab), 388(ab), 987(le), 1172(ab), 1174(ab), 1176(ab), 1191(ab), 1239(ab), 1252(ab)
Nakamura, A, 957(ab), 962(ab), 969(ab)
Nakamura, F, 33(ab), 923(ab)
Nakamura, H, 289(ab), 444(ab), 601
Nakamura, K, 72(ab), 489(ab)
Nakamura, S, 752(ab), 769(ab), 785(ab)
Nakamura, T, 46(ab), 724(ab), 765(ab), 1351
Nakano, S, 1441
Nakano, T, 575
Nakashima, J, 1407(ab)
Nakata, S, 407(ab), 1297
Nakata, T, 1757
Nakatani, D, 809(ab)
Namavari, M, 96, 1153(ab), 1185(ab), 1225
Namdar, T, 723(ab)
Nanasato, M, 1747
Nanda, D, 1159(ab)
Narabayasi, I, 765(ab)
Narayanan, MV, 837(ab), 844(ab), 849(ab)
Narayanan, TK, 914(ab), 1121(ab)
Nargund, VH, 1223(ab)
Nariai, T, 806(ab)
Naruse, H, 845(ab)
Natale, D, 173(ab)
Nathan, MA, 274(ab)
Nathrath, W, 9
Naumovski, L, 309
Navarro, V, 566(ab), 1014(ab), 1021(ab)
Nearman, J, 1068(ab)
Nebu, A, 1446
Necochea, A, 987(ab)
Nedelman, M, 168(ab)
Nehmeh, SA, 124(ab)
Nekolla, SG, 7(ab), 505(ab), 727(ab), 732(ab), 757(ab), 1011, 1579
Nelson, AD, 1222(ab)
Nemoto, EM, 793(ab)
Nepp, J, 591(ab)
Neri, G, 198(ab)
Nerverve, J, 6(ab)
Netusil, N, 410(ab)
Neumaier, B, 451(ab), 1038(ab), 1150(ab)
Newberg, AB, 4(ab), 993(ab), 994(ab)
Newman, DP, 302(ab)
Ng, NT, 453(ab)
Ngai, M, 545(ab)
Ngo, FQH, 251(ab)
Ngo, K, 420(ab)
Ngo, T, 1109(ab)
Nguyen, AT, 1375
Nguyen, C, 1299(ab)
Nguyen, K, 280(ab), 284(ab), 96
Nguyen, KN, 283(ab), 572(ab), 1185(ab)
Nguyen, N, 712(ab)
Nguyen, NTB, 818
Nguyen, T, 1287(ab)
N'Guyen, S, 1438(ab)
N'Guyen, T, 215(ab), 216(ab)
Nibbering, PH, 788
Nichol, C, 1368
Nicholas, RS, 1140(ab)
Nichols, K, 195(ab), 219(ab)
Nichols, KJ, 767(ab)
Nickel, O, 709(ab)
Nickerson, LD, 32(ab)
Nickles, RJ, 54(ab), 55, 536(ab), 924(ab), 930(ab), 934(ab), 1044(ab), 1118(ab)
Nicolai, E, 742(ab)
Nicolas, C, 141
Nierenberg, AA, 1006(ab)
Nies, C, 1354(ab)
Niesen, A, 223(ab)
Nieweg, OE, 436(ab), 574(ab), 430, 826(le)
Nijsen, JFW, 1145(ab)
Nikkhah, G, 538(ab)
Nikkinen, P, 471(ab)
Nikolaus, S, 209(ab), 1691
Nikula, T, 570(ab), 1309(ab), 1310(ab)
Nishide, Y, 702(ab)
Nishido, S, 318(ab)
Nishiguchi, S, 1096(ab), 1359(ab), 1362(ab), 1363(ab), 1367(ab)
Nishijima, C, 183
Nishijima, K, 69(ab), 244(ab)
Nishimoto, Y, 1262(ab), 1436(ab)
Nishimura, G, 466(ab)
Nishimura, K, 985(ab), 1434(ab)
Nishimura, S, 344(ab), 1833
Nishimura, T, 46(ab), 169(ab), 289(ab), 408(ab), 444(ab), 720(ab), 809(ab), 285, 601, 1789
Nishioka, A, 1215(ab)
Nishioka, T, 296(ab)
Nishiumi, N, 989
Nishiyama, S, 1833
Nishiyama, Y, 115(ab), 467(ab), 959(ab), 997(ab), 1138(ab), 1213(ab), 1260(ab)
Nishizawa, N, 801(ab)
Nisida, A, 1228(ab)
Nitzsche, E, 136(ab)
Nitzsche, EU, 591
Nix, W, 411(ab)
Noachtar, S, 236(ab), 237(ab)
Nobezawa, S, 442(ab), 707, 1196(ab)
Nobili, F, 1151
Nocaudie, M, 993
Noda, A, 1833
Noel, MH, 1200(ab)
Nogami, A, 344(ab)
Nogueira, P, 183(ab)
Noh, DY, 1177(ab), 1220(ab)
Noh, T-W, 39(ab), 148(ab)
Nohara, R, 124, 733(ab)
Noll, D, 172(ab)
Nollert, J, 1143(ab)
Nonokawa, M, 1747
Nordal, R, 1169(ab)
Norenberg, JP, 138(ab)
Noriyasu, K, 197(ab), 338(ab), 731(ab), 763(ab), 774(ab), 775(ab), 778(ab), 810(ab)
Norman, A, 1300(ab)
Nosotti, M, 1261(ab)
Nosske, D, 1038(ab), 1265
Nowak, B, 701(ab), 723(ab), 734(ab), 852(ab)
Noz, ME, 235(ab), 1224(ab)
Nuessle, K, 1269(ab)
Nunez, R, 201(ab), 420
Nuri, M, 1250(ab)
Nüssle, K, 1800
Nutt, R, 369(ab)
Nuutila, P, 1643
Nuvoli, S, 87(ab), 1263(ab), 1328(ab), 1348(ab)
Nuyts, J, 814(ab)
Nwogu, C, 565(ab)
Nyáry, I, 247(ab), 996(ab)
Nygard, E, 206(ab), 378(ab)
Nyuts, J, 211(ab)

Oakes, TR, 934(ab)
Obata, A, 1156(ab)
Oberhofer, MT, 1238(ab)
O'Brien, TJ, 1158
Ochi, H, 1096(ab), 1359(ab), 1362(ab), 1363(ab), 1367(ab)
O'Connor, J, 1072(ab)
O'Connor, MK, 882(ab), 1214(ab), 1401(ab)
Odaka, K, 1011
Odano, I, 940(ab)
Odin, P, 538(ab)
ODonnell, JK, 751(ab)
O'Donnell, RT, 1324
O'Donoghue, J, 257(ab), 875(ab), 170, 1251
Oehme, L, 990(ab)
Oei, H-Y, 222
Oertel, M, 992(ab)
Oetting, G, 598(ab)
Offord, SJ, 537(ab)
Ofluoglu, S, 746(ab), 974(ab), 1309
Ogasawara, K, 543
Ogasawara, N, 292
Ogawa, A, 543
Ogawa, M, 962(ab), 969(ab), 1054(ab)
Ogawa, Y, 1215(ab), 1369(ab), 1428(ab)
Oguchi, M, 977(ab), 1489
Ogura, Y, 765(ab)
Oh, P, 728(ab)
Oh, SH, 549(ab)
Oh, SJ, 98(ab), 1097(ab), 1114(ab)
Ohashi, M, 989(ab)
Ohishi, H, 1262(ab), 1410(ab), 1436(ab)
Ohkawa, M, 115(ab), 467(ab), 959(ab), 997(ab), 1138(ab), 1213(ab), 1260(ab)
Ohkura, K, 69(ab), 244(ab)
Ohmichi, M, 821(ab), 985(ab)
Ohta, T, 766(ab), 1017
Ohta, Y, 344(ab)
Ohtawa, N, 821(ab)
Ohtomo, K, 540(ab), 782(ab), 802, 1005
Oikonen, V, 1643
Ojha, BC, 988(ab)
Okada, DR, 716(ab)
Okada, H, 442(ab), 1196(ab), 707
Okada, N, 38
Okada, RD, 715(ab), 716(ab)
Okada, S, 946(ab)
Okada, T, 985(ab), 1434(ab)
Okamoto, K, 977(ab)
Okamoto, Y, 344(ab)
Okazaki, H, 1457
Okazawa, H, 721(ab), 941(ab), 1032
O'Keefe, J, 764
Okizaki, A, 489(ab), 766(ab), 1017, 1368(ab), 1435(ab), 1447(ab)
Oku, N, 408(ab)
Oku, S, 540(ab)
Okuda, K, 124
Okumura, Y, 1427(ab)
Okuyama, C, 46(ab), 1789
Okuyama, M, 747(ab), 776(ab), 784(ab)
Old, LJ, 764, 1288(ab), 1289(ab), 1291(ab)
Oldershaw, JH, 1437(ab)
Oliva, J, 1032(ab)
Oliveira, JI, 1421(ab)
Olle-Martinez, G, 558
Ollier, M, 141
Olmos, RAV, 430
Olmos, RV, 826(le)
Olson, JJ, 558(ab)
Olyaee, M, 319(ab)
Omar, AM, 1411(ab), 1449(ab)
O'Mara, RE, 532(le), 986(le), 1131(le)
Omata, N, 920(ab), 938(ab)
O'michi, M, 1434(ab)
Omiecinski, E, 811(ab)
Onishi, Y, 926(ab)
Ono, CR, 1228(ab)
Ono, S, 1207(ab)
Onoda, A, 989(ab)
Onoma, K, 596
Önsel, C, 567
Onthank, D, 1307(ab)
Oomichi, H, 1364(ab)
Oonuma, M, 1397(ab)
Oosterwijk, E, 568(ab)
Ootani, T, 182(ab)
Ootawa, N, 985(ab)
Orda, C, 1189(ab)
Ordonez, C, 811(ab)
Orel, SG, 578(ab)
O'Riley, M, 1242(ab)
Oriuchi, N, 130, 1282(ab)
O'Rourke, RA, 745(ab)
Orr, MD, 556(ab), 557(ab), 1805
Orskaug, T, 378(ab)
Osada, H, 821(ab), 985(ab), 1364(ab), 1434(ab)
Osaki, Y, 1435(ab)
Osen, M, 670
Osman, M, 533(ab)
Osman, S, 264(ab)
O'Sullivan, F, 370(ab), 813(ab), 973(ab)
O'Sullivan, J, 1300(ab)
Otawa, N, 1434(ab)
Otis, M, 876(ab)
Otite, U, 1223(ab)
Otsuji, H, 1436(ab)
Ott, K, 293(ab)
Ott, RJ, 822(ab)
Otto, D, 598(ab), 1197(ab), 1296(ab), 1376(ab), 1714
Otto, M, 709(ab)
Ouchi, Y, 442(ab), 707, 1196(ab)
Owen, C, 50(ab)
Owen, NK, 1067(ab), 1149(ab), 1847
Oyama, N, 93(ab), 450(ab)
Oyen, WJG, 268(ab), 272(ab), 472(ab), 474(ab), 1020(ab), 1088(ab), 1199(ab), 1279(ab), 1373(ab), 1381(ab), 1389(ab), 117, 917, 1235, 1257, 1405
Oz, O, 1165(ab)
Ozaki, K, 315(ab)
Ozaki, T, 802
Ozalp, E, 594(ab), 595(ab), 1355(ab)
Ozawa, S, 508(ab)

Paans, A, 798(ab)
Pachmayr, F, 288(ab)
Padhy, AK, 484(ab), 1614
Padilla, F, 1768
Paeng, JC, 15(ab), 16(ab), 19(ab), 39(ab), 347(ab), 695, 738(ab), 748(ab), 1040(ab), 1245(ab)
Paganelli, G, 134(ab), 433(ab), 573(ab), 1037(ab), 1198, 1697
Pagetta, C, 1350(ab)
Pai, MS, 98(ab), 406(ab)
Paik, CH, 567(ab), 1141(ab), 1538
Paik, JY, 1065(ab), 1095(ab), 1178(ab), 1181(ab), 1342(ab)
Paik, SW, 1400(ab)
Paillard, M, 151(ab)
Pain, SJ, 1140(ab)
Painuily, NK, 1314(ab)
Paiva, E, 183(ab)
Pajoro, S, 179(ab)
Pak, KC, 711(ab), 715(ab), 716(ab)
Pakbiers, MT, 1048(ab)
Paladini, B, 178(ab)
Palatresi, S, 1444(ab)
Palazzo, E, 21

Palestro, CJ, 165(ab), 166(ab), 494(ab), 596(ab), 1127(ab), 1136(ab), 1137(ab)
Palkovic, S, 245(ab)
Palmedo, H, 294(ab), 600(ab), 1232(ab), 1297(ab), 1393(ab), 1395(ab)
Palmer, J, 1288
Pan, D, 1388(ab)
Pan, DHC, 251(ab)
Pan, HA, 1015(ab)
Pan, M, 100(ab)
Pan, X, 831(ab)
Panareo, S, 355(ab), 1347(ab)
Pancaldi, D, 847(ab)
Pandit, SA, 159(ab)
Pandit-Taskar, N, 278(ab), 1339(ab)
Pangerl, T, 1309, 1856
Panin, VY, 26(ab)
Panina, C, 1713
Pant, GS, 590(ab)
Panteghini, M, 179(ab)
Pantelias, A, 569(ab)
Panza, JA, 200(ab), 743(ab)
Panzacchi, A, 961(ab)
Papavasileiou, P, 78(ab)
Pappas, N, 400(ab), 402(ab), 906(ab), 908(ab), 1011(ab)
Pappas, NR, 410(ab), 1009(ab), 1012(ab)
Parag, Y, 932(ab)
Parellada, E, 1001(ab)
Parent, F, 513(ab), 514(ab)
Parisi, JC, 170(ab), 710(ab)
Park, CH, 1004(ab), 1035(ab), 1039(ab), 1131(ab), 1204(ab), 1319(ab)
Park, CW, 1141(ab)
Park, JH, 1040(ab), 1179(ab), 1180(ab)
Park, JM, 772(ab), 1187(ab), 1245(ab), 1342(ab), 1400(ab)
Park, JS, 354(ab)
Park, KB, 98(ab), 1035(ab), 1039(ab), 1319(ab)
Park, KS, 220(ab), 549(ab), 953(ab), 938
Park, LS, 1141(ab), 1538
Park, MK, 761(ab)
Park, R, 328(ab)
Park, S, 206(ab), 383(ab)
Park, SH, 500(ab)
Park, SJ, 175(ab)
Park, SK, 157(ab)
Park, SW, 175(ab), 1114(ab)
Park, SY, 1192(ab), 1431(ab)
Park, YS, 332(ab)
Parker, JA, 1437(ab)
Parkey, RW, 1165(ab)
Parkman, HP, 321(ab)
Parl, YH, 1416(ab)
Parrein, B, 1370(ab)
Parry-Jones, DR, 1387(ab)
Parsey, RV, 803(ab)
Passchier, J, 1025
Passler, C, 591(ab)
Pastan, I, 567(ab)
Patel, S, 1356(ab)
Pathak, H, 1314(ab)
Pathmaraj, K, 250(ab), 764
Patt, B, 28(ab), 363(ab)
Patton, DD, 19N(2), 22N(11), 24N(1), 26N(6)
Pattou, F, 993
Paul, AK, 720(ab)
Paulke, BR, 1104(ab)
Paulsen, F, 560(ab), 1253(ab)
Paulusma-Annema, A, 788
Pauwels, EK, 348(ab), 509(ab), 788
Pauwels, S, 462(ab)
Pavía, J, 1001(ab), 1014(ab)
Pavlinkova, G, 1519
Pavlinovic, Z, 1046(ab), 1335(ab)
Payne, JK, 545(ab), 1059
Pearson, DA, 258(ab)
Pechan, P, 239(ab)
Peers, SH, 154, 1722
Peeters, C, 95(ab)
Péglion, J-L, 932
Peker, C, 1385(ab)
Pelizzo, MR, 1338(ab), 1350(ab)
Pellegrini, V, 1311(ab)
Penate Medina, O, 471(ab)
Pener, S, 1003(ab)
Peng, CJ, 1154(ab)
Peng, HH, 824(ab)
Peng, NJ, 780(ab), 1365(ab)
Penney, BC, 831(ab)
Penol, S, 1003(ab)
Pentlow, K, 124(ab)
Pentlow, KS, 863(ab), 875(ab), 1281
Pereira, NPS, 1108(ab), 1110(ab)
Pereira Neto, CA, 1280(ab)
Perez, A, 57(ab)
Perez, T, 771(ab)
Pereztol-Valdés, O, 558
Perico, ME, 1697
Perkins, AC, 726
Perrier, N, 302(ab)
Perrig, S, 232(ab)
Perry, TW, 718(ab)
Pérusse, K, 1217(ab)
Peschel, C, 456(ab), 1251(ab)
Peschke, P, 317
Petegnief, Y, 103(ab), 487(ab)
Peter, J, 363(ab), 529(ab)
Peter, L, 1360(ab)
Peter, RU, 1276(ab)
Peters, AM, 149(ab), 322(ab), 375(ab), 488(ab), 1140(ab), 1387(ab), 1392(ab)
Petersen, V, 1251(ab)
Peterson, C, 878(ab)
Peterson, LM, 106(ab), 679
Petkov, V, 1309
Petretta, M, 742(ab)
Petric, A, 241(ab), 242(ab)
Petrich, T, 259(ab), 1376(ab)
Petruzella, FD, 1388
Pettinato, C, 847(ab)
Pettway, V, 13(ab)
Petzold, J, 1117(ab)
Pezzoli, G, 961(ab)
Phelps, M, 225(ab), 551(ab), 814(ab), 992(ab)
Phelps, ME, 228(ab), 230(ab), 277(ab), 301(ab), 440(ab), 461(ab), 464(ab), 546(ab), 562(ab), 790(ab), 952(ab), 955(ab), 1023(ab), 1075(ab), 1078(ab), 1130(ab), 1153(ab), 1185(ab), 1190(ab), 1249(ab), 11N(4), 15, 96, 586, 1139, 1225, 1334
Philip, P, 107(ab)
Phillips, D, 1086(ab)
Phillips, WT, 1163(ab), 1379(ab), 1380(ab), 446
Piao, R, 408(ab)
Piato, JR, 1228(ab)
Pica, CM, 285(ab)
Picchio, M, 879(ab), 1268(ab)
Picco, P, 1151
Pichard, C, 864, 998(ab)
Pichler, BJ, 213(ab), 382(ab), 473(ab), 871(ab)
Picker, F, 369(ab)
Picus, J, 450(ab)
Piel, M, 928(ab)
Piepsz, A, 564
Pierard, G, 1241(ab)
Pieroni, C, 178(ab)
Piers, DA, 432, 579, 759(ab), 1144(ab)
Piert, M, 483(ab), 1091, 1168(ab), 1408(ab)
Pieterman, RM, 579
Piffanelli, A, 355(ab), 1347(ab)
Pike, VW, 264(ab), 1058(ab)
Pilowsky, LS, 939(ab)
Pimpl, W, 382(ab)
Pinckard, RN, 1379(ab)
Pinkas, L, 33, 1398(ab)
Pinkert, J, 1320(ab)
Pinotti, JA, 1228(ab)
Piotto, A, 1338(ab), 1350(ab)
Pirich, C, 746(ab), 974(ab)
Pirich, CH, 741(ab)
Pirina, P, 1263(ab)
Pistorius, G, 1128(ab)
Pitman, AG, 191(ab)
Pitombo, RNM, 1108(ab)
Pitre, S, 867(ab)
Piwnica-Worms, D, 285(ab), 418(ab), 426(ab)
Pizzamiglio, M, 433(ab)
Pizzocaro, C, 179(ab)
Plascjak, PS, 1084(ab)
Platsch, G, 1357(ab)
Plenevaux, A, 894(ab)
Pless, M, 136(ab)
Plössl, K, 240(ab), 393(ab), 541(ab), 968(ab), 1002(ab), 1113(ab), 1556
Plotkin, M, 71
Pocock, N, 1205(ab)
Podda, M, 1043(ab)
Podoloff, DA, 76(ab), 97(ab), 263(ab), 311(ab), 1028(ab), 1082(ab), 1099(ab), 1283(ab)
Podugu, R, 751(ab)
Poelstra, K, 265(ab)
Poepperl, G, 237(ab), 972(ab)
Pointurier, I, 754(ab)
Poldermans, D, 79
Policaro, F, 330(ab), 971(ab)
Pollycove, M, 17N(7), 26N(9)
Pomeroy, KM, 78(ab), 822(ab)
Ponomarev, V, 260(ab), 1161(ab)
Pons, F, 1014(ab)
Ponto, LL, 64(ab), 935(ab)
Ponzo, F, 161(ab), 477(ab), 482(ab), 1327(ab)
Poole, K, 264(ab)
Pooley, R, 882(ab)
Poot, L, 759(ab)
Popov, V, 960
Popp, D, 1243
Pöpperl, G, 236(ab)
Porcu, A, 87(ab)
Porenta, G, 189, 741(ab), 746(ab)
Porn, U, 144(ab), 1424(ab)
Porta, F, 738
Post, AM, 309, 479(ab), 1383(ab)
Potter, NT, 964(ab)
Pötzi, C, 974(ab)
Pouillart, F, 771(ab)
Pourdehnad, M, 122(ab), 269(ab), 477(ab), 44, 1412
Powe, J, 172(ab)
Powers, RT, 919(ab)
Powers, RW, 1286(ab)
Powers, WJ, 1195
Powers-Risius, P, 270(ab), 272
Pozderac, RV, 1405(ab), 1433(ab)
Prang, J, 451(ab)
Prante, O, 422(ab)
Prause, J, 1399(ab), 1413(ab)
Press, OW, 586(ab)
Preston, DF, 1382(ab)
Pretorius, PH, 837(ab), 849(ab)
Price, BH, 1006(ab)
Price, DT, 556(ab), 557(ab), 1713, 1805
Price, J, 921(ab)
Price, JC, 63(ab), 793(ab)
Price, DC, 237
Price, MR, 726
Prigent, A, 1464
Primi, F, 1212(ab)
Prins, MH, 393
Prior, J, 1780
Prisco, G, 433(ab), 573(ab)
Pritzkow, M, 501(ab)
Proeschild, A, 223(ab)
Proulx, G, 579(ab)
Proye, C, 993
Pruim, J, 432, 449(ab)
Przetak, C, 37(ab), 223(ab)
Pu, M, 3(ab)
Pugsley, JM, 106(ab), 559(ab)
Pujol, JF, 894(ab)
Pursel, SE, 287(ab)
Purushotham, AD, 1140(ab)
Pyrsopoulos, N, 318(ab)

Qing, CZ, 1218(ab)
Qing, ZH, 1218(ab)
Qu, T, 1870
Quak, JJ, 1364
Que, TH, 759(ab)
Quinn, J, 554(ab)
Quinn, TP, 416(ab), 417(ab), 1069(ab), 1070(ab), 1847
Quinones, E, 1133(ab)
Quinones, M, 340(ab)

Rabins, PV, 44(ab)
Rabut, B, 1200(ab)
Rachinsky, I, 1419(ab)
Radau, P, 25(ab)
Radeka, V, 872(ab)
Raderer, M, 1134(ab), 1309, 1856
Raedler, TJ, 903(ab)
Raes, B, 9(ab)
Rafecas, M, 382(ab), 871(ab)
Raffel, DM, 712(ab)
Raffelt, K, 1324(ab)
Raijmakers, PGH, 1139(ab)
Rain, JD, 848(ab)
Raja, S, 233(ab)
Rajapadhye, M, 412(ab)
Rajendran, JG, 584(ab), 586(ab)
Rajopadhye, M, 472(ab), 474(ab), 1020(ab), 1307(ab)
Rakhorst, G, 1144(ab)
Rakotondrajoana, B, 151(ab)
Ramachandran, A, 817(ab)
Ramadane, G, 1358(ab)
Ramasamy, R, 271(ab)
Ramdave, S, 250(ab), 300(ab)
Ramirez, A, 180(ab)
Rammohan, R, 262(ab)
Rammurthi, S, 327(ab)
Ramos, CD, 1016(ab), 1421(ab)
Rao, DV, 253(ab), 254(ab), 162
Rao, J, 853(ab), 1286(ab), 1139, 1334
Rao, PS, 74(ab), 1089(ab)
Rapoport, SI, 243(ab)
Rascher-Friesenhausen, R, 866(ab)
Rasey, JS, 1184(ab)
Rattat, D, 457(ab), 581(ab), 1071(ab), 1294(ab)
Rau, FC, 1170(ab)
Raubitschek, A, 76(ab), 572(ab), 1124(ab)
Rauch, SL, 1006(ab), 1007(ab)
Raugei, I, 476(ab), 1412(ab)
Rauseo, PA, 1274
Ravert, HT, 309(ab), 537(ab), 1281(ab), 1274
Ravizzini, GC, 343(ab), 871
Raylman, RR, 352, 960
Reader, AJ, 880(ab)
Reaven, P, 756(ab)
Reber, H, 84(ab)
Reddy, K, 74(ab)
Reddy, VG, 486(ab)
Reder, S, 712(ab)
Reed, J, 369(ab)
Reed, L, 967
Reed, NS, 986(le)
Reffad, A, 462(ab)
Regan, DD, 83(ab)
Rehak, P, 872(ab)
Reich, R, 1232(ab)

Reichart, B, 505(ab), 1011
Reichert, TE, 1202(ab)
Reichnitzer, C, 142(ab)
Reidel, G, 456(ab), 818, 978(ab)
Reidl, G, 1144
Reihlac, A, 34(ab)
Reilly, P, 994(ab)
Reilly, RM, 1072(ab), 1073(ab), 1169(ab)
Reiman, E, 756(ab)
Reiman, R, 1805
Reimold, M, 31(ab), 107(ab), 398(ab), 1010(ab), 1253(ab)
Reinders, S, 798(ab)
Reinhard, G, 1232(ab)
Reinhardt, MJ, 591, 1393(ab)
Rempel, TD, 884(ab)
Rennen, H, 1373(ab), 1381(ab)
Rennen, HJ, 268(ab), 272(ab), 1088(ab), 117, 917, 1257
Resche, I, 1229(ab)
Rescigno, J, 292
Reske, SN, 109(ab), 305(ab), 451(ab), 457(ab), 581(ab), 721, 804(ab), 1038(ab), 1071(ab), 1150(ab), 1269(ab), 1276(ab), 1294(ab), 1800
Resnick, MI, 1222(ab)
Resol, E, 1122(ab)
Restrepo, J, 159(ab)
Reszka, R, 238(ab)
Rettenbacher, L, 424
Rettenbacher, T, 424
Rettig, W, 1291(ab)
Reubi, JC, 1064(ab)
Reuland, P, 1276(ab)
Reutelingsperger, C, 177(ab), 1048(ab), 382
Reutter, BW, 27(ab), 272
Rey, AM, 788
Reynolds, C, 369(ab)
Reynolds, III, CF, 63(ab)
Ricard, M, 867(ab)
Ricaurte, G, 958(ab)
Rice, KC, 927(ab)
Rice, OV, 53(ab), 897(ab)
Richardson, H, 165(ab)
Richartz, BM, 49
Richel, H, 967
Richmond, JC, 935(ab)
Richter, E, 255(ab), 866(ab), 1277(ab), 1323(ab)
Richter, S, 704(ab)
Richter, W-S, 1101
Rickert, CH, 245(ab)
Riddell, C, 214(ab), 215(ab), 216(ab), 376(ab), 519(ab), 521(ab), 1316
Rieber, J, 335(ab)
Riedel, ER, 420
Riemann, B, 245(ab), 917(ab), 1390(ab)
Riggert, J, 585(ab)
Riggin, SL, 817(ab)
Rigo, P, 312(ab), 1195(ab), 1241(ab)
Rigopoulos, A, 764
Rikimaru, A, 1397(ab)
Rikimaru, H, 315(ab)
Rini, JN, 1136(ab), 1137(ab)
Riou, L, 1090(ab)
Risa, B, 191(ab)
Risse, J, 294(ab), 1043(ab), 1340(ab), 1393(ab), 1395(ab)
Risse, JH, 163(ab), 334(ab), 496(ab), 951(ab), 1211(ab)
Rivkees, S, 593(ab)
Ro, HK, 991(ab)
Robert, F, 80(ab)
Roberts, AD, 54(ab), 930(ab), 934(ab), 1044(ab), 1118(ab)
Roberts, DW, 986(ab)
Roberts, M, 1388(ab)
Robeson, W, 1025(ab)
Robin, F, 1438(ab)
Robinson, D, 1398(ab), 33
Robinson, S, 880(ab)
Roca, M, 505
Rockstroh, JK, 1395(ab)
Rodari, M, 45(ab)
Rodenhiser, J, 57(ab), 60(ab)
Rodés-Cabau, J, 1768
Rodrigue, S, 154(ab), 719(ab)
Rodriguez, D, 3(ab)
Rodriguez, G, 45(ab), 1151
Roelsgaard, K, 795
Roesch, F, 110(ab)
Rogers, J, 1250(ab), 1256(ab)
Rogers, WL, 206(ab), 383(ab), 887(ab)
Rognoni, M, 1261(ab), 1444(ab)
Rogoz, R, 53(ab)
Rojas, JC, 1034(ab)
Roland, PS, 548(ab)
Rolland, C, 1331(ab)
Rolph, S, 149(ab)
Romeike, B, 916(ab)
Rommelfanger, SG, 83(ab)
Rook, DW, 1145(ab)
Roos, JC, 1364
Rösch, F, 84(ab), 252(ab), 928(ab), 1146(ab)
Rose, AH, 1313(ab)
Rose, CA, 306(ab)
Roselló, J, 738
Rosemark, PJ, 1234(ab)
Rosen, J, 1317(ab)
Rosen, M, 1437(ab)
Rosenberg, J, 76(ab)
Rosenfelt, F, 445(ab)
Rosenthal, DI, 1233(ab)
Rosenzweig, K, 124(ab), 1255(ab)
Rossi, G, 1228(ab)
Rossi, R, 1470
Rossini, PL, 179(ab)
Rossleigh, MA, 91
Rossman, MD, 1412
Rossmueller, B, 144(ab), 1424(ab)
Rosso, J, 771(ab), 845
Rosso, L, 1261(ab)
Rothfusz, BC, 817(ab)
Rothman, RB, 927(ab)
Rothmund, M, 1354(ab)
Roti, E, 1470
Rousseau, C, 1229(ab)
Rousseau, J, 1076(ab)
Rousset, O, 533(ab)
Rouze, NC, 364(ab)
Roy, S, 813(ab)
Rozenman, Y, 783(ab)
Ruan, S, 257(ab), 1281
Rübe, C, 1375
Rubello, D, 1338(ab), 1350(ab)
Rubin, AD, 588(ab)
Rubin, RH, 1386(ab)
Rubinstein, J, 737(ab)
Ruddy, TD, 171(ab), 359(ab), 739(ab), 1730
Rudi, J, 465(ab)
Rudolph, F, 1270(ab)
Rueckert, JC, 1258(ab)
Rueckert, RI, 1374(ab)
Ruers, TJ, 1279(ab)
Ruiz, M, 1090(ab), 1388
Rusckowski, M, 73(ab), 261(ab), 414(ab), 553(ab), 1083(ab), 1102(ab), 1660, 1870
Rush, AJ, 535, 1019(ab)
Russell, DC, 55
Ruszczynska, M, 1188(ab)
Ruszkiewicz, J, 905(ab), 921(ab)
Rutar, FJ, 907
Rutgers, EJ, 574(ab)
Ruth, TJ, 29(ab)
Ruthke, S, 298(ab)
Rutz, W, 1270(ab)
Ryan, CM, 63(ab)
Ryu, JS, 98(ab), 406(ab)
Ryu, S, 1192(ab)
Saabe, M, 1358(ab)
Sabri, O, 24(ab), 734(ab), 852(ab)
Sacco, E, 1037(ab)
Sachinidis, J, 250(ab)
Sachs, J, 127(ab), 164(ab), 998
Sacilotto, G, 227(ab)
Sadar, P, 593(ab)
Sadato C, 982(ab)
Sadato, N, 920(ab), 922(ab)
Sadek, S, 576(ab)
Sadelain, M, 1161(ab)
Safaei, A, 562(ab), 1190(ab)
Safei, A, 1130(ab)
Saffer, JR, 481(ab)
Saga, T, 105(ab), 292(ab), 987(le), 1087(ab), 1172(ab), 1174(ab), 1176(ab), 1191(ab), 1239(ab), 1252(ab), 1457
Sagan, C, 1229(ab)
Saha, G, 233(ab), 14N(4)
Sahlmann, C, 1377(ab), 1378(ab)
Said, S, 914(ab)
Saidi, L, 1331(ab)
Saäi-Maurel, C, 146
Saito, H, 1747
Saitta, B, 345(ab)
Saji, H, 1054(ab), 1093(ab)
Sakahara, H, 105(ab), 292(ab), 378(ab)
Sakaki, T, 467
Sakamoto, I, 1369(ab)
Sakamoto, S, 48(ab), 922(ab)
Sakhuja, V, 1446(ab)
Sakomura, Y, 1346
Sakuma, H, 702(ab)
Sakuma, T, 1489
Sakurai, A, 1476
Salame, E, 290(ab)
Saleemi, K, 320(ab)
Saleh-Mghir, A, 1385(ab)
Salgarello, M, 730(ab)
Salis, F, 183(ab)
Sallusti, E, 1212(ab)
Saloner, DA, 27(ab)
Saltröe, E, 597(ab)
Salusky, I, 337(ab), 356(ab)
Salvat-Brillault, C, 848(ab)
Salvatore, M, 742(ab), 884
Salvatore, V, 153(ab)
Šámal, M, 150(ab), 1084
Samii, M, 538(ab), 544(ab)
Samnick, S, 704(ab), 916(ab)
Sampaio, AP, 1228(ab)
Sampson, WH, 367(ab)
Samuelson, D, 486(ab)
Sanacora, G, 61(ab)
Sanchec-Pernaute, R, 50(ab)
Sanches, A, 1448(ab)
Sanci, V, 899(ab)
Sandell, J, 419(ab), 907(ab), 1058(ab)
Sanderson, JA, 569(ab)
Sanderson, SD, 1306(ab)
Sandhu, J, 1073(ab)
Sandler, MP, 1
Sandrock, D, 1374(ab)
Sanger, M, 11N(7)
Sansana, CRM, 1111(ab)
Santambrogio, L, 1261(ab)
Santana, CA, 722(ab), 811(ab), 1185
Santana-Boado, C, 558
Santens, P, 43(ab)
Santiago, J, 352(ab)
Santiago, JF, 1236(ab)
Santos, AO, 1016(ab), 1421(ab), 1448(ab)
Saouaf, R, 195(ab)
Saperstein, LA, 123(ab)
Sapienza, MT, 1228(ab)
Saraswat, VA, 1360(ab)
Sarda, L, 167(ab), 1375(ab), 1385(ab)
Sarkar, SD, 1127(ab)
Sarmiento, AH, 531(le)
Sarmiento, AJH, 531(le)
Sarmiento, FM, 531(le)
Sarosiek, I, 319(ab)
Sasai, K, 292
Sasajima, T, 1435(ab), 1447(ab)
Sasaki, M, 48(ab), 1132(ab)
Sasaki, N, 1359(ab), 1362(ab), 1363(ab), 1367(ab)
Sasaki, Y, 873(ab), 942(ab)
Sasayama, S, 124, 733(ab)
Sashin, D, 793(ab)
Sasso, DE, 1109
Sato, A, 73(ab), 1102(ab)
Sato, J, 489(ab), 766(ab), 1368(ab), 1425(ab), 1435(ab), 1447(ab), 1017
Sato, N, 1087(ab), 1141(ab), 1172(ab), 1282(ab)
Sato, S, 1427(ab), 1430(ab), 183
Satoh, K, 115(ab), 467(ab), 959(ab), 997(ab), 1138(ab), 1260(ab)
Satoh, T, 1361(ab)
Satter, M, 799(ab), 1243(ab)
Sattler, B, 1117(ab)
Satyamurthy, N, 51(ab), 65(ab), 96, 241(ab), 242(ab), 1023(ab), 1075(ab), 1078(ab), 1153(ab), 1225
Sauer, U, 727(ab), 732(ab)
Savelli, GB, 1329(ab)
Savi, A, 879(ab)
Savio, EO, 788
Sawicki, W, 1188(ab)
Sawyers, CL, 283(ab)
Sayeram, S, 846(ab)
Sayre, J, 1139
Schackert, G, 990(ab)
Schaefer, A, 704(ab)
Schaefer, W, 701(ab), 734(ab)
Schaefer, WM, 723(ab)
Schalij, MJ, 509(ab)
Scheffel, U, 533(ab), 1162(ab), 1274
Scheidhauer, K, 49(ab), 456(ab)
Scheinberg, DA, 27, 1308(ab), 1311(ab)
Schelbert, HR, 337(ab), 340(ab), 356(ab), 924
Schelling, M, 9
Schettino, CJ, 1224(ab)
Schiavini, M, 1337(ab)
Schicha, H, 5(ab), 49(ab), 1324(ab)
Schieck-Dowd, C, 397(ab)
Schieffer, H, 1375
Schiepel, N, 505(ab)
Schiepers, C, 12N(2), 277(ab), 301(ab), 386(ab), 440(ab), 461(ab), 464(ab), 586, 814(ab), 1130(ab), 1249(ab), 1334
Schiesser, M, 162(ab)
Schiffer, W, 424(ab), 1062(ab)
Schiffer, WK, 52(ab), 56(ab), 901(ab), 909(ab)
Schild, G, 591(ab)
Schillaci, O, 1212(ab)
Schilsky, ML, 494(ab)
Schima, W, 1134(ab), 1309
Schinkel, AH, 425(ab)
Schipper, M, 160(ab)
Schirrmacher, R, 269(ab)
Schirrmeister, H, 305(ab), 451(ab), 581(ab), 1269(ab), 1800, 721
Schisterman, E, 174(ab), 346(ab), 749(ab)
Schlemmer, H, 246(ab)
Schliefer, K, 1395(ab)
Schlösser, NJ, 1265(ab)
Schlüter, B, 71
Schlyer, D, 906(ab), 908(ab)
Schlyer, DJ, 377(ab), 872(ab)
Schmalfeldt, B, 298(ab)
Schmid, E, 1310(ab)
Schmid, R, 335(ab), 1210(ab)
Schmid-Kotsas, A, 581(ab)
Schmidt, AN, 445(ab)
Schmidt, B, 456(ab)
Schmidt, H, 259(ab)
Schmidt, M, 49(ab)

Schmidt, MA, 137(ab), 413(ab), 469(ab), 1064(ab)
Schmidt, R, 106(ab)
Schmidt, T, 990(ab)
Schmiedehausen, K, 1357(ab)
Schmiedl, O, 1010(ab)
Schmitt, G, 58(ab)
Schmitt, O, 163(ab), 1393(ab)
Schmitz, A, 163(ab), 269(ab)
Schneider, CA, 5(ab)
Schneider, JS, 541(ab)
Schneider, ML, 54(ab), 930(ab), 934(ab)
Schneider, RF, 337
Schneider, TH, 1372(ab)
Schnell, O, 6(ab)
Schober, O, 245(ab), 917(ab), 1272(ab), 1390(ab)
Schöder, H, 1139
Schoenes, S, 212(ab)
Scholfield, DP, 726
Schopphoff, H, 49(ab)
Schosser, R, 1265
Schottelius, M, 429(ab), 555(ab)
Schramel, F, 1254(ab)
Schreck, CE, 27(ab)
Schreckenberger, M, 110(ab), 411(ab), 928(ab)
Schreiman, JS, 960
Schrobilgen, GJ, 1079(ab)
Schubert, EK, 85(ab), 303(ab), 575(ab)
Schueller, MJ, 54(ab), 924(ab), 930(ab), 934(ab), 1044(ab), 1118(ab)
Schuenke, M, 1391(ab)
Schuhmacher, C, 1310(ab)
Schuhmacher, J, 249(ab), 1053
Schuler, G, 757(ab)
Schulte, M, 109(ab)
Schultheiß, S, 109(ab)
Schultz, J, 569(ab)
Schumacher, CH, 1309(ab)
Schumacher, T, 136(ab)
Schumacher, U, 646
Schümichen, C, 1270(ab)
Schönsiegel, F, 1155(ab)
Schuster, D, 823(ab)
Schuster, E, 741(ab)
Schuster, SL, 583(ab)
Schuster, T, 1424(ab)
Schustz, AM, 270(ab)
Schvartz, C, 1464
Schwaiger, M, 6(ab), 7(ab), 9, 47(ab), 224(ab), 293(ab), 298(ab), 306(ab), 326, 382(ab), 429(ab), 456(ab), 473(ab), 505(ab), 548, 555(ab), 712(ab), 727(ab), 732(ab), 757(ab), 818, 871(ab), 915(ab), 929(ab), 933(ab), 978(ab), 1011, 1018(ab), 1144, 1170(ab), 1251(ab), 1310(ab)
Schwartz, D, 828(ab)
Schwartz, JL, 1184(ab)
Schwarz, SW, 213
Schwarzbach, M, 713, 1274(ab)
Schwarzrock, A, 245(ab)
Schwenzer, K, 1210(ab)
Schwimmer, J, 1S
Schwitter, MR, 42(ab)
Sciacca, RR, 63, 271(ab), 767(ab), 807(ab), 1439(le), 201
Sciuk, J, 1272(ab), 1390(ab)
Scopinaro, F, 1212(ab)
Scott, AM, 250(ab), 300(ab), 1288(ab), 1289(ab), 1291(ab), 764, 1251
Scott, J, 545(ab)
Sdraiati, C, 227(ab)
Sebastian, G, 1201(ab)
Sedler, M, 402(ab), 1012(ab)
Seeck, M, 232(ab)
Seese, A, 199(ab), 1117(ab), 1189(ab)
Segall, GM, 609
Segars, WP, 23(ab), 217(ab), 218(ab), 530(ab), 837(ab), 705(ab)
Segol, P, 290(ab)
Seibyl, J, 61(ab), 539(ab), 550(ab), 925(ab), 1013(ab)
Seidl, C, 1309(ab), 1310(ab)
Seifert, H, 1375
Seimbille, Y, 1076(ab)
Seitz, U, 1150(ab)
Seki, H, 1489
Seki, K, 69(ab), 244(ab)
Sekiya, M, 182(ab)
Selivanov, V, 517(ab), 854(ab)
Sellers, D, 121(ab)
Seltzer, M, 562(ab), 1249(ab), 586
Seltzer, MA, 1023(ab), 1334
Selva-O'Callagan, A, 738
Semba, Y, 1297
Senda, M, 922(ab)
Seneca, N, 925(ab)
Seneca, NM, 61(ab)
Senekowitsch-Schmidtke, R, 326, 473(ab), 570(ab), 818, 1146(ab), 1170(ab), 1309(ab), 1310(ab)
Sengupta, S, 951(ab)
Seo, DW, 853
Seo, HK, 851(ab)
Seo, K, 39(ab), 148(ab), 983
Serafini, AN, 895
Serganova, I, 260(ab)
Sergeyev, NS, 286(ab)
Serra-Grima, R, 516(ab)
Seth, R, 359(ab)
Sethi, RS, 1050(ab)
Sevillano, MM, 1219(ab)
Sewatkar, AB, 1360(ab)
Sfakianakis, GN, 318(ab), 330(ab), 362(ab), 971(ab), 1445(ab)
Sgouros, G, 27, 499, 1216, 1251
Shah, S, 1034(ab)
Shahinian, A, 1183(ab), 1682
Shalaby-Rana, E, 878
Shankar, LK, 1238(ab)
Shankar, UR, 1614
Shao, L, 518(ab), 838(ab)
Shapiro, B, 1656
Sharir, T, 346(ab), 831, 1630
Sharkey, RM, 79(ab), 81(ab), 459(ab), 552(ab), 583(ab), 588(ab)
Sharma, C, 1099(ab)
Sharma, S, 1089(ab)
Sharma, U, 1098(ab)
Sharma, V, 418(ab)
Sharp, TL, 93(ab), 655
Sharpe, CS, 302(ab)
Shaw, E, 1316(ab)
Shaw, LJ, 745(ab), 1424
Shaw, LK, 343(ab), 871
Shea, C, 52(ab), 906(ab), 908(ab), 909(ab), 1062(ab), 1120(ab)
Shea, CE, 53(ab), 897(ab)
Sheetz, M, 1317(ab)
Shehab, D, 1411(ab)
Shehata, M, 1863
Sheikh, A, 1281
Shekhar, R, 233(ab)
Shelef, I, 1419(ab)
Shelton, SE, 934(ab)
Shen, C, 581(ab), 1071(ab), 721
Shen, S, 80(ab), 1324
Sherry, CM, 828(le)
Sheybani, A, 342(ab)
Shi, B, 1121(ab)
Shi, R, 1166
Shiau, SY, 251(ab)
Shibayama, H, 444(ab)
Shibuya, H, 38
Shidahara, M, 795(ab), 926(ab), 937(ab)
Shields, AF, 107(ab), 108(ab), 308(ab)
Shiga, T, 33(ab), 414, 448(ab), 923(ab), 1325(ab), 1333(ab), 1334(ab)
Shigematsu, M, 1096(ab), 1359(ab)
Shih, LS, 1330(ab)
Shikanai-Yasuda, M, 1371(ab)
Shim, BS, 354(ab)
Shimada, K, 508(ab)
Shimamoto, K, 1757
Shimizu, Y, 821(ab), 985(ab), 1364(ab), 1434(ab)
Shimoji, K, 535(ab), 936(ab)
Shimomura, Y, 765(ab)
Shimonagata, T, 736(ab)
Shin, BC, 1141(ab)
Shin, DG, 354(ab)
Shin, JH, 1142(ab), 1182(ab)
Shin, L, 927(ab)
Shin, LM, 1007(ab)
Shin, S-A, 782
Shin, SC, 991(ab)
Shin, WC, 853
Shinkai, T, 1262(ab), 1410(ab), 1436(ab)
Shinohara, M, 809(ab)
Shinohara, N, 448(ab)
Shiomi, S, 1096(ab), 1359(ab), 1362(ab), 1363(ab), 1367(ab)
Shiozaki, H, 289(ab)
Shirahata, T, 378(ab)
Shirato, H, 296(ab)
Shishido, T, 747(ab), 776(ab), 784(ab)
Shiue, C-Y, 269(ab), 1077(ab)
Shiue, GG, 269(ab), 1077(ab)
Shively, JE, 572(ab), 1075(ab), 1078(ab)
Shnier, D, 44
Shoghi-Jadid, K, 242(ab), 790(ab)
Shohtsu, A, 989, 1285(ab)
Shokouhi, S, 377(ab)
Shotzman, DH, 1356(ab)
Shuke, N, 489(ab), 766(ab), 1017, 1368(ab), 1425(ab), 1435(ab), 1447(ab)
Shulkin, B, 143(ab), 592(ab)
Shulman, A, 550(ab)
Sickle, E, 584(ab)
Siddiqui, AR, 331(ab)
Siderowf, A, 541(ab)
Sidhu, K, 124(ab)
Sieckman, GL, 1067(ab), 1149(ab)
Siegal, JA, 907
Siegel, AH, 234(ab), 986(ab)
Siegel, AM, 986(ab)
Siegel, B, 576(ab)
Siegel, BA, 291(ab), 450(ab), 1134
Siegel, J, 1293(ab)
Siegel, JA, 1027(ab), 492
Sieger, S, 1155(ab)
Sierralta, P, 180(ab)
Siessmeier, T, 110(ab), 411(ab), 928(ab)
Siewert, JR, 293(ab)
Si-jin, L, 1440(ab)
Silagan, N, 1193(ab)
Silberstein, EB, 12N(1), 20N(4), 1134, 1358
Sillevis Smitt, PA, 1159(ab)
Silva, CPG, 1108(ab), 1110(ab)
Silva, PJ, 1307(ab)
Silverman, D, 562(ab), 1249(ab)
Silverman, DH, 30(ab), 76(ab), 225(ab), 228(ab), 301(ab), 440(ab), 461(ab), 464(ab), 546(ab), 944(ab), 952(ab), 955(ab), 1115(ab), 1124(ab), 1130(ab), 586, 1S
Simkin, PH, 844(ab)
Simms, MS, 726
Simó, M, 558
Simon, J, 1311(ab), 1339(ab)
Simonneau, G, 513(ab), 514(ab)
Simonova, ML, 286(ab)
Simpson, N, 421(ab), 1057(ab)
Simpson, NR, 271(ab)
Singh, B, 1050(ab), 1446(ab)
Singh, K, 1098(ab)
Singh, S, 166(ab)
Sinusas, AJ, 173(ab), 528(le)
Sisson, J, 592(ab), 975
Sitbon, O, 513(ab), 514(ab)
Sitek, A, 193(ab), 1704
Sjögreen, K, 1563
Skehan, SJ, 149(ab), 488(ab), 1387(ab)
Skinner, RWS, 1656
Skov, L, 145(ab)
Slama, M, 511(ab), 512(ab), 513(ab), 514(ab), 515(ab), 754(ab), 770(ab), 1043
Slart, R, 759(ab)
Slawski, J, 987(ab)
Slegers, G, 43(ab), 1056(ab), 1061(ab), 1722, 1818
Slevin, NJ, 1209(ab)
Slifstein, M, 396(ab), 797(ab)
Slipman, C, 481(ab), 485(ab)
Sloka, S, 156(ab)
Slomka, P, 25(ab), 37(ab), 223(ab)
Slonin, JH, 1445(ab)
Slooter, GD, 1304(ab)
Slosman, DO, 232(ab), 840(ab), 864, 998(ab), 1206(ab)
Small, GW, 228(ab), 230(ab), 241(ab), 242(ab), 546(ab), 952(ab)
Smilowitz, HM, 1109
Smit, E, 1254(ab)
Smit, EF, 112(ab)
Smit, H, 425(ab)
Smith, CJ, 1067(ab), 1149(ab)
Smith, GT, 818(ab)
Smith, LG, 292
Smith, MF, 526(ab)
Smith, MP, 55(ab)
Smith, RJ, 1821
Smith-Jones, PM, 458(ab), 566(ab), 1021(ab), 1051(ab)
Smyth, FE, 764, 1288(ab)
Snow, GB, 1364
Snyder, WH, 1356(ab)
Snyderman, CH, 133(ab)
So, Y, 991(ab)
Sobhani, I, 103(ab)
Sochor, H, 189, 741(ab), 746(ab)
Sodee, DB, 1222(ab), 1226(ab)
Soede, A, 568(ab)
Soh, KS, 948(ab)
Sohn, HS, 1441(ab)
Sojkova, J, 986(ab)
Sokole, EB, 1863
Sokoloff, L, 936(ab)
Solal, M, 867(ab)
Solanki, CK, 1387(ab)
Solanki, K, 567
Solans, R, 738
Solbach, C, 1119(ab)
Soldner, JM, 884(ab)
Soler, M, 278(ab)
Soler-Soler, J, 558, 1768
Solin, O, 1397, 1643
Solinas, ME, 1263(ab), 1328(ab), 1348(ab)
Solinas, P, 87(ab)
Sommer, FT, 804(ab)
Song, CJ, 991(ab), 670
Song, HC, 409(ab), 480(ab)
Song, JK, 175(ab)
Song, X, 836(ab)
Soni, R, 437(ab)
Sonmezoglu, K, 567
Sonmezoglu, M, 567
Sood, A, 1360(ab)
Soret, M, 214(ab), 376(ab), 519(ab), 521(ab)
Sorger, D, 199(ab)
Soricelli, A, 484(ab)
Sossi, V, 29(ab)
Soto, A, 1768
Southwick, SM, 1013(ab)
Souto, B, 788
Sóvágó, J, 419(ab), 900(ab), 907(ab), 1058(ab)
Spaepen, K, 95(ab), 446(ab)

Spanu, A, 87(ab), 1263(ab), 1328(ab), 1348(ab)
Sparks, R, 1023(ab), 1027(ab), 1028(ab), 492
Spelle, L, 940(ab)
Spence, AM, 370(ab), 913(ab), 973(ab)
Spencer, RH, 1384
Spencer, SS, 987(ab)
Spermon, JR, 1199(ab)
Spetsieris, P, 1591
Spicer, KM, 1109(ab)
Spiegel, S, 224(ab)
Spies, S, 1115(ab)
Spies, SM, 194(ab), 755(ab), 884(ab), 1773
Spillman, S, 1406(ab)
Spinelli, L, 742(ab)
Spitz, FR, 578(ab)
Springer, K, 1066(ab)
Squire, O, 124(ab), 815(ab), 1255(ab)
Srinivasan, A, 137(ab), 413(ab), 469(ab), 1064(ab)
Srivastava, S, 77(ab), 1066(ab), 1085(ab)
Srivastava, SC, 253(ab), 1086(ab)
Stabin, MG, 492, 662, 916, 1027(ab), 1029(ab), 1033(ab), 1037(ab), 1238
Stachowiak, A, 1240(ab)
Stadtmauer, E, 583(ab)
Staelens, L, 1056(ab)
Stafford, SE, 303(ab)
Stahl, A, 293(ab)
Stahlschmidt, A, 483(ab), 1091, 1408(ab)
Standl, E, 6(ab)
Stanko, P, 55
Staudenherz, A, 150(ab)
Stein, R, 967
Steinert, H, 1208(ab), 1237(ab)
Steinert, HC, 130(ab), 1235(ab), 1276(ab), 1278(ab)
Steinmetz, AP, 975(ab)
Steinmetz, ND, 312(ab)
Stelmachow, J, 1188(ab)
Stern, MB, 541(ab)
Sterry, W, 438(ab), 1231(ab), 1276(ab)
Steuart, R, 8(ab)
Stevens, H, 404(ab), 1008(ab), 1265(ab)
Steventon, R, 1656
Stief, C, 1197(ab)
Stochino, B, 87(ab)
Stöcklin, G, 818
Stodilka, RZ, 1116
Stoegbauer, F, 917(ab)
Stoessl, AJ, 29(ab)
Stokkel, MPM, 393
Stokking, R, 987(ab)
Stoll, H-P, 1375
Stoll, S, 377(ab)
St.Omer, S, 566(ab), 1021(ab)
Stomper, P, 579(ab)
Stone, CK, 55
Stone, D, 569(ab)
Stone, JL, 1078(ab)
Stopeck, AT, 312(ab)
Stout, D, 51(ab), 790(ab), 1023(ab)
Straehler-Pohl, HJ, 294(ab)
Strand, SE, 835(ab), 1026(ab), 1031(ab), 1563
Strashun, A, 550(ab)
Sträter, R, 245(ab)
Strätz, M, 47(ab)
Strauss, HW, 28(ab), 168(ab), 169(ab), 479(ab), 1383(ab), 1406(ab), 309, 1198
Strauss, LG, 120(ab), 125(ab), 465(ab), 788(ab), 1274(ab), 248, 713
Strauss, WH, 313(ab)
Stroobants, S, 95(ab), 112(ab), 446(ab), 1254(ab)
Studenov, AR, 424(ab), 1062(ab)
Studholme, C, 975(ab), 987(ab)
Stumpe, KD, 162(ab)
Stumpf, M, 35(ab), 399(ab)
Sturm, V, 238(ab)
Sturrock, S, 1288(ab)
Styblo, T, 434(ab)
Stypinski, D, 1418
Su, Z, 414(ab), 1169(ab)
Subirana, M, 516(ab)
Sud, K, 1446(ab)
Sudo, Y, 392(ab), 394(ab), 420(ab)
Sueyosi, K, 765(ab)
Suga, K, 292
Suga, Y, 769(ab)
Sugahara, H, 444(ab), 601
Sugawara, MD, 947(ab)
Sugawara, Y, 295(ab), 407(ab), 1297, 1446
Sugihara, H, 777(ab)
Sugimoto, K, 721(ab), 941(ab)
Sugimoto, T, 1430(ab)
Sugimura, K, 405(ab), 922(ab)
Suginami, Y, 1325(ab), 1334(ab)
Sugita, T, 1397(ab)
Sugiura, T, 752(ab), 769(ab)
Suh, YS, 1180(ab)
Suhara, T, 394(ab)
Suk, JW, 88(ab), 89(ab), 91(ab), 157(ab), 599(ab), 1366(ab)
Sukovic, P, 206(ab), 860(ab)
Sullivan, A, 22N(2), 26N(1)
Sullivan, GW, 1090(ab)
Sumkin, J, 1186(ab)
Sun, BM, 1005(ab)
Sun, CM, 251(ab)
Sun, D, 1322(ab)
Sun, H, 308(ab)
Sundaram, SK, 121(ab)
Sundaresan, G, 281(ab), 572(ab)
Sunderland, T, 903(ab)
Sung, MM, 791(ab)
Suzuki, K, 394(ab)
Suzuki, M, 962(ab), 965(ab), 969(ab)
Suzuki, S, 575
Suzuki, T, 130
Suzuki, Y, 725(ab), 1285(ab)
Svarer, C, 826(ab)
Swensen, SJ, 274(ab)
Swensson, R, 862(ab)
Sybrecht, GW, 276(ab)
Sykes, A, 1209(ab)
Syrbu, S, 1109
Syrota, A, 339(ab), 504(ab), 1415(ab), 1464, 1737
Szabo, Z, 958(ab), 1274
Szeverenyi, NM, 510(ab)
Szilvasi, I, 484(ab)
Sznyter, LA, 596(ab)
Szulc, M, 1050

Tadamura, E, 2(ab), 184(ab), 341(ab), 733(ab), 1239(ab)
Taddei, G, 45(ab), 116(ab), 476(ab), 781(ab), 1412(ab)
Tae, WS, 853
Taillefer, R, 14(ab)
Tait, J, 169(ab), 313(ab), 479(ab), 1383(ab), 309
Taizo, A, 1248(ab)
Tajima, T, 1285(ab)
Takahashi, J, 983(ab)
Takahashi, M, 721(ab), 805(ab), 821(ab), 941(ab), 1434(ab)
Takahashi, S, 1106(ab)
Takahashi, T, 707(ab), 708(ab), 821(ab), 985(ab), 1364(ab), 1434(ab), T, 575
Takahashi, W, 989
Takahashi, Y, 38
Takai, Y, 1106(ab)
Takamatsu, H, 1833
Takamatsu, S, 310(ab), 938(ab)
Takano, A, 394(ab)
Takano, K, 702(ab)
Takasaki, M, 1441
Takasawa, T, 408(ab)
Takazawa, K, 806(ab), 812(ab)
Takeda, K, 506(ab), 702(ab), 750(ab), 999(ab)
Takeda, Y, 1427(ab)
Takegami, T, 1476
Takehana, K, 752(ab), 1388
Takehara, K, 183
Takei, T, 448(ab), 1325(ab), 1333(ab), 1334(ab)
Takeishi, Y, 747(ab), 776(ab), 784(ab)
Takeuchi, N, 1215(ab)
Taki, J, 336(ab), 183, 1457, 1571, 1579
Taki, S, 977(ab), 1244(ab), 1284(ab), 1489
Talbot, JN, 463(ab), 487(ab)
Tam, Yk, 1418
Tamagnini, P, 1338(ab)
Tamaki, M, 1333(ab)
Tamaki, N, 2(ab), 33(ab), 69(ab), 197(ab), 222(ab), 244(ab), 296(ab), 313(ab), 338(ab), 341(ab), 448(ab), 731(ab), 763(ab), 773(ab), 774(ab), 775(ab), 778(ab), 810(ab), 923(ab), 1175(ab), 1325(ab), 1334(ab), 414, 780, 838, 1551
Tamaki, T, 344(ab)
Tamamura, H, 977(ab)
Tamim, W, 563(ab)
Tamir, A, 753(ab)
Tamizu, A, 1427(ab)
Tan, AS, 1302(ab)
Tan, C, 703(ab)
Tanada, S, 873(ab), 942(ab)
Tanaka, A, 69(ab), 821(ab), 1434(ab)
Tanaka, M, 575
Tanaka, R, 724(ab), 1351
Taneja, S, 1224(ab)
Tang, G, 1055(ab), 1063(ab)
Tang, HR, 891(ab), 237, 772, 1713
Tang, M, 30(ab)
Tang, X, 1055(ab), 1063(ab)
Tani, M, 1126(ab)
Taniguchi, M, 977(ab), 1244(ab), 1284(ab), 1489
Tanis, PJ, 436(ab), 574(ab)
Tanswell, P, 1291(ab)
Tao, YH, 703(ab)
Tapia-Palacios, M, 330(ab)
Tarkiainen, J, 419(ab), 1052(ab)
Tarutani, K, 870(ab)
Tashiro, M, 1397(ab)
Tasukamoto, E, 1334(ab)
Tateno, M, 782(ab), 1005
Tatlidil, R, 1194(ab)
Tatsch, K, 58(ab), 236(ab), 237(ab), 288(ab), 972(ab), 1059(ab)
Tatsumi, M, 289(ab), 444(ab), 601
Tausig, A, 335(ab)
Tavernier, R, 1(ab)
Tawakol, A, 87
Taylor, A, 101(ab), 1091(ab)
Taylor, LG, 384(ab)
Taylor, M, 55
Taylor, MR, 828(le)
Taylor, SE, 270(ab), 272
Tazawa, S, 707(ab), 708(ab)
Teipel, SJ, 47(ab), 1018(ab)
Telang, F, 424(ab)
Tembl, A, 516(ab)
Tempero, M, 1306(ab), 907
Templeton, NS, 284(ab)
Tenma, T, 1093(ab)
ter Linden, T, 509
Ter Veen, J, 1144(ab)
Terzi, A, 179(ab)
Tesar, R, 11N(4), 1286(ab)
Teule, GJ, 869(ab), 1139(ab)
Tewson, T, 64(ab),1080(ab), 679
Teytelboym, O, 592(ab)
Thadani, VJ, 986(ab)
Thakur, ML, 28N(10), 74(ab), 1089(ab)
Theilgaard, SA, 297(ab)
Theodore, L, 569(ab)
Thie, JA, 818(ab), 821(ab)
Thierens, H, 1722
Thille, A, 1195(ab)
Thimister, P, 177(ab), 312(ab), 1048(ab)
Thirion, J-P, 845
Thomas, CT, 829(ab)
Thomas, FD, 510(ab), 893(ab), 1216(ab)
Thomas, G, 300(ab)
Thomas, J, 446(ab)
Thomas, JD, 3(ab)
Thomas, M, 1264(ab)
Thomas, SR, 1033(ab), 520
Thompson, R, 1234(ab)
Thomson, LEJ, 534(le)
Thornback, JR, 154, 1722
Thrall, RS, 1109
Tian, Y, 1166
Tibballs, JM, 99(ab)
Tibbals, J, 1318(ab)
Tiepolt, C, 478(ab), 502(ab), 1104(ab)
Tikofsky, RS, 123(ab)
Tiling, R, 288(ab)
Tillapaugh-Fay, GM, 510(ab), 893(ab)
Timorek, A, 1188(ab)
Ting, G, 408, 542(ab), 543(ab), 956(ab), 967(ab), 1036(ab), 1303
Tjon Pian Gi, NP, 449(ab)
Tjuvajev, J, 239(ab), 260(ab), 1160(ab), 1161(ab)
Tobey, EA, 545(ab), 548(ab)
Tocharoenchai, C, 190(ab), 865(ab)
Tochon-Danguy, H, 250(ab), 300(ab)
Todd-Pokropek, A, 216(ab), 808(ab), 1737
Togasaki, D, 51(ab)
Togashi, K, 1087(ab)
Togni, LM, 1219(ab)
Togni, PH, 1219(ab)
Tokareva, E, 918(ab), 1125(ab)
Tokita, N, 169(ab), 285, 601
Tomas, MB, 165(ab), 166(ab), 596(ab), 1136(ab), 1137(ab)
Tominaga, A, 1054(ab)
Tomiyoshi, K, 1282(ab)
Tomoike, H, 747(ab), 776(ab), 784(ab)
Tompkins, RG, 147(ab), 1404(ab), 1420(ab)
Tonami, H, 977(ab), 1244(ab), 1284(ab)
Tonami, N, 336(ab), 466(ab), 1147(ab), 1151(ab), 1430(ab), 183, 596, 1457,1489, 1571, 1579
Tong, LX, 1218(ab)
Toniato, A, 1338(ab)
Torizuka, T, 442(ab), 1196(ab)
Tornai, MP, 363(ab), 888(ab)
Torre, DM, 132(ab)
Toubert, ME, 848(ab), 1464
Toulouse, KA, 1112(ab)
Touya, E, 577(ab)
Townsend, C, 384(ab)
Townsend, DW, 129(ab), 133(ab), 210(ab), 211(ab), 369(ab), 524(ab), 1186(ab), 533(le)
Toyama, H, 806(ab), 812(ab)
Toyama, Y, 959(ab)
Toyoda, H, 2(ab), 341(ab), 982(ab)
Toyohara, J, 310(ab), 1156(ab)
Toyokuni, T, 96, 572(ab), 1075(ab), 1078(ab), 1153(ab), 1185(ab)
Tran, C, 283(ab)
Tran, H, 1242(ab)
Tran, LL, 154
Traub, T, 1134(ab), 1309, 1856
Travaini, L, 573(ab)
Travin, MI, 1757
Treffert, J, 369(ab)

Treleaven, JG, 1300(ab)
Tremblay, M, 854(ab)
Treves, ST, 209
Trifirò, G, 573(ab)
Trivedi, MH, 535, 1059
Troost, J, 963(ab)
Trouillet, JL, 167(ab)
Trubatch, S, 14N(6), 24N(5)
Truong, DC, 787(ab)
Tsai, S-C, 17
Tsay, DG, 780(ab), 1365(ab)
Tseng, YJ, 824(ab)
Tsopelas, C, 460
Tsuboi, N, 1747
Tsuchida, D, 965(ab), 1439(ab)
Tsuchida, T, 1156(ab)
Tsuchihashi, K, 1757
Tsuchimochi, M, 378(ab)
Tsui, BM, 23(ab), 190(ab), 203(ab), 217(ab), 527(ab), 530(ab), 718(ab), 833(ab), 836(ab), 837(ab), 846(ab), 865(ab)
Tsujimura, E, 285
Tsujitani, M, 1106(ab)
Tsukada, H, 1833
Tsukamoto, E, 69(ab), 222(ab), 244(ab), 296(ab), 313(ab), 414, 448(ab), 763(ab), 780, 810(ab), 1175(ab), 1325(ab), 1333(ab), 1551
Tuda, N, 1425(ab)
Tuncel, A, 507(ab)
Tunç, L, 507(ab)
Tuomivaara, V, 802(ab)
Turcot-Lemay, L, 1418(ab)
Turkington, T, 131(ab), 367(ab)
Türkmen, C, 567
Turlakow, A, 420
Turner, JH, 1313(ab)
Turoglu, HT, 1352(ab)
Turzo, A, 1370(ab)
Tweddle, A, 186(ab)
Twieg, DB, 981(ab)
Tyndale-Hines, L, 1251(ab)
Tzen, KY, 542(ab), 543(ab), 967(ab), 408

Uchida, H, 1262(ab), 1410(ab), 1436(ab)
Uchida, Y, 946(ab)
Uchiyama, A, 812(ab)
Uchiyama, H, 1439(ab)
Uchimaya, M, 965(ab), 1439(ab)
Udelsman, R, 594(ab), 595(ab), 1355(ab)
Ueberfuhr, P, 505(ab), 1011
Ueda, T, 407(ab), 773(ab), 1297
Ueda, Y, 1284(ab), 1476, 1489
Uemura, K, 806(ab), 812(ab)
Ueno, M, 982(ab)
Ueno, Y, 809(ab)
Uffelman, W, 14N(10), 16N(11), 18N(4), 22N(2), 26N(1), 27N(12), 28N(7), 30N(6), 31N(8), 33N(9), 34N(5)
Ukena, D, 276(ab)
Ulbrich, E, 744
Uldall, P, 145(ab)
Uma Devi, M, 327(ab)
Umemura, K, 1833
Ünlü, M, 507(ab)
Uno, M, 1441
Unzek, S, 737(ab)
Urbain, J-LC, 106, 1670
Uren, RF, 452
Uribe, J, 365(ab), 624
Ushijima, Y, 46(ab), 1789
Uslu, I, 567
Usui, K, 489(ab), 1447(ab)
Usui, Y, 1434(ab)
Utunomiya, K, 765(ab)

Vaalburg, W, 314(ab), 432, 449(ab), 712(ab), 1025, 1167(ab)
Vabuliene, E, 473(ab)
Vafaee, M, 1032
Vaggu, K, 326(ab), 327(ab)
Valdés Olmos, RA, 436(ab), 574(ab)
Valdazo, A, 299(ab)
Valdivia, A, 279(ab)
Valent, P, 706(ab)
Valente, N, 455(ab)
Valentin, L, 867(ab)
Valentine, JD, 717(ab)
Valette, H, 932
Valk, P, 562(ab), 1190(ab), 586
Valk, PE, 853(ab), 1286(ab), 1139, 1334
Valkema, R, 79, 135(ab), 222, 1353(ab)
Vallabhajosula, S, 441(ab), 443(ab), 458(ab), 566(ab), 1021(ab), 1051(ab)
Vallieres, E, 106(ab), 559(ab)
Vallis, K, 1073(ab)
Van Acker, F, 44
van Balen, SC, 843(ab)
Van Belle, S, 1818
van Berckel, BN, 531(ab)
VanBrocklin, HF, 270(ab), 272
Van Crombrugge, P, 1343(ab)
Vandecapelle, M, 1056(ab)
van de Heuvel, JJB, 856(ab)
van den Aardweg, G, 468(ab)
Vandenberghe, P, 95(ab), 446(ab)
Vandenberghe, S, 41(ab), 705(ab), 1266(ab), 1396(ab)
Vandenbossche, B, 1266(ab)
VandenBroecke, R, 1818
van den Hoff, J, 544(ab), 1174, 1438(le)
Van den Wijngaard, RM, 317(ab)
van der Groep, P, 94(ab)
van der Hoeven, JJ, 94(ab)
van der Leest, A, 579
van der Meer, JWM, 117
van der Wall, EE, 94(ab), 348(ab), 509(ab)
Van der Wall, H, 11N(7)
van der Wee, NJ, 404(ab), 1008(ab)
van der Weerdt, AP, 842(ab), 1622
Van de Wiele, C, 1(ab), 705(ab), 764(ab), 1266(ab), 1396(ab), 1722, 1818
van Diest, PJ, 94(ab)
van Dijk, A, 1302(ab)
van Dongen, AJ, 86(ab)
van Dongen, GA, 509
van Dongen, GAMS, 1364
van Eck Smit, BLF, 1863
van Eerd, J, 272(ab), 568(ab), 1389(ab), 1405
van Eijck, HJ, 1304(ab), 1305(ab)
Van Every, B, 191(ab)
van Gameren, A, 470(ab), 1303(ab), 1841
Van Hagen, M, 413(ab)
Van Harskamp, E, 470(ab)
van Heerdan, BB, 484(ab)
Van Heertum, R, 57(ab), 60(ab), 123(ab), 396(ab), 531(ab), 850(ab)
Van Heertum, RL, 22N(1)
van het Schip, AD, 1145(ab), 1302(ab)
Van Horn, JR, 1144(ab)
Van Hove, C, 1432(ab)
Vanhove, C, 401, 726(ab), 1171(ab)
Van Laere, KJ, 41(ab), 43(ab), 229(ab), 231(ab), 361
van Lier, JE, 96(ab), 1076(ab)
Vanlingen, A, 869(ab)
van Lingen, A, 79, 808, 843(ab)
van Megen, HJ, 1008(ab)
van Putten, JWG, 579
van Putten, WL, 222
Van Raemdonck, D, 1254(ab)
van Rijk, PP, 86(ab), 404(ab), 856(ab), 1008(ab), 1265(ab), 1302(ab)
van Schaijk, FG, 568(ab)
Vansteenkiste, J, 112(ab), 1254(ab)
Van Train, KF, 391(le)
Van Valen, F, 1390(ab)
van Vliet, IM, 404(ab)
van Waarde, A, 314(ab), 1025
van Zandwijk, N, 1254(ab)
Vanzetto, G, 1395
Vaporciyan, A, 1099(ab)
Varga, J, 958(ab)
Vargas, JP, 1448(ab)
Varrone, A, 795(ab), 925(ab)
Vas, A, 907(ab)
Vasdev, N, 1079(ab)
Vaska, P, 872(ab)
Vatamaniuk, M, 269(ab)
Veatch, J, 1713
Vedala, G, 196(ab), 360(ab)
Veen, F, 404(ab)
Venegas, R, 868(ab)
Vensel, E, 330(ab)
Vento, J, 1109
Vera, DR, 386(ab), 430(ab), 110, 733, 951
Vera, P, 1030(ab)
Vercouille, J, 419(ab), 1052(ab)
Verdonck, P, 705(ab)
Veress, A, 193(ab)
Verga, U, 1337(ab)
Verhey, F, 963(ab)
Verhoef, G, 95(ab), 446(ab)
Verhoeff, NP, 61(ab)
Vermaelen, P, 95(ab)
Vernaleken, I, 59(ab), 928(ab)
Vernon, C, 813(ab),1275(ab)
Veronesi, U, 573(ab)
Versijpt, J, 41(ab), 43(ab), 361, 1343(ab)
Vespa, PM, 992(ab)
Vessella, RL, 554(ab)
Vesselle, H, 40(ab), 106(ab), 520(ab), 559(ab)
Veyre, A, 141
Veyrelle, P, 90(ab)
Viale, G, 433(ab), 573(ab), 1198
Videen, TO, 1195
Viergever, MA, 856(ab)
Vigário, AO, 1228(ab)
Vighi, C, 894(ab)
Vignola, S, 1151
Viguet, M, 1165(ab), 1356(ab)
Vilain, D, 511(ab)
Vilardell, M, 738
Villa, G, 45(ab), 116(ab), 476(ab), 781(ab), 1198, 1412(ab)
Villemagne, PM, 146(ab)
Villemagne, V, 328(ab), 921(ab), 1423(ab), 146(ab)
Vincent, J, 1086(ab)
Vincent, RM, 726
Vini, L, 78(ab)
Vining, M, 1307(ab)
Vinot, S, 848(ab)
Vinters, HV, 242(ab)
Virgolini, I, 706(ab), 1134(ab), 1309, 1856
Visser, CA, 79, 1622
Visser, FC, 842(ab), 79, 1622
Visser, GW, 509
Visser, TJ, 75(ab), 1841
Vissuzaine, C, 103(ab)
Visvikis, D, 384(ab)
Vitale, GD, 1730
Vitali, P, 45(ab), 1151
Vitola, JV, 183(ab)
Viviani, LF, 1228(ab)
Vlček, P, 1084
Vlock, D, 1291(ab)
Voges, J, 238(ab), 467
Vogg, AT, 109(ab), 1150(ab)
Volenberg, I, 494(ab)
Volkert, WA, 1067(ab), 1149(ab)
Volkow, ND, 52(ab), 53(ab), 56(ab), 377(ab), 400(ab), 402(ab), 403(ab), 410(ab), 897(ab), 904(ab), 906(ab), 908(ab), 1009(ab), 1011(ab), 1012(ab)
Voltini, F, 1444(ab)
vom Dahl, J, 723(ab), 734(ab)
Vonck, K, 231(ab)
von Forstner, C, 475(ab), 1422(ab), 1545
von Scheidt, W, 1011
von Schilling, C, 456(ab)
von Schulthess, GK, 42(ab), 130(ab), 162(ab), 212(ab), 740(ab), 1208(ab), 1235(ab), 1237(ab), 1276(ab), 1278(ab)
Vosberg, H, 209(ab), 1691
Vose, J, 1292(ab)
Vose, JM, 907
Votaw, JR, 376, 701, 861(ab), 911(ab), 1053(ab)
Voth, E, 5(ab)
Vranjes, S, 1309(ab)
Vranjesevic, D, 301(ab), 461(ab), 464(ab), 1130(ab)
Vreeling, F, 963(ab)
Vresilovic, E, 481(ab), 485(ab)

Wachsmuth, C, 929(ab)
Wackers, FJ, 173(ab), 177(ab), 349(ab)
Wackers, FJT, 528(le)
Wada, H, 1106(ab)
Wada, Y, 920(ab), 938(ab)
Waechter, P, 174(ab), 758(ab)
Waechter, PB, 1630
Wagenknecht, G, 24(ab)
Wagner, HN, 146(ab), 415(ab), 12N(8)
Wagner, R, 238(ab)
Wagner, W, 1202(ab)
Wahl, R, 460(ab), 582(ab), 1292(ab), 1293(ab)
Wahl, RL, 83(ab), 92(ab), 295(ab), 307(ab), 388(ab), 829(ab), 1173(ab)
Waiter, C, 577(ab)
Wakabayashi, H, 467(ab)
Wakabayashi, T, 1757
Wakasugi, S, 976(ab), 1267(ab)
Wakefield, M, 1115(ab)
Waki, A, 310(ab), 920(ab), 938(ab), 1152(ab), 1156(ab)
Waldherr, C, 136(ab)
Waldmann, TA, 567(ab), 1538
Waldrop, S, 434(ab)
Walgraeve, N, 726(ab)
Waligora, M, 755(ab)
Walker, B, 23N(1)
Wallace, AM, 430(ab), 951
Wallace, S, 1074(ab), 1530
Wallack, M, 576(ab)
Wallhaus, TR, 55
Wallis, JW, 1192
Walsh, JC, 1075(ab), 1078(ab)
Walz, A, 268(ab)
Wan, WX, 703(ab)
Wand, G, 399(ab)
Wang, CH, 187(ab)
Wang, CK, 376
Wang, GJ, 400(ab), 402(ab), 403(ab), 410(ab), 906(ab), 908(ab), 1009(ab), 1011(ab), 1012(ab)
Wang, HE, 251(ab), 1036(ab), 1154(ab), 345
Wang, J, 492(ab), 495(ab), 1073(ab), 1315(ab)
Wang, JK, 792(ab)
Wang, LG, 1315(ab)
Wang, M, 1055(ab)
Wang, Q, 1322(ab)
Wang, RF, 390(ab), 1092(ab), 1301(ab), 1443(ab)
Wang, S, 556(ab), 557(ab), 1805
Wang, SC, 67(ab)
Wang, W, 190(ab)
Wang, WT, 527(ab), 832(ab), 865(ab)

Wang, Y, 73(ab), 203(ab), 261(ab), 365(ab), 423(ab), 833(ab), 1060(ab), 1063(ab), 1102(ab), 624, 1660
Wang, YL, 280(ab), 282(ab)
Wang, Y-S, 345
Ward, CA, 935(ab)
Ware, R, 1158
Ware, RE, 1596, 1605
Warnaar, S, 1289(ab)
Washimi, Y, 962(ab)
Wasmuth, HH, 597(ab)
Wassmann, H, 245(ab)
Watabe, H, 795(ab), 925(ab), 926(ab), 937(ab)
Watanabe, K, 182(ab), 707(ab), 708(ab), 729(ab)
Watanabe, N, 873(ab), 942(ab)
Watanabe, T, 1228(ab), 1371(ab)
Watanabe, W, 1364(ab), 1434(ab)
Watanabe, Y, 702(ab), 750(ab), 999(ab)
Watawana, L, 1314(ab)
Waterhouse, RN, 421(ab), 531(ab)
Waterstram-Rich, K, 10N(1)
Watkins, GL, 64(ab), 935(ab), 1080(ab)
Watkinson, AJ, 99(ab), 1318(ab)
Watson, CC, 369(ab)
Watson, DD, 1388
Watumull, LM, 1356(ab)
Watzlowik, P, 712(ab)
Waxman, AD, 104(ab), 113(ab), 445(ab), 1193(ab), 1234(ab)
Webb, EG, 1064(ab)
Webber, RL, 1121
Weber, W, 1170(ab), 9, 326
Weber, WA, 293(ab), 298(ab), 306(ab), 473(ab), 915(ab), 978(ab), 1251(ab), 1144
Weckesser, E, 544(ab), 598(ab), 1197(ab), 1296(ab), 1376(ab), 1174
Weckesser, M, 245(ab)
Wedel, N, 1072(ab)
Wegman, TD, 1167(ab)
Weilhammer, P, 206(ab)
Weinberg, IN, 302(ab), 868(ab)
Weinberg, WA, 1059
Weinberger, DR, 397(ab), 401(ab), 903(ab)
Weiner, MF, 943(ab), 1131(le)
Weiner, RE, 1109
Weinstein, RS, 578(ab)
Weinzapfel, BT, 483
Weise, S, 128(ab), 918(ab)
Weisenbach, S, 902(ab)
Weisenberger, AG, 960
Weisner, N, 238(ab)
Weissleder, R, 286(ab)
Welch, MJ, 93(ab), 450(ab), 655
Welcke, U, 160(ab), 1354(ab)
Wellens, H, 177(ab)
Welling, MM, 788
Wells, C, 1225(ab)
Wells, JM, 370(ab)
Wells, RG, 523(ab)
Welsh, RJ, 287(ab)
Welt, S, 764, 1251, 1281, 1291(ab)
Wémeau, J-L, 993
Wen, WT, 187(ab)
Wen, X-X, 1074(ab), 1530
Wencker, M, 744
Wendt, RE, 830(ab)
Wenzel, B, 255(ab)
Werbin, N, 998
Wermke, M, 1018(ab)
Wescott, C, 73(ab), 1102(ab)
Wess, J, 535(ab)
Wessell, DE, 203(ab), 833(ab)
Wessels, BW, 81(ab), 1034(ab)
Westenberg, HG, 404(ab), 1008(ab)
Westendorp, B, 1145(ab)
Wester, HJ, 429(ab), 473(ab), 555(ab), 915(ab), 1146(ab), 1170(ab), 326
Wey, SP, 542(ab), 543(ab), 956(ab), 967(ab), 408, 1303
Whang, J, 118(ab)
Whatley, M, 121(ab), 1316, 1359
Wheatley, JM, 1288(ab)
White, CA, 76(ab), 1115(ab), 1124(ab)
White, CL, III, 943(le), 1131(le)
White, M, 701
Whiteley, M, 76(ab)
Whitener, D, 1070(ab)
Whybrow, PC, 955(ab)
Wiebe, L, 1159(ab), 1168(ab), 1418, 1679
Wienhard, K, 238(ab), 467
Wiens, L, 1184(ab)
Wikström, HV, 1058(ab)
Wilbert, S, 569(ab)
Wilbur, DS, 554(ab), 1516
Wilcox, K, 911(ab)
Wilderman, SJ, 206(ab), 383(ab), 887(ab)
Wildt, L, 1357(ab)
Wiley, CW, 905(ab)
Wilhelm, AJ, 1364
Wilk, M, 882(ab)
Willeke, F, 713
Willemsen, A, 798(ab)
Willemsen, ATM, 1167(ab), 1025
Willendrup, P, 826(ab)
Williams, CM, 113(ab), 445(ab), 1193(ab)
Williams, K, 1730
Williams, M, 186(ab), 1388(ab)
Williams, RC, 302(ab)
Williamson, PD, 234(ab), 986(ab)
Willoch, F, 47(ab), 224(ab), 548
Wilson, AA, 62(ab), 391(ab), 392(ab), 895(ab)
Wilson, DL, 36(ab), 1226(ab)
Wilson, DM, 258(ab)
Wilson, JM, 240(ab)
Windhorst, AD, 425(ab)
Wingárdh, K, 1563
Winkle, WL, 1375
Winkler, J, 199(ab)
Winter, H, 438(ab), 1231(ab)
Winters, S, 917(ab)
Winthrop, MD, 571(ab)
Winzer, KJ, 439(ab)
Wisecarver, J, 1519
Wiseman, GA, 76(ab), 580(ab), 1115(ab), 1124(ab), 1289(ab), 1291(ab)
Wiseman, RW, 913(ab)
Witjes, JA, 1199(ab)
Witzig, TE, 1115(ab)
Wojcik, R, 960
Wolf, B, 269(ab)
Wolf, I, 456(ab), 818
Wolff, H, 1277(ab)
Wolpers, H-G, 1174
Woltering, EA, 530(le)
Won, KJ, 354(ab)
Won, KS, 1097(ab)
Wong, C, 400(ab), 402(ab), 1011(ab), 826(le)
Wong, CO, 24N(12)
Wong, CS, 1169(ab)
Wong, CT, 410(ab), 1009(ab), 1012(ab)
Wong, CYO, 287(ab)
Wong, DF, 59(ab), 146(ab), 309(ab), 374(ab), 533(ab), 537(ab), 800(ab), 927(ab), 928(ab)
Wong, FC, 1028(ab)
Wong, GR, 952(ab)
Wong, GW, 1028(ab)
Wong, KH, 891(ab), 772
Wong, KJ, 567(ab), 1141(ab), 1538
Wong, KP, 789(ab)
Wong, TZ, 131(ab)
Wong, WH, 365(ab), 624
Wong, WL, 525(ab)
Woo, JI, 950(ab)
Woo, KS, 1158(ab)
Woo, M, 342(ab)
Woo, SK, 851(ab)
Wood, DE, 106(ab), 559(ab)
Woodcock, J, 1409(ab)
Woody, CL, 377(ab), 872(ab)
Woolf, A, 1426(ab)
Woolfenden, JM, 312(ab)
Wörmann, B, 1227(ab)
Wormstall, H, 31(ab)
Worsley, D, 8(ab)
Wrase, J, 398(ab)
Wright, GA, 350(ab)
Wu, AM, 572(ab), 1075(ab), 1078(ab)
Wu, CH, 1330(ab)
Wu, H, 125(ab)
Wu, HM, 230(ab), 551(ab), 814(ab), 992(ab)
Wu, J, 561(ab)
Wu, K, 492(ab), 495(ab)
Wu, L, 282(ab)
Wu, LC, 21(ab), 111(ab), 358(ab), 452(ab), 491(ab), 792(ab), 824(ab), 979(ab)
Wu, LS, 453(ab)
Wu, MC, 205(ab), 891(ab), 772
Wu, MH, 358(ab)
Wu, Q-P, 1074(ab), 1166, 1530
Wu, Y, 395(ab), 786(ab)
Wu, YW, 1154(ab)
Wunderlich, G, 744, 1104(ab), 1320(ab)
Wyillie, E, 233(ab)
Wyndaele, DN, 9(ab)
Wyss, CA, 740(ab)

Xian-feng, L, 1440(ab)

Yaban, B, 101(ab)
Yachiku, S, 1447(ab)
Yaes, RJ, 1041(ab)
Yaghoubi, SS, 1153(ab), 1225
Yama, N, 1361(ab)
Yamada, M, 535(ab)
Yamada, S, 731(ab), 1106(ab), 838
Yamada, T, 736(ab), 957(ab), 962(ab)
Yamaga, L, 1371(ab)
Yamaguchi, H, 1369(ab)
Yamaguchi, K, 315(ab), 1207(ab), 1397(ab)
Yamaguchi, S, 747(ab), 776(ab), 784(ab)
Yamaguchi, Y, 28(ab)
Yamamoto, AJ, 1412
Yamamoto, I, 977(ab), 1244(ab), 1284(ab), 1476, 1489
Yamamoto, N, 1297
Yamamoto, S, 870(ab)
Yamamoto, W, 489(ab), 766(ab), 1447(ab), 1017
Yamamoto, Y, 115(ab), 467(ab), 959(ab), 997(ab), 1138(ab), 1213(ab), 1260(ab)
Yamane, T, 1262(ab), 1410(ab), 1436(ab)
Yamane, Y, 1106(ab)
Yamashita, S, 1213(ab)
Yamauchi, A, 1213(ab)
Yamauchi, H, 941(ab)
Yamazaki, N, 1435(ab)
Yamazaki, T, 1106(ab)
Yamazaki, Y, 809(ab)
Yanai, K, 537(ab)
Yang, D, 1028(ab)
Yang, DJ, 97(ab), 263(ab), 311(ab), 409(ab), 1082(ab), 1099(ab), 1283(ab)
Yang, H, 283(ab)
Yang, JC, 121(ab)
Yang, SC, 1281(ab)
Yang, SD, 1180(ab)
Yanik, G, 143(ab)
Yano, M, 289(ab)
Yao, WJ, 1015(ab)
Yao, Z, 567(ab), 1141(ab), 1538
Yap, CS, 277(ab), 1249(ab), 1139, 1334
Yaster, M, 146(ab)
Yasuda, S, 1285(ab), 989
Yasuda, T, 289(ab)
Yasumura, Y, 503(ab), 762(ab)
Yasuno, F, 394(ab)
Yatsuyanagi, A, 1435(ab)
Yau, E, 569(ab)
Yazaki, PJ, 572(ab)
Ye, J, 838(ab)
Yefremov, N, 127(ab), 164(ab)
Yeh, E, 551(ab), 992(ab)
Yeh, SD, 420
Yeh, SH, 21(ab), 111(ab), 251(ab), 358(ab), 452(ab), 453(ab), 979(ab)
Yeldell, D, 79(ab), 588(ab)
Yen, SH, 453(ab), 345
Yen, TC, 542(ab), 543(ab), 967(ab), 408
Yeo, JS, 15(ab), 16(ab), 17(ab), 19(ab), 39(ab), 148(ab), 220(ab), 497(ab), 500(ab), 738(ab), 748(ab), 782, 938, 950(ab), 980(ab), 1094(ab), 1135(ab), 1142(ab), 1177(ab), 1182(ab), 1220(ab), 1245(ab)
Yeshurun, D, 490(ab)
Yeung, H, 1236(ab)
Yeung, HW, 815(ab), 1339(ab), 420, 1129(le), 1130(le)
Yin, D, 1063(ab)
Yip, TK, 728(ab)
Yokoi, T, 940(ab)
Yokota, H, 977(ab)
Yokota, M, 1747
Yokoyama, I, 782(ab), 802, 1005
Yokoyama, J, 1207(ab)
Yokoyama, K, 344(ab), 466(ab), 1147(ab), 1151(ab), 1430(ab), 596
Yokoyama, S, 624
Yokozuka, K, 845(ab)
Yonase, J, 1407(ab)
Yonekura, K, 782(ab), 1005
Yonekura, Y, 310(ab), 777(ab), 801(ab), 920(ab), 926(ab), 938(ab), 1152(ab), 1156(ab), 755
Yoneyama, T, 1579
Yonezawa, T, 720(ab)
Yoo, H, 126(ab)
Yoo, IR, 1416(ab), 1441(ab)
Yoon, CH, 332(ab)
Yoon, JH, 1101(ab)
Yoon, J-K, 772(ab), 954(ab), 1187(ab), 1342(ab), 1400(ab)
Yoon, SN, 1004(ab), 1039(ab), 1131(ab), 1204(ab), 1319(ab)
Yoon, SY, 332(ab)
Yoon, YK, 497(ab)
Yordanov, A, 1538
Yoriyaz, H, 662
Yorke, E, 124(ab), 1255(ab)
Yoshida, S, 1215(ab)
Yoshikawa, E, 442(ab), 1196(ab), 707
Yoshikawa, K, 802
Yoshikawa, T, 408(ab)
Yoshimoto, M, 920(ab), 1152(ab), 1156(ab)
Yoshimoto, T, 543
Yoshimura, I, 1407(ab)
Yoshinaga, K, 197(ab), 338(ab), 414, 731(ab), 763(ab), 774(ab), 775(ab), 778(ab), 810(ab), 838
Yoshioka, J, 809(ab)
Yoshioka, K, 378(ab)
Yoshioka, S, 820(ab)
Young, JW, 1286(ab)
Young, SA, 318(ab)
Young, VR, 1404(ab), 1420(ab)
Younsi, N, 463(ab), 487(ab)

Yousry, TA, 972(ab)
Yovanovich, J, 180(ab)
Ysteng, PK, 597(ab)
Yu, CL, 452(ab), 453(ab), 792(ab)
Yu, DF, 97(ab), 311(ab), 1099(ab)
Yu, HM, 1036(ab), 1154(ab)
Yu, KH, 1180(ab)
Yu, X, 387(ab)
Yu, YL, 1336(ab)
Yu, YM, 1404(ab), 1420(ab)
Yuan, CC, 453(ab)
Yuan, ZB, 714(ab)
Yuda, S, 1757
Yue, D, 492(ab), 495(ab)
Yuki, K, 747(ab), 776(ab), 784(ab)
Yuki, M, 1106(ab)
Yumoto, K, 344(ab)
Yun, M, 4(ab), 118(ab), 275(ab), 485(ab), 498(ab), 1198(ab), 1233(ab), 1259(ab), 1414(ab), 1417(ab), 1795
Yurt, F, 1105(ab)
Yusuf, E, 124(ab)
Yutani, K, 845(ab), 285
Yuyama, R, 752(ab), 769(ab)

Zabel, PL, 71(ab), 1123(ab)
Zaid, T, 1409(ab)
Zaidi, H, 840(ab)
Zajko, A, 1317(ab)
Zakko, S, 311(ab), 1082(ab)
Zaknun, JJ, 949(ab)
Zalutsky, MR, 454(ab), 1508
Zamora, PO, 1297(ab)
Zamora, PP, 1298(ab)
Zanco, P, 198(ab), 345(ab)
Zander, A, 438(ab), 439(ab)
Zanzonico, PB, 875(ab), 1653
Zasadny, K, 83(ab), 307(ab), 388(ab), 829(ab)
Zasloff, MA, 1077(ab)
Zavosky, LA, 192(ab), 817(ab)
Zawarzin, V, 302(ab)
Zea-Ponce, Y, 910(ab)
Zehetgruber, M, 746(ab)
Zelenetz, A, 1292(ab)
Zeng, GL, 26(ab), 518(ab)
Zeng, S, 492(ab), 495(ab)
Zettinig, G, 591(ab)
Zhang, CL, 1092(ab)
Zhang, D, 1322(ab)
Zhang, G, 1388(ab)
Zhang, L, 397(ab), 887(ab), 1063(ab)
Zhang, LF, 703(ab)
Zhang, LY, 119(ab)
Zhang, M, 567(ab)
Zhang, MR, 394(ab)
Zhang, RJ, 703(ab)
Zhang, WJ, 970(ab)
Zhang, X, 1166
Zhang, YM, 261(ab), 1083(ab), 1102(ab)
Zhang, Y-M, 1660
Zhang, Z, 201(ab), 202(ab), 265(ab), 424(ab), 1230(ab)
Zhao, CL, 1368(ab), 1447(ab)
Zhao, DS, 279(ab)
Zhao, J, 970(ab), 1005(ab)
Zhao, S, 313(ab), 1175(ab)
Zhano, XD, 846(ab)
Zhano, XG, 454(ab)
Zhano, Z, 518(ab), 838(ab)
Zhao, C, 1017
Zhao, S, 1551
Zhao, X-G, 1508
Zheng, L, 552(ab)
Zhou, JS, 1284(ab), 1476
Zhou, X, 67(ab)
Zhou, Y, 374(ab), 533(ab), 537(ab), 800(ab), 928(ab)
Zhu, J, 714(ab)
Zhu, M, 1301(ab)
Zhu, RS, 714(ab), 1164(ab), 1336(ab)
Zhu, SL, 1301(ab)
Zhu, TC, 1233(ab)
Zhu, W, 22(ab)
Zhu, Z, 67(ab), 73(ab), 414(ab), 420(ab), 910(ab), 1660
Zhuang, H, 44, 1412
Zhuang, HM, 122(ab), 161(ab), 273(ab), 275(ab), 328(ab), 477(ab), 482(ab), 1246(ab), 1257(ab), 1280(ab), 1327(ab)
Zhuikov, BL, 1086(ab)
Ziegler, SI, 306(ab), 382(ab), 473(ab), 871(ab), 915(ab), 1170(ab), 1011, 1265
Ziegler, SJ, 213(ab)
Ziessman, HA, 316(ab), 1238(ab)
Zijlstra, JM, 1139(ab)
Zilleruelo, G, 330(ab)
Zimák, J, 1084
Zimmer, L, 894(ab)
Zimmer, M, 1115(ab)
Zimny, M, 852(ab)
Zimran, A, 1129(ab)
Zinn, KR, 258(ab)
Zinzani, PL, 1126(ab)
Zito, F, 227(ab)
Zittel, T, 483(ab), 1408(ab), 1091
Ziviello, M, 884
Zoboli, S, 134(ab)
Zoe, H, 441(ab), 443(ab), 458(ab)
Zoghbi, SS, 61(ab), 539(ab), 925(ab), 1013(ab)
Zonnenberg, BA, 1302(ab)
Zubaid, M, 713(ab)
Zubal, IG, 633, 889(ab), 987(ab)
Zubeldia, JM, 304(ab), 1221(ab)
Zubieta, JK, 44(ab)
Zuckerman, E, 490(ab)
Zuckier, LS, 987(le), 1346(ab)
Zuhayra, M, 475(ab), 1399(ab), 1545
Zündorf, G, 902(ab)
Zuo, CHT, 1005(ab)
Zuo, CT, 970(ab)
Zuo, Y, 569(ab)
Zweit, J, 764, 880(ab), 1209(ab)
Zylla, S, 727(ab)
Zyuzin, A, 1086(ab)

A

Abdomen, whole-body FDG PET, combined with CT, 129(ab)
Absorptiometry, femoral neck and total hip bone, mineral density comparison, 486(ab)
Academy of Molecular Imaging, 26N(2)
Acetate
choline and, cell growth markers of lipid synthesis, 1152(ab)
metabolism, androgenic control, prostate cancer, 93(ab)
2-^{14}C, preferential labeling with, brain tumors, 1243
Acetazolamide
balloon occlusion test, cerebral blood flow during, 407(ab)
challenge, internal carotid artery balloon test, cerebral vascular reserve, 982(ab)
^{123}I IMP SPECT, detection of misery perfusion by, 408(ab)
stress brain perfusion SPECT, after carotid endarterectomy, 406(ab)
Acetylcholine esterase, activity, parametric imaging, Alzheimer disease, 902(ab)
Actinium
^{225}Ac in nanogenerators for therapy, 32N(12)
Activation study
brain SPECT, statistical parameter for, validation of, 41(ab)
cognitive, brain bolus arrival time, normal subjects, 935(ab)
direct comparison of $^{10}CO_2$, H_2, ^{14}O, and $H_2{}^{15}$, 924(ab)
posterior parietal cortex, discrimination of upper limb gestures, 929(ab)
speech, language dominant hemisphere, 996(ab)
visual, ^{18}F fluoromethane in Rhesus monkey, 934(ab)
Addiction
alcohol detoxification, receptor imaging before and after, 1010(ab)
cocaine detoxification, effects on benzodiazepine-induced changes in cerebral metabolism, 1011(ab)
effects of low-dose cocaine, dopamine transporter pre-blockade, 403(ab)
methamphetamine, loss of dopamine transporters, recovery after detoxification, 402(ab)
methamphetamine detoxification, thalamic but not striatal metabolism recovery, 1012(ab)
vigabatrin role in, synthesis and PET studies, 424(ab)
Adenocarcinoma. *see also* specific type or site
pancreas, CA19–9 and blood glucose as tumor marker, CT and PET, 1105(ab)
three-step pretargeting mAb protocol, biodistribution and dosimetry, 670
Adenoma. *see also* specific type or site
colonic, FDG PET detection, 989
parathyroid
comparison of ^{99m}Tc delayed imaging in, 1355(ab)
ectopic, localization with ^{99m}Tc sestamibi, 595(ab)
^{99m}Tc sestamibi localization, hyperparathyroid patients, 594(ab)
pituitary, ^{201}Tl SPECT for evaluation of, 575
Adenosine triphosphate, stress perfusion imaging, safety profile, 182(ab)
Adhesion molecules, ^{111}In-labeled intracellular, oleic acid-induced lung injury, 1109
Adrenal masses
CT or MRI, characterization with FDG PET, 1795
detected on CT or MRI, FDG PET in characterization of, 1259(ab)
in lung cancer, FDG PET characterization of, 564(ab)
nonhypersecreting, radionuclide imaging in, 884, 893
Aerosols, lung deposition, planar scintigraphy, 1077
Aging
effects on heterogeneity, cerebral glucose metabolism, 953(ab)
effects on myocardial substrate utilization, dobutamine-induced changes, 196(ab)
healthy, voxel-based morphometry *versus* perfusion SPECT, 229(ab)
increased lung uptake and, likelihood of cardiovascular events, 783(ab)
normal, effects on regional cerebral glucose metabolism, 954(ab)
Albumin, macroaggregated, safety, letter to the Newsline editor, 20N(4)
Alcoholism
craving and relapse in, opioid receptor availability and, PET study, 398(ab)
detoxification, receptor imaging before and after, ^{11}C CFT in, 1010(ab)
detoxification effects, brain dopamine transporters and D2 receptors, 400(ab)
partial volume correction, brain Mu opioid receptor binding before and after, 399(ab)
primate model, serotonin transporter availability with alcohol intake, 401(ab)
Alendronate, effects on ^{99m}Tc MDP bone scanning, 1359
Alpha-particle emitters
bismuth accumulation in kidneys, lysine protection, 570(ab)
cellular dose conversion factors in radionuclide therapy, 1216, 1222
cellular retention of, 1538
high-level production, ^{211}At-labeled antibody preparation and, 1508, 1516
recurrent glioma, 454(ab)
Alzheimer's disease
acetylcholine esterase activity, parametric imaging, 902(ab)
amyloid assessments in, lipophilic ^{11}C-labeled derivative of thioflavin-T for, 423(ab)
atrophy and FDG uptake changes, persons at risk for, partial volume effect for investigation of, 230(ab)
audiovisual stimulation, functional reorganization of cerebral responses to, 47(ab)
blood flow changes correlate with cognitive function changes, ^{99m}Tc HMPAO SPECT, 950(ab)
cerebral blood flow distribution, fractal analysis of, 1446
cerebral glucose metabolism, decrease in heterogeneity, 948(ab)
cerebral hypometabolism in, affect on ultimate education level, PET, 546(ab)
comparing brain images, cognitively impaired and normal patients, 952(ab)
differences of cerebral response to passive audiovisual stimulation, depression and, 1018(ab)
donepezil effects on rCBF, statistical parametric mapping in, 1441
donepezil therapy
rCBF and cognitive function improvement, 46(ab)
^{99m}Tc HMPAO SPECT follow-up, 45(ab)
early and late onset, differences in metabolic impairment, 48(ab)
FDDNP and a new analog for synthetic amyloid fibrils, 241(ab)
fractal analysis, cerebral blood flow distribution, 947(ab)
Lewy body variant of
mixed neurodegenerative disease, evaluation with FDG PET, 4943(ab)
statistical parametric mapping in, 943(ab)
mild cognitive impairment, glucose changes associated with, PET study, 224(ab)
Mu opioid receptors, statistical parametric mapping analysis, 44(ab)
perceived loss of memory function, correlation with decline in hippocampal metabolism, 228(ab)
PET and SPECT scans, spatially normalized, direct comparison, 49(ab)
plaque and tangles in brain, labeling of, 242(ab)
preclinical, normal controls and, quantitative brain SPECT with OSEM, 945(ab)
prediction of cognitive decline, measure of functional reserve, 226(ab)
regional cerebral blood flow in, donepezil hydrochloride effects, 1441
senile dementia, SPECT of microglia in, 43(ab)
SPECT diagnosis, 34N(6)
therapy control with cholinesterase inhibitors, PET, 951(ab)
American Academy of Neurology, functional imaging in dementia, 34N(6)
American Board of Nuclear Medicine (ABNM), celebrating 30 years, 22N(1)
American Board of Science in Nuclear Medicine, 14N(4)
American Chemical Society (ACS), Gopal Subramanian, 26N(2)
American Medical Association, ethics website, 28N(2)
Amifostine, with ^{186}Re HEDP or ^{153}Sm-EDTMP, high-dose treatment in rabbit model, 1545
Amino acids
fluorinated, for tumor imaging, 558(ab)
preloading, modulation of ^{123}I IMT uptake after, 1171(ab)
radiolabeled
in oncology, 432
tumor uptake, 752
transport
prognosis in brain tumors and, 245(ab)
survival in glioma patients and, 1144
Ammonia
acetate comparison, as quantitative tracer for myocardial perfusion imaging, 1174, 1183
metabolism, PET, skeletal muscle, cirrhosis patients, 1359(ab)
Amphetamine challenge, oral, regional cerebral blood flow response to, 535
Amphetamines
dopamine released by, effect on binding of D1 agonist, rat brain, 899(ab)
striatal displacement of ^{11}C raclopride induced by, LY354740 effects, 531(ab)
striatal dopamine release induced by, MRI-PET coregistration in, 800(ab)
Amyloids
assessments in Alzheimer's disease, lipophilic ^{11}C-labeled derivative of thioflavin-T for, 423(ab)
fibrils, biological probe for, binding potential, 241(ab)
radioligand, assessments, lipophilic derivative of congo red for, 1060(ab)
Anatomic standardization, spatial normalization methods, FDG PET, 922(ab)
Anger, Hal O., 13N(6)
Angina
unstable, BMIPP SPECT, 508(ab)
vasospastic, MIBG uptake and, 729(ab)
Angiocardiography, radionuclide
left ventricular function, 1043, 1050
patient selection for aortic valve replacement, 331(ab)
Angiogenesis
targeted, tumor vascular imaging, with radiolabeled endostatin, 263(ab)
tumor targeting and, glycosylated RGD-containing peptides, 326
Angiography
coronary, infarction correlation with site of perfusion defects, 558
planar, ^{201}Tl *versus*, validation of myocardial tracking, 845
Angioplasty, restenosis after, liquid-filled balloons for prevention, 1375, 1384
Angiotensin-converting enzyme (ACE) inhibitor
cardiac ^{123}I BMIPP uptake and, in congestive heart failure, 747(ab)
cessation of, before stress myocardial scintigraphy, 5(ab)
kinetics, in vivo measurements, 823(ab)
Anisotropic diffusion algorithms, smoothing scintigraphic images, 866(ab)
Ankylosing spondylitis
alpha-emitter ^{224}Ra treatment, bone metabolism before and after, 1399(ab)
^{224}Ra chloride for, clinical follow-up, 1413(ab)
^{224}Ra treatment in, 478(ab)
Annexin V, ^{99m}Tc-radiolabeled

cyclophosphamide-induced intramedullary apoptosis, rats, 309
intravenous, patient dosimetry of, 382
Anthrax, early imaging of, 11N(12)
Antiangiogenesis
endostatin, nonlinear response of blood flow and glucose metabolism, 1242(ab)
2-methoxyestradiol for, radioimmunotherapy in colon cancer, 1151(ab)
PET monitoring, tumor blood flow and FDG metabolism during therapy, 1243(ab)
Antibody conjugates, radiometal-labeled, metabolite production after, lymphoma, 1324
Antibody/ligand pairs, 36N(9)
Antibody targeting, chimeric anti-GD3 monoclonal antibody KM871, metastatic melanoma, 1288(ab)
Anti-CEA antibodies, genetically engineered, tumor imaging with MicroPET, 572(ab)
Anti-DNA antibody, radiolabeled, detection in SLE, 138
Anti-DTPA antibody, infection imaging, pretargeting strategy, 1405
Anti-EGF receptor antibody C225, imaging, ^{111}In DTPA effects, 1530
Anti-GD$_2$ antibody, alpha emitting, preclinical pharmacology of, 1308(ab)
Antigranulocyte antibody, ^{99m}Tc-labeled-, diabetic pedal osteomyelitis, 165(ab)
Antimacrocyclic antibodies, humoral immune response to, 1697
Antimicrobial peptides, ^{99m}Tc-labeled, bacterial and *Candida albicans* infections, 788
Antimony trisulfide, ^{99m}Tc-labeled and unlabeled, particle size analysis, 460
Antiphospholipid antibodies, positive, deep venous thrombosis and pulmonary thromboembolism with, 1430(ab)
Antisense DNA, ^{99m}Tc-labeled, tumor targeting with, 1660, 1670
Antisense imaging, ^{99m}Tc-labeled, tumor targeting, 1660, 1670
Antitrypsin, inhalation of ^{123}I−α_1, 744
Antral motility, post-synchronized scintigraphic data, patients with idiopathic dyspepsia, 1370(ab)
Aortic aneurysm
ascending, surgical repair of, 1346
dissecting, immunoscintigraphy with ^{99m}Tc anti-SM-MAb, 130
Aortic regurgitation, aortic valve replacement for, use of radionuclide angiocardiography in, 331(ab)
Apoptosis
in acute and chronic abscess, 1383(ab)
detected by ^{99m}Tc annexin, in acute myocardial infarction, 177(ab)
detection using radiolabeled annexin V, human lung tumor cells, 1099(ab)
in experimental rheumatoid arthritis, 479(ab)
growth and development of long bones, 1406(ab)
intramedullary, cyclophosphamide-induced, ^{99m}Tc radiolabeled annexin V, rats, 309
sequence of timing to radiation dose, in P53 mutant human breast cancer, 571(ab)
^{99m}Tc annexin imaging to evaluate, autoimmune myocarditis, rat, 169(ab)
^{99m}Tc annexin V imaging, untreated and treated tumors, 312(ab)
Z-Val-DL-Asp fmk as potential scintigraphic marker, 1157(ab)
Application specific emission tomography, breast imaging, 363(ab)
L-Arginine, endothelial nitric oxide synthase activity and, augmentation of cerebral blood flow, 918(ab)
Arterial blood volume, regional values of, effects of vascular radioactivity, 1032, 1040
Arthritis, *see also* Rheumatoid arthritis
multifocal, medication-refractory patients, radionuclide therapy in, 1395(ab)
Arthroplasty
hip, nonspecific tracer uptake on FDG after, 477(ab)
lower limb, infection in, FDG PET in detection of, 44
painful hip prosthesis, periprosthetic infection in, evaluation by FDG PET, 482(ab)
^{99m}Tc ciprofloxacin imaging, post-operative osteoarticular infections, 1375(ab)
Artifacts
hot bladder, reduction using single camera rotation dynamic SPECT, 523(ab)
motion correction, myocardial perfusion SPECT, 687
recognition and prevention, transmission emission tomography systems, 839(ab)
respiratory motion, cardiac SPECT attenuation correction in, 191(ab)
Artificial intelligence
data mining techniques, SPECT studies by expert system, 811(ab)
development of normal limits, quantification of myocardial perfusion SPECT, 174(ab)
interpretation of myocardial perfusion SPECT, 1185, 1192
Artificial neural network, absolute activity quantitation, ^{123}I/^{99m}Tc brain SPECT, 300
Asialoglycoprotein receptor
density, portal-systemic shunt effects, 110
regional liver, estimation from single blood sample and SPECT, 489(ab)
Tc-GSA measurements of, functional hepatocellular mass, 733
Astrocytoma, progressive low-grade from radiation injury, FDG, ^{123}I IMP and ^{99m}Tc MIBI comparison, 246(ab)
Atherosclerosis
detection, 8 radiotracers for, rabbit model, 168(ab)
FDG uptake
thoracic aortas, risk factors in, 202(ab)
thorax, PET assessment, 201(ab)
risk factors, FDG uptake in large arteries and, 4(ab)
Attention deficit hyperactivity disorder
stimulant medication for, effect on D2 receptor levels, 1003(ab)
^{99m}Tc ECD brain SPECT, children with or without comorbidity, 1004(ab)
Attenuation correction
commercial techniques, multi-center evaluation, 882(ab)
complete European beta test results, myocardial SPECT, 9(ab)
CT-based, imaging with arms in field of view, 211(ab)
dual-head PET, ^{133}Ba, oncology patients, 817(ab)
dual modality CT/SPECT imaging device, 860(ab)
emission activity reconstruction and, emission data using discrete data consistency, 26(ab)
FDG PET, diagnosis of abdominal and pelvic tumors, 1239(ab)
FDG SPECT/PET coincidence detection with, myocardial imaging study, 390(ab)
gating and, role in accuracy of myocardial perfusion SPECT, 14(ab)
image fusion and, SPECT, separate X-ray CT use in, 845(ab)
imaging protocol and gender with, post-stress dilation, 188(ab)
improved estimate, activity in skull-like structures, 830(ab)
improvement of quantitative accuracy, post-injection transmission scans, cardiac PET, 842(ab)
myocardial perfusion imaging, impact of transmission scan reconstruction, 189(ab)
myocardial perfusion scans, multi-line source method for, 8(ab)
myocardial SPECT
changes in pattern of abnormalities, 760(ab)
intra- and inter-operators differences, 730(ab)
non-uniform
least square SPECT reconstruction, 216(ab)
for SPECT iterative reconstruction, 215(ab)
optimization of, count-based transmission scans, thorax and pelvis, 843(ab)
optimizing, clinical cerebral 3D PET, 840(ab)
partial volume effect and, SPECT dopamine receptor imaging, 214(ab)
PET, transformation of CT-values into 511 keV coefficients for, 212(ab)
PET model, functional brain imaging, 483
planar scintigraphy, aerosol deposition in lungs, 1077
post-injection transmission correction, PET, 525(ab)
profile, interpretation of myocardial perfusion imaging and, 759(ab)
quantitative differences in FDG lymph node uptake, early HIV infection, 828(ab)
reconstructed SPECT images, noise properties of, 519(ab)
scatter correction and, ^{201}Tl studies, 11(ab)
scatter correction and depth-dependent resolution recovery, ^{201}Tl studies, 1451
segmented
OSEM and, FDG PET, 384(ab)
for PET, 841(ab)
SPECT, coincidence mode 511 keV transmission measurement for, 213(ab)
stress only myocardial perfusion imaging, in coronary artery disease, 185(ab)
^{99m}Tc cardiac SPECT reconstructions, ROC optimization study, 849(ab)
^{99m}Tc/^{111}In studies, SPECT, 831(ab)
transmission, evaluation of equivalence, myocardial perfusion imaging, 13(ab)
whole-body PET oncology images, 524(ab)
Auditory cortex
postlingual deafness, PET evidence of cross-modal plasticity in, 549(ab)
preoperative functional assessment, fCBR, SPECT study, 548(ab)
Automatic quantitation, reproducibility of, ^{99m}Tc sestamibi gated myocardial SPECT, 695
Autonomic neuropathy
cardiac, type II diabetes and, gated blood pool scintigraphy, 761(ab)
diabetic patients, gallbladder ejection fraction and ^{99m}Tc DISIDA for prediction of, 1366(ab)
Autoradiography
orthostatic study, absolute rCBF in upright posture, 707
sequential dual study, MIBG and BMIPP radiolabeled, cardiomyopathy, 702(ab)
storage phosphor, comparison with animal PET, 1691
tritiated FDG, histological localization in GI tract, 92(ab)
vascular reactivity effects, regional cerebral blood flow, 1032, 1040
^{14}C deoxyglucose uptake and ^{201}Tl, autoimmune myocarditis in rats, 285
Avidin, novel tumor-targeting and internalizing therapeutic agent, synthesis of, 1087(ab)

B

Basal ganglia
disorders, ^{123}I β-CIT quantitative dopamine transporter SPECT, atypical tremor, 966(ab)
ictal hyperperfusion of, in temporal lobe epilepsy, SPECT subtraction in, 853
pre- and postsynaptic dopaminergic system in, narcolepsy, 237(ab)
and thalamic activation, intractable epilepsy, ictal SPECT in, 986(ab)
Basic Science of Nuclear Medicine CD-ROM, 32N(10)
Behçet's disease, juvenile, brain perfusion in, 1151
Benzodiazepine receptors
brain, distribution using ^{123}I NNC 13–8241, 802(ab)
decreased binding, prefrontal cortex, posttraumatic stress disorder and, 1013(ab)
distribution, intractable central tinnitus, 550(ab)
peripheral, ^{11}C 2′iodo-PK11195 and ^{123}I 2′iodo-PK11195 comparison for, 1061(ab)
Beta-adrenoreceptors, cardiac, evaluated using ^{11}C CGP12388, rat heart, 712(ab)
Beta-blocker therapy, idiopathic dilated cardiomyopathy, cardiac adrenergic activity after, 49
Beta-cell imaging agents, for diabetes mellitus, 269(ab)
Beta-irradiation, methylxanthine effects, human colon cancer cells, 596
Beta-ray emitters, effects on chondrocyte viability and metabolism, 1391(ab)
Biliary atresia, with hyperbilirubinemia, infants, one-hour dynamic DISIDA imaging in, 328(ab)
Biliary cirrhosis, primary, prognosis, ^{99m}Tc pertechnetate and per-rectal portal scintigraphy, 1363(ab)
Biliary leak, differentiation from blind end sign and, liver transplant patients, 318(ab)

Binding potential, human DAT measurements, altropane, 794(ab)
Biodistribution
cell uptake and, ^{11}C choline and ^{18}F FI, 1180(ab)
dendrimer-based biotin radiopharmaceuticals, enhanced whole-body clearance, 1141(ab)
dosimetry and, ^{99m}Tc phenthioate-annexin V, 1048(ab)
dosimetry and, ^{99m}Tc RP527, 1722
^{18}F FMAU, in PET, 308(ab)
^{125}I antisense probe, ERBB2 oncogene mRNA, lung cancer, 1164(ab)
imaging and, with ^{99m}Tc EC-DG, 97(ab)
^{111}In DOTA-J591 and ^{177}Lu DOTA-J591, ^{90}Y dosimetry and, 1021(ab)
intracellular localization of ^{125}I-labeled agents, assessing therapeutic efficacy, 1047(ab)
ligand concentration effects, ^{99m}Tc THIO-β-D-glucose as tumor-seeking agent, 98(ab)
peptide receptors, dogs, 412(ab)
PET studies, ^{11}C verapamil as tracers of P-glycoprotein function, 425(ab)
radiation dosimetry and, ^{18}F FECNT dopamine transporter ligand, 376
recombinant knob domain, adenovirus fiber protein, imaging potential of, 1066(ab)
^{99m}Tc-labeled model drug carriers, organ distribution and, rat, 1104(ab)
three-step pretargeting mAb protocol, mouse adenocarcinoma, 670
^{18}F FETNIM, hypoxia marker for PET, 1397
^{99m}Tc-labeled divalent and tetravalent CC49 single-chain Fv's, imaging of colon cancer, 1519, 1528
^{99m}Tc-labeled interleukin-8, scintigraphic detection of infection with, 117
^{99m}Tc RP527, visualization of GRP receptor-expressing malignancies, 1722
Biomedical imaging
interagency council, 28N(1)
symposium, 30N(11)
Biopsy
breast, surgical, radioguided localization, nonpalpable breast lesions, 433(ab)
excisional, cutaneous melanoma, 424, 430
Bispecific antibody, ^{188}Re-labeled, targeting of xenografted colon carcinoma, 146
Bisphosphonates
^{99m}Tc MDP bone scanning and, 1359
^{117m}Sn-labeled, isolated limb perfusion, in bone tumors, 1144(ab)
Bi213-HuM195, leukemia therapy with, parametric images of antibody pharmacokinetics, 27
Bladder cancer
FDG PET in, 38S
transitional cell, ^{188}Re C595 antibody for radioimmunotherapy of, 726
Blood–brain barrier, meningioma, somatostatin receptor-negative, scintigraphic analysis, 1338
Blood clearing agent, biotinylated, pretargeting tumors, 554(ab)
Blood flow, *see also* specific site
bone, ^{18}F fluoride ion PET, correlation with histomorphometry, porcine, 1091
deliver of ^{99m}Tc MDP to bone, intermittent compression effects, 1409(ab)
liver, glucose metabolism, FDG PET, pigs, 795
Blood-pool imaging
ECG-gated
left and right ventricular ejection fraction and volume, 515(ab)
left ventricular ejection fraction calculation, 511(ab), 512(ab)
measurement of right ventricular ejection fraction, 513(ab)
gated
left ventricular ejection fraction, 401
right and left ventricular parameters, 195(ab)
type II diabetes with cardiac autonomic neuropathy, 761(ab)
gated SPECT
left ventricular function, 1043, 1050
planar imaging *versus*, ventricular performance, 1773
gated tomography, left ventricular volumes and ejection fraction, 726(ab)
planar and SPECT, evaluation of ventricular function, 510(ab)
Blood sampling, continuous system, positron detector with gamma rejection capability, 870(ab)
Blood–spinal cord barrier, breakdown, radiation-induced, hypoxia imaging in, 1169(ab)
Blue dye, ^{99m}Tc-labeled liposomes encapsulating, sentinel node identification, 446, 452
Body surface area, standardized uptake value normalized to, pediatric patients, 815(ab)
Bone cancer, metastatic
radionuclide therapy with ^{153}Sm EDTMP and chemotherapy, 1301(ab)
^{186}Re HEDP and ^{153}Sm EDTMP, skeletal uptake, 230
treatment with ^{89}Sr, 1322(ab)
Bone densitometry
DEXA for, radioisotope effects on accuracy, 1401(ab)
femoral neck, total hip bone and, 486(ab)
Bone formation, blood flow and metabolism relations, PET, mini pigs, 483(ab)
Bone lesions, malignant and benign, differentiation with PET FDG studies, 125(ab)
Bone marrow
biologic dosimetry of, 162
clycophosphamide-induced intramedullary apoptosis, ^{99m}Tc radiolabeled annexin V, 309
dosimetry, radionuclide therapy, multi-institutional comparison, 81(ab)
palliative treatment, radiation dose of ^{186}Re HEDP for, 82(ab)
toxicity, ^{131}I, high level functioning thyroid cancer, 975
transplantation, obstructive lung disease and interstitial pneumonitis after, children, 1439(ab)
Bone marrow scintigraphy
in Gaucher disease, 1129(ab)
new bone-seeking agent, ^{99m}Tc incadronate, animal studies, 1096(ab)
Bone metabolism, ^{18}F fluoride ion, PET, porcine, 1091
Bone metastases
alendronate effects, effects on ^{99m}Tc MDP bone scanning, 1359
alpha-particle emitting radium-223 treatment, 431(ab)
from breast cancer, FDG PET measures response th therapy, 303(ab)
detection with ^{99m}Tc MIBI, 1267(ab)
early detection, FDG compared with ^{99m}Tc MDP, 1268(ab)
FDG PET
bone scintigraphy comparison, 1271(ab)
osseous sarcomas, comparison with conventional staging, 1272(ab)
^{18}F fluoride, ^{99m}Tc MDP SPECT comparison, 1270(ab)
high-let type cell killing, ^{117}m SN(4+)DTPA, 253(ab)
lung cancer, planar bone scans, SPECT, and ^{18}F-labeled NaF PET, 1800
lung cancer patients, planar bone scanning with SPECT or FDG PET, 1269(ab)
prostate cancer, palliation with ^{186}Re, 1302(ab)
therapy of pain, 895
^{99m}Tc MIBI scintigraphy, 33
Bone pain
metastatic, palliative treatment with ^{186}Re HEDP, 82(ab)
palliation, Tin-117m(4+)DTPA, 77(ab)
Bone scan, asymptomatic lower extremity uptake abnormality, clinical significance of, 209
Bone scintigraphy
comparison with MRI, in infectious spondylitis, 1416(ab)
effects on diagnosis, reflex sympathetic dystrophy, 1411(ab)
^{18}F MAF scanning, back pain patients, 481(ab)
Gaucher's disease, 1403(ab)
longitudinal tibial fatigue stress fracture, 1405(ab)
prostate-specific antigen level and, newly diagnosed prostate cancer, 1407(ab)
three-phase, diagnosis of repetitive strain injury, 1421(ab)
tibial stress fractures, grading, military recruits, 1392(ab)
unexplained back pain, 484(ab)
3-phase, tracer accumulation in femoral head, after renal transplant, 1789
^{99m}Tc MDP, leukemia in children, 878
Bone tumors
clinical evaluation with ^{201}Tl, 1410(ab)
isolated limb perfusion, ^{117m}Sn bisphosphonate safety, 1144(ab)
Book reviews
An Atlas of Planar and SPECT Bone Scans, second edition, 1878
Atlas of Clinical Positron Emission Tomography, 388
Clinical Positron Emission Tomography (PET): Correlation with Morphological Cross-Sectional Imaging, 1295
A Clinician's Guide to Nuclear Medicine, 1586
Myocardial Viability: A Clinical and Scientific Treatise, 1437
Nuclear Hepatology: A Textbook of Hepatobiliary Diseases, 824
Nuclear Medicine Imaging: A Teaching File, 176
The Sentinel Node in Surgical Oncology, 1128
Textbook of Nuclear Medicine, 1728
Thyroid Cancer: A Comprehensive Guide to Clinical Management, 984
Vascular Disease: A Multi-Specialty Approach to Diagnosis and Management, 2nd Ed., 527
Brachytherapy
^{125}I interstitial, glomectomized patients, 1315(ab)
intercavitary, resected brain tumors, 1316(ab)
intracoronary radiation therapy, liquid-filled balloons, 1375, 1384
^{103}Pd, production from silver targets, 1086(ab)
vascular, ^{188}Re-labeled stent, dosimetry of, 701(ab)
Brain
anatomic standardization of spatial normalization, FDG PET, 922(ab)
benzodiazepine receptors, distribution using ^{123}I NNC 13–8241, 802(ab)
bolus arrival time, normal subjects, 935(ab)
capillary endothelial cells, ^{123}I IMT activity of transport in, pig, 917(ab)
functional neuroimaging, MR atlas of baboon, 921(ab)
functional PET imaging, attenuation correction model 483
hemodynamic disease, temporal changes in, PET, 806(ab)
imaging, CRASIS, automated co-registration software, 799(ab)
immature and adult compared, hypoxic neurotoxicity positron autoradiography, 920(ab)
infarcted tissue, ^{99m}Tc ECD dimer metabolism, rats, 802
metabolism
FDG, early Huntington's disease, 1591
FDG PET, metabolic network abnormalities in Huntington's disease, 1591
PET and fMRI comparisons, spatial distributions, 32(ab)
PET/SPECT quantification, new approach, 31(ab)
remote regions, ictal hyperperfusion of, SPECT subtraction, 853
serotonin receptors, ^{18}F MPPF binding to, PET, 1025
SPECT
in clinical practice, perfusion in, 259, 611
juvenile Behçet's disease, 1151
tumors, FDG PET in, 32S
3D region-of-interest atlas, MRI-based, partial volume analysis, 24(ab)
Brain death, substantially reduced partial perfusion in prediction of, 994(ab)
Brain imaging
glucose metabolism, brain stem, with traumatic injury, 992(ab)
glucose metabolism and, persistent vegetative state, 990(ab)
motor sequence imagery, functional anatomy, 933(ab)
obsessive-compulsive disorder
cerebral metabolic predictors, in response to anterior cingulotomy, 1006(ab)
rCBF predictors of response to pharmacotherapy, 1007(ab)

Brain injury, traumatic
cerebral glucose metabolism after, 551(ab)
glucose metabolism in brain stem with, 992(ab)
^{99m}Tc HMPAO SPECT role in legal consultation, 991(ab)
Brain mapping, ^{18}F FDG PET, Alzheimer's disease, 548
Brain tumor
amino acid transport, prognosis and, 245(ab)
glial and meningeal, preferential labeling with 2-^{14}C acetate, 1243
growth rate, ^{18}F FMAU indication of, PET, 309(ab)
kinetics of ^{18}F FET in, 915(ab)
malignant, 2-^{11}C thymidine PET imaging of, 370(ab)
metastatic, metabolic characteristics on FDG PET, 980(ab)
primary or recurrent, prediction of outcome with ^{18}F FMT, FDG and PET, 251(ab)
resected, intracavitary brachytherapy, 1316(ab)
therapeutic options, FDG and ^{11}C methionine, therapeutic options, 247(ab)
^{18}F-labeled choline analogs as oncologic tracers, PET, 1805, 1815
^{201}TL brain SPECT, therapeutic outcome of stereotactic surgery, 977(ab)
Breast
biopsy, positron emission mammography, 960
dedicated PICO-SPECT, 888(ab)
dense tissue, adding ^{99m}Tc sestamibi scintimammography to mammography in, 1221(ab)
lactating, uptake and excretion of ^{18}F FDG, 1238
Breast cancer
advanced and inflammatory, ^{99m}Tc sestamibi scintimammography in, 1212(ab)
apoptosis in cells, ^{99m}Tc EC annexin V measurement of, 311(ab)
^{11}C acetate and FDG comparison, PET, 452(ab)
chemotherapy effects on detection, sentinel node imaging, 1228(ab)
dedicated imaging, application specific emission tomography, 363(ab)
detection of malignant lesions, ^{99m}Tc sestamibi use in, 1219(ab)
drainage patterns in lymphoscintigrams, during sentinel node imaging, 579(ab)
efficacy of ^{99m}Tc tetrofosmin
axillary planar, SPECT and pinhole-SPECT in, 87(ab)
multi-centre study, 86(ab)
estrogen receptor imaging, addition of 4-fluoro and 11β-methoxy group, 1076(ab)
estrogen-responsive cells, FDG uptake in, estradiol enhancement of, 1178(ab)
ETACT for scintimammography, 1121
excisional biopsy of breast mass, value, accuracy or success rate of sentinel node imaging, 576(ab)
FDG imaging, dedicated PET camera use in, 302(ab)
FDG PET, image quality, reconstruction algorithms for, 306(ab)
FDG PET in, 26S
^{18}F FDG PET, correlative studies, 94(ab)
^{18}F fluorine PET imaging, 107(ab)
glucose metabolism in, ^{18}F-FDG PET, 9
impalpable axillary nodes, ^{99m}Tc humanized HHMFG1 monoclonal antibody, 1225(ab)
interpretation criteria for, double-phase ^{99m}Tc MIBI scintimammography, 91(ab)
locally advanced, ^{99m}Tc sestamibi uptake and washout in, 85(ab)
lymphatic mapping, tracer dosage and colloid particle concentration, 436(ab)
lymphoscintigraphy, sentinel load localization and, 420
management, whole-body FDG PET effects, 1236(ab)
MDA-MB-84 xenografts, anti-tumor effect of ^{111}In HEGF, 1073(ab)
metastatic
preliminary evaluation with FDG PET, 304(ab)
trastuzumab immunotherapy, toxicity and efficacy of, 1227(ab)
MR-guided percutaneous cryosurgery, scintimammography in follow-up, 1217(ab)
newly diagnosed, attenuation corrected and noncorrected FDG PET images, 307(ab)
nonpalpable lesions, radioguided localization and surgical biopsy, 433(ab)
outside the axilla, sentinel nodes, 574(ab)
palpable masses, ^{99m}Tc scintimammography, 1614
with palpable masses, ^{99m}Tc sestamibi scintimammography, 1614
PET, correlation of expression with FDG uptake, 1177(ab)
PET in follow-up of, comparison of MRI, 1237(ab)
primary
combined mammography and scintimammography with ROC curves, 3
iodine-labeled tamoxifen uptake in, 1818
primary and metastatic, diagnostic radiopharmaceutical for, 1067(ab)
proliferative activity in, preoperative FDG uptake correlation with, 305(ab)
radioiodide therapy, endogenous mammary gland Na^+I^- symporter, 987(le)
recurrent, FDG PET in management of, 1238(ab)
resistance to neoadjuvant chemotherapy, single-view ^{99m}Tc sestamibi scintimammography, 90(ab)
response to chemotherapy, scintigraphic prediction, 1215(ab)
restaged, prognostic value of FDG PET in, 301(ab)
sentinel lymph node biopsy, without axillary dissection, 578(ab)
sentinel lymph nodes in
optimum injection methods, 434(ab)
subareolar injection, 437(ab)
^{99m}Tc albumin colloid and blue dye in detection, 435(ab)
sentinel lymph node technique, in lymphoscintigraphy, 1229(ab)
sentinel node mapping, need for axillary dissection, 575(ab)
sentinel node randomized trial in, 573(ab)
sentinel nodes in, peritumoral and subareolar application of ^{99m}Tc nanocolloid, 439(ab)
staging and management, FDG PET, 1334
surgery, radioguided sentinel lymph node biopsy, 1198
suspected, ^{99m}Tc MIBI axillary planar, SPECT and pinhole SPECT in, 88(ab)
^{99m}Tc sestamibi, correlation between uptake and prognostic factor, 1218(ab)
^{99m}Tc sestamibi imaging, multidrug resistance and, 1213(ab)
TPMP accumulation, comparison with ^{99m}Tc MIBI, 1162(ab)
tumor biologic characterization, ^{99m}Tc MIBI uptake in breast mass, 1220(ab)
ultrasound role, comparison with ^{99m}Tc MIBI scintimammography, 89(ab)
^{18}F-labeled choline analogs as oncologic tracers, PET, 1805, 1815
Bridwell, Robert N. 11N(12)
By-laws, proposed changes, 30N(12)
Bronchioloalveolar carcinoma
detection and staging, FDG PET, 276(ab)
sensitivity of metabolic imaging for, FDG PET, 277(ab)
Bronchogenic carcinoma, staging, whole-body FDG PET and spiral CT, image fusion, 130(ab)
Burn injury, bone uptake of ^{99m}Tc MDP, ^{18}F, ^{125}I tetracycline and FDG, 147(ab)

C

Calcaneus, quantitative ultrasound measurements, 1418(ab)
Calcium channel inhibitor, S22658, ^{11}C-labeled enantiomers, myocardial kinetics, 932
Cancer. *see also* specific type
combined dedicated PET/CT system for evaluation, 127(ab)
evaluation of FMAU, transduced cells and tumor-bearing mice (*see also* specific type)
metabolite production, after radiometal-labeled antibody administration, 1324
metastatic bone pain, therapy, 895
Cancer imaging
fast surgical specimen, 868(ab)
high-resolution intra-operative hand-held gamma camera, cancer surgery, 867(ab)
Candida albicans, detection with ^{99m}Tc-labeled antimicrobial peptides, 788
Carbohydration, new approach to ^{18}F octreotide analogs, 555(ab)
Carbon-11
amyloid assessments, lipophilic derivative of congo red for, 1060(ab)
derivative of thioflavin-T, for amyloid assessment, Alzheimer's disease, 423(ab)
radiopharmaceuticals labeled with, evaluation of automated production, 1121(ab)
Carbon-11 acetate
age-related accumulation, normal prostate, usefulness in detection of cancer, 448(ab)
cardiac oxidative metabolism, hyperthyroidism effects, 7(ab)
versus endogenous cardiac natriuretic peptides, chronic heart failure patients, 733(ab)
PET
evaluation of myocardial blood flow, 63
first clinical experience in prostate cancer, 451(ab)
quantification of myocardial blood flow, 1438(le)
recurrent and metastatic cervical cancer, FDG comparison, 453(ab)
whole-body, detection of breast cancer, FDG PET comparison, 452(ab)
as quantitative perfusion tracer, myocardial perfusion imaging, 1174, 1183
radiation dose estimates for, whole-body PET, 1023(ab)
synthesis of amino acid, glioma, 979(ab)
Carbon-11 arachidonic acid, palmitic acid and, brain incorporation, PET, 243(ab)
Carbon-11 A69024, enantiomerically pure, radioligand for dopamine D1 receptors, 897(ab)
Carbon-11 carfentanil
preparation using ^{11}C diazomethane, 1119(ab)
receptor imaging, alcoholics before and after detoxification, 1010(ab)
Carbon-11 carvedilol, PET, monitoring of P-glycoprotein function, 1167(ab)
Carbon-11 CGP-12177, synthesis, improved with iron oxide III, 69(ab)
Carbon-11 CGP-12388, evaluation of cardiac beta-adrenoreceptors, rat heart, 712(ab)
Carbon-11 choline
biodistribution, cell uptake and, 1180(ab)
PET
malignant pelvic tumors, 1196(ab)
stage of lymph nodes in prostate cancer, 449(ab)
Carbon-11 clorgyline, reduction in binding of deuterium, across brain regions, 908(ab)
Carbon-11 cocaine
reversible radiotracer, mechanical ventilation effects on transport constant of, 909(ab)
^{11}C WIN35,428 PET and, dopamine transporter occupancy, baboons, 927(ab)
Carbon-11 CVG, PET, role in drug addiction, 424(ab)
Carbon-11 DASB, PET, serotonin reuptake sites by paroxetine, in depression, 62(ab)
Carbon-11 diazomethane, preparation of ^{11}C carfentanil, 1119(ab)
Carbon-11 flumazenil, receptor binding studies, short-time PET measurements, 940(ab)
Carbon-11 HDA, PET, studies of myocardial metabolism, 271(ab)
Carbon-11 HED, PET, cardiac presynaptic sympathetic nerve terminals, transplanted heart, 1011
Carbon-11 L-753,037, in vivo labeling of endothelin receptors, mice and dog studies, 1274
Carbon-11 5MA, nicotinic acetylcholine receptor, development, 1054(ab)
Carbon-11 MCN5652, derivation of serotonin transporter parameters, 392(ab)
Carbon-11 (+)MCN5652, binding, graphical analysis in Parkinson's disease, 958(ab)
Carbon-11 MDL 100907, mapping serotonin receptors, human brain, 396(ab)
Carbon-11 methionine
amino acid imaging, in oncology, 432
FDG comparison, PET for evaluation of lung cancer after stereotactic radiotherapy, 1252(ab)

PET, preoperative, in primary hyperparathyroidism, 598(ab)
uptake, cerebrovascular disease, 984(ab)
Carbon-11 MG
metabolites, pig liver, 1673, 1679
3-O-, metabolites of FDG and, liver, 1673, 1679
Carbon-11 phosgene, production, catalysts and carrier carbon in, 70(ab)
Carbon-11 PK11195
PET, cluster analysis and, normal brain tissue, 804(ab)
PET visualization with, peripheral benzodiazepine receptor expression, in HIV, 905(ab)
Carbon-11 raclopride
binding, partial volume effect in ventral striatum, 797(ab)
FDG PET combination, prediction of effects of L-dopa in Parkinson's disease, 960(ab)
PET
amphetamine-induced striatal dopamine release, 800(ab)
assessment of radiation exposure, 1038(ab)
striatal displacement, amphetamine-induced, LY354740 effects, 531(ab)
Carbon-11 stavudine, tissue pharmacokinetics of, 1386(ab)
Carbon-11 S12968, PET, myocardial kinetics, 932
Carbon-11 toluene
biodistribution of commonly abused solvent, imaging brain pharmacokinetics, 1062(ab)
intravenous, plasma radioactivity after, robotic SPE and HPLC after, baboon, 1120(ab)
Carbon-11 tyrosine, amino acid imaging, in oncology, 432
Carbon-11 vinpocetine, intravenously administered, PET studies on brain uptake, 907(ab)
Carbon-13 breath test, gastric emptying scintigraphy correlation, pediatric patients, 334(ab)
Carbon-13 octanoic acid breath test, comparison with scintigraphy, gastric emptying of solid food, 491(ab)
Carbon-13 urea breath test, diagnosis of *Helicobacter pylori*, 1365(ab)
Carbon-14 acetate, preferential labeling with, glial and meningeal brain tumors, 1243
Carbon-14 deoxyglucose, ^{201}Tl uptake and, autoimmune myocarditis in rats, 285
Carbon-14 FMAU, in transduced cells, tumor-bearing mice, 1183(ab)
Carbon-64 TETA octreotide, PET, in neuroendocrine tumors, 213
Cardiac adrenergic activity, after β-blocker therapy, assessment by ^{123}I MIBG uptake, 49
Cardiac electrophysiology, radionuclide imaging and, co-registration, 713(ab)
Cardiac function, type II diabetes, gated blood pool scintigraphy, 761(ab)
Cardiac hypertrophy, physiologic, coronary flow reserve, PET assessment, 339(ab)
Cardiac imaging
dobutamine-induced changes, impact of aging, 196(ab)
hemodynamically significant subset of CAD, coronary calcific atherosclerosis and, 357(ab)
perfusion acquisitions, respiratory motion in, 837(ab)
profile multiple line source array, TCT/ECT system, physical phantom evaluation, 893(ab)
quantitative gated SPECT data, patient-specific myocardial perfusion, shape and function, 217(ab)
respiratory motion artifacts, attenuation correction effects, 191(ab)
SPECT, Bayesian emission reconstruction of, 518(ab)
3D SPECT, automatic warping, clinical interests of, 221(ab)
unexplained septal perfusion defects, in severe emphysema, 10(ab)
Cardiac natriuretic peptides, endogenous, *versus* ^{11}C acetate, chronic heart failure, 733(ab)
Cardiac neurotransmission imaging, cardiomyopathy, 1062
Cardiac perfusion tracers, iodophenylpiperazinium quaternary amine, 270(ab)
Cardiac phantom
dynamic beating heart, SPECT, 718(ab)
NURBS-based Torso, development and application, 23(ab)
supraquadric-based, modeling respiratory motion in, 529(ab)
Cardiology, FDG PET literature summary, 1S
Cardiomyopathy
cardiac neurotransmission imaging in, 1062
dilated, carvedilol effects on neuronal damage, 708(ab)
hypertrophic, ^{123}I MIBG SPECT and ^{99m}Tc tetrofosmin SPECT, 1017
hypertrophic, ^{201}Tl SPECT assessment of, 772(ab)
idiopathic dilated
cardiac adrenergic activity after, 49
^{15}O water PET, 1737
MIBG and BMIPP radiolabeled sequential dual autoradiographic study with, 702(ab)
prognosis, MIBG activity and, 1757
Cardiovascular function, pinhole imaging, mice, 891(ab)
Cardioverter-defibrillator implantation, tetrofosmin perfusion scintigraphy in evaluation, cost-effectiveness of, 509(ab)
Carrier iodine, effects in radioiodine therapy, isomorphic model, 1049(ab)
Cartilage imaging, ^{99m}Tc NTP 15–5, joint scintigraphy, 141
Carvedilol, adrenergic neuronal damage and, in dilated cardiomyopathy, 708(ab)
Case-based reasoning, dipyridamole ^{201}Tl myocardial SPECT, 189
Cell proliferation, ^{18}F FLT as marker of, asynchronously growing tumor cells, 310(ab)
Cell trafficking, imaging, with reporter gene/reporter probe approach, MicroPET, 1185(ab)
Cellular retention, Alpha-particle emitters, 1538
Centers for Medicare and Medicaid Services (CMS), 14N(12)
Coverage of PET, 27N(12)
Hospital Outpatient Prospective Payment System (HOPPS), 27N(12)
Cerebellum, ictal hyperperfusion of, in temporal lobe epilepsy, SPECT subtraction in, 853
Cerebral blood flow (CBF)
acute effects of smoking, ^{99m}TC ECD SPECT, 997(ab)
Alzheimer's disease on donepezil therapy improvement, 46(ab)
^{99m}Tc HMPAO SPECT follow-up, 45(ab)
distribution, fractal analysis of, Alzheimer's disease, 947(ab)
endothelial nitric oxide synthase-dependent, chronic statin treatment effects, 918(ab)
fractal analysis, in Alzheimer's disease, 1446
in hypothyroidism, SPECT imaging of, 1017(ab)
internal carotid artery balloon test, ECD SPECT with Diamox challenge, 982(ab)
local, ^{18}F P-TZTP effects, rat, 936(ab)
mean hemispheric, HMPAO radionuclide angiography, healthy *versus* dementia patients, 949(ab)
measurement, whole-body dosimetry for, 1044(ab)
muscarinic cholinergic receptor availability and, 903(ab)
perfusion in brain SPECT, 259
PET measurement, modulated delivery of ^{17}F fluoromethane for, 930(ab)
quantitative measurement, repetitive transcranial magnetic stimulation and, Parkinson's disease, 959(ab)
regional
absolute, upright posture and, PET, 707
auditory cortex, SPECT, 548(ab)
basal ganglia, non-alcoholic liver cirrhosis, ^{99m}Tc ECD SPECT, 999(ab)
changes in subarachnoid hemorrhage, ^{99m}TC ECD, 985(ab)
donepezil effects, Alzheimer's disease, 1441
elderly late-onset major depression, SPECT, 1014(ab)
integrated lab for PET imaging, 1118(ab)
iterative reconstruction *versus* filtered backprojection, PET, 798(ab)
juvenile neuro-Behçet's disease, 1151
in obsessive-compulsive disorder, predictors of response to pharmacotherapy, 1007(ab)
occipital deficits, depression in children and, 1059
OSEM and FBP comparison, 805(ab)
postmenopausal depression, SPECT, 1015(ab)
response to oral amphetamine challenge, 535
SPECT patterns, Parkinson's disease, 227(ab)
subcortical and somatosensory changes, in osteoarthritis, 995(ab)
regional values of, effects of vascular radioactivity, 1032, 1040
repeat measurements, shortening scan intervals, ^{15}O water PET, 937(ab)
substantially reduced partial perfusion, prediction of brain death and, 994(ab)
visual cortex, ^{15}O butanol *versus* water for, 931(ab)
^{133}Xe SPECT, T-scores, 864
Cerebral blood volume, measurement, new simplified method in PET, 941(ab)
Cerebral glucose metabolism
before and after capsulotomy, in obsessive-compulsive disorders, PET study, 1005(ab)
after traumatic brain injury, 551(ab)
alterations of, chronic fatigue syndrome, 411(ab)
audiovisual stimulation in Alzheimer's, functional reorganization of cerebral responses to, 47(ab)
brain imaging and, persistent vegetative state, 990(ab)
brain stem, traumatic brain injury patients, 992(ab)
correlation with hypoxic cell fraction, gliomas, PET, 250(ab)
decrease in heterogeneity, Alzheimer's disease, 948(ab)
heterogeneity, aging effects, 953(ab)
low-dose alcohol effects, PET measurement of, 1009(ab)
mild cognitive impairment, Alzheimer's disease, PET study, 224(ab)
Parkinson's disease, FDG PET study, 538(ab)
regional, effects of normal aging process, 954(ab)
Rett syndrome, 146(ab)
technique for measurement, discrete linear least squares method, 792(ab)
Cerebral infarction
prognostification with ^{99m}Tc MN brain SPECT, 409(ab)
subacute, ^{133}Xe comparison with ^{99m}Tc ECD SPECT, 543
^{99m}Tc ECD dimer metabolism, in tissue, rats, 802
Cerebral ischemia
focal, brain distribution of ^{14}C octanoate, rat model, 244(ab)
transient, early ischemic neuronal death, FK506, monkey model, 1833
transient forebrain, binding of radioiodinated iomazenil in hippocampus, gerbil, 942(ab)
Cerebral oxygen metabolism, WILT approach, PET, 793(ab)
Cerebral vascular reserve, acetazolamide stress brain perfusion SPECT, after carotid endarterectomy, 406(ab)
Cerebrovascular disease
^{11}C methionine uptake, FDG PET and ^{99m}Tc HMPAO SPECT comparison, 984(ab)
hemodynamically compromised area, ^{99m}Tc HMPAO SPECT, 405(ab)
Cervical cancer
^{11}C acetate and FDG comparison, PET, 453(ab)
FDG PET in, 35S
FDG PET, standardized uptake value, 1187(ab)
intraoperative lymphatic mapping, undergoing radical hysterectomy, 577(ab)
management, FDG PET imaging in, 1195(ab)
PET and CT in, 32N(11)
sentinel node identification, combined with intraoperative lymphatic mapping and preoperative lymphoscintigraphy, 1240(ab)
staged, preoperative FDG PET, 1189(ab)
uterine, prognostic value of FDG PET in radiotherapy patients, 295(ab)
Chemotactic peptides, vascular permeability, response selective agonist of human C5A, 1306(ab)
Chemotaxis, viability and labeling stability, leukocytes labeled with ^{99m}Tc exametazime, 505
Chemotherapeutic protocol, FOLFOX, dynamic FDG PET prediction of response in colorectal cancer, 465(ab)

Chemotherapy
early response, monitoring with FDG, tumor-mouse model, 95(ab)
effects on somatostatin receptors, in pancreatic tumor cells, 1856
paclitaxel, non-small cell lung cancer, ^{99m}Tc tetrofosmin imaging, 17
thymus hyperplasia after, FDG PET, 591
Chest pain, diagnosis, early rest or exercise myocardial SPECT, 178(ab)
Chinese Society of Nuclear Medicine, meeting, 35N(9)
Cholecystokinin (CCK)
B-gastrin receptor binding peptides and, diagnosis and therapy of medullary thyroid cancer, 587(ab)
gastrin receptor ligands, radiopeptide therapy with, 252(ab)
Cholescintigraphy
gallbladder lumen, hepatic bile entry into and transit within, 493(ab)
sincalide, establishment of gallbladder ejection fraction, 316(ab)
Choline
acetate and, cell growth markers of lipid synthesis, 1152(ab)
^{18}F, synthesis and metabolism, tumor cells, 68(ab)
^{18}F-labeled analogs as oncologic tracers, PET, 1805, 1815
Chromogranin A assay, ^{131}I MIBG scintigraphy and, diagnosis and follow-up of pheochromocytoma, 993
Chronic fatigue syndrome, alterations of regional cerebral glucose metabolism in, 411(ab)
Ciprofloxacin, ^{99m}Tc-labeled
bacterial and *Candida albicans* infections, 788
biodistribution in normal and infected rats, 1110(ab)
Cirrhosis, functional liver volume in, liver-spleen scan, SPECT, 490(ab)
Cocaine
addiction, CTDP31,446 medication, 55(ab)
detoxification, effects on benzodiazepine-induced changes in cerebral metabolism, 1011(ab)
effects on prefrontal cortex, acute toluene exposure and, 901(ab)
low-dose, effects of dopamine transporter pre-blockade on, 403(ab)
Coincidence detection camera
alternative to FDG PET, staging of esophageal carcinoma, 288(ab)
FDG, chronic orthopedic infections, 1396(ab)
FDG PET
accuracy for detection and staging of lung cancer, 1265(ab)
evaluation of fever of unknown origin, 1378(ab)
evaluation of postoperative fever, 1377(ab)
follow-up in malignant lymphoma, 1131(ab)
^{18}F FDG SPECT/PET, with attenuation correction, myocardial imaging, 390(ab)
^{18}F F Na bone pet and ^{99m}Tc HMDP bone scan, comparison of performance, 487(ab)
SPECT attenuation correction, 511 keV transmission measurement for, 213(ab)
triple-head, FDG imaging in oncology, 1266(ab)
Coincidence imaging
dual and triple-detector hybrid PET, comparison, 366(ab)
dual-head PET, ^{133}Ba attenuation correction, oncology patients, 817(ab)
dual isotope/single photon, myocardium, 944
dual layer small animal PET, recovering inter-crystal scatter in, 871(ab)
dual or triple-head mode, performance measurements on a Marconi Irix hybrid PET system, 883(ab)
FDG, head and neck tumors, 1210(ab)
Fourier rebinning, effects on resolution and contrast, 852(ab)
HCFA (now CMS) ruling, 11N(8)
optimization of energy window, hybrid PET system, LROC study, 865(ab)
Coincidence imaging, high-speed gamma camera, pileup recovery method, 624, 633
Coincidences Technologies, SA, 38N(10)
Colitis
experimental rapid imaging with ^{99m}Tc interleukin-8, 1381(ab)
^{99m}Tc interleukin-8 imaging, rabbits, 917
Collimation
collimators
detector response, tumor SPECT imaging using ^{111}In, 846(ab)
multisegment rotating slant-hole, SPECT, 833(ab)
pinhole
cardiovascular function, mice, 891(ab)
sensitivity with penetration, determination of, 526(ab)
scatter and penetration compensation, high-energy emission in ^{123}I imaging, 527(ab)
varying focal-length fan-beam, for cardiac SPECT, 22(ab)
pinhole, ETACT for scintimammography, 1121
Colloid particles, large, use in optimized mammary lymphoscintigraphy, 826(le)
Colon cancer
FDG PET detection, 989
human cells, sensitivity to ^{186}Re-labeled monoclonal antibody, methylxanthine effects, 596
human xenograft, sheep, preclinical 2-step radioimmunotherapy, 1313(ab)
measurement of suicide gene expression, PET, 1682
multidrug resistant cell line, tracer characteristics of, 646
novel imaging agents for, 1519, 1528
radioimmunotherapy in, 2-methoxyestradiol for enhancement of, 1151(ab)
radiosensitization of xenografts with pentoxifylline, ^{131}I monoclonal antibody RIT, 1147(ab)
suicide gene expression, PET, 1682
universal bispecific antibody pretargeting system for, 552(ab)
xenograft, radiolabeled monoclonal antibody A33, 1251
xenografted, targeting with ^{186}Re-labeled bispecific antibody, 146
Colonic transit, scintigraphy and radiopaque marker comparison, constipation patients, 321(ab)
Colorectal cancer
cryotherapy, biokinetics of ^{111}In labeled platelets after, 1128(ab)
dynamic FDG PET, response to FOLFOX therapy and, 465(ab)
FDG PET in, 9S
^{131}I labeled A33 antibody, combined with external beam, 257(ab)
immuno-PET of ^{124}I HuA33, humanized monoclonal antibody, 764, 770
management, FDG PET, 586
metastatic, liver resection, monitoring with FDG PET, 1279(ab)
metastatic liver lesions from, FDG PET and CT/MRI comparison, 1280(ab)
recurrent
CDET FDG detection, 463(ab)
therapeutic choice for, FDG PET effects, 462(ab)
restaging
FDG PET for prediction of outcome, 464(ab)
FDG PET impact on clinical stage by conventional imaging, 461(ab)
Compartmental models
analysis tool, COMKAT, 636
liver kinetics of glucose analogs, PET, pigs, 795
plasma-input function, dynamic whole-body PET, 790(ab)
Simplified Reference Tissue Model, noise reduction in, 786(ab)
Compton camera
high-resolution PET detector, 383(ab)
optimal geometry for, estimation, 889(ab)
scintimammography, feasibility of, 887(ab)
Compton detector concept, high-resolution animal PET, 206(ab)
Computed tomography (CT)
attenuation maps, application in PET with respiratory motion correction, 520(ab)
electron beam, PET *versus*, in CAD, 358(ab)
emission, attenuation correction model, brain, 483
PET scanner combined, 533(le)
SPECT and, dual modality imaging device, 860(ab)
thoracic, automated nonlinear 3D registration of FDG PET with, 37(ab)
transformation of CT-values into 511 keV coefficients, PET attenuation correction, 212(ab)
transmission, brain SPECT receptor data using, 361
Congenital heart disease
coronary microcirculatory abnormalities, after Fontan-like operations, 732(ab)
myocardial perfusion after coronary reimplantation, 727(ab)
regional pulmonary blood flow in, dynamic SPECT, 1425(ab)
Congestive heart failure
cardiac ^{123}I BMIPP uptake, ACE inhibitor effects, 747(ab)
MIBG cardiac imaging, beta-blocker effects on prognostic value, 504(ab)
Conjugate view, whole-body images, scintillation camera, 1562
Constipation, colon transit scintigraphy, radiopaque marker comparison, 321(ab)
Consumer Assurance of Radiologic Excellence (CARE) Act, 27N(12)
Contrast agents, attenuation correction in presence of, dual-modality PET/CT, 210(ab)
Copper-diacetyl-bis(N^4-methylthiosemicarbazone (Cu-ATSM), tumor uptake of, hypoxia effects, 655
Coronary angioplasty, percutaneous transluminal, acute myocardial infarction, 1351
Coronary arteries, vulnerable plaque in, device for localization, 28(ab)
Coronary artery bypass graft (CABG)
effects on LVEF, ischemic cardiomyopathy patients, 79, 87
myocardial infarction after, residual foci of, 765(ab)
Coronary artery disease (CAD)
after stent implantation, myocardial ischemia, 1768
comparative study, PET and electron beam CT, 358(ab)
diabetes and left ventricular dysfunction, myocardial glycose utilization and, 1730
dipyridamole stress in, value of transient ischemic dilatation, 2(ab)
dual isotope imaging, resting perfusion defects, 749(ab)
hemodynamically significant, SPECT *versus* MRI, 361(ab)
hemodynamically significant subset of, myocardial perfusion imaging, 357(ab)
myocardial perfusion imaging, inadequate exercise effects on accuracy, 780(ab)
myocardial perfusion reserve measurements, ^{15}O water PET, 1737
myocardial perfusion scan for, cost-effectiveness of, 728(ab)
nitroglycerin effects, myocardial blood flow, 341(ab)
PET, ^{13}N ammonia/FDG PET, 345(ab)
reduction of coronary flow reserve in, stress perfusion SPECT, 775(ab)
revascularization in, FDG PET and angiography for decision-making, 362(ab)
single-vessel, exercise effects on myocardial blood flow, 757(ab)
SPECT, correlation with subsequent infarction site, 558
stress only myocardial perfusion imaging, with and without attenuation correction, 185(ab)
stress ^{82}Rb PET normal database for, 359(ab)
^{99m}Tc sestamibi and ^{99m}Tc tetrofosmin SPECT comparison, 343(ab)
Coronary artery stenosis
reversible regional wall motion abnormality, single-day exercise ^{99m}Tc sestamibi SPECT, 353(ab)
^{188}Re TIN colloid, balloons coated with, 266(ab)
Coronary blood flow, altered, in muscular dystrophy, 1415(ab)
Coronary collaterals, pressure-derived fractional blood flow, severity of myocardial perfusion defect, 175(ab)
Coronary disease, RNA ejection fraction measurements, during pharmacologic stress testing, 871
Coronary flow reserve
estimation of, dynamic planar and SPECT images, 777(ab)
in muscular dystrophy, 1415(ab)

myocardial blood flow and, ^{15}O water PET for quantification of, 763(ab)
PET assessment, physiological cardiac hypertrophy and, 339(ab)
PET assessment of, bicycle exercise740
reduced
normal and angina patients, 746(ab)
in well-controlled hypercholesterolemia, 338(ab)
reduction, coronary artery disease patients, SPECT, 775(ab)
^{99m}Tc sestamibi retention, pharmacological hyperemia and, 336(ab)
vasodilator stress imaging, canine model of subendocardial infarction, 1388, 1395
^{99m}Tc sestamibi retention, hyperemia in human myocardium, 1457
Coronary reimplantation, myocardial blood flow after, after arterial switch and Ross operation, 727(ab)
Cost-effectiveness
myocardial perfusion scan, in CAD, 728(ab)
noninvasive imaging, evidence-based risk assessment, 1424
Craniotomy, free flap *versus* osteoblastic flap, ^{99m}Tc MDP assessment of viability, 1419(ab)
Cre-loxP system, modulation of gene expression with, PET reporter gene, 281(ab)
Cross-talk correction
Klein-Nishina priors for, $^{99m}Tc/^{123}I$ brain SPECT, 521(ab)
$^{123}I/^{99m}Tc$ brain SPECT, absolute activity quantitation, 300
Curve-plate NaI(T1) detectors, whole-body PET scanner, 1821, 1831
Cyclic RGD-DTPA-octreotate analog, radiolabeled, tumor imaging and radionuclide therapy, 413(ab)
Cyclosporine, bioavailability, renal transplant recipients, 1446(ab)
Cyclotron, ^{18}F fluoride produced by, targets view of the beam, 64(ab)
Cytokines
recombinant human IL-8, infection imaging, 1656
^{131}I-labeled, infection imaging, 1656
Cytokines, ^{99m}Tc-labeled CXC, for infection imaging, 268(ab)
CZT detector, for scintimammography, 1214(ab)

D

Data acquisition system
design, use in animal PET scanners, 874(ab)
high-speed PC-based list-mode, Sherbrooke animal PET scanner, 876(ab)
Data analysis, cluster analysis to find normal brain tissue, different data weighing methods, 804(ab)
Data correction techniques, quantitative accuracy, microPET, 864(ab)
Deep venous thrombosis, lower limbs and pelvis, pulmonary thromboembolism and, with antiphospholipid antibodies, 1430(ab)
Dementia
brain metabolism in, thyroid disease effects, 955(ab)
diagnosis, perfusion SPECT imaging, cognitive disorder clinic, 946(ab)
evaluation, subsequent cognitive impairment, brain PET, 225(ab)
SPECT imaging in, 1131(le)
work-up with FDG PET, 71S
Dentatorubropallidoluysian atrophy, brain uptake of FDG in, PET imaging of, 964(ab)
Department of Energy (DOE)
facility to produce stable isotopes, 21N(3)
isotope appropriation for 2002, 27N(12)
Missouri Research Reactor, 36N(6)
Phelps recognized with award, 21N(3)
Depression
in Alzheimer's disease, differences of cerebral response to passive audiovisual stimulation, 1018(ab)
children, occipital brain perfusion defects and, 1059
elderly late-onset, rCBF SPECT imaging, 1014(ab)
paroxetine treatment, occupancy of serotonin reuptake sites, PET, 62(ab)
postmenopausal, hypofrontality in, cognitive function and, 1015(ab)
treatment-resistant, vagal nerve stimulation and rCBF in, 1019(ab)
unipolar major, cortical benzodiazepine receptor binding and GABA levels in, 61(ab)
Desmoid tumors, recurrent, FDG PET detection, 1278(ab)
Dextrorphan, ^{123}I radiolabeling, biodistribution and, imaging the NMDA receptor complex, 1059(ab)
Diabetes mellitus
β-cell imaging agents for, 269(ab)
coronary disease and left ventricular dysfunction, myocardial glycose utilization and, 1730
non-insulin-dependent, ^{99m}Tc DTPA dynamic renography in, 1440(ab)
pulmonary clearance of ^{99m}Tc DTPA aerosol, 157(ab)
type 2
coronary microvascular function in, 6(ab)
PET imaging of serotonin receptors, 63(ab)
troglitazone effects on insulin resistance and skeletal muscle glucose, 1005
Diastolic function, systemic sclerosis patients, gated SPECT, 183
DICOM image display, four software packages of different manufacturers, 153(ab)
Dipyridamole
dobutamine and, myocardial hyperemia achieved with, after caffeine intake, 184(ab)
exercise supplementation and, use in ^{99m}Tc sestamibi imaging, 183(ab)
DISIDA scan, one-hour dynamic, biliary atresia, infants with hyperbilirubinemia, 328(ab)
Diuresis, renography, renal cortical scintigraphy and, infants and children, 91
Dobutamine
dipyridamole and, myocardial hyperemia achieved with, after caffeine intake, 184(ab)
gated SPECT with, identification of myocardial viability, 838
Donepezil, therapy in Alzheimer's disease
effects on regional cerebral blood flow, 1441
rCBF and cognitive function improvement, 46(ab)
^{99m}Tc HMPAO SPECT follow-up, 45(ab)
Dopamine
depletion, in vivo binding of ^{11}C FLB 457 and ^{123}I epidepride, 910(ab)
effective distribution volume, estimator of early Parkinson's disease, 29(ab)
released by amphetamines, effect on binding of D1 agonist, rat brain, 899(ab)
synthesis capacity, human brain, regulation assessed by FDOPA PET, 59(ab)
Dopamine D1 receptors
enantiomerically pure A69024 as radioligand for, 897(ab)
prefrontal, upregulation of, poor working memory performance and, 60(ab)
Dopamine D2 receptors
^{11}C raclopride binding, partial volume effect in ventral striatum, 797(ab)
dopamine transporters and, alcohol detoxification effects in alcoholics, 400(ab)
^{18}F FMT and ^{18}F FAL PET studies, in utero alcohol exposure and maternal stress, 54(ab)
imaging with PET, comparison with phosphor screen imaging, 1691
kinetic analysis, scatter correction in, SPECT, 796(ab)
pre- and postsynaptic, with subclinical REM sleep behavior disorder, 236(ab)
quantification of binding, PET, 928(ab)
serotonin radiotracer binding and, neurotransmitter effects, 53(ab)
stimulant medication effects, attention deficit hyperactivity disorder, 1003(ab)
striatal, PET, comparison with storage phosphor autoradiography, 1691
upregulation, in chronic schizophrenia, 1001(ab)
in vivo binding of ^{11}C FLB 457 and ^{123}I epidepride, dopamine depletion and, 910(ab)
Dopamine D3 radioligand, uptake and distribution, PET studies, brain, 900(ab)
Dopamine D3 receptors
^{11}C-labeled, synthesis of, 1056(ab)
development of PET radioligand, 1057(ab)
Dopamine D4 receptors, selective antagonists, PET and SPECT, 422(ab)
Dopamine neurons, function, oxidative metabolism and, in Parkinson's disease, 50(ab)
Dopaminergic system
impairment, correlation with cortical dysfunction, in Parkinson's disease, 957(ab)
interaction, regional uptake of FDOPA and, 969(ab)
pre- and post-synaptic, drug naive schizophrenic patients, SPECT, 58(ab)
Dopamine transporters
altropane, human DAT binding measurements with, 794(ab)
availability, MK-801 increase in, PET study, 56(ab)
binding, ^{99m}Tc TRODAT SPECT, changes in behavior and, 1002(ab)
highly selective DAT ligand, human brain SPECT, 896(ab)
imaging, ^{99m}Tc O15O5T, phase I clinical trial, 1125(ab)
imaging agent, ^{18}F FP-β-CIT, PET, 67(ab)
isoflurane and sevoflurane interaction with, 911(ab)
loss of, in methamphetamine abuse, recovery after detoxification, 402(ab)
occupancy, ^{11}C WIN35,428 and ^{11}C cocaine PET for assessment of, 927(ab)
occupancy by a transport inhibitor, therapeutic efficacy for Parkinsonism, 898(ab)
olfactory function and behavior, in movement disorder patients, 968(ab)
PET evaluation, early and late onset Parkinson's disease, 961(ab)
release and reuptake, phencyclidine treated primates, PET, 52(ab)
in social anxiety disorders, ^{123}I-β-CIT SPECT, 404(ab)
SPECT, correlation with motor symptoms, severe Parkinson's disease, 539(ab)
synthesis of ^{18}F β-CIT, brain imaging agent, 1055(ab)
^{99m}Tc TRODAT-1, pharmacological safety in human research volunteers, 1113(ab)
^{99m}Tc TRODAT-1 diagnosis, Parkinsonian movement disorders, 541(ab)
^{18}F FECNT, radiation dosimetry and biodistribution, 376
^{99m}Tc TRODAT imaging, early-stage Parkinson's disease, 1303
Dose calibrator, radionuclide, assay of ^{153}Sm, nuclear pharmacy, 1116(ab)
Dose conversion factors, α-particle-emitting radionuclides, 1216, 1222
Dosimetry
Bexxar, elderly patients with non-Hodgkin's lymphoma, 582(ab)
biodistribution and, ^{99m}Tc phenthioate-annexin V, 1048(ab)
biodistribution and, ^{99m}Tc RP527, 1722
biologic, bone marrow, 162
biological, chromosome aberrations and, thyroid cancer after ^{131}I therapy, 1336(ab)
bone marrow, radionuclide therapy, multi-institutional comparison, 81(ab)
cell nucleus-level, IUDR, hepatic tumor model, 1036(ab)
cellular, nonuniform distributions of radioactivity, bystander effects, 254(ab)
^{166}Ho DTPA filled balloon, for endovascular radiation therapy, 1035(ab)
^{131}I absorbed, up-to-date diagnostic, 1046(ab)
^{131}I CHTNT-1/B, prostate and pancreatic cancer, 1034(ab)
individual patient, using quantitative SPECT, 1032(ab)
internal assessment, consensus bone and marrow model for, 1029(ab)
internal organ techniques, ^{131}I and ^{90}Y-labeled antibodies, 79(ab)
intracellular localization of ^{125}I-labeled agents, assessing therapeutic efficacy, 1047(ab)
marrow-to-blood, maximum safe doses of ^{131}I therapy, in thyroid cancer, 1025(ab)
measurement of absorbed dose of ^{166}Ho, skin patch for cancer therapy, 1039(ab)
MIBG therapy, refractory neuroblastoma, 1713

α-particle-emitting radionuclides, cellular dose conversion factors, 1216, 1222
patient-specific, Monte Carlo MCNP-4B-based absorbed dose, 662
quantitative, source-depth maps and pseudo 3D activity maps, 822(ab)
Radar, radiation dose assessment resource, 1027(ab)
radiation
biodistribution and, ^{18}F FECNT, 376
new model for small intestine, 1031(ab)
non-marrow targeting of ^{90}Y-antibody therapy, myelotoxicity prediction, 80(ab)
underdosing and overdosing in non-Hodgkin's lymphoma, 1293(ab)
^{18}F FES PET studies in estrogen receptors, 679
^{90}Y and ^{177}Lu labeled antibodies, 1051(ab)
^{90}Y DOTATOC, renal protection in, 1037(ab)
^{99m}Tc annexin V, 382
^{131}I tositumomab, non-Hodgkin's lymphoma patients, 1292(ab)
radiation dose estimates for ^{11}C acetate, whole-body PET, 1023(ab)
radionuclide-liposome, internal radiotherapy, 499
^{188}Re N_2S_2-lipiodol, after transhepatic arterial administration, liver cancer, 1040(ab)
^{188}Re P2045, primates, 258(ab)
revised dynamic bladder model, MIRD pamphlet No. 14, 1033(ab)
three-dimensional, application to multiple treatments of radionuclide therapy, 78(ab)
three-sphere models, radionuclides for locoregional therapy or extravasation, 1028(ab)
three-step pretargeting mAb protocol, mouse adenocarcinoma, 670
tracer, thyroid stunning after, 1129(le)
tumor and whole-body, refractory neuroblastoma treated with ^{131}I MIBG, 1713
3D-voxel-based Monte Carlo simulation, absorbed dose calculations, 1026(ab)
3D VoxelDose program, validation of, 1030(ab)
whole-body, blood flow tracers, 1044(ab)
^{90}Y, biodistribution of ^{111}In DOTA-J591 and ^{177}Lu DOTA-J591 and, 1021(ab)
^{86}Y and ^{111}In-labeled binding peptides, dogs, 1020(ab)
^{18}F FDG, uptake and excretion in lactating breast, 1238
^{18}F FHBG, imaging of herpes simplex virus type I, 1225, 1235
^{99m}Tc RP128, inflammation imaging, 154
^{99m}Tc RP527, visualization of GRP receptor-expressing malignancies, 1722
^{123}I IAZA estimates, healthy volunteers, 1418
^{131}I, high level functioning thyroid cancer, 975
^{186}Re-MAb U36, myelotoxicity of radioimmunotherapy, 1364

DOTA
humoral immune response to, carrier molecule, 1697
macrocyclic chelating agent, humoral immune response to, 1697

Dual-energy X-ray absorptiometry (DEXA), accuracy, radioisotope effects, for bone densitometry, 1401(ab)

Dual time point imaging, FDG PET, malignancy or inflammatory processes, 1412

E

Echocardiography
blood pool imaging and MRI comparison, evaluation of ventricular function, 510(ab)
dobutamine
myocardial ischemia prior to wall motion change, 773(ab)
underestimation of viable tissue after acute MI, 742(ab)
dobutamine stress, functional recovery, oxidative metabolism and, 731(ab)
gated SPECT with, correlation of left ventricular ejection fraction, 768(ab)
stress, dobutamine gated SPECT comparison, myocardial viability, 838

Effective renal plasma flow, determination, renal depth influence on, 1444(ab)

Ejection fraction
calculation with gated SPECT, validation of myocardial tracking, 845
RNA measurements, during pharmacologic stress testing, 871

Electrotechnical Commission, curve-plate NaI(T1) detectors, whole-body PET scanner, 1821, 1831

Emission activity reconstruction, attenuation map and, emission data using discrete data consistency, 26(ab)

Emission-transmission imaging
endocrine neoplasms, 998
simultaneous dual-isotope, down-scatter for, 832(ab)

Emission tuned-aperture computed tomography (ETACT), scintimammography, 1121

Emphysema, pulmonary, severity of, fractal analysis, 177(le)

Endocrine tumors, combined transmission and emission tomography, 998

Endocytosis, receptor-mediated, Mu-opioid receptor binding and, 532(ab)

Endoscopic imaging capsule, 32N(11)

Endostatin, radiolabeled, targeted angiogenesis tumor vascular imaging with, 263(ab)

Endothelial function, coronary microvascular, type 2 diabetes mellitus, 6(ab)

Endothelin, release, marker of exercise-induced myocardial ischemia, 18(ab)

Endothelin receptors, in vivo labeling of, ^{11}C L-753,037, mice and dog studies, 1274

Epidermal growth factor, anti receptor antibody C225, conjugation with ^{111}In DTPA-PEG and, 1074(ab)

Epidermal growth factor receptor, imaging, ^{111}In DTPA effects, 1530

Epilepsy
difference calculation versus SPM, ictal-interictal SPECT, 987(ab)
difference SPECT images, iterative image reconstruction can improve, 856(ab)
$GABA_A$ receptor binding, vigabatrin treatment, children, 14i(ab)
intractable, basal ganglia and thalamic activation effects, ictal SPECT, 986(ab)
localization, ictal ^{99m}Tc HMPAO SPECT and FDG PET complementary methods, 988(ab)
localization of foci, FDG PET and SPECT imaging in, 232(ab)
neocortical, repeated ictal SPECT studies, intra-patient variability, 234(ab)
presurgical evaluation, FDG PET, 1158
temporal lobe
extent-specified quantified asymmetry-of-lobe analysis, 30(ab)
ictal hyperperfusion of cerebellum and basal ganglia in, SPECT subtraction, 853

Erythema multiforme, reaction to sestamibi, 534(le)

Erythromycin, effects on gastric emptying, after Billroth II resection, 492(ab)

Esophageal cancer, FDG PET
additional value in follow-up patients, 292(ab)
complementary role of intraluminal ultrasound, 287(ab)
evaluation after chemo- or chemoradiotherapy, 289(ab)
quantitative evaluation, 291(ab)
staging
chemo- and radiotherapy in, 290(ab)
coincidence imaging as alternative, 288(ab)

Esophagitis, in GERD, transit delay effects, 1360(ab)

Estrogen, regulation of serotonin receptor binding activity, frontal cortex, rat, 397(ab)

Estrogen receptors
imaging, breast cancer, addition of 4-fluoro and 11β-methoxy group, 1076(ab)
^{18}F FES PET study, 679

Ethanol, percutaneous injection, treatment of radioiodine-negative thyroid cancer, 1333(ab)

European Association of Nuclear Medicine (EANM), Wolfgang Becker, 9N(3)

European Congress of Radiology, international cooperation, 24N(4)

Ewing's sarcoma, cell lines, fibroblast and, ^{123}I IMT transport characteristics, 1390(ab)

Exercise training, effects on myocardial blood flow, single-vessel CAD patients, 757(ab)

Expert systems, interpretation of myocardial perfusion SPECT studies, 1185, 1192

Extracranial and intracranial bypass surgery, validation of candidates, ^{123}I IMP brain SPECT for, 983(ab)

F

Factor analysis
automatic generation of input and output functions, oncological PET studies, 814(ab)
dynamic renal tomographic data
acquired by slow rotation, 1704
reconstruction of, 1704
$H_2{}^{15}O$ PET and, regional myocardial blood flow, 782

Fallopian tube carcinoma, recurrent, PET/CT imaging in, 1186(ab)

Fast Flux Test Facility (FFTF), 37N(10)

Fatty acid imaging
BMIPP SPECT, in unstable angina, 508(ab)
myocardial, ^{99m}Tc-labeled long chain derivative, 1093(ab)
^{99m}Tc CpTHA, myocardial imaging, 1095(ab)
with ^{123}I 9MPA, myocardial viability in acute MI, 776(ab)

Fatty acids
cardiac, metabolism
peroxisome proliferator-activated receptor α and, 707(ab)
right ventricular apex pacing and, 736(ab)
extraction, during acute low-flow ischemia, rat heart, 1101

Femoral muscle, glucose utilization, FDG measurement of, 782(ab)

Fibroblast activation protein positive cancer, advanced or metastatic, dose-escalation study of BIBH-1, 1291(ab)

Fibrosis, liver, novel radiotracer for evaluation, 265(ab)

Filtered backprojection, *versus* iterative reconstruction, gated SPECT for measurement of LVEF, 754(ab)

FK506, early ischemic neuronal death and, monkey model of stroke, 1833

Fluorine-18
bone uptake, burn injury effects, rat, 147(ab)
dual solid-state intraoperative probe system with, in cancer treatment, 352
PET, blood flow and metabolism measured by, 483(ab)
SPECT and PET, estimation of defect size, 1579

Fluorine-18 β-CIT, synthesis, as brain dopamine transporter imaging agent, 1055(ab)

Fluorine-18 choline, synthesis and evaluation, as PET tracer, 1805, 1815

Fluorine-18 cis-FPro, uptake, urologic tumors, 752

Fluorine-18 F-α-MT, improved synthesis, purification and, 1079(ab)

Fluorine-18 FAZA, marker, tumor tissue hypoxia, 1168(ab)

Fluorine-18 FCH, preliminary metabolic studies with, oncologic probe for, 557(ab)

Fluorine-18 FDG
in differentiated thyroid cancer, negative ^{131}I scanning results after therapy, 1464
evaluation of myocardial metabolism, in congestive heart failure, 55
PET
malignant or inflammatory process, 1412
management of colorectal cancer, 586
metabolic activity in thymus gland with, 591
staging and managing breast cancer, 1334
statistical brain mapping in Alzheimer's disease, 548
scintigraphy, diagnosis of thyroid cancer, 414
SPECT, LVEF and heart failure symptoms, 79, 87
^{15}O water and, PET, pretreated melanoma, 248, 257

Fluorine-18 FDOPA
nucleophilic enantioselective, chiral catalytic phase-transfer alkylation, 1063(ab)
PET, regulation of dopamine synthesis capacity, brain, 59(ab)
regional uptake, several subdivisions of normal brain, 969(ab)
uptake, Parkinson's disease with and without dementia, 962(ab)

Fluorine-18 FdUrd, PET tracer, solid malignomas, 109(ab)
Fluorine-18 FECh
automated synthesis of, tumor cells, 68(ab)
PET, utility in prostate cancer imaging, 447(ab)
Fluorine-18 FECNT, dopamine transporter ligand, radiation dosimetry and biodistribution, 376
Fluorine-18 FES, radiation dosimetry, PET studies of estrogen receptors, 679
Fluorine-18 FE-SA5845, sigma receptor ligand, suitability for tumor imaging, 314(ab)
Fluorine-18 FET
kinetics, brain tumor patients, 915(ab)
lymph nodes, tumor and inflammation imaging, small animal PET, 1170(ab)
PET, metastatic malignant melanoma, 110(ab)
Fluorine-18 FETNIM
PET
blood flow and hypoxia in head and neck cancer, 1643, 1653
hypoxia in head and neck cancer, 1643, 1653
pharmacokinetics, hypoxia marker for PET, 1397
Fluorine-18 FHBG
measurement of suicide gene expression, PET, 1682
PET, suicide gene expression, 1682
pharmacokinetic and dosimetry studies, imaging herpes simplex virus, 1225, 1235
Fluorine-18 FLT
as cell proliferation marker, asynchronously growing tumor cells, 310(ab)
PET
breast cancer imaging, 107(ab)
gastrointestinal tumors, 108(ab)
non-Hodgkin's lymphoma, mouse model, 1150(ab)
non-small cell lung cancer, 106(ab)
rates of accumulation and retention, different cell lines, 1184(ab)
routine synthesis, in high activities, 1081(ab)
tweaking the synthesis of, 1080(ab)
uptake in tumor cells, cell lines, mouse and rat studie1156
Fluorine-18 fluoride
compared with ^{99m}Tc MDP SPECT, detection of bone metastases, 1270(ab)
cyclotron produced, targets view of the beam, 64(ab)
PET, Paget's disease, skeletal kinetic indices, 1402(ab)
reactive no-carrier-added, oxygen gas target system for, 6465(ab)
Fluorine-18 fluoride ion, PET, bone metabolism, porcine, 1091
Fluorine-18 fluormethane
modulated delivery, PET measurement of cerebral blood flow, 930(ab)
visual activation, Rhesus monkey, 934(ab)
Fluorine-18 fluoropropylsqualamine, synthesis, as angiogenesis imaging agent, 1077(ab)
Fluorine-18 FMAU, PET
biodistribution and metabolism, 308(ab)
brain tumor growth rate, 309(ab)
Fluorine-18 FMISO
limited usefulness, tissue hypoxia in hibernating myocardium, 21(ab)
PET, tumor hypoxia in hepatocellular carcinoma, 111(ab)
Fluorine-18 FMT, FDG PET, outcome of radiation therapy in primary or recurrent brain tumors, 251(ab)
Fluorine-18 FP-β-CIT, dopamine transporter imaging agent, PET, 67(ab)
Fluorine-18 FPS, PET, sigma-1 receptor radioligand, 421(ab)
Fluorine-18 FP-TZTP, regional brain uptake, M2 knockout mice, 535(ab)
Fluorine-18 FTHA, evaluation of myocardial metabolism, in congestive heart failure, 55
Fluorine-18 FUdR, for HSV-1 thymidine kinase gene therapy, noninvasive gene probe in, 1154(ab)
Fluorine-18 galacto RGD, PET, imaging of αVβ3 expression, 473(ab)
Fluorine-18 labeling agents
radiolabeling of oligodeoxynucleotides, 1075(ab)
synthesis and development, 1078(ab)
Fluorine-18 MPPF, binding, serotonin receptors, brain, 1025
Fluorine-18 NaF
PET, perfusion imaging of back pain patients, 485(ab)
PET bone scanning, back pain patients, 481(ab)
Fluorine-18 (N-methyl)benperidol, storage phosphor autoradiography, comparison with animal PET, 1691
Fluorine-18 (-*N*-Methyl)benperidol, validation of animal PET system, 1691
Fluorine-18 octreotide analogs, carbohydration, 555(ab)
Fluorine-18 paclitaxel, biodistribution, radiation dose estimates and PGP modulation studies, 1166(ab)
Fluorine-18 P-TZTP, effects on local cerebral blood flow, rat brain, 936(ab)
Fluorine-18 6FPWAY, synthesis, investigation as prospective serotonin receptor radioligand, 1058(ab)
Fluorodeoxyglucose (FDG)
bone uptake, burn injury effects, rat, 147(ab)
camera-based PET, follow-up in primary head and neck cancer, 1204(ab)
CDET, detection of recurrent colorectal cancer, 463(ab)
change in uptake, prediction of survival in sarcoma patients, 1275(ab)
^{11}C methionine comparison, PET for evaluation of lung cancer after stereotactic radiotherapy, 1252(ab)
compared with ^{99m}Tc MDP, earlier detection of bone metastases, 1268(ab)
comparison with ^{99m}Tc EC-DG, cellular uptake, 1082(ab)
detection, surgical gamma and beta probes for, 1285(ab)
differential uptake, tumors on immunocompetent and immunodeficient mice, steroids and, 1172(ab)
double-head coincidence camera
evaluation of fever of unknown origin, 1378(ab)
evaluation of postoperative fever, 1377(ab)
dual-head cardiac imaging, attenuation correction, 192(ab)
dynamic positron autoradiography, expression of stress proteins after hypoxic preconditioning, 938(ab)
early chemotherapy response with, tumor-mouse model, 95(ab)
evaluation, recurrent ovarian cancer, 1194(ab)
^{18}F FMT comparison, diagnosis in whole-body PET, 1282(ab)
hybrid camera and, staging, restaging and follow-up of malignant melanoma, 1277(ab)
increase in availability, 36N(9)
kinetics, liver, FDG PET, pigs, 795
measurement, femoral muscle glucose utilization, 782(ab)
multidrug resistant human colon cancer cell line, tracer characteristics, 646
^{13}N ammonia, prognostic value, CAD patients, 345(ab)
PET
accuracy in characterization of pulmonary nodule, 273(ab)
automated nonlinear 3D registration, with thoracic CT, 37(ab)
brain uptake in dentatorubropallidoluysian atrophy, 964(ab)
camera-based, follow-up in malignant lymphoma, 1131(ab)
cardiac, determination of MRGlu in, 1622
cardiac, MRGlu determination in, 1622
characterization of adrenal lesions, 1795
colonic adenomas, 989
correlative studies of breast cancer, 94(ab)
CT nodule enhancement comparison, solitary pulmonary nodule, 274(ab)
diagnosis of abdominal and pelvic tumors, attenuation correction effects, 1239(ab)
differential regional brain metabolism during fasting, 410(ab)
in differentiated thyroid cancer, 71, 77
dilated cardiomyopathy and left bundle branch block, 198(ab)
distant metastases, 21N(3)
dobutamine gated SPECT comparison, myocardial viability, 838
early Huntington's disease, 1591
effects on patient management, 34N(6)
glucose metabolism of breast cancer, 9
glucose transporter subtype expressions and, tumor and inflammation models, 1551
hypermetabolic bone marrow and diffuse bone metastases, 1135(ab)
imaging of splenic involvement in Hodgkin's disease, 1136(ab), 1137(ab)
infected lower limb prosthesis implants, 44
internal positron-emitting markers for identification of anatomical structures, 829(ab)
lesion size on CT scan in characterizing pulmonary nodules, 275(ab)
locoregional evaluation of oral squamous cell cancer, 1203(ab)
management of breast cancer, 1236(ab)
management of cervical cancer, 1195(ab)
management of head and neck tumors, 1208(ab)
medullary thyroid cancer, 496(ab)
metabolic network abnormalities in Huntington's disease, 1591
metabolites, pig liver, 1673
metabolites of, liver, 1673, 1679
monitoring treatment of head and neck cancer, 1206(ab)
MRI/CT comparison, recurrence of head and neck cancer, 1207(ab)
myocardial glycose utilization, 1730
myocardial metabolism during heart failure, 762(ab)
negative ^{131}I scanning results after therapy, thyroid cancer, 1464
newly diagnosed non-small cell lung cancer, 1596
nonhypersecreting adrenal masses, 884, 893
non-invasive monitoring of myocardial ischemia, 709(ab)
optimal scan time, suspected pancreatic cancer, 105(ab)
oral intake, exercise effects on digestion and glucose absorption, 315(ab)
ovarian cancer, without recurrence, 1191(ab)
post-therapy differentiated thyroid cancer, 1330(ab)
prediction in re-staged lymphoma patients, 1130(ab)
prediction of poor treatment response to radioiodine, 1325(ab)
preoperatively irradiated advanced oral cancer, 1202(ab)
presurgical evaluation in thyroid cancer, 497(ab)
presurgical evaluation of epilepsy, 1158
pretreated melanoma, 248, 257
primary and recurrent soft-tissue sarcomas, 713
primary head and neck cancer, 1205(ab)
primary tumors with squamous cell carcinoma, malignant neck nodes, 1209(ab)
recurrent medullary thyroid carcinoma, 1337(ab)
recurrent non-small cell lung cancer, after curative therapy, 1605
relevance in hypermetabolic differentiated thyroid cancer, 499(ab)
second look surgery in ovarian cancer with chemotherapy, 1192(ab)
sentinel lymph node scintigraphy and, head and neck cancer, 1211(ab)
spatial normalization methods, anatomic validation of, 922(ab)
in staged uterine cervical cancer, 1189(ab)
staging newly diagnosed non-small cell lung cancer, 1596
staging of nonseminomatous germ cell tumors, 1199(ab)
steady-state, tumor metabolism during photodynamic therapy, 96(ab)
suspected recurrent non-small cell lung cancer, 1605
tabulated summary of literature, 1S
uptake, normal liver, 1265
uterine cervical cancer, 1187(ab)
whole-body, decision-making in malignant lymphoma, 1132(ab)
^{11}C raclopride combination, L-dopa effects in Parkinson's disease, 960(ab)
^{201}Tl comparison, pulmonary nodules, 1489, 1497
3D PET, glucose utilization in sarcoma, 813(ab)
preoperative evaluation, disease distribution, 1193(ab)

preoperative uptake, correlation with proliferative activity in breast cancer, 305(ab)
radioligand for staging esophageal cancer, coincidence imaging as alternative, 288(ab)
right ventricular uptake
in chronic ischemic heart disease, 743(ab)
chronic ischemic left ventricular dysfunction, 200(ab)
tetrabutylammonium bicarbonate preparation of, rapid gas chromatography, 66(ab)
transport kinetics, 36B-10 glioma and normal fibroblast cell lines, 913(ab)
tritiated, localization in GI tract, autoradiographic study, 92(ab)
two-phased PET, hexokinase II and glucose transporter, pancreatic cancer, 1174(ab)
uptake
changes in tumor cell cultures after radiation, 255(ab)
correlation with endoscopic and histopathologic findings, gastric cancer, 293(ab)
estradiol enhancement of, breast cancer cells, 1178(ab)
granulocytes, infection imaging, 1384(ab)
hypoxia effects, MCF7 cells, 170
insulin and glucose loading effects, inflammatory lesions, 1175(ab)
Ki-67 immunostaining and, pancreatic cancer, 721
large arteries, risk factors of atherosclerosis and, 4(ab)
mediastinal nodes, non small cell lung cancer patients, 1179(ab)
multivariate analysis, pancreatic cancers, 1176(ab)
non-small cell lung cancer, correlation with DNA grading, 561(ab)
PET in breast cancer, 1177(ab)
shoulder and hip joints, 1417(ab)
surgical stage and tissue relations, non-small cell lung cancer, 559(ab)
thoracic aortas, risk factors, 202(ab)
thoracic aortas, PET assessment, 201(ab)
uptake and excretion, lactating breast, 1238
uptake and expression, hexokinase II and GLUT-1, non small cell lung cancer, 11721173(ab)
whole-body hybrid PET, staging of non-Hodgkin's lymphoma, 601, 609
whole-body PET, malignant lymphoma patients, 1139
6-Fluoro-meta-tyrosine, uptake, monkey brain, 536(ab)
Folate receptor, tumor-associated, targeting with ^{111}In DTPA conjugate of pteroic acid, 427(ab)
Food and Drug Administration (FDA)
guidance on foreign clinical studies, 35N(5)
National Cancer Institute and, 34N(9)
online course on drug approval process, 24N(3)
radiation concerns, 29N(7)
rules for children in clinical trials, 34N(6)
Fractal analysis
cerebral blood flow distribution, in Alzheimer's disease, 1446
regional severity of emphysema, SPECT, 177(le)
Fractal dimension
analysis
differential diagnosis of lung disease, 821(ab)
lung perfusion image transformation, 818(ab)
FDG PET studies, primary and recurrent soft tissue sarcomas, 713
quantification of dynamic PET studies, 788(ab)
Fractionation, multiple radionuclide dosing, radioimmunotherapy strategy, 1295(ab)
Fusion, emission-transmission imaging, endocrine neoplasms, 998
Fuzzy clustering, noninvasive determination of arterial input function, myocardial blood flow, ^{13}N ammonia PET, 809(ab)

G

GABA, levels, cortical benzodiazepine receptor binding and, in major depression, 61(ab)
Galactosemia, infant, ^{99m}Tc pertechnetate and per-rectal portal scintigraphy in, 1367(ab)
Gallbladder, concentration function of, hepatic bile entry into and transit within, 493(ab)
Gallbladder ejection fraction
values for sincalide, cholescintigraphy, 316(ab)
^{99m}Tc DISIDA and, prediction of autonomic neuropathy in diabetic patients, 1366(ab)
Gallium, scintigraphy
restaging of mediastinal lymphoma, 1126(ab)
somatostatin receptor scintigraphy and, sarcoidosis, 21
Gallium-67
during chemotherapy, prognostic test for non-Hodgkin's lymphoma, 1139(ab)
paracoccidioidomycosis, diagnosis and follow-up, 1371(ab)
scintigraphy, CT and, bone lymphoma, 117(ab)
^{99m}Tc and, simultaneous emission-transmission imaging, 844(ab)
^{99m}Tc pertechnetate compared with, detection of gastric Non-Hodgkin's lymphoma, 1138(ab)
Gallium-67 citrate
evaluation of prognosis, lymphoma patients, 1133(ab)
leukocytes and, SPECT/CT, evaluation of fever of unknown origin and suspected infection, 164(ab)
^{111}In DOTA-TYR3-OCT comparison, staging of B-cell lymphoma, 1134(ab)
Gallium-68, PET, somatostatin receptors, meningiomas, 1053, 1057
Gallium-68 DOTATOC, SMS receptor PET, pre-therapeutic dosimetry of neuroendocrine tumors, 1296(ab)
Gamma camera
coincidence dual-head, staging and management of head and neck cancer, 1205(ab)
four-headed small-field-of-view, for brain imaging, 886(ab)
high-resolution intra-operative hand-held, for cancer surgery, 867(ab)
hybrid PET, geometric sensitivity in, 1116
pileup recovery method, 624, 633
prototype cadmium telluride, 378(ab)
rotating, sodium-iodide detectors for SPECT and PET, 367(ab)
slotted crystal, performance evaluation, 884(ab)
Gamma probe
intraoperative, radioguided surgery and, primary hyperparathyroidism, 1350(ab)
radioguided surgery, thyroid cancer, 1323(ab)
Gastric antrum, role in gastric emptying, after different gastric operations, 495(ab)
Gastric bypass, Roux-en Y, radionuclide gastrointestinal study, 320(ab)
Gastric cancer
application of sentinel node biopsy concept to, 466(ab)
FDG uptake, correlation with endoscopic and histopathologic findings, 293(ab)
Gastric emptying
accelerated, high-frequency electrical stimulation effects, gastroparetic patients, 319(ab)
after different gastric operations, role of antrum in, 495(ab)
comparative study, ^{13}C octanoic acid breath test and scintigraphy, 491(ab)
delayed, after abdominal surgery, intestinal inflammation and, 317(ab)
scintigraphy, ^{13}C breath test correlation, pediatric patients, 334(ab)
Gastric motility, after Billroth II resection, erythromycin effects, 492(ab)
Gastrin receptor ligands, CCK-B, radiopeptide therapy, 252(ab)
Gastrin-releasing peptide, visualization of GRP receptor-expressing malignancies, 1722
Gastrin-releasing peptide agonist, biodistribution and dosimetry, visualization of malignancies, 1722
Gastroesophageal cancer, FDG PET in, 40S
Gastroesophageal reflux disease (GERD), esophagitis in, transit delay effects, 1360(ab)
Gastrointestinal tract
malignant neuroendocrine tumors, ^{131}I and octreotide scintigraphy in, 600(ab)
radionuclide study, evaluation of Roux-en Y gastric bypass surgical leak, 320(ab)
wall hyperactivity, sestamibi cardiac SPECT, 779(ab)
Gastrointestinal tumors, ^{18}F fluorine PET, 108(ab)
Gastroparesis, severe, high-frequency electrical stimulation effects on gastric emptying, 319(ab)
Gate segmented registration (GSR), respiratory motion correction with, CT attenuation maps, 520(ab)
Gaucher disease
bone marrow scintigraphy in, 1129(ab)
efficacy of enzyme replacement therapy, assessed by ^{99m}Tc sestamibi bone marrow scintigraphy, 476(ab)
type 1, clinical interest of bone scan, 1403(ab)
^{99m}Tc sestamibi bone marrow scintigraphy in, 1412(ab)
Gemcitabine, somatostatin receptors and, pancreatic tumor cells, 1856
Gender differences
aging and, effects on myocardial metabolism, PET, 360(ab)
attenuation corrected stress myocardial perfusion imaging, 12(ab)
Gene expression
HSV1-tk reporter, 8-^{18}F FPCV PET, 96, 106
imaging, ^{99m}Tc TRODAT-1 and SPECT, 240(ab)
quantitative PET correlation, FDG in bone tumors, 120(ab)
radiation adaptive response, low level radiation from ^{99m}Tc in cells, 256(ab)
target, prostate-specific amplification of, 282(ab)
Gene therapy
HSV thymidine kinase, on ganciclovir, medullary thyroid carcinoma, 1155(ab)
HSV-TK suicide, using nucleoside analogue FIRU, 1159(ab)
HSV-1 thymidine kinase model, noninvasive gene probe in, 1154(ab)
imaging with increased sensitivity, linking PET and therapeutic reporter gene expression, 280(ab)
LDL receptor defect, ^{111}In LDL scintigraphy, 259(ab)
with microPET, HSV1-TK suicide, 1153(ab)
molecular imaging and, 1368
PET, Penciclovir analog for measurement, 1682
radioiodinated IVDU and IVFRU as monitoring agents, hepatocellular carcinoma, 1158(ab)
radioiodine concentrator, sodium/iodide symporter gene for, colon cancer cell line, 1182(ab)
radiolabeled probe, penciclovir analog for measurement, 1682
research, 29N(7)
sodium iodide symporter gene, hepatoma cells, 317
Z-Val-DL-Asp fmk, as potential scintigraphic marker for apoptosis, 1157(ab)
Geometric sensitivity, hybrid PET, 1116
Germ cell tumor, nonseminomatous, FDG PET for staging, 1199(ab)
Glioblastoma, buildup pattern in early kinetics of ^{201}Tl, 976(ab)
Glioma
amino acid in, ^{11}C acetate for synthesis, 979(ab)
delineation, ^{123}I IMT and ^{99m}Tc DTPA SPECT for, 978(ab)
gene therapy trial, HSV-1-tk gene expression, PET-based imaging, 238(ab)
imaging, ^{123}I IPA, whole-body kinetics and dosimetry, 916(ab)
malignant
FDG uptake before and after radiotherapy, 973(ab)
intralesional radioimmunotherapy, serial FDG PET in, 972(ab)
postoperative uptake of ^{123}I IMT, survival and, 1144
recurrent, radioimmunotherapy with alpha-particle emitting astatine-211, 454(ab)
^{18}F FDG and ^{11}C methionine PET for follow-up, double tracer investigations, 974(ab)
^{125}I interstitial brachytherapy for, 1315(ab)
Glomerular filtration rate (GFR)
estimation in children, 322(ab)
interstitial space, functional volumes of, 149(ab)
microalbuminuria relations, in sickle cell disease, 1448(ab)
renal dynamic imaging with radionuclides, different IGA neuropathies, 1443(ab)
using plastic scintillation counter, 1484
^{99m}Tc BPHA, new potential renal imaging agent, 1092(ab)

Glucagon-like peptide-1 receptor agonists, comparison, detection of insulinomas and neuroendocrine tumors, 1148(ab)
Glucose
metabolism, liver, PET and dual-input blood sampling, pigs, 795
myocardial metabolic rate of
determination with cardiac FDG PET, 1622
FDG PET, 1622
preloading, modulation of ^{123}I IMT uptake after, 1171(ab)
Glucose loading, insulin and, effects on FDG uptake, in inflammatory lesions and malignant tumors, 1175(ab)
Glucose metabolism
androgenic control, prostate cancer, 93(ab)
skeletal muscle, insulin resistance and, troglitazone effects, diabetes, 1005
Glucose transporter
FDG transport kinetics, 36B-10 glioma and normal fibroblast cell lines, 913(ab)
hypoxia-induced increase in FDG uptake, MCF7 cells, 170
subtype expression, tumor and inflammation models, FDG PET, 1551
GLUT-1, correlation of expression with FDG uptake, PET in breast cancer, 1177(ab)
P-Glycoprotein
function
biodistribution and PET studies, 425(ab)
monitoring with ^{11}C carvedilol and PET, 1167(ab)
human MDR1, ^{99m}Tc carbonyl complex, 426(ab)
multidrug resistance-mediated, expression non-small cell lung cancer, 17
multidrug resistance protein and mRNA correlation, lung cancer, 1476
tumor accumulation and washout rate of ^{99m}Tc MIBI, lung cancer, 1284(ab)
Graft-versus-host disease, radioimmunoconjugates in, labeling and biodistribution studies, mice, 1146(ab)
Graves hyperthyroidism, ^{131}I for treatment, 592(ab)
Green fluorescent protein-HSV1-TK reporter gene, for molecular imaging, 285(ab)
Gynecological malignancy
disease distribution in ovarian cancer, FDG PET, 1191(ab)
evaluation, ^{99m}Tc MIBI as additional test support ultrasound, 1188(ab)

H

Hazardous Material Legislation, 13N(11)
Head and neck cancer
advanced, preoperatively irradiated, FDG PET value in, 1202(ab)
blood flow and hypoxia in, ^{18}F FETNIM PET, 1643, 1653
cervical lymph node metastases, FDG PET effects on treatment management, 297(ab)
combined FDG PET/CT imaging, impact on patient management, 133(ab)
FDG PET, monitoring treatment with, 1206(ab)
FDG PET after irradiation, residual tumor viability, 296(ab)
FDG PET in, 21S
management, FDG PET impact in, 1208(ab)
morphological imaging, FDG coincidence, 1210(ab)
primary, camera-based FDG PET in follow-up, 1204(ab)
recurrence, comparison of FDG PET and MRI/CT, 1207(ab)
sentinel lymph node scintigraphy, FDG PET and, 1211(ab)
squamous cell
dual-head FDG PET for locoregional evaluation, 1203(ab)
dual-head FDG PET gamma camera for staging and management, 1205(ab)
FDG PET imaging, 3D radiation therapy, 1233(ab)
^{123}I anti-epidermal growth factor antibody, 1143(ab)
therapy management of, FDG PET effects on, 294(ab)
tissue polypeptide specific antigen, as a proliferation tumor marker, 1098(ab)
Head injury
mild to moderate, consequences as determined by PET, 993(ab)
role of brain perfusion SPECT in, 989(ab)
Health Care Financing Administration (HCFA)
expanded coverage of PET, 11N(4)
FDG PET literature, 1S
name change, 30N(7)
PET decision, 9N(5)
rules on medicare self-referral, 26N(2)
ruling on coincidence imaging, 11N(8)
Health Insurance Portability and Accountability Act (HIPAA), privacy, 9N(2)
Heart
comparison of cardiac PET studies, 701
myocardial metabolic rate of glucose, FDG PET, 1622
segmentation, classification of factor volumes, myocardial perfusion studies, 808(ab)
Heart failure
chronic, β-blocker therapy in, effectiveness, 733(ab)
LVEF and, FDG SPECT, 79, 87
pacing-induced, detection of lipid metabolism with BMIPP, 124
prognosis, MIBG activity and, 1757
Heart transplantation
orthotopic, sympathetic reinnervation and allograft performance after, 505(ab)
reappearance of cardiac presynaptic sympathetic nerve terminals in, 1011
Helicobacter pylori, infection, ^{13}C urea breath test for diagnosis, 1365(ab)
Hematologic risk factors, Bexxar toxicity and efficacy, 460(ab)
Hemodialysis
radioiodine treatment during, activity kinetics and exposure, 1340(ab)
radiotracer assessment of function, 375(ab)
^{153}Sm treatment for bone pain and, 391(le)
Hepatic blood flow, portal-systemic shunt and, ^{99m}Tc DTPA-galactosyl-neoglycoalbumin, 110
Hepatic blood supply, dual, FDG uptake, PET, 1265
Hepatocellular carcinoma
cirrhosis with, ^{99m}Tc GSA and portal circulation relations, 1364(ab)
FDG PET, clinical receiver operating characteristic study, 126(ab)
FDG PET in, 44S
HSV-TK gene induced, gene therapy for, 1158(ab)
skeletal metastases in, bone scintigraphy, 1400(ab)
targeting therapy using ^{131}I anti-HBX monoclonal antibody in, 1290(ab)
treatment, ^{90}Y-labeled microspheres, 1317(ab)
tumor hypoxia in, ^{18}F FMISO PET in, 111(ab)
Hepatocellular mass, receptor measurements via Tc-GSA kinetic modeling, 733
Hepatoma, radiolabeled iododeoxyuridine and thymidylate synthase inhibitor, locoregional delivery of, 345
Hepatoma cells, iodide uptake in, sodium iodide symporter gene effects, 317
Herpes simplex virus, type 1
thymidine kinase (HSV1-tk), reporter gene expression, 8-^{18}F FPCV PET, 96, 106
^{18}F FHBG pharmacokinetic and dosimetry studies, 1225, 1235
Hippocampus, metabolism, correlation with loss of memory function, Alzheimer's disease, 228(ab)
Hirudin, recombinant, diagnosis of thrombin formation, 703(ab)
Histamine receptors, cerebral, occupancy of three antihistamine drugs, PET, 537(ab)
Histologic malignancy, prostate cancer, comparison of SPECT and PET imaging for, 1226(ab)
Histomorphometry, bone, ^{18}F fluoride ion PET, porcine, 1091
Hodgkin's disease
aggressive lymphoma and, FDG PET after first cycle of chemotherapy, 441(ab)
first-line treatment, FDG PET after, 446(ab)
splenic involvement, ^{67}Ga, ^{18}FDG and CT for detection of, 1136(ab), 1137(ab)
Holmium-166
intralesional injection therapy, recurrent pelvic malignancy, 1319(ab)
measurement of absorbed dose, skin patch for cancer therapy, 1039(ab)
microspheres, treatment of liver tumors, rabbit, 1145(ab)
Holmium-166 DOTMP, high-level dosages, skeletal targeted radiotherapeutic, 1122(ab)
HSV-tk gene, T cells modified with, dual camera x-ray/gamma imaging of, 1388(ab)
Human immunodeficiency virus (HIV)
peripheral benzodiazepine receptor expression, PET visualization, 905(ab)
stavudine, tissue pharmacokinetics of, 1386(ab)
Huntington's disease
early, metabolic network abnormalities in, PET, 1591
metabolic network abnormalities, FDG PET, 1591
Hydrocephalus, H_2O^{15} PET study, before and after ventriculoperitoneal shunting, 544(ab)
Hydronephrosis
neonates and infants, diuretic renography in, 1780
unilateral, subnormal differential renal function, 329(ab)
Hydroxymethylglutaryl coenzyme A (HMG CoA) reductase, inhibitors, ^{125}I-LDL binding and, 706(ab)
Hypercholesterolemia, well-controlled, reduced coronary flow reserve, 338(ab)
Hyperemia, pharmacologic, tracer retention during, human myocardium, 1457
Hyperparathyroidism
dual-phase ^{99m}TC MIBI imaging, immediate/delay image ratios, 1351(ab)
neck high resolution pinhole SPECT, ^{99m}Tc MIBI double-phase planar scintigraphy and, 1348(ab)
parathyroid imaging, experiences with specialized endocrine surgeons, 1354(ab)
preoperative PET with ^{11}C methionine, 598(ab)
primary
comparison of ^{99m}Tc delayed imaging in, 1355(ab)
preoperative scintigraphy and minimally invasive surgery, 597(ab)
radioguided surgery with intraoperative gamma probe, low MIBI doses and, 1350(ab)
Hypertension
exercise renography, as an alternative to ACE inhibitor, 323(ab)
with and without nephropathy, ^{99m}Tc DTPA losartan renography, 326(ab)
Hyperthyroidism
cardiac oxidative metabolism and, efficiency and, 7(ab)
Graves, ^{131}I for treatment, 592(ab)
with iodine excess, ^{99m}Tc sestamibi imaging in, 1331(ab)
pediatric, ^{131}I for treatment, 593(ab)
treatment with ^{131}I, 975
^{131}I turnover in, 1344(ab)
Hypopharyngeal cancer, chemotherapy, ^{11}C methionine PET in monitoring of, 299(ab)
Hypothyroidism
brain SPECT imaging in, 1017(ab)
primary congenital, ^{99m}Tc pertechnetate scintigraphy in, 1429(ab)
Hypoxia
cell fraction, correlation with glucose metabolic rate, gliomas, PET, 250(ab)
Cu-ATSM selectivity for, 655
effects on FDG uptake, MCF7 cells, 170
head and neck cancer, ^{18}F FETNIM PET, 1643, 1653
imaging, radiation-induced blood-spinal cord barrier breakdown, 1169(ab)
measurement, ^{18}F FETNIM PET, head and neck cancer, 1643, 1653
measuring with radiodiagnostic markers, rat prostate cancer, 337
PET marker, ^{18}F FETNIM pharmacokinetics, 1397
preconditioning, expression of stress proteins after, dynamic positron autoradiography, 938(ab)
tumor tissue, ^{18}F FAZA as marker of, 1168(ab)
^{123}I IAZA estimates, healthy volunteers, 1418
Hysterosalpingoscintigraphy, ^{99m}Tc aggregated albumin, velocity of tubular transport, 1357(ab)

I

Ileus, intestinal inflammation, after abdominal surgery, delayed gastric emptying, 317(ab)
Image analysis
comparing brain images, cognitively impaired and normal patients, 952(ab)
noise detection, bootstrap method, PET, 38(ab)
pixelized small imaging CDTE probe, intra-operative use, prototype, 869(ab)
segmentation, change detection, and volume browsing, using connectivity analysis, 816(ab)
Image coregistration
automated, for brain imaging, 799(ab)
dynamic PET, movement correction in, 861(ab)
thoracic CT and PET datasets, evaluation of mediastinal disease in lung cancer patients, 128(ab)
^{99m}Tc sestamibi SPECT, regional myocardial uptake, 772, 780
Image fusion
attenuation correction and, SPECT, separate X-ray CT use in, 845(ab)
camera-based PET and CT, clinical oncology applications, 131(ab)
cardiac FDG PET and EBT, postischemic mitral valve insufficiency, 223(ab)
CT/PET
automatic multimodality registration with deformations, chest, 40(ab)
respiratory movement effects on accuracy, 42(ab)
FDG PET and CT imaging, head and neck cancer, 133(ab)
intermodality, FDG PET and CT/MRI, oncology, 132(ab)
whole-body FDG PET and spiral CT, staging of bronchogenic carcinoma, 130(ab)
Image quality, JPEG, Wavelet, and JPEG2000 evaluation, PET brain images, 791(ab)
Image reconstruction
data correction techniques and, comparison of 3D and 2D PET, 855(ab)
iterative, improvement in different SPECT images, 856(ab)
myocardial SPECT, inconsistent projections, iterative least-squares method, 859(ab)
prototype real-time system, design of, for PET, 854(ab)
real-time, for emission tomography, 517(ab)
resolution and uniformity, SPECT myocardial perfusion imaging, 836(ab)
SPECT, noise properties of, 519(ab)
tomographic, non-iterative methods, 850(ab)
wavelet-vaguelette decomposition, wavelet shrinkage and, PET, 851(ab)
Image registration
cardiac PET, contractile motion compensation via tagged MRI priors, 27(ab)
harmonized, prostate cancer detection, 825(ab)
medical imaging data analysis, AMIDE, 827(ab)
whole-body, scintillation camera images, 1562
Image warping, 3D automatic, cardiac SPECT, clinical interests, 221(ab)
Immunization, mass, safety of needleless jet injector systems, 1382(ab)
Immunoassays, signal amplification of, 262(ab)
Immunogenicity, macrocyclic chelating agent DOTA, 1697
carrier molecule, 1697
Immunoglobulin, thyroid-stimulating, ^{131}I, high level functioning thyroid cancer, 975
Immunohistochemistry
colon cancer multidrug resistance, 646
glucose metabolism in breast cancer, ^{18}F-FDG PET, 9
Immunoscintigraphy, ^{111}In-labeled alCAM-1, oleic acid-induced lung injury, 1109
Independent component analysis, myocardial PET, blind separation of cardiac components, 938
Independent diagnostic testing facilities (IDTFs), 14N(12)
Indium-111, dual solid-state intraoperative probe system with, in cancer treatment, 352
Indium-111 capromab pendetide, image fusion with MR or CT, recurrent prostate cancer patients, 1224(ab)
Indium-111 DOTA-α-MSH analog, peptide cyclization for, increasing tumor targeting capacity for, 416(ab)
Indium-111 DOTA-HU-J591, dose escalation studies with, monoclonal antibodies to prostate-specific membrane antigen, 458(ab)
Indium-111 DOTA-lantreotide, scintigraphy, tumors of the lung, 1309
Indium-111 DOTA-ReCCMSH(Arg^{11}), optimization of biological properties, targeting melanoma, 1069(ab)
Indium-111 DOTA-rhenium, cyclized α-MSH analog, tumor-targeting properties, 1847
Indium-111 DTPA conjugate of pteroic acid, targeting tumor-associated folate receptor with, 427(ab)
Indium-111 DTPA-OC, PET, in neuroendocrine tumors, 213
Indium-111 DTPAOC, SPECT, imaging somatostatin receptors in meningiomas, 249(ab)
Indium-111 DTPA octreotide, SPECT, 4 and 24 hour, comparison in neuroendocrine tumors, 101(ab)
Indium-111 DTPA-PEG
conjugation with, anti-EGF receptor antibody C225 and, 1074(ab)
improved imaging of EGF receptor, 1530
Indium-111 HEGF, anti-tumor effect, against MDA-MB-84 breast cancer xenografts, 1073(ab)
Indium-111 HuM195, radiotoxicity, human leukemia cells expressing CD33, 1072(ab)
Indium-111-labeled platelets, biokinetics, after cryotherapy of colorectal cancer, 1128(ab)
Indium-111 LDL, monitoring of gene therapy, LDL-receptor defect, 258(ab)
Indium-111 leukocyte scan, surrogate for colloid marrow scan, diagnosis of osteomyelitis, 488(ab)
Indium-111 octreotide
receptor-targeted therapy with, colon cancer, 1305(ab)
scintigraphy, comparative study with CT/MRI, 100(ab)
somatostatin receptor scintigraphy, soft-tissue sarcoma, 102(ab)
Indium-111 pentetreotide
palliative treatment, metastatic gastro-entero-pancreatic neuroendocrine tumors, 1299(ab)
somatostatin receptor scintigraphy, 1134
therapy, tumor regression patterns, 139(ab)
Indium-111 peptides, targeting of prostate cancer, 1149(ab)
Infarct-avid imaging agent, ^{99m}Tc glucarate, use in acute myocardial infarction, 711(ab)
Infection imaging
acute osteomyelitis, ^{99m}Tc labeled interleukin-8 use in, 1257
bone, FDG PET for diagnosis, 162(ab), 163(ab)
extra-osseous inflammation, ^{99m}Tc anti-granulocyte antibody fragment immunoscintigraphy in, 1372(ab)
FDG, coincidence camera, chronic orthopedic infections, 1396(ab)
FDG lymph node uptake, quantitative differences, early HIV infection, 828(ab)
FDG PET for diagnosis, 161(ab)
FDG uptake, granulocytes, 1384(ab)
^{67}Ga citrate and leukocytes, evaluation of fever of unknown origin and suspected infection, 164(ab)
inflammatory foci, ^{99m}Tc leukokinin residue analogs for imaging of, 1089(ab)
lower limb prosthesis implants, FDG PET in detection of, 44
novel chemotactic peptide antagonists, 1107(ab)
osteomyelitis, ^{111}In leukocyte scan for diagnosis, 488(ab)
periprosthetic infection in hip prosthesis patients, FDG PET, 482(ab)
radiolabeled ^{99m}Tc C5A and C5A-DES-ARG^{74} for, 1088(ab)
recombinant human IL-8, 1656
scintigraphic detection, ^{99m}Tc-labeled interleukin-8, 117
^{99m}Tc ciprofloxacin, diagnosis of prosthetic joint infection, 1385(ab)
^{99m}Tc-labeled CXC-cytokines for, 268(ab)
^{99m}Tc-labeled interleukin-8, scintigraphic detection, 272(ab)
^{99m}Tc liposomes, viral infections, 1380(ab)
3-step pretargeting strategy, 1389(ab), 1405
^{99m}Tc ciprofloxacin (infection), chronic orthopedic infections, 567
^{99m}Tc interleukin-8, experimental colitis, rabbits, 917
^{99m}Tc-labeled antimicrobial peptides, bacterial and *Candida albicans* infections, 788
^{131}I-labeled recombinant human IL-8, 1656
Inflammation imaging
acute and chronic abscess, apoptosis in, 1383(ab)
FDG PET
arthritic disease in hands and feet, 1414(ab)
localization of inflammatory foci, 1376(ab)
FDG uptake, shoulder and hip joints, 1417(ab)
glucose transporter subtype expressions, FDG PET, 1551
immunoscintigraphy, after implantation of endovascular abdominal aortic stent, 1374(ab)
labeling neutrophils in human blood, ^{99m}Tc-labeled LTB4 use in, 1090(ab)
malignancy or, FDG PET, 1412
oleic acid-induced lung injury, ^{111}In-labeled alCAM-1, 1109
^{99m}Tc leukokinin residue analogs, 1089(ab)
^{99m}Tc RP128, dosimetry, 154
Inflammatory bowel disease
experimental, ^{99m}Tc interleukin-8 imaging, rabbits, 917
temporal correlation of ESR with ^{99m}Tc WBC uptake, children, 1423(ab)
Inhalation therapy, α_1-potease inhibitor, 744
In memoriam
Allen, E. William, 24N(4)
Bell, Persa Raymond, 18N(3)
Bennett, Leslie R., 12N(2)
Lambrecht, Richard, 28N(10)
Murray, I.P.C., 23N(1)
Totter, John Randolph, 20N(3)
Input functions, image-derived, cardiac FDG PET, 1622
Institute for Clinical PET, reorganization as Academy of Molecular Imaging, 26N(2)
Institute of Medicine (IOM), report on American health care, 22N(4)
Insulin resistance, troglitazone effects, skeletal muscle glucose use and, type II diabetes, 1005
Insulin sensitizer, treatment, insulin resistant coronary vasomotion, PET myocardial blood flow, 340(ab)
Interleukin-8 (IL-8)
human recombinant, ^{131}I-labeled, infection imaging, 1656
recombinant human, infection imaging, 1656
^{99m}Tc labeled, imaging acute osteomyelitis, 1257
^{99m}Tc-labeled, scintigraphic detection of infection with, 117
Internet, knowledge-based toolkit, generation of nuclear medicine reports, 819(ab)
Intersocietal Commission for the Accreditation of Nuclear Medicine Laboratories (ICANL), 35N(5)
Interstitial space, functional volumes of, 149(ab)
Intervertebral disk, injury, radiolabeled monoclonal antibody detection, 476
Intralesional therapy
beta emitters, tumor retention of, 1320(ab)
radionuclides for locoregional therapy or extravasation, three-sphere dosimetry models for, 1028(ab)
^{166}Ho, in recurrent pelvic malignancy, 1319(ab)
Iodine-31 recombinant human IL-8, infection imaging, 1656
Iodine-123
thyroid tumor scanning, 1326(ab)
whole body scans, thyroglossal duct uptake in thyroid cancer patients, 1327(ab)
Iodine-123 ADAM, SPECT, quantification of serotonin transporters, 1556
Iodine-123 anti-epidermal growth factor antibody, head and neck squamous cell cancer, 1143(ab)
Iodine-123 α_1-Pi, inhalation, 744
Iodine-123 β−CIT
quantitative dopamine transporter SPECT, atypical tremor, 966(ab)
SPECT
serotonin and dopamine transporters, social anxiety disorder, 404(ab)

serotonin and dopamine transporters in obsessive-compulsive disorders, 1008(ab)
Iodine-123 BMIPP
canine pacing model, myocardial lipid metabolism, in advanced heart failure, 124
ECG gated myocardial SPECT, left ventricular function, 1747
SPECT, acute myocardial infarction, 1351
uptake, congestive heart failure, ACE inhibitor effects, 747(ab)
Iodine-123 CNS-1261, novel NMDA receptor tracer, for SPECT, kinetic modeling of, 939(ab)
Iodine-123 epidepride, SPECT, measurement of striatal and extrastriatal dopamine D2 receptors, scatter correction in, 925(ab)
Iodine-123 FIRU, expression of HSV-TK suicide gene, 1159(ab)
Iodine-123 IAZA, dosimetry estimates, healthy volunteers, 1418
Iodine-123 IMB, distribution, medial frontal lobes, statistic parametric mapping, 923(ab)
Iodine-123 IMP
brain distribution of ^{14}C octanoate comparison, focal cerebral ischemia, 244(ab)
brain SPECT
EC/IC bypass candidates validation by, 983(ab)
triple-energy window scatter correction in, 33(ab)
comparative study, blood flow of cerebellum and brainstem in spinocerebellar degeneration, 965(ab)
Iodine-123 IMT
activity of transport, brain capillary endothelial cells, pig, 917(ab)
postoperative uptake, survival and, gliomas, 1144
transport characteristics, Ewing's sarcoma cell lines and fibroblasts, 1390(ab)
uptake, modulation after preloading with glucose and amino acids, 1171(ab)
^{99m}Tc DTPA comparison, SPECT, glioma delineation, 978(ab)
Iodine-123 IPA, initial evaluation, cerebral gliomas, 916(ab)
Iodine-123 IPPA, acute low-flow ischemia, rat heart, 1101
Iodine-123-labeled angiostatin, angiogenesis inhibitor, tumor imaging with, 1065(ab)
Iodine-123 methyl-tyrosine, SPECT, non-small cell lung cancer, 579
Iodine-123 MIBG
myocardial uptake, β-blocker therapy and, 49
SPECT, cardiomyopathy, 1017
surgical repair, ascending aortic aneurysm, 1346
sympathetic innervation, identification of high risk of cardiac death and, 1757
Iodine-123 tamoxifen, uptake, primary breast cancer, 1818
Iodine-123 9MPA, fatty acid imaging, myocardial viability in acute MI, 776(ab)
Iodine-124, prediction and validation with, GE advance PET scanner for non-pure positron emitters, 880(ab)
Iodine-124 FIAU, quantitative kinetics, cat and man, 467
Iodine-124 HuA33, immuni PET, humanized monoclonal antibody, colorectal cancer, 764, 770
Iodine-125
biodistribution, sodium-iodide symporter and, 1346(ab)
interstitial brachytherapy, glomectomized patients, 1315(ab)
Iodine-125 antisense probe, biodistribution, ERBB2 oncogene mRNA, lung cancer, 1164(ab)
Iodine-125 iodo-α-methyltyrosine, amino acid imaging, in oncology, 432
Iodine-125 iodorotenone, as deposited myocardial flow tracer, comparison with ^{99m}Tc sestamibi, 272, 282
Iodine-125 iomazenil, binding, hippocampus after transient forebrain ischemia, gerbil, 942(ab)
Iodine-125 LDL, binding to mast cells and basophils, HMG CoA reductase inhibitors and, 706(ab)
Iodine-125 monoclonal antibody A33, therapeutic efficacy, colon cancer xenograft, 1251
Iodine-125 seeds, 103PD-implanted stents and, effects on vascular smooth muscle cells, 714(ab)
Iodine-125 tetracycline, bone uptake, burn injury effects, rat, 147(ab)
Iodine-131
diagnostic whole-body scanning, thyroid stunning after, 986(le)
monoclonal antibody RS7, human lung cancer xenograft, 967
pharmacokinetics of, therapeutic absorbed doses, thyroid cancer, 1084
scintigraphy, diagnosis of thyroid cancer, 414
SPECT
tumor activity, effect of object shape in, 389(ab)
whole-body, differentiated thyroid cancer, 1341(ab)
therapy
dosimetry and therapeutic outcome, differentiated thyroid cancer, 1022(ab)
maximum safe doses, treatment of thyroid cancer, 1025(ab)
methimazole pretreatment effects, multinodular goiter, 1343(ab)
radiation adaptive response, differentiated thyroid cance4, 1022(ab)
thyroid cancer
chromosome aberrations or biological dosimetry in, 1336(ab)
stunning and, 1335(ab)
treatment, functioning of thyroid cancer, 975
treatment of Graves hyperthyroidism, 592(ab)
turnover, normal thyroid and hyperthyroidism, 1344(ab)
whole body san, thymic uptake in, 1339(ab)
Iodine-131 anti-B1 antibody, outpatient treatment, radiation exposure to family, 907, 916
Iodine-131 anti-CD20 antibody, high-dose radioimmunotherapy
mantle cell lymphoma, 585(ab)
relapsed or refractory mantle cell lymphoma, 586(ab)
Iodine-131 anti-HBX monoclonal antibody, targeting therapy, hepatocellular carcinoma, 1290(ab)
Iodine-131 BC-8 antibodies, radioimmunotherapy with, in acute leukemia, children and adolescents, 584(ab)
Iodine-131 chimeric G250 monoclonal antibody, renal cell carcinoma patients, 1289(ab)
Iodine-131 lipiodol, radiochemoembolization, liver metastases of neuroendocrine tumors, 1318(ab)
Iodine-131 MIBG
adrenal tumor imaging, 884, 893
biodistribution and sensitivity, neuroblastoma, in children, 1321(ab)
chromogranin A assay and, diagnosis and follow-up of pheochromocytoma, 993
CT scanner-scintillation camera and, neuroblastoma imaging, 237
in neuroblastoma, 28N(1)
octreotide and, in malignant neuroendocrine tumors of GI tract, 600(ab)
refractory neuroblastoma treated with
dosimetry and toxicity, 1713
tumor and whole-body dosimetry, 1713
Iodine-131 monoclonal antibodies
high-dose labeling, large reaction volume and temporary coating, 509
radiosensitization of xenografts with pentoxifylline, colon cancer, 1147(ab)
Iodine-131 monoclonal antibody A33, therapeutic efficacy, colon cancer xenograft, 1251
Iodine-131 sodium, therapy, thyroid cancer therapy with doxorubicin, 1332(ab)
Iodine-131 tositumomab, tumor radiation dose and response to, follicular lymphoma, 83(ab)
Iodine-131 74 MBq, stunning after, differentiated thyroid cancer, 589(ab)
Iododeoxyuridine
radiolabeled, locoregional delivery of, hepatoma model, 345
radiolabeled (IUDR), cell nucleus-level tumor dosimetry of, hepatic tumor model, 1036(ab)
IODO-GEN, antibody coated with, high-dose ^{131}I labeling of antibodies in large reaction volume, 509
Ischemic heart disease
chronic, right ventricular FDG uptake in, 743(ab)
poststress ejection fraction and, gated myocardial perfusion SPECT, 831
Isoflurane, interaction, dopamine transporter, 911(ab)
Isotretinoin, for redifferentiated thyroid cancer, 502(ab)
Iterative deconvolution techniques, comparison, contrast recovery in brain SPECT perfusion imaging, 858(ab)
Iterative reconstruction
accuracy of OSEM, dynamic PET, 808
brain benzodiazepine distribution, ^{123}I NNC 13–8241 in, 802(ab)
versus filtered backprojection, gated SPECT for measurement of LVEF, 754(ab)
least square SPECT, mpm-uniform attenuation correction, 216(ab)
oncology FDG PET, noise reduction in, 1316

J

Java virtual machine, remote viewing, nuclear medicine images, 390(le)
Journal of Nuclear Medicine
online, 17N(3)
recent and upcoming trends, 18N(1)
seven words to watch, 21N(3)
turnaround: time to take a look, editorial, 1
whose liability is it anyway?, editorial, 1729
Journal of Nuclear Medicine Technology, online, 17N(3)

K

Keratan sulfate, radiolabeled monoclonal antibody against, detection of intervertebral disk injury, 476
Ketamine, binding to serotonin reuptake site, evaluation of PET or SPECT ligands and, 912(ab)
Kidney. *see also* Renal entries
late sequelae, DMSA scintigraphy and, 564
tomographic studies, acquired by slow rotation, 1704
tumors, uptake of ^{18}F cis-FPro, 752
Kidney function. *see also* Renal entries
new imaging agent and chemistry of the analog, 1091(ab)
renal excretion mechanism and, study with ^{99m}Tc BPHA, 1092(ab)
split, renal parenchymogram, 151(ab)
subnormal differential, in unilateral hydronephrosis, 329(ab)
Taylor and Tonnesen formulas, *versus* blood clearance with single sample method, 1444(ab)
^{99m}Tc isonitrils for imaging, 267(ab)
^{99m}Tc MAG3 renography evaluation, 1445(ab)
Kinetic analysis
discrete linear least squares method, measurement of cerebral glucose metabolism, 792(ab)
D2 receptor ligand
scatter correction and, SPECT, 926(ab)
scatter correction in, SPECT, 796(ab)
OSEM *versus* filtered backprojection, 3D brain PET, 803(ab)
Simplified Reference Tissue Model, noise reduction in, 786(ab)
striatal and extrastriatal D2 receptors, scatter correction and, ^{123}I epidepride SPECT, 925(ab)
tracer model, server-based application program for nuclear medicine, 787(ab)
Kinetic modeling
^{11}C flumazenil receptor binding studies, short-time PET measurements, 940(ab)
^{123}I CNS-1261, NMDA receptor tracer for SPECT, 939(ab)

L

Lacrimal glands
dysfunction, after radioiodine therapy, 738
function, radioiodine effects, 591(ab)
Lanreotide, ^{111}In DOTA, lung tumors, 1309
Left ventricular dysfunction
chronic, right ventricular FDG uptake and, 200(ab)

coronary disease and diabetes, myocardial glycose utilization and, 1730
glucose utilization in, FDG dynamic PET, 197(ab)
ischemic
isotope and acquisition protocol, 194(ab)
post-stress dilation, 188(ab)
semi-quantitative algorithm, 744(ab)
mitral regurgitation in, surgical correction, scintigraphic prediction of outcome, 3(ab)
transient, post-exercise stunning, gated myocardial SPECT, 774(ab)
viability after, PET and SPECT assessment of, 1166
Left ventricular ejection fraction
accuracy, gated myocardial SPECT, 1571
algorithms for, planar radionuclide venctriculography, 705(ab)
automatic determination, gated blood pool imaging, 401
calculation, ECG-gated blood pool imaging, 511(ab), 512(ab)
correlation of, gated SPECT with echocardiography, 768(ab)
decrease after bicycle stress, gated SPECT, 764(ab)
ECG-gated PET, contrast left ventriculography comparison, 734(ab)
evolution of, ^{201}Tl myocardial gated SPECT, 771(ab)
gated blood pool SPECT, *versus* planar imaging, 1773
gated blood-pool SPECT, 1043, 1050
gated cardiac PET for, 741(ab)
gated myocardial SPECT, patients without CAD, 346(ab)
heart failure symptoms and, FDG SPECT, 79, 87
measurements, filtering effects in quantitative SPECT, 350(ab)
overestimation, quantitative gated SPECT, 454
parameters, from ^{99m}Tc tetrofosmin SPECT, 723(ab)
quantification of, ECG-gated SPECT, 349(ab)
quantitative gated SPECT for determination, 528(le)
variability of, ^{201}Tl myocardial gated SPECT, 770(ab)
volume and, ECG-gated blood pool imaging *versus* cardiac angiography, 515(ab)
^{99m}Tc tetrofosmin gates SPECT, after myocardial infarction, 1(ab)
Left ventricular function
algorithm comparison, gated blood pool tomography, 726(ab)
ECG gated myocardial SPECT, with ^{123}I-labeled fatty acid analog, 1747
exercise-induced ischemia effects, 720(ab)
LV time-volume curve, from ECG-gated SPECT, 725(ab)
measurement, $^{13}NH_3$ gated PET, 721(ab)
normal values, gated SPECT, comparison of two programs, 722(ab)
post-stress changes, different stress-test modalities and, 355(ab)
rest and post-stress measurements, dual-isotope myocardial perfusion SPECT, 753(ab)
short- and long-term pacing effects, Fourier-filtered volume curves for assessment, 755(ab)
^{99m}Tc tetrofosmin gated SPECT, correction by multivariate analysis, 766(ab)
Left ventricular mass, measurement, quantitative gated SPECT, 351(ab)
Left ventricular volume
determination using ventricular casts, 3D gates SPECT programs, 173(ab)
regional wall motion, patient motion effects, ECG-gated SPECT, 758(ab)
Leukemia
Bi213-HuM195 therapy, parametric images of antibody pharmacokinetics, 27
cells expressing CD33, radiotoxicity of ^{111}In HuM195, 1072(ab)
stem cell transplantation in, ^{188}Re labeled anti-CD-66 MAb radioimmunotherapy before, 457(ab)
^{99m}Tc MDP bone scintigraphy, children, 878
Leukocytes
labeled, uptake, pulmonary activity on, 166(ab)
labeled with ^{99m}Tc HMPAO, activation during labeling, 685(le)
migrating, leukoscan targeting of, 1387(ab)
^{99m}Tc exametazime-labeled, chemotaxis and viability, 505
LeuTech, 11N(12)
Lewy body disease, Alzheimer's disease
mixed neurodegenerative disease, evaluation with FDG PET, 944(ab)
statistical parametric mapping in, 943(ab)
Linear regression models, reversible neuroreceptor binding, parametric imaging, 801(ab)
Liposomes
analytic dosimetry study, internal radiotherapy, 499
cationic, MicroPET and optical imaging, 284(ab)
new phage display peptides, related to endothelium of tumor vasculature, 471(ab)
radiolabeled, tissue sequestration of, inflammatory mediators and, 1379(ab)
^{99m}Tc-labeled, identification of sentinel lymph node, 446, 452
Liver
FDG uptake, using dynamic PET, 1265
fibrosis, novel radiotracer for evaluation, 265(ab)
function
estimation with ^{99m}Tc early phase index, 1361(ab)
hepatectomy, relation to percutaneous transhepatic portal embolization, dynamic SPECT, 467(ab)
hepatocellular carcinoma and cirrhosis, ^{99m}Tc GSA and portal circulation relations, 1364(ab)
regional, estimation from single blood sample and SPECT, 489(ab)
functional mass, Tc-GSA measurements, 733
glucose metabolism, PET and dual-input blood sampling, pigs, 795
hypertrophy, after preoperative portal vein embolization, ^{99m}Tc GSA SPECT, 1369(ab)
irradiated, whole and regional function using ^{99m}Tc GSA, 820(ab)
^{11}C MG and ^{18}F FDG metabolites, pig, 1673, 1679
Liver cancer
treatment with ^{166}Ho microspheres, 1145(ab)
^{90}Y microspheres for, 1587(le)
Liver disease
chronic, per-rectal portal scintigraphy and ^{99m}Tc GSA, clinical need for both, 1362(ab)
non-alcoholic cirrhosis, measurement of rCBF with ^{99m}Tc ECD SPECT, 999(ab)
Liver transplantation, hepatobiliary leak in, blind end sign and, 318(ab)
Locoregional delivery, radiolabeled iododeoxyuridine, hepatoma model, 345
Loevinger-Berman Award, 2001, 26N(10)
Lung
aerosol deposition in, planar scintigraphy, 1077
embolism, ventilation/perfusion SPECT, 1288
V/Q SPECT, diagnosis of pulmonary embolism, 1432(ab)
Lung cancer
adrenal masses in, FDG PET characterization of, 564(ab)
bone metastases from, planar bone scans, SPECT, and ^{18}F-labeled NaF PET, 1800
bronchioloalveolar, FDG PET for detection and staging, 276(ab)
clearance of radiolabeled YAC-1 tumor cells, study of natural killer cells, mice, 1165(ab)
detection and staging, accuracy of FDG PET with dual-head coincidence camera, 1265(ab)
early prognosis, usefulness of ^{99m}Tc SPECT, 1248(ab)
ERBB2 oncogene mRNA, biodistribution of ^{125}I antisense probe, 1164(ab)
expression of P-glycoprotein, MRP and LRP in, ^{99m}Tc MIBI with, 1284(ab)
FDG PET, management of thoracic oncology, 565(ab)
FDG PET in, 2S
glucose metabolism in, FDG PET evaluation, 388(ab)
local recurrence, local response to treatment and, ^{201}Tl SPECT in prediction of, 1262(ab)
mediastinal lymphadenopathy, accurate characterization on FDG PET, 563(ab)
metabolic imaging
prognostic value of, 1249(ab)
sensitivity for bronchioloalveolar carcinoma, 277(ab)
Mu and Delta-opioid receptor imaging, PET study, 1281(ab)
multidrug resistance of, 1476
non-small cell
chemotherapy, FDG as surrogate marker for response, 1251(ab)
FDG PET for staging before radio-chemotherapy, 560(ab)
FDG PET in patients with, 156(ab)
FDG uptake, correlation with DNA grading, 561(ab)
FDG uptake and surgical stage and tissue relations, 559(ab)
FDG uptake of hexokinase II and Glut I in, 11721173(ab)
^{18}F FLT PET, 106(ab)
measurement of perfusion with $H_2{}^{15}O$ PET, 112(ab)
mediastinal nodes, FDG uptake and Glut-1 expression, 1179(ab)
neoadjuvant radiochemotherapy, FDG PET for monitoring of, 1253(ab)
newly diagnosed, FDG PET, 1596
N2 mediastinal lymph nodes, ^{99m}Tc MIBI thoracic SPECT for, 1261(ab)
prognostic value of FDG PET, 1245(ab)
radiotherapy treatment planning, PET role in, 1255(ab)
recurrence, FDG uptake as prognostic factor of, 1244(ab)
recurrent, FDG PET, 1605
response to paclitaxel chemotherapy, ^{99m}Tc tetrofosmin imaging, 17
stage IIIA-N2, induction chemotherapy in, FDG PET assessment, 1254(ab)
staging, FDG PET, 1596
suspected recurrent, FDG PET, 1605
SUV as prognostic factor after FDG PET, 1246(ab)
^{123}I methyl-tyrosine SPECT in, 579
occult malignancy, FDG PET in pleural effusion patients, 1256(ab)
post-therapy, evaluation of mediastinal disease in, thoracic CT and PET datasets, 128(ab)
pulmonary nodules, FDG PET and ^{201}Tl comparison, 1489, 1497
regional pulmonary ventilation function, maximal inspiration and expiration, 1435(ab)
respiratory gated 3D PET, thorax, 154(ab)
restaging of, FDG PET, substantial impact, 562(ab)
small cell, FDG PET management of, 278(ab), 279(ab)
squamous cell, chemoradiotherapeutic response, ^{99m}Tc MIBI and ^{201}Tl SPECT, 1260(ab)
staging and management, FDG PET, 1250(ab)
tumor cells, detection of apoptosis using radiolabeled annexin V, 1099(ab)
xenograft, radioimmunotherapy of, 967
^{111}In DOTA-lanreotide scintigraphy, 1309
Lung disease
differential diagnosis, ventilation/perfusion ratio map, fractal analysis, 821(ab)
obstructive, interstitial pneumonitis and, after bone marrow transplant in children, 1439(ab)
Lung injury, radiation, ^{99m}Tc DTPA clearance, irradiated canine lung, 292
Lung perfusion, image transformation, heterogeneity and fractal behavior, 818(ab)
Lung tumor, motion, gated PET, technique for reduction, 124(ab)
Lutetium-177 DOTA-TYR^3 octreotate, radiotherapeutic efficacy, rat tumor models, 469(ab)
Lymphatic flow studies, radiolabeled protein, lymphatico-venous communications, forearm, 1140(ab)
Lymphatic mapping, lymphoscintigraphy and sentinel node imaging, breast cancer, 420
Lymphedema, peripheral, lymphoscintigraphy in, improved protocol for, 781(ab)
Lymph nodes, sentinel
draining the peritoneum, localization approach, 1163(ab)
radioguided biopsy, breast cancer surgery, 1198
Lymphoma
after radiometal labeled antibodies, metabolite production, 1324
aggressive, Hodgkin's disease and, FDG PET after first cycle of chemotherapy, 441(ab)
B-cell, successful radioimmunotherapy, low-dose rate irradiation and antibody use in, 1312(ab)

bone marrow infiltration with, FDG PET for detection of, 118(ab), 119(ab)
disseminated, targeting alpha particle emitting isotope generators to tumors, 1311(ab)
FDG PET in, 16S
follicular, ^{131}I tositumomab therapy for, 83(ab)
malignant
camera-based FDG PET in follow-up, 1131(ab)
decision-making with whole-body FDG PET, 1132(ab)
FDG PET, early therapy monitoring, 442(ab)
whole body FDG PET for staging and management, 1139
mantle cell
high-dose radioimmunotherapy, 585(ab)
relapsed or refractory, high-dose radioimmunotherapy in, 586(ab)
mediastinal, gallium scintigraphy restaging for, 1126(ab)
prognosis, ^{67}Ga evaluation of, 1133(ab)
restaging, FDG PET clinical stage by conventional image, 440(ab)
restaging, FDG PET prediction in, 1130(ab)
skeletal, ^{67}Ga scintigraphy and CT for monitoring treatment, 117(ab)
Lymphoma cells, triple helix-forming oligonucleotides in, antigene effects of BCL-2 targeting, 581(ab)
Lymphoscintigraphy
lymphatic disorders in children, 1428(ab)
optimized mammary, larger colloid particles in, 826(le)
optimum injection methods, sentinel lymph nodes in breast cancer, 434(ab)
particle size analysis, two colloids, 460
in peripheral lymphedema, improved protocol for, 781(ab)
preoperative, combined with intraoperative mapping, in cervical cancer, 1240(ab)
reproducibility of, cutaneous melanoma, 424, 430
sentinel load localization and, breast cancer, 420
sentinel lymph node biopsy, breast cancer surgery, 1198
^{99m}Tc cysteine rhenium colloid, compared to other colloids, rabbit model, 1123(ab)
Lysine, protection, against bismuth accumulation in the kidneys, 570(ab)

M

Machado-Joseph disease, gene carriers, dopamine transporter binding in, 543(ab)
Macroautoradiography, ^{99m}Tc-labeled divalent and tetravalent CC49 single-chain Fv's, imaging of colon cancer, 1519, 1528
Magnetic resonance angiography, measurement of pulmonary blood flow, 1434(ab)
Magnetic resonance imaging (MRI)
blood pool imaging and echocardiography comparison, evaluation of ventricular function, 510(ab)
functional, neurophysiologic component, 37N(10)
Magnetic resonance spectroscopy, phosphorus-31, differentiated thyroid cancer, 1324(ab)
Major depressive disorder, children, occipital brain perfusion defects and, 1059
Malignomas, solid, ^{18}F FdUrd PET tracer, 109(ab)
Mammary tumor, spontaneous, ^{90}Y-labeled radiotherapeutic agent effects, 1307(ab)
Mammography
application specific emission tomography and, breast imaging, 363(ab)
positron emission, guided breast biopsy, 960
^{99m}Tc MIBI, ROC curves, suspected breast cancer, 3
Marijuana, cannabinoid receptor agonist, in vivo binding, 904(ab)
Mean transit time, parenchymal, 1439(le)
Mediastinal staging, non-small cell lung cancer, ^{123}I methyl-tyrosine SPECT, 579
Mediastinal tumors
FDG PET diagnosis, 1258(ab)
nonspecific uptake of ^{99m}Tc Depreotide, 1264(ab)
Mediastinitis, post-sternotomy, relapse, ^{99m}Tc leukocyte scintigraphy in diagnosis, 167(ab)
Melanocyte-stimulating hormone, cyclized analog, tumor-targeting properties, 1847
Melanoma
cutaneous
localization of sentinel nodes, surgical intervention, 1231(ab)
reproducibility of lymphoscintigraphy, 424, 430
FDG PET in, 13S
lead/bismuth radiolabeled α-MSH peptide analogs, scintigraphy, 1070(ab)
malignant
loco-regional lymph node staging, sentinel node imaging and FDG PET, 1241(ab)
metastatic, ^{18}F FET PET first results in, 110(ab)
sentinel nodes in, temporary shielding of hot spots, 438(ab)
staging, restaging and follow-up with FDG and hybrid camera, 1277(ab)
staging with whole-body FDG PET, 1276(ab)
metastatic, chimeric anti-GD3 monoclonal antibody KM871 in, 1288(ab)
pretreated, quantitative PET studies, 248, 257
radioiodination of rhenium cyclized α-MSH analogs, via D-lysine, 417(ab)
solitary metastases of, ^{188}Re labeled somatostatin analog RC 160, 1298(ab)
staging, comparison of sentinel node biopsy and FDG PET, 1232(ab)
targeting, ^{111}In-DOTA-Rhenium cyclized analog, 1847
targeting, ^{111}In-labeled DOTA-rhenium cyclized MSH analogs, 1069(ab)
Meningioma
recurrent, ^{201}Tl brain SPECTS, image registration of, 975(ab)
scintigraphically negative, somatostatin receptor imaging, 248(ab)
somatostatin receptor-negative, scintigraphic analysis, 1338
somatostatin receptors, ^{68}Ga PET imaging, 1053, 1057
Metaiodobenzylguanidine (MIBG)
cardiac imaging
beta-blocker effects on prognostic value, in heart failure, 504(ab)
idiopathic dilated cardiomyopathy, 503(ab)
impaired uptake in Parkinson's disease, 506(ab)
detection of cardiac adrenergic neuronal damage, carvedilol effects, 708(ab)
sequential dual autoradiographic study with, in cardiomyopathy, 702(ab)
vasospastic angina, abnormal wall motion and, 729(ab)
Metallothionein, cell-surface targeted mutants, nuclear imaging, marker protein expression, 286(ab)
Methamphetamine
abuse, loss of dopamine transporters in, recovery after detoxification, 402(ab)
detoxification, thalamic but not striatal metabolism recovery, 1012(ab)
Methimazole, pretreatment, ^{131}I dose and, multinodular goiter, 1343(ab)
Methionine, choline and, comparative study of FDG, human astrocytoma, 914(ab)
Methylene blue, leukocytes labeled with ^{99m}Tc exametazime, stability, 505
Methylene blue stabilizer, effects on chemotaxis, labeling efficiency and stability, ^{99m}Tc exametazime leukocytes, 1112(ab)
Methylphenidate, behavior changes induced by, ^{99m}Tc TRODAT uptake and, 1002(ab)
Methylxanthine, sensitization, human colon cancer cells to ^{188}Re-labeled monoclonal antibody, 596
MIB1 labeling index, ^{201}Tl index correlation, pituitary adenomas, 575
Microangiopathy, mechanisms of reduced coronary flow, 746(ab)
Microelectrodes, measurement of hypoxia, rat prostate cancer, 337
Micronuclei, in reticulocytes, biologic dosimetry of bone marrow, 162
MicroPET
monitoring, HSV1-TK suicide gene therapy, 1153(ab)
prostate cancer mouse models, using PET reporter gene approach, 283(ab)
quantitative accuracy, data correction techniques, 864(ab)
with reporter gene/reporter probe approach, cell trafficking, 1185(ab)
tumor imaging, genetically engineered anti-CEA antibodies, 572(ab)
^{124}I and ^{66}Ga with, imaging and quantitation, 875(ab)
MicroPET I, linking therapeutic reporter gene expression, imaging gene therapy, 280(ab)
Microprobe, intracerebral beta, studying radiotracer kinetics, freely moving animals, 377(ab)
Microspheres, particle-based preparations of ^{99m}Tc peptides, 74(ab)
Microvascular permeability, initiated by inflammatory mediators, radiolabeled liposomes in, 1379(ab)
Missouri Research Reactor, 36N(6)
Mitral regurgitation, ischemic, surgical correction, scintigraphic prediction of, 3(ab)
Mitral valve, postischemic insufficiency, fusion of cardiac FDG PET and EBT, 223(ab)
Molecular imaging
HSV1-TK, dual-function green fluorescent protein for, 285(ab)
^{124}I FIAU quantitative kinetics, PET, 467
Molecular medicine, gene therapy and, 1368, 1384
Molecular nuclear medicine, gene expression, mediated by oncolytic HSV-1 mutant vectors, PET-based imaging, 239(ab)
Molinoff, Perry, 11N(12)
Monoamine oxidase A (MAO A)
inhibitors, deuterium vs hydrogen-substituted clorgyline, across brain regions, 908(ab)
peripheral, PET studies, 906(ab)
Monoamine synthesis, assessment, 6FMT PET use in, 536(ab)
Monoclonal antibodies
humanized, immuno-PET of ^{124}I HuA33, 764, 770
radiolabeled, detection of intervertebral disk injury, 476
^{186}Re-MAb U36, myelotoxicity of radioimmunotherapy, 1364
^{211}At-labeled, α-particle-emitters and, 1508, 1516
Monoclonal antibody A33, radiolabeled, human colon cancer xenograft, 1251
Monte Carlo simulation
dual-planar circular-orbit cone-beam SPECT, 890(ab)
MCNP-4B-based absorbed dose distribution estimates, patient-specific, 662
new dosimetry model, small intestine, 1031(ab)
optimal geometry, Compton camera, 889(ab)
quantitative gated SPECT, 835(ab)
rotating slant-hole SPECT, 833(ab)
scatter in 3D PET, detailed analysis, 877(ab)
simultaneous dual-isotope SPECT, 528(ab)
3D voxel-based program, absorbed dose calculations, 1026(ab)
Motion correction
accuracy of quantitative uptake measurements, myocardial PET, 719(ab)
cardiac, 4D optical flow use in, 530(ab)
myocardial perfusion SPECT, 687
Motor sequence imagery, functional anatomy of, 933(ab)
Movement disorders, dopamine transporters, olfactory function, behavior and, 968(ab)
Mucosa-associated lymphoid tissue (MALT), ^{67}Ga citrate, ^{111}In DOTA-TYR3-OCT comparison, 1134(ab)
Multidrug resistance, tumors, radioiodinated agent for imaging, 1068(ab)
Multidrug-resistance-associated protein, messenger RNA and, ^{99m}Tc sestamibi with, lung cancer, 1476
Multimodality imaging
new reporter gene for, xanthine phosphoribose; transferase and ref fluorescent protein fusion, 260(ab)
respiratory motion, bias of tumor activity estimates from respiratory motion, 385(ab)
SPECT, X-ray and CT combined system, small animals, 205(ab)
Multinodular goiter, toxic and non-toxic, ^{131}I dose, methimazole pretreatment effects, 1343(ab)
Multiple myeloma
bone marrow involvement in, ^{201}Tl chloride and bone scintigraphy in, 115(ab)
evaluation, FDG PET, 114(ab)

mephalan therapy, ^{153}Sm EDTMP and, 580(ab)
whole-body FDG PET, 113(ab)
^{99m}Tc sestamibi, characterization and follow-up, 116(ab)
Multiple tracer imaging, pre- and post-treated myocardium, assessment of functional changes, 812(ab)
Multivalency, ^{99m}Tc-labeled CC49 single-chain Fv's, colon cancer, 1519, 1528
Mu opioid receptors
in Alzheimer's, statistical parametric mapping analysis, 44(ab)
availability, craving and relapse in alcoholics, PET study, 398(ab)
binding, receptor internalization effects, 532(ab)
binding changes, before and after partial volume correction, alcoholics, 399(ab)
Muscarinic acetylcholine receptors, regional brain uptake, M2 knockout mice, 535(ab)
Muscarinic cholinergic receptor, availability, cerebral blood flow and, 903(ab)
Muscle and connective tissue tumors, FDG PET in, 46S
Muscles
blood flow, measurement by $H_2{}^{15}O$ PET, 1404(ab)
glucose uptake, during severe exercise, FDG PET study, 1397(ab)
glucose use, whole-body insulin resistance and, troglitazone effects, in diabetes, 1005
local protein synthesis rate, burn patients, 1420(ab)
Muscular dystrophy, altered myocardial blood flow in, 1415(ab)
Musculoskeletal tumors, ^{99m}Tc MIBI scintigraphy in, 33
Myeloprotection, amifostine, with ^{186}Re HEDP or ^{153}Sm-EDTMP, 1545
Myocardial blood flow
after coronary reimplantation, after arterial switch and Ross operation, 727(ab)
comparison of estimates, $H_2{}^{15}O$ and $^{13}N^3H$, 807(ab)
coronary calcification and, in chronic renal failure, 356(ab)
coronary flow reserve and, ^{15}O water PET for quantification of, 763(ab)
exercise training effects, single-vessel CAD patients, 757(ab)
insulin-resistant coronary vasomotion, PET, 340(ab)
measurement, $^{13}NH_3$ gated PET, 721(ab)
measurement with ^{11}C acetate PET, 63
microcirculatory abnormalities, after Fontan-like operations, 732(ab)
nitroglycerin effects, coronary artery disease patients, 341(ab)
noninvasive measurements, microcirculatory function in chronic renal failure, 337(ab)
parametric image, $H_2{}^{15}O$ dynamic myocardial PET, linear least squares method, 220(ab)
PET, wavelet transforms in analysis of, 194
PET using independent component analysis, 938
quantification of, PET, 1174, 1183
quantification with ^{11}C acetate PET, 1438(le)
regional
$H_2{}^{15}O$ PET and factor analysis, 782
regional, simplified quantification with ^{15}O water PET, 810(ab)
stress scintigraphy, cessation of angiotensin-converting enzyme inhibitor before, 5(ab)
^{13}N ammonia PET quantification, fuzzy clustering in, 809(ab)
^{99m}Tc tetrofosmin gated SPECT, after acute infarction, 723(ab)
Myocardial dysfunction, diabetes, coronary artery disease, and left ventricular dysfunction, 1730
Myocardial infarction
acute
apoptosis detected by ^{99m}Tc annexin, 177(ab)
correlation with site of perfusion defects, SPECT, 558
dobutamine echocardiography underestimation of viable tissue after, 742(ab)
primary angioplasty for, fractional collateral blood flow, 175(ab)
quantitative-gated SPECT early after reperfusion, 752(ab)
rest ejection fraction and perfusion defect size on follow-up, 179(ab)
reverse redistribution of ^{99m}Tc sestamibi, 784(ab)
^{99m}Tc glucarate in imaging of, 711(ab)
^{99m}Tc tetrofosmin SPECT in, 1351
canine model, vasodilator stress imaging, coronary flow reserve, 1388, 1395
prediction, gated myocardial perfusion SPECT, 831
residual foci of, after coronary artery bypass graft, 765(ab)
threatening ventricular arrhythmias after, ^{99m}Tc tetrofosmin gates SPECT, 1(ab)
viability after, PET and SPECT assessment of, 1166
viability after, ^{201}Tl rest-redistribution and ^{18}F FDG SPECT, 180(ab)
Myocardial ischemia
detection, after coronary stent implantation, 1768
effects on ventricular function, gated SPECT, 737(ab)
exercise-induced, endothelin release as marker of, 18(ab)
^{18}F FRP170 and deoxyglucose for, diabetic and non-diabetic rats, 1106(ab)
low-flow, extraction of long-chain fatty acids, rat heart, 1101
non-invasive monitoring, FDG PET and MIBI SPECT, porcine model, 709(ab)
wall motion change and, dobutamine stress ECG and stress perfusion SPECT, 773(ab)
Myocardial metabolism
evaluation with ^{18}F FTHA and ^{18}F FDG, congestive heart failure, 55
fatty acids, advanced heart failure, canine pacing model with BMIPP, 124
Myocardial perfusion imaging, *see also* Myocardial SPECT; Single-photon emission computed tomography (SPECT)
attenuation correction
complete European beta test results, 9(ab)
impact of transmission scan reconstruction, 189(ab)
multi-line source method for, 8(ab)
for CAD, inadequate exercise effects on accuracy, 780(ab)
classification of factor volumes, segmentation of heart cavities and myocardium, 808(ab)
dual-isotope measurement of left ventricular function, 753(ab)
in coronary artery disease, cost-effectiveness of, 728(ab)
cyclopentadienyl tricarbonyl ^{99m}Tc hexadecanoic acid for, 1095(ab)
depth-dependent resolution recovery, ^{201}Tl studies, 1451
detection of motion abnormalities, effect of number of gated frames, 218(ab)
diagnostic accuracy, ECG gating *versus* attenuation correction, 751(ab)
dipyridamole stress, in severe coronary artery disease, 2(ab)
dipyridamole ^{201}Tl
case-based reasoning, 189
prognostic impact in elderly patients, 344(ab)
dual-isotope, optimization of acquisition parameters in, 190(ab)
in ER, 35N(9)
expert system for interpretation of, 1185, 1192
function and perfusion, left ventricular, 1043, 1050
gated, prediction of infarction *versus* cardiac death, 831
gated, ^{99m}Tc tetrofosmin, left ventricular function, 766(ab)
gated SPECT
myocardial wall motion and thickening, 1630, 1639
ventricular volume and ejection fraction measured by, 1571
interpretation, Profile attenuation correction effects, 759(ab)
ischemia detection, after coronary stent implantation, 1768
versus magnetic resonance angiography, hemodynamically significant CAD, 361(ab)
multiple tracer, pre- and post-treatment, assessment of functional changes, 812(ab)
nitrate enhanced, collateral dependent myocardium, 186(ab)
normal limits for quantification, combined protocols, 174(ab)
overestimation of left ventricular ejection fraction, 454
^{15}O water PET, regional blood flow, 810(ab)
patient-specific, NCAT phantom with quantitative gated SPECT data, 217(ab)
pattern of abnormalities, changes with attenuation correction, 760(ab)
prognosis assessment, MI treated by primary PTCA with stenting, 181(ab)
prognostic value of, bias due to incomplete follow-up, 348(ab)
regional motion and thickening, quantitative analysis, 1630, 1639
reserve measurements, ^{15}O water PET scans, 1737
resting perfusion defects, prediction of severe CAD, 749(ab)
residual coronary stenosis, subendocardial infarction, canine model, 1388, 1395
serial PET, response to therapy, 171(ab)
SPECT
by expert system, data mining techniques, 811(ab)
motion artifacts and validation of new motion-correction program, 687
new algorithm for, 391(le)
reconstructed resolution and uniformity in, 836(ab)
technical aspects, 1499
stress, safety profile of adenosine triphosphate, 182(ab)
stress ^{201}Tl gated, transient ischemic stunning, 352(ab)
sublingual nitroglycerin augments perfusion, ischemia patients, 187(ab)
^{99m}Tc-labeled long chain fatty acid derivative for, 1093(ab)
^{99m}Tc teboroxime optimization of, 717(ab)
thallium, correlation of cardiovascular events with, 783(ab)
^{201}Tl, changes with myocardial bridge, energetic males, 735(ab)
1-^{11}C acetate as quantitative perfusion racer, 1174, 1183
^{13}N ammonia PET, fast nonlinear parametric imaging, 924
^{82}Rb and wavelet-based noise reduction, human subjects, 201
^{99m}Tc sestamibi, absolute quantification, porcine model, 772, 780
^{125}I iodorotenone, comparison with ^{99m}Tc sestamibi, 272, 282
Myocardial PET
cardiac quantification, impact of respiratory motion, 719(ab)
comparison with SPECT, 710(ab)
gated
left ventricular ejection fraction, 734(ab)
left ventricular volume and ejection fraction, 741(ab)
2D and 3D, comparison, 170(ab)
$^{13}NH_3$ gated PET, blood flow and ejection fraction measurement, 721(ab)
Myocardial SPECT
attenuation corrected and prone, evaluation of equivalence of transmission, 13(ab)
attenuation corrected stress, gender differences in, 12(ab)
attenuation correction, gating and, role in accuracy of, 14(ab)
attenuation correction effects, diagnostic accuracy, 730(ab)
collimated, comparison with PET, 710(ab)
dynamic, without stress test, detection of ischemic myocardium, 750(ab)
estimated wall thickening from, different automated quantitative algorithms, 222(ab)
gated
decrease of left ventricular ejection fraction after stress, 764(ab)
detection of stunned myocardium after coronary angioplasty, 785(ab)
detection of wall motion abnormalities, 219(ab)
evolution of left ventricular ejection fraction, 771(ab)
ischemia effects on ventricular function, 737(ab)
left ventricular function, comparison between two programs, 722(ab)
left ventricular systolic pressure, 723725(ab)

left ventricular volumes and ejection fraction, 723(ab)
myocardial blood flow after acute infarction, 723(ab)
myocardial contractility evaluation, 20(ab)
patients without CAD, 346(ab)
transient left ventricular dysfunction due to post-exercise stunning, 774(ab)
variability of left ventricular ejection fraction, 770(ab)
versus 24-hour redistribution study, for myocardial viability, 19(ab)
Gaussian model for scatter correction, 847(ab)
intracoronary pressure wire, stress echocardiography and, 335(ab)
rapid dynamic reconstruction, inconsistent projections, iterative least-squares method, 859(ab)
rest or exercise, strategy for diagnosis of chest pain syndromes, 178(ab)
single-day exercise ^{99m}Tc sestamibi, high-grade angiographic stenosis, 353(ab)
^{99m}Tc-labeled lipophilic cations for use in, 1094(ab)
^{99m}Tc MIBI, regional myocardial wall motion and systolic thickening on, 748(ab)
Myocardial tracking, ejection fraction calculated with gated SPECT, validation of, 845
Myocardial viability
after acute infarction, dobutamine echocardiography underestimation of, 742(ab)
after acute MI, fatty acid imaging with ^{123}I 9MPA, 776(ab)
after recent myocardial infarction, ^{201}Tl rest-redistribution and ^{18}F FDG SPECT, 180(ab)
dobutamine quantitative gated SPECT
myocardial contractility evaluation, 20(ab)
versus 24-hour redistribution study, 19(ab)
dysfunctional, quantitative gated SPECT to quantitative perfusion SPECT values, 347(ab)
estimation of defect size, cardiac SPECT and PET, 1579
FDG PET in, 70S
^{18}F FRP170 and deoxyglucose for, diabetic and non-diabetic rats, 1106(ab)
identification, dobutamine gated SPECT in, 838
LVEF and heart failure symptoms, FDG SPECT, 79, 87
previous infarction and left ventricular dysfunction, ^{99m}Tc MIBI SPECT and ^{18}F FDG PET, 1166
quantitative ECG-gated SPECT imaging at end-diastole, in myocardial infarction, 769(ab)
quantitative gated SPECT, functional improvement after CABG, 15(ab)
regional differences in optimal threshold, FDG SPECT, 778(ab)
^{99m}Tc MIBI infusion, *versus* nitroglycerin ^{99m}Tc MIBI, 176(ab)
^{201}Tl assessment, stratification by stress-rest reversibility, 16(ab)
24-hour redistribution study, *versus* nitroglycerin challenged gates SPECT, 17(ab)
Myocardial wall, motion and thickening, gated SPECT, 1630, 1639
Myocarditis
autoimmune, ^{14}C deoxyglucose and ^{201}Tl uptake, rats, 285
autoimmune, ^{99m}Tc annexin imaging to evaluate apoptosis, 169(ab)
Myocardium
collateral dependent, nitrate enhanced perfusion scans, 186(ab)
dual-isotope coincidence/single photon imaging, 944
glucose utilization, left ventricular dysfunction, FDG dynamic PET, 197(ab)
hibernating, tissue hypoxia in, usefulness of ^{18}F FMISO, 21(ab)
metabolism
during heart failure, FDG PET study for, 762(ab)
PET studies with ^{11}C HDA, 271(ab)
perfusion and wall motion, observer variability of stress ^{99m}Tc sestamibi vs tetrofosmin, 739(ab)
pharmacologic stress-induced stunning, gated SPECT, 354(ab)
regional motion and thickening, quantitative analysis with perfusion SPECT, 1630, 1639
reperfused, selective detection of infarct with ^{99m}Tc glucarate, 715(ab)
retention of technetium-labeled tracers, porcine, 818
segmentation, classification of factor volumes, myocardial perfusion studies, 808(ab)
stunned
gated SPECT detection of, after primary coronary angioplasty, 785(ab)
quantitative-gated SPECT early after reperfusion, 752(ab)
sympathetic innervation, ^{99m}Tc FBPBAT derivative for, 704(ab)
tracer retention, during pharmacologic hyperemia, 1457
wall motion abnormalities, detection by myocardial perfusion gated SPECT, 219(ab)
wall motion and systolic thickening
automatic quantitation on ^{99m}Tc MIBI SPECT, 748(ab)
^{13}N^{3}H cardiac PET scans, 767(ab)
wall thickening and motion, automatic segmental scoring of, 744(ab)
wall thickening of left ventricle, without edge detection, gates SPECT images, 193(ab)
Myosin, anti-smooth muscle monoclonal antibody, immunoscintigraphy of aortic dissection, 130

N

Narcolepsy, pre- and postsynaptic dopaminergic system in, analysis, 237(ab)
Nasopharyngeal cancer, differentiation of late radiation injury of brain stem, FDG PET, 970(ab)
National Electrical Manufacturers Association, 32N(12)
curve-plate NaI(T1) detectors, whole-body PET scanner, 1821, 1831
National Human Genome Research Institute (NHGRI), 30N(7)
National Institute of Biomedical Imaging and Bioengineering (NIBIB), 12N(2)
National Institutes of Biomedical Imaging and Bioengineering (NIBIB), 12N(6), 30N(11)
National Institutes of Health (NIH)
mutant mouse repositories, 36N(9)
research protections course on line, 22N(3)
National Regulatory Commission (NRC)
Part 35, 27N(12)
Natural killer cells, activated or depleted, lung clearance of radiolabeled YAC-1 tumor cells for study of, 1165(ab)
Needleless jet injector systems, for mass immunization, safety of, 1382(ab)
Nerve growth factor, radioiodine labeled, gene transfer in neuroblastoma cells, 1181(ab)
Neural networks, weighted nonlinear regression and nonlinear function, FDG PET data, 372(ab)
Neuro-Behçet's disease, juvenile, brain SPECT in, 1151
Neuroblastoma
CT scanner-scintillation camera, ^{131}I MIBG and, 237
MIBG in, 28N(1)
refractory
dosimetry of MIBG therapy, 1713
treated with ^{131}I MIBG, tumor and whole-body dosimetry, 1713
^{131}I MIBG scans, in children, 1321(ab)
Neuroendocrine tumors
advanced, treatment with 200 mCi/m^2 ^{90}Y DOTATOC, 136(ab)
biodistribution and dosimetry, ^{86}Y and ^{111}In octreotide, differences, 84(ab)
combined radiopharmaceutical and chemotherapy, 140(ab)
detection, glucagon-like peptide-1 receptor agonist comparison, 1148(ab)
gastroenteropancreatic, ^{111}In pentetreotide somatostatin receptor imaging, 103(ab)
liver disease in, optimal imaging of, 99(ab)
liver metastases of, radiochemoembolization with ^{131}I lipiodol, 1318(ab)
malignant, MIBG and octreotide scintigraphy, 600(ab)
metastatic gastro-entero-pancreatic, palliative treatment with ^{111}In pentetreotide, 1299(ab)
pre-therapeutic dosimetry, ^{68}Ga DOTATOC SMS receptor PET, 1296(ab)
4 and 24 hours ^{111}In DTPA octreotide SPECT, comparison, 101(ab)
^{64}Cu TETA octreotide, PET, 213
Neuroimaging
functional, MR atlas of baboon brain, 921(ab)
^{99m}Tc and ^{123}I IMP distribution, medial frontal lobes, statistic parametric mapping, 923(ab)
Neurology
brain SPECT in clinical practice, perfusion, 259, 611
FDG PET literature summary, 1S
Neuroprotection, FK506, early ischemic neuronal death, monkey model, 1833
Neuropsychology, traumatic brain injury, ^{99m}Tc HMPAO SPECT role in legal consultation, 991(ab)
Neuroreceptor binding, reversible, parametric imaging, linear regression models, 801
Neuroreceptor imaging
small laboratory animals, PET camera for, 209(ab)
^{11}C raclopride binding, partial volume effect in ventral striatum, 797(ab)
Neuroreceptors, quantification models, PET and SPECT, 755
Neurotoxicity
coupling of glucose utilization to, ultra-high-resolution PET, 919(ab)
hypoxic, immature rat brain compared to adult, positron autoradiography, 920(ab)
Neurotransmitters
nicotinic acetylcholine receptors, human imaging of, 533(ab)
^{18}F FDOPA, imaging agent for, 1063(ab)
Nicotine, chronic administration, withdrawal from, temporal changes caused by, 534(ab)
Nicotinic acetylcholine receptor imaging, development of novel agent for, 1054(ab)
Nicotinic receptors
human imaging, ^{123}I IODO-A- 85380, 533(ab)
temporal changes in, withdrawal from chronic nicotine administration, rat brain, 534(ab)
Nitric oxide synthase, endothelial, L-arginine and, augmentation of cerebral blood flow, 918(ab)
Nitriles, use as coligands, ^{99m}Tc HYNIC peptide complexes, 1102(ab)
Nitrogen-13 ammonia
cardiac PET, adenosine-induced change of left ventricular center, 756(ab)
PET
fast nonlinear parametric imaging, 924
quantification of myocardial blood flow, 809(ab)
Nitroglycerin, sublingual, use in myocardial perfusion imaging, ischemia patients, 187(ab)
NMDA antagonist, increase in dopamine availability, PET study, 56(ab)
NMDA receptors
imaging, radiolabeling and biodistribution of dextrorphan, 1059(ab)
^{123}I CNS-1261, for SPECT, kinetic modeling of, 939(ab)
Noise reduction
cardiac PET
wavelet transform-based, 201
wavelet transforms in analysis of, 194
iterative reconstruction, oncology FDG PET, 1316
Non-Hodgkin's lymphoma
B-cell
^{131}I rituximab radioimmunotherapy in, 456(ab)
Zevalin radioimmunotherapy, ^{90}Y clearance after, 1124(ab)
Bexxar efficacy and safety
in elderly patients, 582(ab)
large multicenter expanded access study, 455(ab)
chemotherapy, ^{67}Ga use during, 1139(ab)
FDG PET
comparison with soluble interleukin-2 receptor, 444(ab)
response to ^{131}I tositumomab therapy, 443(ab)
whole-body FDG PET scanning value in, 445(ab)
^{18}F FLT as PET tracer for, 1150(ab)
gastric, ^{67}Ga compared with oral ^{99m}Tc pertechnetate, 1138(ab)
low-grade, somatostatin receptor scintigraphy in, 222

radiolabeled antibodies, underdosing and overdosing in, 1293(ab)
relapsed/refractory, ^{90}Y-labeled epratuzumab, 583(ab)
staging, whole-body hybrid FDG PET, 601, 609
treated with ^{131}I tositumomab, radiation dosimetry, 1292(ab)
zevalin profile, radiolabeled with ^{90}Y from different suppliers, 76(ab)
Noninvasive imaging, risk assessment, 1424
Norepinephrine, release, cardiac presynaptic sympathetic nerve terminals, transplanted heart, 1011
Nuclear Energy Research Advisory Committee (NERAC), 27N(12)
Nuclear medicine
chemistry, 14N(1)
first annual Newsline review, 9N(1)
gene therapy and, 1368
government regulation and response in, 21N(1)
hybrid imaging, 10N(5)
medical imaging data analysis, AMIDE, 827(ab)
in the military, 16N(1)
procedures, radiation adaptive response, individual variation, 1045(ab)
reports, knowledge-based toolkit for, 819(ab)
safety of, 24N(3)
sympathetic innervation, identification of high risk of cardiac death and, 1757
tracer kinetic model for, server-based application program, 787(ab)
at the 2000 Olympic Games, 11N(7)
2001 lecture, 12N(8)
Nuclear Medicine Ambulatory Payment Classification Task Force (NMAPCTF), 27N(12)
Nuclear medicine pharmaceuticals, shortfalls, 16N(10)
Nuclear pharmacy
assay of ^{153}Sm, with radionuclide dose calibrator, 1116(ab)
online education, 26N(2)
preparing radiolabeled Zevalin, using radiolabeling cold kit, 1115(ab)
Nuclear Regulatory Commission (NRC)
Dicus elected to governing board, 27N(1)
how to renew a license, 14N(6), 24N(5)
online regulatory guide errors, 1879(le)
regulations on potassium iodide, 28N(2)
workers at nuclear facilities, 34N(9)

O

Obesity
brain changes in, PET, 24N(3)
fasting in, differential regional brain metabolism during, 410(ab)
Obsessive-compulsive disorder
cerebral metabolic predictors, response to anterior cingulotomy, 1006(ab)
glucose metabolism before and after capsulotomy, PET study, 1005(ab)
rCBF during symptom provocation, predictors of response to pharmacotherapy, 1007(ab)
serotonin and dopamine transporters in, ^{123}I-βCIT SPECT of, 1008(ab)
Occipital cortex, perfusion defects, depression in children and, 1059
Oncology
FDG PET literature summary, 1S
PET, conducting research studies on, 826(le)
radiolabeled amino acid imaging in, 432
Optimum transmission scan time, estimation of, SPECT, 838(ab)
Oral cancer
advanced, preoperatively irradiated, FDG PET value in, 1202(ab)
squamous cell, dual-head FDG PET for locoregional evaluation, 1203(ab)
Oral radioactivity, salivary gland scintigraphy, Sjögren's syndrome, 38
Ordered subset expectation maximization (OSEM)
accuracy, dynamic PET, 808
collimator detector response, SPECT, 846(ab)
versus filtered backprojection
regional cerebral blood flow, 805(ab)
3D brain PET, 803(ab)
reconstruction, brain SPECT, Alzheimer's disease, 945(ab)
segmented attenuation correction and, calculation of SUVS for FDG PET, 384(ab)
sinogram rebinning and, clinical comparison of FDG PET by, 853(ab)
Osteoarthritis, subcortical and somatosensory rCBF changes, painful stimulation, 995(ab)
Osteogenic sarcoma
bone metastases, FDG PET and conventional staging comparison, 1272(ab)
neoadjuvant chemotherapy effects, prediction with FDG PET, 1273(ab)
Osteomyelitis
acute, ^{99m}Tc interleukin-8 for, 1373(ab)
acute, ^{99m}Tc labeled interleukin-8, 1257
diabetic pedal, ^{99m}Tc-labeled antigranulocyte antibody in diagnosis, 165(ab)
diagnosis, ^{111}In leukocyte scan for, 488(ab)
infection imaging, ^{99m}Tc ciprofloxacin (infection) use in, 567
recombinant human IL-8, infection imaging, 1656
^{131}I recombinant human IL-8, 1656
Osteonecrosis, tracer accumulation in femoral head, after renal transplant, 1789
Osteopenia, high-turnover, after gastrectomy, ^{18}F fluoride ion PET, mini pigs, 1408(ab)
Ovarian cancer
advanced, FDG PET effects in response to chemotherapy, 298(ab)
chemotherapy, complete response to, FDG PET scan in, 1192(ab)
disease distribution, use of FDG PET scans for preoperative evaluation, 1193(ab)
FDG PET in, 35S
recurrent, FDG PET in, 1194(ab)
recurrent, PET/CT imaging in, 1186(ab)
staging and managing, whole-body PET with FDG effects, 1190(ab)
without recurrence, FDG PET, 1191(ab)
Oxidative metabolism, myocardial, dobutamine stress echocardiography, 731(ab)
Oxygen, measurement, tissue, tumor uptake of Cu-ATSM and, 655
Oxygen extraction fraction, PET, prediction of stroke risk, 1195
Oxygen gas target system, production of reactive no-carrier-added ^{18}F fluoride ion, 6465(ab)
Oxygen-15 butanol, versus water, cerebral blood flow assessment in visual cortex, 931(ab)
Oxygen-15 water
PET
dynamic, regional myocardial blood flow, 782
factor analysis on, renal cortical blood flow, 39(ab), 148(ab)
nasal deposition measured by, 155(ab)
simplified quantitation of regional myocardial blood flow, 810(ab)
quantification, myocardial blood flow and coronary flow reserve, 763(ab)
stress perfusion SPECT, reduction of coronary flow reserve in CAD patients, 775(ab)
^{18}F FDG and, PET, pretreated melanoma, 248, 257

P

Paclitaxel
chemotherapy, non-small cell lung cancer, ^{99m}Tc tetrofosmin imaging, 17
^{18}F, biodistribution, radiation dose estimates and PGP modulation studies, 1166(ab)
Paget's disease, skeletal kinetic indices, ^{18}F fluoride PET, 1402(ab)
Palatin Pharmaceutical Technologies, 11N(12)
Palladium-103, production, from silver targets, 1086(ab)
Pancreatic cancer
adenocarcinoma, CA19–9 and blood glucose as tumor marker, CT and PET, 1105(ab)
dosimetry estimates for ^{131}I CHTNT-1/B, 1034(ab)
FDG PET in, 50S
FDG uptake, multivariate analysis, 1176(ab)
hexokinase II and glucose transporter expression, two-phased FDG PET, 1174(ab)
Ki-67 immunostaining in, FDG uptake effects, 721
neurotensin analogs as potential agents for, 1064(ab)
suspected, optimal scan time, FDG PET, 105(ab)
^{99m}Tc-labeled carbohydrated SSTR-ligands, 429(ab)
Pancreatic tumor cells, chemotherapy effects, somatostatin receptors, 1856
Pancreatitis, Ki-67 immunostaining in, FDG uptake effects, 721
Paracoccidioidomycosis, ^{67}Ga imaging, diagnosis and follow-up, 1371(ab)
Parametric imaging
antibody pharmacokinetics, Bi213-HuM195 therapy of leukemia, 27
attention deficit hyperactivity disorder, children with or without comorbidity, 1004(ab)
fast nonlinear, myocardial perfusion by dynamic ^{13}N ammonia PET, 924
FDG PET data, weighted nonlinear regression and nonlinear function, 372(ab)
linear least squares method, $H_2{}^{15}O$ dynamic myocardial PET, 220(ab)
spatial constraint for, dynamic PET studies, 374(ab)
Parametric mapping, statistical
absolute rCBF in upright posture, 707
donepezil effects on rCBF, Alzheimer's disease, 1441
Parathyroid gland
abnormal, preoperative localization with ultrasound and sestamibi, 1356(ab)
adenoma, comparison of ^{99m}Tc delayed imaging in, 1355(ab)
dual-phase imaging, ^{99m}TC tetrofosmin or ^{99m}Tc sestamibi for, 1353(ab)
dual-phase MIBI scan, lesion detectability in, 1352(ab)
imaging, experiences with specialized endocrine surgeons, 1354(ab)
lesion localization, preoperative, pinhole *versus* parallel hole imaging, 596(ab)
^{99m}Tc-labeled agents with double subtraction images, 1349(ab), 1358(ab)
Parenchymogram, renal, split renal function evaluation with, 151(ab)
Parietal cortex, posterior, discrimination of upper limb gestures and, 929(ab)
Parkinson's disease
cortical dysfunction in, dopaminergic impairment correlation with, 957(ab)
differential diagnosis, ^{99m}Tc TRODAT use in, 408
dopaminergic function, oxidative metabolism and, 50(ab)
dopamine transport inhibitors for, PET imaging, 898(ab)
early
dopamine effective distribution volume in, 29(ab)
evaluation with ^{99m}Tc TRODAT-1, 956(ab)
early and late onset, PET evaluation of dopamine transporters, 961(ab)
early and late onset dementia, rCBF SPECT patterns in, 227(ab)
early-stage, ^{99m}Tc TRODAT imaging, 1303
graphical analysis of ^{11}C (+)MCN5652 binding, 958(ab)
imaging of serotonin receptors in, 963(ab)
L-dopa effects, prediction by ^{11}C raclopride and FDG PET, 960(ab)
MIBG imaging, impaired uptake, 506(ab)
motor symptoms in, dopamine transporter SPECT measures correlate with, 539(ab)
MPTP induced dopamine neurogeneration, 6-FMT and FWIN kinetic estimates, 51(ab)
myocardial sympathetic nerve function, striatal dopaminergic function and, 540(ab)
repetitive transcranial magnetic stimulation, quantitative cerebral blood flow measurement and, 959(ab)
resting cerebral glucose metabolism, FDG PET study, 538(ab)
^{99m}Tc TRODAT-1 diagnosis in, 542(ab)
with and without dementia, ^{18}F FDOPA uptake changes, 962(ab)
Partial volume analysis, brain, MRI-based individual 3D region-of-interest atlas, 24(ab)
Partial volume correction, PET, segmented high resolution CT or MR scans, 826(ab)
Partial volume effect

attenuation correction and, SPECT dopamine receptor imaging, 214(ab)
investigation of atrophy and FDG uptake, persons at risk for Alzheimer's disease, 230(ab)
MRI-driven
automated software for, PET, 35(ab)
MIS segmentation effects on, 3D PET, 34(ab)
Patent ductus arteriosus, coil embolization for, lung perfusion scintigraphic follow-up for, 1427(ab)
Patent foramen ovale, embolic distribution through, ^{99m}Tc MAA SPECT, 859
Pediatric patients
acute leukemia, radioimmunotherapy with ^{131}I BC-8 antibodies, 584(ab)
acute pyelonephritis, renal scatting after, ^{99m}Tc DMSA use in, 332(ab)
bone marrow transplant, obstructive lung disease and interstitial pneumonitis, 1439(ab)
CT spill over, 17N(3)
depression in, occipital brain perfusion defects and, 1059
diuresis renography, renal cortical scintigraphy and, infants and children, 91
epilepsy, $GABA_A$ receptor binding, vigabatrin treatment effects, 141(ab)
estimating GFR in, 322(ab)
fever of unknown origin, whole-body FDG PET in, 142(ab)
galactosemia in newborn, ^{99m}Tc pertechnetate and per-rectal portal scintigraphy in, 1367(ab)
gastric emptying scintigraphy, ^{13}C breath test correlation, 334(ab)
hyperthyroidism, ^{131}I for treatment, 593(ab)
inflammatory bowel disease, temporal correlation of ESR with ^{99m}Tc WBC uptake, 1423(ab)
juvenile Behçet's disease, brain SPECT in, 1151
leukemia, ^{99m}Tc MDP bone scintigraphy, 878
lower urinary tract disorders, radionuclide cystography and urodynamics, 1424(ab)
lymphatic disorders, lymphoscintigraphy in, 1428(ab)
lymphomas, FDG PET imaging in, 143(ab)
mental retardation of unknown etiology, FDG PET use in, 145(ab)
neonates and infants, diuretic renography in, 1780
speech and language development, neuroanatomy of, 545(ab)
standardized uptake value, normalized to body surface area, 815(ab)
tumors, FDG PET imaging in, 144(ab)
unilateral upper junction obstruction, long-term follow-up of kidney function, 333(ab)
urinary tract infection, vesicoureteric reflux and renal parenchymal damage in, 1426(ab)
utility of ictal SPECT, correlation with video EEG and postsurgical outcome, 233(ab)
^{131}I MIBG scans, neuroblastoma in children, 1321(ab)
Pelvic cancer, recurrent, intralesional ^{166}Ho injection therapy, 1319(ab)
Pelvic tumors, malignant, ^{11}C choline comparison with ^{18}F FDG PET, 1196(ab)
Peptide nucleic acid, tumor-targeting peptide conjugates, development of, 428(ab)
Peptide receptor imaging
monomeric and dimeric analog of ^{99m}Tc-labeled RGD peptide, comparative biodistribution, 472(ab)
neurotensin analogs, use in pancreatic cancer, 1064(ab)
radiolabeled integrin $\alpha V\beta 3$ binding RGD peptides, nude mouse tumor model, 474(ab)
radionuclide therapy, using somatostatin analogs, 468(ab)
radiotherapy
long-term histological organ damage in animals, 138(ab)
patients with somatostatin receptor positive tumors, 137(ab)
renal uptake, combined lysine and arginine infusion, 135(ab)
tumor imaging and radionuclide therapy, cyclic RGD-DTPA-octreotide analog for, 413(ab)
Peptides
new phage display, related to endothelium of tumor vasculature, 471(ab)
^{86}Y and ^{111}In-labeled, dosimetric study in dogs, 1020(ab)
Percutaneous transluminal coronary angioplasty (PTCA)
dosimetry of ^{166}Ho DTPA filled balloon, endovascular radiation therapy, 1035(ab)
reverse redistribution of ^{99m}Tc sestamibi after, acute MI, 784(ab)
Perfusion lung scan
perfusion lung scan, in primary pulmonary hypertension, 1431(ab)
persisting perfusion defects, after pulmonary embolism, 160(ab)
triage by, diagnosis of pulmonary embolism, 159(ab)
Peroxisome proliferator-activated receptor α (PPAR α), cardiac fatty acid metabolism, 707(ab)
Per-rectal portal scintigraphy
^{99m}Tc GSA and, clinical need for both in chronic liver disease, 1362(ab)
^{99m}Tc pertechnetate and
diagnosis of galactosemia in infants, 1367(ab)
prognosis of primary biliary cirrhosis, 1363(ab)
PET
3D, effects of scatter, Monte Carlo software use in, 877(ab)
absolute calibration of, multicentric comparative evaluation, 881(ab)
activation measurements, statistical parametric mapping, cerebral blood flow, 798(ab)
Alzheimer's disease, therapy control with cholinesterase inhibitors, 951(ab)
animal scanners
design of data acquisition system for, 874(ab)
high-speed PC-based list-mode data acquisition system, 876(ab)
^{124}I and ^{66}GA with, 875(ab)
animal studies, comparison with storage phosphor autoradiography, 1691
APC rates, 14N(10)
automatic multimodality registration with deformations, chest, 40(ab)
brain
automated attenuation correction model, 483
dementia evaluation, subsequent cognitive impairment, 225(ab)
hemodynamic disease, temporal changes in, 806(ab)
JPEG, Wavelet, and JPEG2000 evaluation, 791(ab)
MRI-driven partial volume effect software, 35(ab)
speech and language development, normal children, 545(ab)
temporal lobe epilepsy, 30(ab)
uptake and distribution of dopamine D3 radioligand, 900(ab)
uptake of ^{11}C vinpocetine, 907(ab)
brain changes in obesity, 24N(3)
bridging medical disciplines: Nora Volkow, 16N(2)
in bulimia nervosa, 35N(9)
^{11}C acetate, prostate cancer, 451(ab)
^{11}C acetate and FDG comparison
cervical cancer, 453(ab)
imaging of breast cancer, 452(ab)
camera-based, CT fusion with, clinical oncology applications, 131(ab)
camera comparison, highly-reproducible whole-body phantom, 368(ab)
^{11}C arachidonic acid and ^{11}C palmitic acid, brain incorporation, 243(ab)
cardiac
assessment of myocardial wall motion, 767(ab)
cardiomyopathies, 1062
contractile motion compensation via tagged MRI priors, 27(ab)
post-injection scans, quantitative accuracy, 842(ab)
wavelet transforms in analysis of, 194
cardiac, estimation of defect size, 1579
cardiac presynaptic sympathetic nerve terminals, transplanted heart, 1011
^{11}C carfentanil, opioid receptor availability in alcoholics, 398(ab)
^{11}C cocaine, CNS pharmacodynamics of a novel cocaine medication, 55(ab)
^{11}C doxepin study, occupancy of three antihistamine drugs, histamine receptors, 537(ab)
cerebral activation, integrated lab for, 1118(ab)
cerebral glucose metabolism, low-dose alcohol effects, 1009(ab)
cerebral hypometabolism, Alzheimer's disease, affect on ultimate education level, 546(ab)
cerebral oxygen metabolism, WILT method, 793(ab)
cerebral physiological parameters in, new method for measurement, 941(ab)
cerebral 3D, optimizing attenuation correction in, 840(ab)
^{11}C methionine, chemotherapy monitoring of hypopharyngeal cancer, 299(ab)
in cognitive decline, 30N(11)
coincidence imaging, myocardium, 944
COMKAT, compartmental model analysis tool, 636
compact detector module, for DOI measurement, 382(ab)
comparison with MRI, breast cancer, 1237(ab)
coronary flow reserve, bicycle exercise for assessment of
count-based transmission scans, thorax and pelvis, 843(ab)
^{11}C raclopride study, assessment of radiation exposure, 1038(ab)
cross-modal plasticity evident on, auditory cortex of postlingual deafness, 549(ab)
CT and, cervical cancer, 32N(11)
CT combined
evaluation of cancer patients, 127(ab)
tumor activity estimates from respiratory motion, 385(ab)
Ct co-registration, with warping, quantitative pulmonary imaging, 36(ab)
2-^{11}C thymidine, malignant brain tumor, 370(ab)
CT scanner combined, 533(le)
CT scanner combined with, Positrace, 1287(ab)
DAT and AADC, MPTP induced dopamine neurogeneration, 51(ab)
detection of image noise in, bootstrap method, 38(ab)
development of dopamine D3 radioligand, evaluation of ^{11}C BP897, 1057(ab)
dopamine D2 receptor binding, in vivo quantification of, 928(ab)
DOTATOC, somatostatin receptors, meningiomas, 1053, 1057
drug tracking with, 22N(4)
dual-head, attenuation correction, FDG oncology imaging, 817(ab)
dual layer small animal, recovering inter-crystal scatter in, 871(ab)
dual-modality CT
attenuation correction in presence of contrast agents, 210(ab)
CT-based attenuation-correction, arms in field of view, 211(ab)
dynamic
accuracy of OSEM in, 808
movement correction in, 861(ab)
new parameter for quantification, fractal dimension, 788(ab)
ROI-based time activity analyses, for oncology, 387(ab)
dynamic FDG, bone tumors, gene expression and, 120(ab)
dynamic whole-body, reconstruction of plasma-input function from, 790(ab)
electron beam CT *versus*, in CAD, 358(ab)
evaluation of dopamine transporters, Parkinson's disease, 961(ab)
FDG
accurate characterization of mediastinal lymphadenopathy, 563(ab)
additional value in evaluating esophageal cancer, 292(ab)
adrenal lesions from CT or MRI, 1795
adrenal lesions seen on CT or MRI, 1259(ab)
adrenal masses, lung cancer patients, 564(ab)
advanced ovarian cancer, prediction and response to chemotherapy in, 298(ab)
after first cycle chemotherapy, aggressive lymphoma and Hodgkin's disease, 441(ab)
after first-line treatment in Hodgkin's disease, 446(ab)

after neoadjuvant radiochemotherapy, non small cell lung cancer, 1253(ab)
angiography and, revascularization in severe CAD, 362(ab)
arthritic disease in hands and feet, 1414(ab)
attenuation corrected and noncorrected images, breast cancer, 307(ab)
bone infection imaging, 162(ab), 163(ab)
bone marrow infiltration with lymphoma, 118(ab), 119(ab)
bone scintigraphy comparison, detection of bone metastases, 1271(ab)
brain investigations, radiation burden on staff, 1117(ab)
calculation of SUVs, OSEM and segmented attenuation correction in, 384(ab)
camera-based, follow-up in malignant lymphoma, 1131(ab)
cardiac, determination of MRGlu in, 1622
cardiac, MRGlu determination in, 1622
cerebral radiation necrosis or tumor recurrence, 971(ab)
childhood mental retardation of unknown etiology, 145(ab)
choice of therapy for recurrent colorectal cancer and, 462(ab)
clinical impact of, recurrent breast cancer, 1238(ab)
^{11}C methionine, therapeutic options in brain tumors, 247(ab)
colonic adenomas, 989
combined CT, head and neck cancer, 133(ab)
comparison with triple-head coincidence FDG imaging, in oncology, 1266(ab)
conventional staging comparison, osseous sarcomas, 1272(ab)
CT/MRI and, intermodality image fusion, for oncology, 132(ab)
dedicated camera for breast imaging, 302(ab)
detection and management of renal cell carcinoma, 300(ab)
detection and staging of bronchioloalveolar carcinoma, 276(ab)
diagnosis of pediatric tumors, 144(ab)
diagnosis of spondylodiscitis, 1393(ab)
diagnostic value in malignant pleural mesothelioma, 1257(ab)
differentiated thyroid cancer, 71, 77
differentiation of malignant and benign bone lesions, 125(ab)
dilated cardiomyopathy and left bundle branch block, 198(ab)
distant metastases, 21N(3)
dual-head cardiac, attenuation correction of, 192(ab)
dual-head coincidence camera, pulmonary neoplasms, 1265(ab)
dual-time point imaging, factors affecting accuracy, 122(ab)
early after irradiation, head and neck cancer, 296(ab)
early Huntington's disease, 1591
early therapy monitoring in malignant melanoma, 442(ab)
effects on patient management, 34N(6)
enhancement of tumor foci with PCA, 386(ab)
epilepsy localization, 988(ab)
evaluation after chemo- or chemoradiotherapy, 289(ab)
evaluation of Lewy body variant of Alzheimer's disease, 944(ab)
exercise effects on digestion and glucose absorption, 315(ab)
glucose metabolism in lung cancer, 388(ab)
glucose transporter subtype expressions and, tumor and inflammation models, 1551
head and neck squamous cell cancer, 3D radiation therapy, 1233(ab)
hypermetabolic bone marrow and diffuse bone metastases, 1135(ab)
hypoxia effects on uptake, MCF7 cells, 170
image quality, reconstruction algorithms for, breast cancer, 306(ab)
image reconstruction, clinical comparison by OSEM and AWOSEM, 853(ab)
imaging of infection, 161(ab)
impact on restaging of lung cancer, 562(ab)
impact on therapy in head and neck tumors, 294(ab)
induction chemotherapy, stage IIIA-N2 non small cell lung cancer, 1254(ab)
infected lower limb prosthesis implants, 44
intraluminal ultrasound and, in esophageal cancer, 287(ab)
liver kinetics of glucose analogs, 795
localization of inflammatory foci, 1376(ab)
long-term outcome in solitary pulmonary nodules, 1247(ab)
low glucose uptake, skeletal muscles during exercise, 1397(ab)
malignant or inflammatory process, 1412
management of colorectal cancer, 586
management of small cell lung carcinoma, 278(ab), 279(ab)
management of thoracic oncology patient, 565(ab)
mediastinal tumors, 1258(ab)
medullary thyroid cancer, 496(ab)
metabolic activity in thymus gland with, 591
metabolic network abnormalities in Huntington's disease, 1591
metabolites of, pig liver, 1673, 1679
metastatic brain tumor, metabolic characteristics, 980(ab)
metastatic breast cancer, 304(ab)
metastatic colorectal cancer, liver resection, 1279(ab)
metastatic lesion from colorectal cancer, CT/MRI comparison, 1280(ab)
monitoring tumor response to angiangiogenic therapy, 1243(ab)
multidrug resistant human colon cancer cell line, 646
multiple myeloma, 114(ab)
myocardial glycose utilization and, 1730
negative ^{131}I scanning results after therapy, thyroid cancer, 1464
newly diagnosed non-small cell lung cancer, 1596
noise reduction by iterative reconstruction, 1316
nonhypersecreting adrenal masses, 884, 893
non-small cell lung cancer, 156(ab)
staging before radio-chemotherapy, 560(ab)
nonspecific tracer uptake after hip arthroplasty, 477(ab)
occult malignancy in pleural effusion patients, 1256(ab)
parametric images in, spatial constraint for, 374(ab)
pediatric lymphomas, 143(ab)
planar bone scanning with SPECT and, staging lung cancer patients, 1269(ab)
prediction in re-staged lymphoma patients, 1130(ab)
prediction of chemotherapeutic response, osseous sarcoma3, 1272(ab)
prediction of outcome of restaged colorectal cancer, 464(ab)
presurgical evaluation in thyroid cancer, 497(ab)
presurgical evaluation of epilepsy, 1158
primary and recurrent soft-tissue sarcomas, 713
prognostic value, restaged breast cancer, 301(ab)
prognostic value in non small cell lung cancer, 1245(ab)
prognostic value in radiotherapy patients, 295(ab)
prognostic value of metabolic imaging, lung cancer, 1249(ab)
quantitative evaluation of esophageal cancer, 291(ab)
in radiation therapy planning, 1234(ab)
recurrence of resected non small cell lung cancer, 1244(ab)
recurrent desmoid tumors, 1278(ab)
recurrent non-small cell lung cancer, 1605
regional myocardial glucose uptake in pulmonary hypertension, 199(ab)
response to therapy in bone-dominant breast cancer, 303(ab)
response to ^{131}I tositumomab therapy, non-Hodgkin's lymphoma, 443(ab)
restaging of colorectal cancer, 461(ab)
restaging of lymphoma patients, 440(ab)
role in radiotherapy treatment planning, non small cell lung cancer, 1255(ab)
sensitivity for bronchioloalveolar carcinoma, 277(ab)
serial, intralesional radioimmunotherapy in malignant glioma, 972(ab)
shoulder and hip joints, 1417(ab)
soft tissue sarcomas, 1274(ab)
SPECT comparison, Alzheimer's disease, 49(ab)
spiral CT and, staging of bronchogenic carcinoma, 130(ab)
staging, chemo- and radiotherapy in esophageal carcinoma, 290(ab)
staging and management of malignant lymphoma, 1139
staging and management with, lung cancer, 1250(ab)
staging and managing breast cancer, 1334
staging newly diagnosed non-small cell lung cancer, 1596
surrogate marker for response to chemotherapy in non small cell lung cancer, 1251(ab)
suspected recurrent non-small cell lung cancer, 1605
SUV, evaluation of solitary pulmonary nodules, 123(ab)
SUV as prognostic factor after, small cell lung cancer, 1246(ab)
tabulated summary of literature, 1S
testicular uptake with age and chemotherapy effects, 1198(ab)
thyroid disease effects on brain metabolism, in dementia, 955(ab)
treatment management and, cervical lymph node metastases, 297(ab)
uptake before and after radiotherapy, malignant glioma, 972(ab)
whole-body
abdomen, combined with CT, 129(ab)
decision-making in malignant lymphoma, 1132(ab)
fever of unknown origin, children, 142(ab)
impact on radiation therapy treatment strategy, 1235(ab)
managing ovarian cancer, 1190(ab)
multiple myeloma, 113(ab)
staging for malignant melanoma, 1276(ab)
whole-body, ^{18}F FMT comparison, 1282(ab)
3D whole-body imaging, metastatic renal cancer, 1200(ab)
whole-body scanning, value in non-Hodgkin's lymphoma, 445(ab)
^{201}Tl comparison, lung cancer, 1489, 1497
FDG and ^{11}C acetate, prostate cancer recurrence, 450(ab)
FDG and ^{11}C methionine, follow-up after treatment, double tracer investigations, 974(ab)
^{18}F F-α-MT synthesis and purification, improvement in, 1079(ab)
^{18}F FLT
routine synthesis in high activities, 1081(ab)
tweaking the synthesis of, 1080(ab)
^{18}F fluoride, measuring regional skeletal kinetics with, 371(ab)
^{18}F fluoride ion, high-turnover osteopenia after gastrectomy, mini pigs, 1408(ab)
^{18}F FMT and ^{18}F FAL studies, in utero alcohol exposure and maternal stress, 54(ab)
^{18}F galacto RGD and, imaging of αVβ3 expression, 473(ab)
^{18}F-labeled serotonin antagonists, with intermediate affinity, 395(ab)
fMRI comparison, spatial distributions, 32(ab)
^{18}F NaF, perfusion imaging of back pain patients, 485(ab)
gated, technique for reduction of lung tumor motion, 124(ab)
gated 3D, respiratory, thorax, 154(ab)
GE advance scanner for non-pure positron emitters, use of ^{124}I, 880(ab)
generalized energy-based scatter correction schemes, 522(ab)
high-resolution animal, design, 206(ab), 207(ab)
high-resolution detector, 383(ab)
high-speed gamma camera, pileup recovery method, 624, 633
HSV1-TK, comparison of imaging probes, 1160(ab)
HSV-1-tk gene expression
clinical glioma gene therapy trial, 238(ab)
mediated by oncolytic HSV-1 mutant vectors, 239(ab)

hybrid
dual and triple-detector, comparison, 366(ab)
energy window for, LROC study, 865(ab)
Fourier rebinning effects on resolution and contrast, 852(ab)
geometric sensitivity in, 1116
performance measurements on a Marconi Irix in coincidence mode, 883(ab)
hypoxia marker for, ^{18}F FETNIM pharmacokinetics, 1397
H_2O^{15} study, hydrocephalus before and after ventriculoperitoneal shunting, 544(ab)
H_2O^{15}
dynamic, regional myocardial blood flow, 782
measurement of skeletal muscle blood flow, canine, 1404(ab)
perfusion in non-small cell lung cancer, 112(ab)
H_2O^{15} and $^{13}N^3H$, comparison of estimates of myocardial blood flow, 807(ab)
$^{124}IA_{14}$ iodoinsulin, preparation characterization and preclinical investigations, 264(ab)
image reconstruction, wavelet-vaguelette decomposition and wavelet shrinkage, 851(ab)
image reconstruction system for, prototype real-time, 854(ab)
input function, non-invasive determination by Monte Carlo approach and cluster analysis, 789(ab)
large NaI crystal scanner, comparison with multi-ring PET, 879(ab)
ligand for serotonin transporter, synthesis and characterization of, 420(ab)
low-resolution, partial volume correction of, 826(ab)
LSO whole-body, for 3D whole-body imaging, 1286(ab)
market growth, 37N(10)
measurement of suicide gene expression, 1682
mega-crystal, competitive alternative to, miniature Anger detector, 872(ab)
micro, quantitative accuracy of, data correction techniques, 864(ab)
mild to moderate head trauma, consequences of, 993(ab)
Mu and Delta-opioid receptor imaging, lung cancer, 1281(ab)
multi-planar small animal, LSO-based detector element, 208(ab)
myocardial (*see* Myocardial PET)
independent covariant analysis, 938
iodorotenone as deposited-flow tracer, 272, 282
myocardial metabolism, age and gender effects, 360(ab)
myocardial perfusion, 1-^{11}C acetate as quantitative tracer for, 1174, 1183
mystery of prodigy, 24N(4)
^{13}N ammonia, skeletal muscle metabolism, cirrhosis patients, 1359(ab)
^{13}N ammonia studies, adenosine-induced change of left ventricular center, 756(ab)
neurophysiologic function, 32N(11)
neuroreceptor quantification models, 755
non-iterative reconstruction methods, 850(ab)
novel porous phantom design for, 379(ab)
^{15}O-H_2O, cerebral activation with sexual arousal, heterosexual men, 932(ab)
oncologic
choline analogs for imaging prostate cancer, 556(ab)
conducting research studies on, 826(le)
oncological studies, factor analysis, input and output functions, 814(ab)
oncoloric tracer, ^{18}F-labeled choline analogs as, 1805, 1815
orthostatic study, absolute rCBF in upright posture, 707
^{15}O water
nasal deposition measured by, 155(ab)
repeat measurements of CBF, shortening scan intervals in, 937(ab)
oxygen extraction fraction, prediction of stroke risk, 1195
paraneoplastic neurologic disorder, in, 34N(12)
PET/CT scanner combined, design considerations, 369(ab)
post-injection transmission correction, 525(ab)
preoperative, ^{11}C methionine, hyperparathyroidism patients, 598(ab)
versus Prostascint, prostate cancer, 1222(ab)
quantification, ^{11}C DASB binding to serotonin receptors, 391(ab)
quantitative studies, pretreated melanomas, 248, 257
radiolabeled probe, for gene expression, 1682
radiotracer, serotonin transporter ^{11}C DASB, 895(ab)
real-time image reconstruction, 517(ab)
scatter correction, non-linear spatially-variant object-dependent system model, 824(ab)
segmented attenuation correction for, 841(ab)
selective radioligand, serotonin transporters, monkey brain, 419(ab)
serial scans, standardized uptake value and slope of Patlak comparison, cancer therapy, 121(ab)
sigma-1 receptor radioligand ^{18}F FPS, baboons, 421(ab)
small animal
micro crystal element (MiCE2) detector, 381(ab)
neuroreceptor imaging, 209(ab)
small animal^{18}F FET tumor and inflammation imaging, 1170(ab)
SPECT imager, optimized detector design for, 885(ab)
spurious activity introduced by cascade gamma rays, removal method, 863(ab)
striatal dopamine receptors, comparison with storage phosphor autoradiography, 1691
studies of peripheral monoamine oxidase A, 906(ab)
T lymphocytes, TCR dependent NFAT mediated, 1161(ab)
transport constant of reversible radiotracer, mechanical ventilation effects, 909(ab)
trends and demand, 21N(12), 32N(12)
troglitazone effects, insulin resistance and glucose use, diabetes, 1005
tumor tracers, ^{11}C acetate PET, prostate cancer, 1197(ab)
ultra-high-resolution study, glucose utilization and neuronal toxicity, 919(ab)
uptake of ^{18}F cis-FPro, urologic tumors, 752
use in dyslexia, 35N(5)
ventral and dorsal striatum, D2 receptor occupancy by dopamine, 57(ab)
visualization, peripheral benzodiazepine receptor expression, in HIV, 905(ab)
whole-body
injected dose and scanning duration in, 878(ab)
oncology, acquisition protocol in, 862(ab)
oncology images, not corrected for attenuation, 524(ab)
whole-body high-resolution, changeable transaxial and axial fields, 365(ab)
whole-body hybrid, staging of non-Hodgkin's lymphoma, 601, 609
whole-body scanner, curve-plate NaI(T1) detectors, 1821, 1831
2D and 3D, comparison in cardiac ^{82}Rb PET studies, 701
3D, MRI-driven partial volume effect correction algorithm effects, 34(ab)
3D and 2D, optimization and comparison, 855(ab)
8-^{18}F FPCV, HSV1-tk reporter gene expression, 96, 106
^{11}C acetate
evaluation of myocardial blood flow, 63
quantification of myocardial blood flow, 1438(le)
^{11}C L-753,037, in vivo labeling of endothelin receptors, mice and dog studies, 1274
^{11}C 12968, myocardial kinetics, 932
^{13}N ammonia, fast nonlinear parametric imaging, 924
^{15}O water, cerebral perfusion and blood volume, 1032, 1040
^{15}O water, myocardial perfusion reserve measurements, 1737
^{18}F FDG
Alzheimer's disease, 548
myocardial viability, 1166
uptake, normal liver, 1265
^{18}F-FDG, glucose metabolism of breast cancer, 9
^{18}F FDG and ^{11}C MG, metabolites, pig liver, 1673, 1679
^{18}F FES radiation dosimetry in, 679
^{18}F FETNIM, blood flow and hypoxia in head and neck cancer, 1643, 1653
^{18}F FHBG, imaging of herpes simplex virus type 1, 1225, 1235
^{18}F fluoride ion, bone metabolism, porcine, 1091
^{18}F FTHA and ^{18}F FDG, myocardial metabolism in congestive heart failure, 55
^{18}F-labeled NaF, bone metastases from lung cancer, 1800
^{18}F MPPF, binding to serotonin receptors, brain, 1025
^{64}Cu TETA octreotide, in neuroendocrine tumors, 213
^{82}Rb and wavelet-based noise reduction, myocardial perfusion in humans, 201
^{86}Y-labeled anti-Lewis Y monoclonal antibodies, nude mouse model, 1281
^{124}I FIAU, quantitative kinetics, 467
^{124}I HuA33 immuno-, humanized monoclonal antibody, colorectal cancer, 764, 770
PET/CT scanner, combined, design considerations, 369(ab)
PET reporter gene
expression
imaging of gene therapy, 280(ab)
modulation with the CRE-LOXP system, 281(ab)
MicroPET and optical imaging, cationic liposomes, 284(ab)
MicroPET imaging, prostate cancer mouse models, 283(ab)
three-compartment FHBG model for imaging, 373(ab)
Phantoms
physical, for renography, 380(ab)
porous design, SPECT and PET, 379(ab)
Pharmacokinetics
antibody, parametric images, therapy of leukemia, 27
brain, biodistribution of commonly abused solvent, ^{11}C toluene, 1062(ab)
^{99m}Tc glucarate, myocardial ischemia, hypoxia and aglycemia, 716(ab)
Phencyclidine, treatment, dopamine release and reuptake in, PET, 52(ab)
Pheochromocytoma, ^{131}I MIBG scintigraphy and chromogranin A assay, 993
Phosphor screen imaging, comparison with PET, imaging of striatal dopamine receptors, 1691
Photodynamic therapy, monitoring of tumor metabolism during, steady-state PET, 96(ab)
Photon energy recovery, quantitative validation, scatter removal in ^{123}I and ^{131}I studies, 848(ab)
Pileup-recovery method, high-yield, high-speed gamma camera using, 624, 633
Pinhole, high-resolution SPECT, small rotating animal, 1863
Pituitary embolism, ventilation/perfusion SPECT, 1288
Planar imaging, *versus* gated ECG SPECT, ventricular performance, 1773
Plasma radioactivity, by robotic SPE and HPLC, after intravenous ^{11}C toluene, baboon, 1120(ab)
Plastic scintillation counter, determination of glomerular filtration rate, 1484
Pleural effusion, biodistribution of ^{188}Re-labeled somatostatin analog RC160, biodistribution, 1297(ab)
Pleural mesothelioma, occult malignancy in, FDG PET diagnosis, 1257(ab)
Pneumonitis, interstitial, lung disease and, after bone marrow transplant in children, 1439(ab)
Polycythemia, prediction of, measured RBC volume, 1127(ab)
Polymerase chain reaction, reverse transcriptase, meningiomas negative for somatostatin receptor, 1338
Polymeric peptide nucleic acid, pretargeting with amplification, 261(ab)
Positron autoradiography
dynamic, expression of stress proteins after hypoxic preconditioning, 938(ab)
hypoxic neurotoxicity, rat brain, immature and adult compared, 920(ab)
Positron detector, with gamma rejection capability, continuous blood sampling system, 870(ab)
Positron emission tomography (PET). *see* PET
Positron emitters, intracoronary radiation therapy, liquid-filled balloons to prevent restenosis, 1375, 1384
Poststress ejection fraction, stress-induced ischemia and, gated myocardial perfusion SPECT, 831

Posttraumatic stress disorder, decreased binding of benzodiazepine receptors, prefrontal cortex, 1013(ab)
Posture, upright, absolute regional cerebral blood flow in, PET, 707
Pretargeting
with amplification, polymeric peptide nucleic acid, 261(ab)
biotinylated clearing agent for, 554(ab)
bispecific antibody, renal cell carcinoma, 568(ab)
radioimmunotherapy, C49 or B9E9 single chain FV streptavidin fusion proteins in, 569(ab)
tumor, radiolabeled morpholinos, 553(ab)
universal bispecific antibody system, imaging and therapy, colon cancer, 552(ab)
3-step strategy, for infection imaging, 1389(ab)
3-step strategy, infection imaging, 1405
Pretargeting protocols, two-step radioimmunotherapy, CEA-expressing tumor patients, 459(ab)
Primary pulmonary hypertension, perfusion lung scan, response to Beraprost, 1431(ab)
Probe systems
β, in cancer treatment, 352
oncologic, metabolic studies with ^{18}F FCH, 557(ab)
pixelized small imaging CDTE probe, for intra-operative use, 869(ab)
surgical gamma and beta, detection of FDG, 1285(ab)
Prognosis
outcomes, noninvasive imaging, 1424
perfusion scintigraphy, bias due to incomplete follow-up, 348(ab)
viable myocardium, gated SPECT, 347(ab)
Prostate adenocarcinoma, choline analogs, oncologic PET imaging, 556(ab)
Prostate cancer
^{11}C acetate, age-related accumulation, 448(ab)
^{11}C acetate PET, first clinical experience, 451(ab)
^{11}C acetate PET in, 1197(ab)
dosimetry estimates for ^{131}I CHTNT-1/B, 1034(ab)
FDG PET in, 53S
harmonized image registration, using mutual information, 825(ab)
histological correlation, comparison of SPECT and PET imaging for, 1226(ab)
image fusion, ^{111}In capromab pendetide with MR or CT, 1224(ab)
^{111}In/^{90}Y radiolabeled peptides for targeting, 1149(ab)
marking hypoxia in, measuring with radiodiagnostic markers, 337
newly diagnosed, prostate-specific antigen level and bone scan necessity, 1407(ab)
PET *versus* Prostascint imaging, 1222(ab)
production brachytherapy, from silver targets, 1086(ab)
recurrence, PET imaging of, 450(ab)
skeletal metastases in, ^{186}Re HEDP therapy, hematologic tolerance to, 1300(ab)
staging of lymph nodes in, ^{11}C choline PET, 449(ab)
targeting alpha particle emitting isotope generators to tumors, 1311(ab)
^{99m}Tc MUJ591, against external domain of prostate specific membrane antigen, 1223(ab)
tumor model, androgenic control of glucose and acetate metabolism, 93(ab)
utility of ^{18}F FECh PET in, 447(ab)
^{18}F-labeled choline analogs as oncologic tracers, PET, 1805, 1815
Prostate-specific membrane antigen (PMSA), monoclonal antibodies to, dose escalation studies with ^{111}In DOTA-HU-J591, 458(ab)
Protease inhibitor, α1, inhalation of, 744
Protein synthesis, local rate, skeletal muscle, burn patients, 1420(ab)
Protein transudation, localization with ^{99m}Tc albumin scintigraphy, cluster headache patients, 1000(ab)
Psychiatry, brain SPECT in clinical practice, perfusion, 259, 611
Pulmonary arteriography, CT, diagnosis of acute pulmonary thromboembolism, 1437(ab)
Pulmonary blood flow, regional, quantitative measurement, 1434(ab)
Pulmonary embolism
acute, technegas versus ^{81m}KR ventilation/perfusion scintigraphy, 393
clinical assessment, low probability ventilation-perfusion scan reading, 1433(ab)
diagnosis, V/Q SPECT, 1432(ab)
perfusion lung scan in diagnosis, triage by, 159(ab)
pulmonary perfusion scintigraphy in, persisting perfusion defects, 160(ab)
regional V/Q ratios in, histogram distribution, 1438(ab)
SPECT and monoclonal antibody, 29N(7)
Pulmonary hypertension
chronic post-embolic, thrombo-endarterectomy and hospital mortality in, 514(ab)
postembolic, pulmonary perfusion scintigraphy, 158(ab)
right ventricular failure and, regional myocardial glucose uptake in, 199(ab)
Pulmonary malignancy, utility of Neotect in, 104(ab)
Pulmonary nodules
characterization, use of FDG PET in, 273(ab)
FDG PET and ^{201}Tl comparison, 1489, 1497
solitary
FDG PET and CT nodule enhancement comparison, 274(ab)
FDG PET SUV in evaluation of, 123(ab)
long-term outcome predicted bt FDG PET, 1247(ab)
standardized uptake value, measuring by lesion size on CT, 275(ab)
Pulmonary thromboembolism, diagnosis, CT pulmonary angiography effects on ventilation perfusion scintigraphy, 1437(ab)
Pyelonephritis, acute, risk factors for renal scarring, ^{99m}Tc DMSA, 332(ab)

Q

Quality control
absolute calibration of PET, multicentric comparative evaluation, 881(ab)
camera misalignment, SPECT, 892(ab)
Quantitative image analysis
expert system for, in myocardial perfusion SPECT, 1185, 1192
improved estimate, activity in skull-like structures, 830(ab)
region of interest measurements, standard errors with, 376(ab)

R

Radiation
adaptive response, wide variation, patients undergoing nuclear medicine procedures, 1045(ab)
natural, prolonged exposure to high levels, cancer incidence and, 1042(ab)
Radiation adaptive response, genes associated with, low level radiation from ^{99m}Tc in cells, 256(ab)
Radiation dose, administered cumulated activity, ventilation studies, 520
Radiation exposure
biologic response to, 17N(7), 26N(9)
children, 17N(3)
dose displays, 29N(7)
Radiation injury
brain stem, differentiation from nasopharyngeal cancer, FDG PET, 970(ab)
exposure of family members, outpatient treatment with ^{131}I anti-B1 antibody, 907, 916
progressive low-grade astrocytoma from, FDG, ^{123}I IMP and ^{99m}Tc MIBI, 246(ab)
Radiation necrosis, cerebral, differentiation from tumor recurrence, FDG PET, 971(ab)
Radiation safety
burdens on staff, brain investigations with FDG PET, 1117(ab)
exposure of family members, during outpatient treatment, 907, 916
online source of dose information for, Radar, 1027(ab)
sentinel node imaging technique, in dermatology, 1201(ab)
Radiation, evolution of, 26N(6)
Radiation therapy
estimating radiation tolerance dose for radiopharmaceuticals in, 1041(ab)
external beam, ^{131}I labeled A33 antibody and, colorectal cancer, 257(ab)
FDG uptake after, tumor cell cultures, 255(ab)
internal, analytic dosimetry study for radionuclide-liposome conjugates, 499
internal positron-emitting marker, identification of anatomical structures, PET, 829(ab)
intracoronary, liquid-filled balloons to prevent restenosis, 1375, 1384
metabolic, metastatic bone pain, 895
molecular, locoregional delivery of iododeoxyuridine, hepatoma model, 345
peptide receptor
demonstration of bioequivalence, dogs, 412(ab)
intrahepatic tumor growth after partial hepatectomy, 1304(ab)
optimizing conditions for, 75(ab)
peptide-receptor, renal uptake, combined lysine and arginine infusion, 135(ab)
planning for, FDG PET use in, 1234(ab)
stereotactic, PET for evaluation of treatment response, 1252(ab)
treatment planning, non small cell lung cancer, role of PET, 1255(ab)
treatment strategy, impact of whole-body FDG PET, 1235(ab)
^{90}Y octreotide, receptor mediated, 134(ab)
Radioactivity, nonuniform distributions, bystander effects, 254(ab)
Radiochemical purity, testing methods, ^{99m}Tc tetrofosmin, 1109(ab)
Radiochemistry, metabolites of FDG and ^{11}C MG, pig liver, 1673, 1679
Radiodiagnostic markers, hypoxia measurement with, rat prostate cancer, 337
Radioimmunoassay
CT and PET, CA19–9 and blood glucose as tumor marker, pancreatic cancer, 1105(ab)
taxol, using anti-taxol antibody and radiolabeled derivatives, 1100(ab)
Radioimmunoconjugates, graft-*versus*-host disease, labeling and biodistribution studies, mice, 1146(ab)
Radioimmunodetection, intervertebral disk injury, 476
Radioimmunoimaging, three-step pretargeting mAb protocol, mouse adenocarcinoma, 670
Radioimmunoscintigraphy, ^{99m}Tc anti-SM-MAb, aortic dissection, rats, 130
Radioimmunotherapy
acute leukemia, ^{131}I BC-8 antibodies, children and adolescents, 584(ab)
A431 xenografted mice, antibody-streptavidin and ^{90}Y biotin, 567(ab)
B-cell lymphoma, low-dose rate irradiation and antibody use in, 1312(ab)
Bexxar efficacy and safety
non-Hodgkin's lymphoma, large multicenter expanded access study, 455(ab)
patients with known hematologic risk factors, 460(ab)
bivalent hapten labeled with ^{188}Re, targeting of xenografted colon carcinoma, 146
doxorubicin combined with, medullary thyroid cancer, 588(ab)
α-emitter ^{213}Bi, cytotoxicity and therapeutic effect, 1310(ab)
high-dose ^{131}I labeling of antibodies, optimal quality, 509
internal organ dosimetry techniques, ^{131}I and ^{90}Y-labeled antibodies, 79(ab)
intralesional, in malignant glioma, serial FDG PET, 972(ab)
^{131}I rituximab, in B-cell non-Hodgkin's lymphoma, 456(ab)
MCNP-4B-based absorbed dose distribution estimates, patient-specific, 662
metabolite production after, lymphoma patients, 1324
monoclonal antibody RS7, human lung cancer xenograft, 967
myeloablative
comparison of ^{99m}Tc anti-CD66-MAb and ^{99m}Tc anti-CD45-MAb, 1294(ab)
mantle cell lymphoma, 585(ab)

α-particle-emitters, ^{211}At-labeled antibody preparation and, 1508, 1516
particle energy for, ^{149}TB and ^{213}Bi, 1309(ab)
potentiation of, response-selective agonist of human C5A, 1306(ab)
preclinical 2-step, human colon cancer xenograft in sheep, 1313(ab)
pretargeted, C49 or B9E9 single chain FV streptavidin fusion proteins in, 569(ab)
^{188}Re labeled anti-CD-66 MAb, in leukemia before stem cell transplant, 457(ab)
strategy of, multiple radionuclide dosing (fractionation), 1295(ab)
three-step pretargeting mAb protocol, mouse adenocarcinoma, 670
two-step, pretargeting, CEA-expressing tumor patients, 459(ab)
^{90}Y, radiation dose, sequence and timing of apoptosis to, 571(ab)
^{90}Y-labeled epratuzumab, Non-Hodgkin's lymphoma, 583(ab)
zevalin profile, radiolabeled with ^{90}Y from different suppliers, 76(ab)
^{86}Y anti-Lewis Y monoclonal antibodies, PET, nude mouse model, 1281
^{186}Re-MAb U36, myelotoxicity, 1364
^{188}Re C595 antibody for, transitional cell bladder cancer, 726

Radioiodine
iodophenylpiperazinium quaternary amine, cardiac perfusion tracers, 270(ab)
lacrimal gland function and, 591(ab)
preparation characterization, preclinical investigations and, 264(ab)
for remnant ablation, differentiated thyroid cancer, 590(ab)
Sicca syndrome after, 738
therapeutic absorbed doses, thyroid cancer, 1084
therapy
activity kinetics and exposure in dialysis patients, 1340(ab)
effects of carrier iodine in, isomorphic model, 1049(ab)
uptake and expression, aminophylline effects, rat thyroid, 1342(ab)

Radioisotopes
grounded after September 11, 13N(11)
RNA ejection fraction measurements, during pharmacologic stress testing, 871
spurious activity introduced by cascade gamma rays, removal method, 863(ab)

Radiolabeled antibodies, in leukemia therapy with Bi213-HuM195, 27

Radiolabeled peptides
DOTA, optimizing conditions for, 75(ab)
particle-based preparations of, 74(ab)
stability of ^{99m}Tc HYNIC(TRICINE) complexes, 73(ab)

Radiolabeling cold kit, use in preparing Savlon, nuclear pharmacy and nuclear medicine experience, 1115(ab)

Radiological Society of North America (RSNA)
hybrid PET/CT, 28N(1)
SNM at, 24–26N(11)

Radionuclide imaging, cardiac electrophysiology and, co-registration, 713(ab)

Radionuclides
alpha-emitting, cytotoxicity and therapeutic effect, 1310(ab)
β-emitting, marrow dose correction, 493
guided breast biopsy, 960
novel tumor-targeting and internalizing therapeutic agent, peritonitis carcinomatosa, 1087(ab)
α-particle-emitting, cellular dose conversion factors, 1216, 1222

Radionuclide therapy
doxorubicin, thyroid cancer, ^{131}I sodium imaging in, 1332(ab)
macrocyclic chelating agent DOTA, carrier molecule, 1697
medication-refractory patients, multifocal arthritis, 1395(ab)
multiple treatments, three-dimensional dosimetry application to, 78(ab)
outpatient, exposure of family members, 907, 916
peptide receptor
long-term histological organ damage in animals, 138(ab)
tumor size effects, rat tumor model, 1841
using somatostatin analogs, 468(ab)
receptor-mediated, macrocyclic chelating agent DOTA, 1697
^{186}Re HEDP, hematologic tolerance to, prostate cancer, 1300(ab)
surgery guided by, β-probe systems in cancer treatment, 352
tumor response and kidney function after, rat tumor models, 1303(ab)
using somatostatin analogs, response dependent on tumor size, 470(ab)

Radiopharmaceuticals
anti-angiogenesis, ^{123}I-labeled angiostatin, tumor imaging, 1065(ab)
challenges in development of, 12N(1)
chemistry
effects of carrier on biodistribution, ^{188}Re EDTMP as bone agent, 1097(ab)
^{11}C CGP-12177, iron oxide III and, 69(ab)
^{18}F labeling agents, 1078(ab)
^{18}F labeling agents for oligodeoxynucleotides, 1075(ab)
chemotherapy and, neuroendocrine tumors, 140(ab)
^{11}C-labeled, evaluation of automated production, 1121(ab)
comparison, ^{11}C 2′iodo-PK11195 and ^{123}I 2′iodo-PK11195, 1061(ab)
dendrimer-based, enhanced whole-body clearance, 1141(ab)
development
new automated system, ^{188}Re, 1114(ab)
PET studies on brain uptake, 907(ab)
diagnostic, visualization of primary and metastatic breast cancer, 1067(ab)
estimating radiation tolerance dose for therapy, 1041(ab)
kits labeled with ^{99m}Tc, freeze-drying parameters and hygroscopic profile, 1108(ab)
metastatic bone pain, therapy, 895
plaque and tangles in brain, Alzheimer's disease patient, 242(ab)
receptor-binding
dopamine D3, 1056(ab), 1057(ab)
sentinel node detection, 951
uptake and excretion, lactating breast, 1238
^{123}I IAZA, dosimetry estimates, 1418

Radiosensitization, methylxanthine effects, human colon cancer cells, 596

Radiosurgery, stereotactic, therapeutic outcome, ^{201}TL brain SPECT for, 977(ab)

Radiosynoviorthesis, effects on chondrocyte viability and metabolism, 1391(ab)

Radiotracers, detection of active atheroma, rabbit model, 168(ab)

Radium-223, alpha-particle emitting, treatment for skeletal metastases, 431(ab)

Radium-224
therapy, ankylosing spondylitis, quantification of bone metabolism, 1399(ab)
treatment, ankylosing spondylitis, 478(ab)

Radium-224 chloride, for ankylosing spondylitis, clinical follow-up, 1413(ab)

Receiver operating characteristic curve, FDG PET images, hepatocellular carcinoma, 126(ab)

Receptor imaging
recombinant knob domain, adenovirus fiber protein, 1066(ab)
serotonin-1A receptor agonist, modeling for determination of, 894(ab)

Receptor ligands, brain SPECT data, using single-photon transmission images, 361

Reconstruction, dynamic renal tomographic data, acquired by slow rotation, 1704

Red blood cells, measured volume, prediction of polycythemia and, 1127(ab)

Red marrow, absorbed dose, from total body activity, 493

Reflex sympathetic dystrophy (RSD), diagnosis and management, bone scintigraphy effects, 1411(ab)

Reimbursement seminar, 24N(2)

REM sleep behavior disorder, subclinical, pre- and postsynaptic dopaminergic system in, 236(ab)

Renal. *see also* Kidney

Renal cancer, metastatic, 3D whole-body imaging, FDG PET, 1200(ab)

Renal cell carcinoma
bispecific antibody pretargeting, ^{90}Y-labeled bivalent peptide, 568(ab)
detection and management, FDG PET, 300(ab)
FDG PET in, 56S
^{131}I chimeric G250 monoclonal antibody in, 1289(ab)

Renal cortical blood flow, factor analysis, ^{15}O water dynamic PET, 39(ab), 148(ab)

Renal disease, immunologic, detection of antikidney antibody in SLE, 138

Renal failure, chronic
coronary calcification and blood flow in, 356(ab)
microcirculatory function in, myocardial blood flow measurements, 337(ab)

Renal imaging, cortical scintigraphy, diuresis renography and, infants and children, 91

Renal obstruction
congenital, diuretic renography in predicting need for surgery, 330(ab)
parenchymal and pelvic images and curves for assessment, 150(ab)
unilateral upper junction, long-term follow-up of kidney function, 333(ab)

Renal parenchymal scintigraphy, planar and pinhole, acute urinary tract infection, 1441(ab)

Renal vascular reserve, evaluation, baseline and AZT renography with ^{99m}Tc MAG3, 152(ab)

Renography
aspirin, comparison with captopril, in renovascular hypertension, 324(ab)
diuresis, renal cortical scintigraphy and, infants and children, 91
diuretic
neonates and infants, 1780
parenchymal and pelvic images and curves, 150(ab)
predicting need for surgery in congenital renal obstruction, 330(ab)
exercise
alternative to ACE inhibitor renography, hypertension, 323(ab)
captopril and, revascularization therapy, 325(ab)
physical phantoms for, 380(ab)
radionuclide, immediately after renal transplant recovery period, 1449(ab)
^{99m}Tc DTPA losartan
hypertension with and without nephropathy, 326(ab)
renovascular hypertension, 327(ab)
^{99m}Tc MAG3, combined baseline and AZT, evaluation of renal vascular reserve, 152(ab)

Renovascular hypertension
aspirin renogram, comparison with captopril renogram, 324(ab)
^{99m}Tc DTPA losartan renography in, 327(ab)

Reproducibility
automatic quantitation, ^{99m}Tc sestamibi gated myocardial SPECT, 695
interobserver, ^{99m}Tc DMSA scintigraphy for renal sequelae, 564

Research scanner, high-resolution, high-sensitivity dedicated, IndyPET-2, 364(ab)

Research studies, oncologic PET, 82o(le)

Residence time, ^{131}I, thyroid cancer, 1084

Resin, Sr-selective, for purification of ^{86}Y, 1084(ab)

Respiratory distress syndrome, acute, oleic acid-induced, ^{111}In-labeled alCAM-1, 1109

Respiratory movement, accuracy of PET-CT fusion and, thorax, 42(ab)

Reticulocytes, micronuclei in, biologic dosimetry of bone marrow, 162

Reticuloendothelial system, blockage of uptake of radiolabeled antibodies, 1314(ab)

Retinoic acid
dedifferentiated thyroid cancer, cell growth and radiosensitivity in, 501(ab)

enhancement, human sodium/iodide symporter, cancer cell lines, 1142(ab)
Rett syndrome, cerebral glucose metabolism in, 146(ab)
Revascularization surgery, postop improvement of ^{201}Tl uptake, off-pump method and, 738(ab)
Revascularization therapy, captopril and exercise renography, 325(ab)
RGD-containing peptides, tumor targeting, angiogenesis imaging and, 326
RGE-4C peptides, antagonist of AVB3 integrins, ^{99m}Tc in tumors, 414(ab)
Rhenium colloids, ^{99m}Tc-labeled and unlabeled, particle size analysis, 460
Rhenium-186 HEDP
bone marrow radiation dose, palliative treatment of metastatic bone pain, 82(ab)
efficacy study, bone metastases in prostate cancer, 1302(ab)
high-dose treatment, with amifostine in rabbit model, 1545
quantitative dosimetry, source-depth maps and pseudo 3D activity maps, 822(ab)
^{153}Sm and, bone uptake after amifostine, 475(ab)
^{153}Sm EDTMP and, skeletal uptake in metastatic bone disease, 230
Rhenium-188
bivalent hapten labeled with, targeting of xenografted colon carcinoma, 146
intralesional therapy, tumor retention of, 1320(ab)
lipiodol solution of, tissue uptake and retention, after long chain alkyl groups, 432(ab)
pharmaceuticals labeled with, new automated system for preparation, 1114(ab)
somatostatin analog labeled with
after intrapleural infection, 1297(ab)
local ablation of solitary metastases, 1298(ab)
uptake, sodium-iodide symporter and, 1346(ab)
vascular stent labeled with, dosimetry of, 701(ab)
Rhenium-188 C595, antibody for, radioimmunotherapy for transitional cell bladder cancer, 726
Rhenium-188 EDTMP, potential therapeutic bone agent, effects of carrier on biodistribution, 1097(ab)
Rhenium-188 N_2S_2-lipiodol, transhepatic arterial administration, liver cancer, 1040(ab)
Rhenium-188 P2045, dosimetry evaluation, primates, 258(ab)
Rheumatoid arthritis
experimental, apoptosis in, 479(ab)
response to drug therapy, ^{99m}Tc sestamibi as predictor of, 480(ab)
Rhodamine-123, in multidrug-resistant colon cancer cells, 646
Right ventricular ejection fraction
measurement, ECG-gated blood pool imaging, 513(ab)
volume and, ECG-gated blood pool imaging *versus* cardiac angiography, 515(ab)
Right ventricular function, measurement, ECG-gated blood pool imaging, 514(ab)
Right ventricular pacing, myocardial fatty acid metabolism and, 736(ab)
Risk assessment, evidence-based, noninvasive imaging, 1424
ROC curve analysis, mammography and scintimammography, suspected primary breast cancer, 3
Rubidium-82
PET, comparison of cardiac PET studies, 701
PET normal database for, coronary artery disease, 359(ab)
wavelet-based noise reduction and, myocardial perfusion in humans, 201

S

Salivary glands
dysfunction, after radioiodine therapy, 738
scintigraphy, Sjögren's syndrome, quantitative oral radioactivity in, 38
Samarium-153
assay with radionuclide dose calibrator, in nuclear pharmacy, 1116(ab)
treatment, bone pain, hemodialysis and, 391(le)
Samarium-153 EDTMP
high-dose treatment, with amifostine in rabbit model, 1545
melphalan therapy and, multiple myeloma with peripheral blood stem cell support, 580(ab)
radionuclide therapy with, painful metastatic bone cancer, 1301(ab)
^{186}Re HEDP, skeletal uptake in metastatic bone disease, 230
^{186}Re HEDP and, bone uptake after amifostine, 475(ab)
Sarcoidosis, somatostatin receptor scintigraphy, gallium scintigraphy and, 21
Sarcoma
glucose utilization by, heterogeneity on 3S FDG PET data, 813(ab)
neoadjuvant chemotherapy, FDG uptake as predictor of survival, 1275(ab)
primary and recurrent soft tissue, FDG PET, 713
soft-tissue, ^{111}In octreotide somatostatic receptor scintigraphy in, 102(ab)
Scatter correction
attenuation correction and depth-dependent resolution recovery, ^{201}Tl studies, 1451
attenuation correction combination, ^{201}Tl studies, 11(ab)
dual-energy window acquisition, estimation of ^{99m}Tc MAG3 clearance, 1447(ab)
Gaussian model, myocardial SPECT, 847(ab)
generalized energy-based schemes for, PET, 522(ab)
kinetic analysis of D2 receptor ligand, SPECT, 926(ab)
in kinetic analysis of D2 receptor ligand, SPECT, 796(ab)
measurement of striatal and extrastriatal dopamine D2 receptors, ^{123}I epidepride SPECT, 925(ab)
new method, triple window acquisition to fit energy spectrum, 834(ab)
non-linear spatially-variant object-dependent system model, PET, 824(ab)
photon energy recovery, removal in ^{123}I and ^{131}I studies, 848(ab)
planar scintigraphy, aerosol deposition in lungs, 1077
in receptor ligand study, brain SPECT, 795(ab)
triple-energy window, IMP brain SPECT in normal subjects, 33(ab)
Schizophrenia
chronic, detection of upregulation of dopamine D2 receptors, 1001(ab)
dopamine D2 receptor occupancy, human ventral and dorsal striatum, 57(ab)
poor working memory performance, upregulation of prefrontal D1 receptors and, 60(ab)
pre- and post-synaptic dopaminergic system, drug naive patients, SPECT, 58(ab)
Scintigraphy
anisotropic diffusion for smoothing, 866(ab)
bone (*see* Bone scintigraphy)
joint, ^{99m}Tc NTP 15–5 articular cartilage imaging, 141
planar, aerosol deposition in lungs, 1077
pulmonary radioaerosol, ^{99m}Tc DTPA clearance, irradiated canine lung, 292
renal cortical, diuresis renography and, infants and children, 91
somatostatin receptor
low-grade non-Hodgkin's lymphoma, 222
^{111}In pentetreotide, procedure guidelines, 1134
whole-body, skeletal uptake in metastatic bone disease, 230
^{99m}Tc-labeled interleukin-8, detection of infection, 117
Scintillation camera
combined CT scanner and, ^{131}I MIBG, neuroblastoma imaging, 237
whole-body images, emission and transmission, 1562
Scintimammography
advances in, 22N(4)
application specific emission tomography and, breast imaging, 363(ab)
comparative phantom studies, 1216(ab)
Comptom camera, feasibility of, 887(ab)
follow-up of MR-guided percutaneous cryosurgery, breast cancer, 1217(ab)
small CZT detector for, 1214(ab)
^{99m}Tc MDP, malignant lesions of the breast, 1219(ab)
^{99m}Tc MIBI, ROC curves, suspected breast cancer, 3
^{99m}Tc sestamibi
adding to mammography in dense breasts, 1221(ab)
breast cancer detection with palpable masses, 1614
palpable masses in breast cancer, 1614
Sclerosis, systemic, diastolic dysfuntion in, gated myocardial SPECT, 183
Seizures, work-up with FDG PET, 74S
Sentinel node imaging
biopsy
FDG PET and, loco-regional lymph node staging of malignant melanoma, 1241(ab)
FDG PET comparison, staging of malignant melanoma, 1232(ab)
biopsy concept, application to gastrointestinal tract cancers, 466(ab)
breast cancer
biopsy without axillary dissection, 578(ab)
mapping, need for axillary dissection, 575(ab)
outside axilla, 574(ab)
peritumoral and subareolar application of ^{99m}Tc nanocolloid, 439(ab)
randomized trial in, 573(ab)
cervical cancer patients, intraoperative lymphatic mapping in, 577(ab)
chemotherapy effects on detection, breast cancer, 1228(ab)
count rates, sulfur colloid preparations and, 1230(ab)
FDG PET and, head and neck cancer, 1211(ab)
high-resolution intra-operative hand-held gamma camera, cancer surgery, 867(ab)
identification, use of ^{99m}Tc-labeled liposomes for, 446, 452
lymph nodes draining the peritoneum, localization of, 1163(ab)
lymphoscintigrams obtained during, drainage patterns in breast, 579(ab)
lymphoscintigraphy, breast tumor, 1229(ab)
lymphoscintigraphy and, breast cancer, 420
malignant melanoma, temporary shielding of hot spots, 438(ab)
nonparticulate receptor-binding agent, 430(ab)
preoperative lymphoscintigraphy, combined with intraoperative lymphatic mapping, cervical cancer, 1240(ab)
prototype cadmium telluride gamma camera, radioguided surgery, 378(ab)
radioguided biopsy, breast cancer surgery, 1198
sentinel lymph nodes in, breast cancer, 437(ab)
subdermal application of nanocolloid for, excretion of ^{99m}Tc in breast milk and, 1043(ab)
synthetic macromolecule for, ^{99m}Tc DTPA-mannosyl-dextran, 951
^{99m}Tc colloid, with particle size, preparation of, 72(ab)
^{99m}Tc sulfur colloid, with cysteine and rhenium, 71(ab)
technique in dermatology, radiation safety in non-nuclear medicine environment, 1201(ab)
value, accuracy or success rate, excisional biopsy of breast mass and, 576(ab)
Septal perfusion defects, with severe emphysema, SPECT, 10(ab)
Serotonin
dopamine binding, neurotransmitter effects, 53(ab)
reuptake, ketamine binds to, evaluation of PET or SPECT ligands and, 912(ab)
Serotonin receptors
^{11}C DASB binding to, PET quantification of, 391(ab)
estrogen regulation of binding activity, frontal cortex, rat, 397(ab)
imaging, Parkinson' s disease, 963(ab)
mapping, ^{11}C MDL 100907, human brain, 396(ab)
radioligand, ^{18}F 6FPWAY synthesis and investigation as, 1058(ab)
type 2 diabetes, PET imaging, 63(ab)
^{18}F MPPF binding to, brain, 1025
Serotonin transporters
availability, with alcohol intake, primate model of alcoholism, 401(ab)
comparative evaluation of ligands, brain, 394(ab)
new PET ligand, synthesis and characterization of, 420(ab)
parameters, ^{11}C DASB and ^{11}C ADAM, baboons, 392(ab)
PET examination, selective radioligand for, monkey brain, 419(ab)
PET radiotracer for, 895(ab)

potent and selective ligand for, MADAM, 1052(ab)
potential radiotracers for mapping, new derivatives of ADAM, PET, 1053(ab)
quantification of, SPECT, brain, 393(ab)
quantification with ^{123}I ADAM and SPECT, 1556
in social anxiety disorders, ^{123}I-β-CIT SPECT, 404(ab)
Serotonin-1A receptor agonist, local concentration, modeling for determination of, 894(ab)
Sevoflurane, interaction, dopamine transporter, 911(ab)
Sexual arousal, cerebral activation associated with, ^{15}O-H_2O PET study in heterosexual men, 932(ab)
Sicca syndrome, after radioiodine therapy, 738
Sickle cell disease, microalbuminuria, glomerular filtration rate and, 1448(ab)
Sidenafil citrate, short-term treatment, cardiac innervation and, 507(ab)
Sigma receptor ligand, suitability, tumor imaging, 314(ab)
Single-chain Fvs, ^{99m}Tc-labeled divalent and tetravalent CC49, colon cancer, 1519, 1528
Single photon emission computed tomography (SPECT). *See* SPECT
Sjögren's syndrome, salivary gland scintigraphy, quantitative oral radioactivity in, 38
Skeletal development, apoptosis in, 1406(ab)
Skeletal kinetics, regional, measuring with ^{18}F fluoride PET, 371(ab)
Skeletal metastases, hepatocellular cancer patients treated with arterial embolization, bone scintigraphy, 1400(ab)
Smooth muscle cells, vascular, effects of ^{125}I seeds and 103PD-implanted stents, 714(ab)
Society of Nuclear Medicine
achievement recognized at 2001 meeting, 13N(7)
acting executive director named, 36N(11)
candidate slate for 2001, 17N(4)
conjoint government affairs committee, 35N(5)
education initiatives, 30N(10)
executive director search, 25N(10)
history, 20N(1)
history corner, 19N(2), 22N(11), 24N(1), 26N(6)
international focus in 2001, 19N(5)
international web site launched, 27N(1)
internet symposium, 22N(5)
last call for name change, 14N(11)
lines from the President, 11N(6)
medical physics education programs, 36N(5)
Mid-Winter Meeting 2002, preview, 13N(12)
new officers announced, 25N(6)
New Year's greeting for the SNM President, 9N(1)
New Year's greeting for the SNM-TS President, 10N(1)
nuclear cardiology self-study series, 34N(10)
public affairs update, 14N(10), 16N(11), 22N(2), 26N(1), 28N(7), 30N(6), 31N(8), 33N(9), 34N(5)
public affairs update, 18N(4)
public outreach seminar, 19N(5)
at RSNA, 24–26N(11)
2001 annual meeting preview, 7N(4)
Society of Nuclear Medicine-Technologist Section
annual meeting set records, 14N(9)
candidate slate for 2001, 17N(4)
lines from the President, 12N(6), 12N(9)
Sodium iodide, uptake, NaI symporter gene enhancement of, hepatoma cells, 317
Sodium iodide crystal, PET scanner, presurgical evaluation of epilepsy, 1158
Sodium/iodide symporter
glucose transporter-1 and, relations in differentiated thyroid cancer, 500(ab)
perrhenate, pertechnetate and iodide biodistribution and, 1346(ab)
transfected to cancer cell lines, retinoic acid enhanced, 1142(ab)
Sodium/iodide symporter gene
colon cancer cell expressing, for radioiodine concentrator gene therapy, 1182(ab)
enhancement of iodide uptake, hepatoma cells, 317
Soft tissue, retention of ^{186}Re HEDP and ^{153}Sm EDTMP, metastatic bone disease, 230
Soft-tissue sarcoma, FDG PET in, 1274(ab)
Software, COMKAT, compartmental model analysis tool, 636
Somatostatin analogs, nuclear translocation, 529(le)
Somatostatin receptor imaging
^{111}In octreotide, soft-tissue sarcoma, 102(ab)
^{111}In pentetreotide, neuroendocrine gastroenteropancreatic tumors, 103(ab)
low-grade non-Hodgkin's lymphomas, 222
meningiomas, ^{111}In DTPAOC SPECT, 249(ab)
meningiomas negative for, 1338
meningiomas scintigraphically negative, molecular biological analyses, 248(ab)
scintigraphy
gallium scintigraphy and, sarcoidosis, 21
lung tumors, 1309
^{111}In pentetreotide, procedure guidelines, 1134
Somatostatin receptors
antiproliferative effects, intrahepatic tumor growth after partial hepatectomy, 1304(ab)
chemotherapeutic agent effects, in pancreatic tumor cells, 1856
DOTATOC PET imaging, meningiomas, 1053, 1057
radiolabeled somatostatin analogs for, tumor response and kidney function after, 1303(ab)
subtype 2 transfection, colon cancer model, 1305(ab)
tumor-targeting peptide-PNA conjugates, 428(ab)
SPECT
blood pool, left ventricular ejection fraction from, 401
bone metastases from lung cancer, 1800
brain
automated stereotactic standardization of, 361
in clinical practice, perfusion in, 259, 611
dual-score, quantitation in, 300
evaluation of two serotonin transporters, 394(ab)
gamma camera for, 886(ab)
highly selective DAT ligand, 896(ab)
in hypothyroidism, 1017(ab)
in intractable epilepsy, 986(ab)
iterative deconvolution techniques, 858(ab)
juvenile Behçet's disease, 1151
PET and SPECT comparison in Alzheimer's disease, 49(ab)
scatter correction effects, 795(ab)
statistical parameter for, validation of, 41(ab)
^{201}Tl, image registration in recurrent meningioma, 975(ab)
^{99m}Tc ECD, subacute cerebral infarction, 543
camera misalignment in, 892(ab)
cardiac
Bayesian emission reconstruction of, 518(ab)
cardiomyopathies, 1062
estimation of defect size, 1579
fan-beam collimator for, 22(ab)
gastric wall hyperactivity, 779(ab)
respiratory motion in, 837(ab)
ROC optimization study, 849(ab)
CBF, language dominance, 996(ab)
cerebral perfusion
balloon occlusion test, 407(ab)
errors caused by hypoperfusion, 25(ab)
coincidence imaging, myocardium, 944
cone-beam, Monte Carlo simulation, 890(ab)
in dementias, 1131(le)
diagnosis in Alzheimer's disease, 34N(6)
dipyridamole ^{201}Tl, case-based reasoning, 189
dobutamine gated, identification of myocardial viability, 838
donepezil effects, rCBF in Alzheimer's disease, 1441
dynamic
OSEM algorithm and, intrahepatic cholestasis, 1368(ab)
radiopharmaceuticals with fast uptake and washout, 172(ab)
reconstruction, slow rotation, 1704
regional pulmonary blood flow in congenital heart disease, 1425(ab)
^{99m}Tc Teboroxime optimization of, 717(ab)
^{201}Tl, glioblastoma, 976(ab)
dynamic cardiac beating heart phantom, 718(ab)
dynamic renal, slow rotation, 1704
dynamic single-camera rotation, hot bladder artifact in, 523(ab)
ECG-gated
versus attenuation correction, accuracy of, 751(ab)
patient motion effects, 758(ab)
W-L CQ new method for, 349(ab)
ECG gated myocardial, with ^{123}I-labeled fatty acid analog, 1747
estimation of optimum transmission scan time, 838(ab)
FDG, LVEF and heart failure symptoms, 79, 87
FDG, myocardial viability assessment, 778(ab)
fractal analysis, rCBF in Alzheimer's disease, 1446
gated
baseline and one-year after coronary intervention, 745(ab)
cardiac motion correction, 530(ab)
comparison and validation, for volume determination, 173(ab)
correlation of left ventricular ejection fraction, 768(ab)
at end-diastole, in MI, 769(ab)
functional improvement after CABG, 15(ab)
left ventricular ejection fraction, 454
left ventricular function, 1043, 1050
backprojection or reconstruction, 754(ab)
measurement of diastolic function, 720(ab)
Monte Carlo evaluation, 835(ab)
myocardial tracking with, 845
nitroglycerin challenged, myocardial viability, 17(ab)
pharmacologic *versus* ergometric, 355(ab)
prediction of infarction *versus* cardiac death, 831
reproducibility of quantitation, 695
rest ejection fraction and perfusion defect size, after acute MI, 179(ab)
systemic sclerosis, cardiac involvement and, 183
ventricular performance, 1773
ventricular volume and ejection fraction, 1571
viable myocardium, 347(ab)
wall-thickening of left ventricle, 193(ab)
gated myocardial
hypertrophic cardiomyopathy, 1017
wall motion and thickening, 1630, 1639
high-resolution pinhole
conventional camera, small animals, 203(ab)
small rotating animal, 1863
ictal
neocortical epilepsy, intra-patient variability, 234(ab)
utility in pediatric patients, 233(ab)
ictal/interictal, submaximal differences in images, 235(ab)
imaging of liver disease, in neuroendocrine tumors, 99(ab)
iterative reconstruction, non-uniform attenuation for, 215(ab)
K-L transform on projection data, spatial resolution of, 857(ab)
liver-spleen, functional liver volume in cirrhosis, 490(ab)
low-dose dobutamine stress, myocardial ischemia, 773(ab)
lung V/Q, pulmonary embolism, 1432(ab)
MIBI, non-invasive monitoring of myocardial ischemia, 709(ab)
microglia, senile dementia of Alzheimer type, 43(ab)
monoclonal antibody, pulmonary embolism, 29N(7)
myocardial (*see* Myocardial SPECT)
technical aspects, 1499
myocardial, iodorotenone as deposited-flow tracer, 272, 282
myocardial gated, motion and thickening, 1630, 1639
myocardial perfusion
in ER, 35N(9)
expert system for interpretation of, 1185, 1192
motion correction in, 687
myocardial perfusion, new algorithm for, 391(le)
neuroreceptor quantification models, 755
new scatter estimation method, 834(ab)
novel cannabinoid receptor agonist, in vivo binding, 904(ab)
novel porous phantom design for, 379(ab)
occipital brain perfusion deficits, depression and, children, 1059
oral amphetamine challenge, rCBF response to, 535
perfusion
diagnosis of dementia, cognitive disorder clinic, 946(ab)

measurement of pulmonary blood flow, 1434(ab)
voxel-based morphometry, in healthy aging, 229(ab)
perfusion defects, correlation with subsequent infarction site, 558
PET imager and, optimized detector design for, 885(ab)
PICO, clinical breast imaging, 888(ab)
pinhole
count-rate assessment effects, thyroid diseases, 1347(ab)
neck high resolution, hyperparathyroid patients, 1348(ab)
using micro-pinholes, 204
pinhole collimator sensitivity, determination of, 526(ab)
preoperative functional assessment, auditory cortex, 548(ab)
quantitative
filtering effects on ejection fraction, 350(ab)
individual patient dosimetry with, 1032(ab)
left ventricular mass, 351(ab)
with OSEM, Alzheimer's disease, 945(ab)
quantitative gated, left ventricular ejection fraction, 528(lc)
quantitative gated, stress-induced stunning, 354(ab)
segmentation, change detection, and volume browsing, 816(ab)
separate X-ray, attenuation correction and image fusion, 845(ab)
simultaneous dual-isotope
down-scatter for, 832(ab)
fast simulator for, 528(ab)
small-animal dedicated system, 873(ab)
subtraction, temporal lobe epilepsy, 853
ventilation/perfusion, lung embolism, 1288
X-ray and CT combined system, small animals, 205(ab)
^{99m}Tc MAA, embolic distribution through patent foramen ovale, 859
^{99m}Tc MIBI, myocardial viability, 1166
^{99m}Tc sestamibi, regional myocardial uptake, 772, 780
^{99m}Tc tetrofosmin, normal stress, 342(ab)
^{99m}Tc TRODAT, early-stage Parkinson's disease, 1303
^{99m}Tc TRODAT-1 and, imaging gene expression with, 240(ab)
^{99m}Tc/^{111}In studies, attenuation correction of, 831(ab)
^{99m}Tc/^{123}I brain, cross-talk correction in, 521(ab)
^{123}I ADAM, quantification of serotonin transporters, 393(ab), 1556
^{123}I IMP, detection of misery perfusion by, 408(ab)
^{123}I IMT, survival in glioma patients and, 1144
^{123}I methyl-tyrosine, non-small cell lung cancer, 579
^{131}I, tumor activity, effect of object shape in, 389(ab)
^{131}I MIBG, neuroblastoma imaging, 237
^{133}Xe, cerebral blood flow, 864
^{201}Tl
hypertrophic cardiomyopathy, 772(ab)
pituitary adenomas, 575
prediction in lung cancer, 1262(ab)
Spinocerebellar degeneration, blood flow of cerebellum and brainstem in, comparative study, 965(ab)
Spondylitis, infectious, bone scintigraphy in, MRI comparison, 1416(ab)
Spondylodiscitis, diagnosis, FDG PET, 1393(ab)
Sports injury, asymptomatic lower extremity uptake abnormality, clinical significance of, 209
Sports nuclear medicine, cardiac function, radionuclide monitoring during exhaustive exercise in athletes, 516(ab)
Standardized uptake value (SUV)
measurement by lesion size on CT, characterization of pulmonary nodule on FDG PET, 275(ab)
Patlak slope and, monitoring of cancer therapy, serial PET scans, 121(ab)
Stents
endovascular abdominal aortic, immunoscintigraphy after implantation, 1374(ab)
with tracheobronchial stenosis, role of lung scintigraphy in, 1436(ab)
vascular, ^{188}Re-labeled, dosimetry of, 701(ab)
^{103}PD-implanted, ^{125}I seeds and, effects on vascular smooth muscle cells, 714(ab)
Steroids, pretreatment, evaluation of real tumor activity, immunocompetent host, 1172(ab)
Stress fracture
asymptomatic lower extremity uptake abnormality, clinical significance of, 209
longitudinal, tibial fatigue, bone scintigraphy in, 1405(ab)
Stroke
acute ischemic, hyperactivity of ^{99m}Tc HMPAO, 1297
early ischemic neuronal death, FK506 and, monkey model, 1833
prediction of, PET oxygen extraction fraction, 1195
^{99m}Tc HMPAO SPECT after, recovery related activity patterns in MRI and, 981(ab)
Strontium-89, treatment, metastatic bone cancer, 1322(ab)
Sulfur colloid, ^{99m}Tc-labeled and unlabeled, particle size analysis, 460
Surgical specimens, fast imaging, 868(ab)
Swiss Rolls, magnetic material, 22N(3)
Sympathetic denervation, ascending aortic aneurysm, surgical repair of, 1346
Sympathetic innervation, cardiac, sidenafil citrate effects, 507(ab)
Sympathetic nerve function, cardiac
allograft performance and, after orthotopic heart transplant, 505(ab)
idiopathic dilated cardiomyopathy, MIBG use in, 503(ab)
Sympathetic nervous system, underlying etiology, high risk of cardiac death and, 1757
Sympathetic reinnervation, transplanted heart, 1011
Systemic lupus erythematosus (SLE), radiolabeled lupus antikidney antibody, in vivo detection, 138

T

Tamoxifen, iodine-labeled, uptake in primary breast cancer, 1818
Taxol, radioimmunoassay, using anti-taxol antibody and radiolabeled derivatives, 1100(ab)
T cells, HSV-tk-modified, dual camera x-ray/gamma imaging of, 1388(ab)
Technegas, *versus* ^{81m}Kr, ventilation/perfusion scintigraphy, pulmonary embolism, 393
Technetium-99m
agents with double subtraction images, parathyroid scintigraphy with, 1349(ab), 1358(ab)
antimicrobial peptides labeled with, bacterial and *Candida albicans* infections, 788
antisense DNA labeled with, tumor targeting with, 1660, 1670
chemotactic peptides, infection imaging with, 1107(ab)
ciprofloxacin labeled with, biodistribution in normal and infected rats, 1110(ab)
divalent and tetravalent CC49 single-chain Fv's, imaging of colon cancer, 1519, 1528
dual solid-state intraoperative probe system with, in cancer treatment, 352
^{67}Ga and, simultaneous emission-transmission imaging, 844(ab)
lipophilic cations labeled with, use for myocardial SPECT agents, 1094(ab)
liposomes radiolabeled with, sentinel node identification, 446, 452
model drug carriers labeled with, organ distribution and, rat, 1104(ab)
radiopharmaceutical kits labeled with, freeze-drying parameters and hygroscopic profile, 1108(ab)
secretion in breast milk, after subdermal application of nanocolloid for sentinel node imaging, 1043(ab)
^{201}Tl dual-isotope, myocardial imaging, optimization of acquisition parameters in, 190(ab)
tracing of metastasis, 30N(11)
Technetium-99m aggregated albumin, hysterosalpingoscintigraphy, velocity of tubular transport, 1357(ab)
Technetium-99m albumin, scintigraphy, protein transudation, cluster headache patients, 1000(ab)
Technetium-99m albumin colloid, detection of sentinel lymph nodes, breast cancer, 435(ab), 436(ab)
Technetium-99m annexin, evaluation of apoptosis, autoimmune myocarditis, 169(ab)
Technetium-99m annexin V, radiation dosimetry, 382
Technetium-99m annexin V
cyclophosphamide-induced intramedullary apoptosis, rats, 309
imaging cell death, untreated and treated tumors, 312(ab)
single-dose chemotherapy, tumor response after, 313(ab)
Technetium-99m anti-CD66-MAb, in myeloablative radioimmunotherapy, 1294(ab)
Technetium-99m anti-granulocyte fragment, immunoscintigraphy, extra-osseous inflammation, 1372(ab)
Technetium-99m antisense DNA, tumor targeting with, 1660, 1670
Technetium-99m antisense DNA culture, enhancement of uptake, cationic liposomes, 1083(ab)
Technetium-99m anti-SM-MAb, radioimmunoscintigraphy, dissecting aortic aneurysm, 130
Technetium-99m BPHA, renal excretion mechanism, functional imaging and, 1092(ab)
Technetium-99m carbonyl
new renal imaging agent, 1091(ab)
transported bu MDR1 P-glycoprotein, 426(ab)
Technetium-99m ciprofloxacin
after arthroplasty, post-operative osteoarticular infections, 1375(ab)
diagnosis, prosthetic joint infection, 1385(ab)
infection imaging, chronic orthopedic infections, 567
Technetium-99m colloid, with particle size, preparation of, 72(ab)
Technetium-99m conjugates, internalization kinetics and biodistribution, pancreatic tumor model, 429(ab)
Technetium-99m cysteine rhenium colloid, compared to other colloids, lymphoscintigraphy model, rabbit, 1123(ab)
Technetium-99m C5a and C5adR, for infection imaging, 1088(ab)
Technetium-99m DADT, formation of positive ion, 1103(ab)
Technetium-99m Depreotide, nonspecific mediastinal uptake, 1264(ab)
Technetium-99m DMSA
evaluation, renal scarring after acute pyelonephritis, 332(ab)
scintigraphy, renal sequelae and, 564
Technetium-99m DTPA
aerosol, pulmonary clearance, diabetic patients, 157(ab)
brain scintigraphy, meningiomas negative for, 1338
comparison of 4 methods, monkey, 1870
dynamic renography, whole kidney mean transit times in, diabetes mellitus patients, 1440(ab)
estimation of glomerular filtration rate, plastic scintillation counter, 1484
gated SPECT, diastolic dysfunction in systemic sclerosis, 183
radioaerosol transalveolar clearance, irradiated canine lung, 292
renal dynamic imaging, different IGA neuropathies, 1443(ab)
^{123}I IMT comparison, SPECT, glioma delineation, 978(ab)
Technetium-99m DTPA-galactosyl-neoglycoalbumin, asialoglycoprotein receptor density, portal-systemic shunt and, 110
Technetium-99m DTPA-mannosyl-dextran, synthetic macromolecule for sentinel node detection, 951
Technetium-99m EC annexin V, measurement of apoptosis, breast cancer, 311(ab)
Technetium-99m ECD
detection of changes in regional CBF, subarachnoid hemorrhage, 985(ab)
distribution, medial frontal lobes, statistic parametric mapping, 923(ab)
FDG PET and SPECT imaging, epileptic foci, 232(ab)
labeling of white blood cells with, 1111(ab)
metabolic imaging with, preliminary tumor, 1283(ab)
metabolism, infarcted brain tissue, rats, 802
preoperative acetazolamide stress brain SPECT, after carotid endarterectomy, 406(ab)
quantitative cerebral blood flow measurement, Parkinson's disease, 959(ab)
SPECT
acute effects of smoking on CBF, 997(ab)
^{133}Xe comparison, subacute cerebral infarction, 543

Technetium-99m EC-DG
biodistribution and imaging with, 97(ab)
cellular uptake, comparison with FDG, 1082(ab)
Technetium-99m ethylnedicysteine, vagal nerve stimulation, 231(ab)
Technetium-99m exametazime
leukocytes labeled with, methylene blue stabilizer effects, 1112(ab)
leukocytes labeled with, chemotaxis and viability, 505
Technetium-99m FBPBAT, for myocardial sympathetic innervation, 704(ab)
Technetium-99m generators, yellow eluate from, 827(le)
Technetium-99m glucarate
acute myocardial infarction, 711(ab)
kinetics of, myocardial ischemia, hypoxia and aglycemia, 716(ab)
selective detection of infarct, reperfused myocardium, 715(ab)
Technetium-99m glutaric acid, nuclear imaging, marker protein expression, 286(ab)
Technetium-99m GSA
dynamic SPECT, hepatectomy in relation to percutaneous transhepatic portal embolization, 467(ab)
early phase index, estimation of liver function, 1361(ab)
irradiated liver, whole and regional function, 820(ab)
per-rectal portal scintigraphy and, clinical need for both, chronic liver disease, 1362(ab)
portal circulation relations, hepatocellular carcinoma with cirrhosis, 1364(ab)
receptor measurements, functional hepatocellular mass, 733
SPECT, preoperative portal vein embolization, hypertrophy of the liver after, 1369(ab)
Technetium-99m HDP, skeletal uptake, high-dose treatment with other radiopharmaceuticals and, 1422(ab)
Technetium-99m hexadecanoic acid, cyclopentadienyl tricarbonyl, for myocardial imaging, 1095(ab)
Technetium-99m hHMFG1, humanized monoclonal antibody, axillary nodes in breast cancer, 1225(ab)
Technetium-99m HMDP, conventional bone scan, ^{18}F F Na PET comparison, gamma camera, 487(ab)
Technetium-99m HMPAO
brain perfusion SPECT, role in head injury, 989(ab)
brain SPECT
hemodynamically compromised area in cerebrovascular lesions, 405(ab)
in neurology and psychiatry, 611
Tourette's syndrome, 1016(ab)
epilepsy SPECT scans, difference calculation *versus* SPM, 987(ab)
hyperactivity of, acute ischemic stroke1297
leukocyte scintigraphy, ^{99m}Tc ciprofloxacin (infection) comparison, orthopedic infections, 567
leukocytes labeled with, activation during labeling, 685(le)
radionuclide angiography, mean hemispheric blood flow, normal and dementia patients, 949(ab)
SPECT
blood flow changes correlate with cognitive function changes, Alzheimer's disease, 950(ab)
post-stroke, recovery related activity patterns in MRI and, 981(ab)
SPECT, PET comparison, Alzheimer's disease, 49(ab)
Technetium-99m HYNIC, peptide complexes, nitriles as coligands for, 1102(ab)
Technetium-99m HYNIC(TRICINE) peptide complexes, stability of, 73(ab)
Technetium-99m incadronate, new bone-seeking agent, animal studies, 1096(ab)
Technetium-99m IL-8
imaging
acute osteomyelitis, 1373(ab), 1257
experimental colitis, rabbits, 917
infection imaging with, 272(ab)
rapid imaging, experimental colitis, 1381(ab)
scintigraphy, detection of infection, 117
Technetium-99m isonitriles, renal imaging, 267(ab)
Technetium-99m-labeled LTB4, for inflammation imaging, neutrophils in human blood, 1090(ab)
Technetium-99m labeled RGD peptide, monomeric and dimeric analog of, comparative biodistribution, 472(ab)
Technetium-99m leukocyte, scintigraphy, diagnosis of post-sternotomy mediastinitis relapse, 167(ab)
Technetium-99m leukokinin residue analogues, imaging inflammatory foci, 1089(ab)
Technetium-99m liposomes, imaging of viral infections, 1380(ab)
Technetium-99m MAA
brain SPECT, after valsalva radionuclide venography, 859
lung perfusion scintigraphy, coil embolization for patent ductus arteriosus, 1427(ab)
Technetium-99m MAG3
clearance, dual-energy window acquisition for estimation of, 1447(ab)
comparison of 4 methods, monkey, 1870
renography, evaluating renal function, 1445(ab)
Technetium-99m MDP
blood delivery to bone, intermittent compression effects, 1409(ab)
bone scanning, alendronate effects, 1359
bone scintigraphy, leukemia in children, 878
bone SPECT, painful temporomandibular joint, 1394(ab)
bone uptake, burn injury effects, rat, 147(ab)
free flap *versus* osteoblastic flap craniotomy, assessment of viability, 1419(ab)
three-phase bone scintigraphy, diagnosis of repetitive strain injury, 1421(ab)
Technetium-99m mebrofenin
hepatobiliary clearance, hepatoprotective role of zinc and, protein deficiency and lead toxicity, 1050(ab)
Wilson's disease, hepatic function in, 494(ab)
Technetium-99m MIBI
accumulation, comparison with TPMP, breast neoplasms, 1162(ab)
as additional test support to ultrasound, gynecological malignancy, 1188(ab)
comparison with intracoronary measured fractional flow reserve, 335(ab)
detection of bone metastases, 1267(ab)
dual-phase imaging
immediate/delay image ratios, hyperparathyroidism, 1351(ab)
lesion detectability in, parathyroid, 1352(ab)
evaluation of chemoradiotherapeutic response, lung squamous cell carcinoma, 1260(ab)
infusion, *versus* nitroglycerin, detection of myocardial viability, 176(ab)
loco-regional metastases, in medullary thyroid cancer, 1338(ab)
PET, multidrug resistant human colon cancer cell line, 646
prognosis assessment, MI treated by primary PTCA with stenting, 181(ab)
scintigraphy, musculoskeletal tumors, 33
scintimammography
comparison of ultrasound, breast cancer, 89(ab)
contrast-enhanced MRI and, suspected breast cancer, 88(ab)
interpretation criteria for breast cancer, 91(ab)
reduction of resistance to neoadjuvant chemotherapy, breast cancer, 90(ab)
scintimammography/mammography, ROC curves, primary breast cancer, 3
SPECT, regional myocardial wall motion and systolic thickening on, 748(ab)
thoracic SPECT, N2 mediastinal lymph nodes, in non small cell lung cancer, 1261(ab)
uptake in preoperative assessment, breast mass, 1220(ab)
Technetium-99m MN, brain SPECT, acute cerebral infarction, prognostication with, 409(ab)
Technetium-99m MUJ591, against external domain of prostate specific membrane antigen, prostate cancer, 1223(ab)
Technetium-99m NOET, vasodilator stress imaging, residual coronary stenosis, subendocardial infarction, 1388, 1395
Technetium-99m O15O5T, DAT ligand, phase I clinical trial, 1125(ab)
Technetium-99m peptides, comparison of 4 methods, monkey, 1870
Technetium-99m pertechnetate
preoperative scintigraphy, primary hyperparathyroidism, 597(ab)
^{67}Ga compared with, detection of gastric Non-Hodgkin's lymphoma, 1138(ab)
Technetium-99m phenothioate-annexin V, dosimetry and biodistribution, humans, 1048(ab)
Technetium-99m PMT, SPECT, OSEM algorithm and, intrahepatic cholestasis, 1368(ab)
Technetium-99m Q12, comparison of sestamibi and tetrofosmin, retention in porcine myocardium, 818
Technetium-99m RGD peptide, antagonist of AVB3 integrins, tumor, 414(ab)
Technetium-99m RP128, inflammation imaging agent, dosimetry, 154
Technetium-99m RP527, biodistribution and dosimetry, 1722
visualization of GRP receptor-expressing malignancies, 1722
Technetium-99m sestamibi
bone scintigraphy, in Gaucher disease, 1412(ab)
comparison of tetrofosmin and Q12, retention in porcine myocardium, 818
detection of malignant lesions, breast, 1219(ab)
differential diagnosis, pathological and simple fracture, 1398(ab)
dual-phase scintigraphy, parathyroid, 1353(ab)
erythema multiforme reaction to, 534(le)
exercise supplementation to dipyridamole, heart to liver activity ratio, 183(ab)
gated myocardial SPECT, reproducibility of quantitation, 695
gated SPECT, baseline and one-year after coronary intervention, 745(ab)
Gaucher disease, efficacy of enzyme replacement therapy, 476(ab)
hyperthyroid patients, with iodine excess, 1331(ab)
multidrug resistance and, primary breast cancer, 1213(ab)
multidrug resistance protein and mRNA correlation, lung cancer, 1476
predictor of response to drug therapy, rheumatoid arthritis, 480(ab)
retention characteristics
hyperemia in human myocardium, 1457
pharmacological hyperemia, human myocardium, 336(ab)
scintigraphy, myeloma bone disease, 116(ab)
scintimammography
advanced and inflammatory breast cancer, 1212(ab)
breast cancer detection with palpable masses, 1614
breast cancer with palpable masses, 1614
SPECT
early prognosis in lung cancer, 1248(ab)
regional myocardial uptake, 772, 780
ultrasound and, preoperative localization of abnormal parathyroid, 1356(ab)
SPECT localization, parathyroid adenomas, 594(ab), 595(ab)
tetrofosmin comparison, SPECT results, coronary artery disease, 343(ab)
uptake and prognostic factor correlation, breast cancer, 1218(ab)
uptake and washout, locally advanced breast cancer, 85(ab)
Technetium-99m sulfur colloid
reformulation with cysteine and rhenium, optimal nanometer size, 71(ab)
sentinel node count rates and, 1230(ab)
Technetium-99m TAT-peptide chelates, stereospecific cell uptake, 418(ab)
Technetium-99m teboroxime, myocardial perfusion SPECT, 717(ab)
Technetium-99m tetrofosmin
axillary planar, SPECT and pinhole-SPECT, in breast cancer, 87(ab)
in candidates for cardioverter-defibrillator implantation, cost-effectiveness of, 509(ab)

comparison of sestamibi and Q12, retention in porcine myocardium, 818
diagnosis, malignant breast lesions, 86(ab)
dual-phase scintigraphy, parathyroid, 1353(ab)
dynamic SPECT, detection of ischemic myocardium, 750(ab)
gated SPECT
left ventricular function determination, 766(ab)
myocardial blood flow after acute infarction, 724(ab)
parameters of left ventricular function, 723(ab)
myocardial perfusion SPECT, prognosis, 342(ab)
neck pinhole SPECT, *versus* ultrasound, differentiated thyroid cancer, 1328(ab)
non-small cell lung cancer, response to paclitaxel chemotherapy, 17
PET, prediction to response to chemotherapy in breast cancer, 1215(ab)
radiochemical purity testing methods, 1109(ab)
SPECT
acute myocardial infarction, 1351
cardiomyopathy, 1017
estimation of coronary flow reserve, 777(ab)
primary and secondary malignant thorax lesions, 1263(ab)
Technetium-99m THIO-β-D-glucose, as tumor-seeking agent, ligand concentration effects on biodistribution, 98(ab)
Technetium-99m tricarbonyl bombesin analog, minimal abdominal accumulation, high target/non-target ratios, 415(ab)
Technetium-99m TRODAT
differential diagnosis, Parkinson's disease and vascular Parkinsonism, 408
early-stage Parkinson's disease, 1303
Technetium-99m TRODAT-1
diagnosis
Parkinsonian movement disorders, 541(ab)
Parkinsonism, 542(ab)
dopamine transporter binding, asymptomatic Machado-Joseph disease gene carriers, 543(ab)
evaluation of early Parkinson's disease, 956(ab)
pharmacological safety, human research volunteers, 1113(ab)
Wilson's disease, 967(ab)
Technetium-99m WBC, uptake, temporal correlation of ESR with, children with IBD, 1423(ab)
Telemedicine legislation, 28N(2)
Temporomandibular joint, pain, ^{99m}Tc MDP bone SPECT for, 1394(ab)
Testicular cancer, FDG PET in, 58S
Testicular function, FDG uptake with age, chemotherapy effects and, PET, 1198(ab)
Testicular neoplasms, nonseminomatous germ cell tumors, FDG PET for staging, 1199(ab)
Testosterone therapy, effect on cerebral perfusion, hypogonadal males, 547(ab)
Tetrabutylammonium bicarbonate, preparation of FDG, rapid gas chromatography, 66(ab)
Thakur, Mathew, 11N(12), 32N(12)
Thallium-201
brain SPECT
recurrent meningioma, image registration, 975(ab)
therapeutic outcome of stereotactic surgery, 977(ab)
buildup pattern in early kinetics of, in glioblastoma, 976(ab)
cellular uptake, TSH effects, thyroid tissue cultures, 1345(ab)
clinical evaluation, bone tumor, 1410(ab)
depth-dependent resolution recovery, scatter and attenuation correction effects, 1451
dipyridamole
myocardial perfusion imaging, prognostic impact in elderly patients, 344(ab)
myocardial SPECT, case-based reasoning, 189
FDG PET comparison, pulmonary nodules, 1489, 1497
gated SPECT, measurement of left ventricular function, backprojection vs reconstruction, 754(ab)
myocardial gated SPECT, transient ischemic stunning, 352(ab)
myocardial perfusion imaging, changes with myocardial bridge, energetic males, 735(ab)
PET, prediction to response to chemotherapy in breast cancer, 1215(ab)
versus planar angiography, validation of myocardial tracking, 845
redistribution, myocardial viability assessment, stratification by stress-rest reversibility, 16(ab)
scintigraphy, diagnosis of thyroid cancer, 414
SPECT
biologic behavior of pituitary adenomas, 575
evaluation of chemoradiotherapeutic response, lung squamous cell carcinoma, 1260(ab)
thyroid scintigraphy, differentiation of benign and malignant disease, 599(ab)
uptake, revascularization surgery, off-pump method and, 738(ab)
^{14}C deoxyglucose uptake and, autoimmune myocarditis in rats, 285
^{99m}Tc dual isotope, myocardial imaging, optimization of acquisition parameters in, 190(ab)
Thallium-201 chloride
detectability, radioiodine-negative metastatic thyroid cancer, 1334(ab)
whole-body, bone scintigraphy and, evaluation of multiple myeloma, 115(ab)
Thallium-201 Cl, PET, multidrug resistant human colon cancer cell line, 646
Therapeutic administration, metastatic bone pain, ^{117m}Sn DTPA, 1085(ab)
Thoracic lesions, malignant, ^{99m}Tc tetrofosmin SPECT in detection of, 1263(ab)
Three-compartment model, FHBG, imaging reporter gene expression, 373(ab)
Three-dimensional volume imaging, injected dose and scanning duration, clinical studies, 878(ab)
Thromboembolism, pulmonary, with antiphospholipid antibodies, 1430(ab)
Thrombolytic therapy, hyperactivity of ^{99m}Tc HMPAO, acute ischemic stroke, 1297
Thrombosis imaging, recombinant hirudin for, 703(ab)
Thymus
hyperplasia, FDG PET study, 591
uptake of ^{131}I, during whole body scan in thyroid cancer, 1339(ab)
Thyroglobulin
predictive value of ablation, thyroid remnants, 1329(ab)
serum concentrations, ^{131}I whole-body scan and, thyroid cancer patients, 1470
Thyroid
stunning
after diagnostic whole-body scanning with ^{131}I, 986(le)
after tracer dosimetry, 1129(le)
2 articles, 1129(le)
sub-millimeter resolution ^{125}I imaging, using micro-pinholes
Thyroid cancer
differentiated
after radioiodine therapy with phosphorus-31 NMR spectroscopy, 1324(ab)
dosimetry and therapeutic outcome of ^{131}I therapy, 1022(ab)
FDG PET in post-therapy follow-up, 1330(ab)
FDG PET use in, 71, 77
hypermetabolic, FDG PET relevance in, 499(ab)
^{131}I effects, 589(ab)
negative ^{131}I scanning results after therapy, FDG PET use in, 1464
radiation adaptive response of ^{131}I therapy, 1024(ab)
radioiodine for remnant ablation, 590(ab)
recombinant human thyroid-stimulating hormone in follow-up, 1470
retinoid acid effects, 501(ab)
sodium/iodide symporter and glucose transporter-1 in, 500(ab)
^{99m}Tc tetrofosmin neck pinhole SPECT *versus* ultrasound, 1328(ab)
whole-body ^{131}I SPECT, 1341(ab)
doxorubicin therapy, ^{131}I sodium imaging in, 1332(ab)
FDG PET in, 60S
ganciclovir uptake and proliferation, HSV thymidine kinase gene transfer on, 1155(ab)
high levels of function, treatment with ^{131}I, 975
^{131}I absorbed dose rate, up-to-date diagnostic, 1046(ab)
^{131}I scan negative, FDG for presurgical evaluation, 497(ab)
^{123}I tumor scanning, 1326(ab)
^{131}I use in, thyroid stunning and, 1335(ab)
local recurrence, ultrasound for detection of, 498(ab)
marrow-to-blood dosimetry, maximum safe doses of ^{131}I therapy, 1025(ab)
medullary
diagnosis and therapy with B-gastrin receptor binding peptides and cholecystokinin, 587(ab)
FDG PET in, 496(ab)
loco-regional metastases, ^{99m}Tc MIBI imaging in, 1338(ab)
radioimmunotherapy combined with doxorubicin, 588(ab)
recurrent, FDG PET in, 1337(ab)
metastatic, FDG uptake, prediction of poor treatment response to radioiodine, 1325(ab)
pre-therapy ^{123}I whole body scans, thyroglossal duct uptake, 1327(ab)
radioguided surgery in, 1323(ab)
radioiodine-negative, percutaneous ethanol injection in treatment of, 1333(ab)
radioiodine-negative metastatic, ^{201}Tl chloride improves detectability of, 1334(ab)
radioiodine treatment, therapeutic absorbed doses, 1084
radioiodine uptake and expression, aminophylline effects, rat, 1342(ab)
recurrent or metastatic, comparison of ^{18}F FDG, ^{131}I, and ^{201}Tl, 414
redifferentiated, isotretinoin for, 502(ab)
remnants, thyroglobulin changes as predictive value for ablation, 1329(ab)
Sicca syndrome after radioiodine therapy, 738
Thyroid disease
differentiation of benign and malignant, ^{201}Tl scintigraphy, 599(ab)
effects on brain metabolism, dementia patients, 955(ab)
functional evaluation, count-rate role during pinhole scintigraphy, 1347(ab)
primary congenital hypothyroidism, ^{99m}Tc pertechnetate scintigraphy in, 1429(ab)
Thyroidectomy, near-total, treatment and study of, 531(le)
Thyroid-stimulating hormone (TSH)
effect on cellular uptake of ^{201}Tl, thyroid tissue, 1345(ab)
recombinant human, differentiated thyroid cancer, 1470
Tinnitus, intractable central, benzodiazepine receptors in, 550(ab)
Tin-117m(4+)DTPA, synthesis and structural characterization, 77(ab)
T lymphocytes, localization and activity, TCR-dependent NFAT-mediated, PET, 1161(ab)
Toluene, acute exposure, cocaine effects on prefrontal cortex, 901(ab)
Tourette's syndrome, brain perfusion abnormalities, SPECT, 1016(ab)
Tracheobronchial stenosis, stenting with, role of lung scintigraphy in, 1436(ab)
Transcriptional activation system, target gene expression, prostate-specific amplification of, 282(ab)
Transient ischemic dilation (TID), variability of, isotope and acquisition protocol, 194(ab)
Transitional cell carcinoma, bladder, urinary cytology compared to UBC test, 1101(ab)
Transmission emission tomography system
artifact recognition for, 839(ab)
post-injection, cardiac PET, quantitative accuracy, 842(ab)
profile multiple line source array, physical phantom evaluation, 893(ab)
^{99m}Tc and ^{67}Ga, scanning line source, 844(ab)
Transplantation, *see also* specific site
renal
cyclosporine bioavailability in, 1446(ab)
immediate radionuclide renography after, 1449(ab)
scintigraphically determined function of, 1442(ab)
tracer accumulation in femoral head after, 1789
Trastzumab, immunotherapy, toxicity and efficacy, metastatic breast cancer, 1227(ab)
Triplex forming oligonucleotides (TFO), formation of stable triple helices, inhibition of transcription and, 1071(ab)

TRK-A gene, expression after gene transfer, neuroblastoma cells using radiolabeled nerve growth factor, 1181(ab)
Troglitazone, insulin resistance and skeletal muscle glucose use, type II diabetes, 1005
T-scores
analysis, ^{133}Xe SPECT, normal population, 998(ab)
determination, cerebral blood flow, ^{133}Xe SPECT, 864
Tuftsin receptor, targeting with ^{99m}Tc RP128, inflammation imaging, 154
Tumor cells, ^{18}F FLT uptake in, cell lines, mouse and rat studie1156
Tumor detection, large NaI crystal scanner, comparison with multi-ring PET, 879(ab)
Tumor imaging
astrocytoma, radiolabeled FDG, methionine and choline, 914(ab)
highly-reproducible whole-body phantom, PET camera comparison, 368(ab)
intracranial, aminoisobutyric acid with high uptake, rat model, 558(ab)
radiolabeled amino acids, 432
^{123}I-labeled angiostatin, angiogenesis inhibitor, 1065(ab)
Tumor markers
proliferation, tissue polypeptide specific antigen, head and neck cancer, 1098(ab)
soluble interleukin-2 receptor, whole-body FDG PET and, non-Hodgkin's lymphoma, 444(ab)
Tumor oxygenation, marking hypoxia in prostate cancer, measuring with radiodiagnostic markers, 337
Tumor regression patterns, ^{111}In pentetreotide therapy, unique case, 139(ab)
Tumor response, toxicity and, refractory neuroblastoma treated with ^{131}I MIBG, 1713
Tumor size, octreotide radionuclide therapy and, rat tumor model, 1841
Tumor targeting
angiogenesis and, glycosylated RGD-containing peptides, 326
antisense DNA labeled with ^{99m}Tc, 1660, 1670
increasing capacity, peptide cyclization for ^{111}In DOTA-α-MSH analog, 416(ab)
^{99m}Tc antisense DNA, 1660, 1670

U

Ultrasonography, detection of recurrence of thyroid cancer, 498(ab)
University ofCalifornia-Davis, reactor to produce ^{125}I, 37N(10)
Urinary bladder, revised dynamic model, MIRD pamphlet No. 14, 1033(ab)
Urinary bladder cancer, UBC test, usefulness compared to urinary cytology, in transitional cell bladder cancer, 1101(ab)
Urinary tract disorders
infection, role of vesicoureteric reflux and renal parenchymal damage, 1426(ab)
lower, radionuclide cystography and urodynamics, children, 1424(ab)
Urinary tract infection, planar and pinhole renal cortical scintigraphic findings, clinical parameters and, 1441(ab)
Urologic tumors, uptake of ^{18}F cis-FPro, 752
Uterine cancer, FDG PET in, 35S

V

Vagal nerve, stimulation
long-term mesial temporal and thalamic perfusion changes, 231(ab)
rCBF and, treatment-resistant depression, 1019(ab)
Vascular parkinsonism, Parkinson's disease and, differential diagnosis with ^{99m}Tc TRODAT, 408
Venography, radionuclide, valsalva, ^{99m}Tc MAA brain SPECT after, 859
Ventilation/perfusion scintigraphy
comprehensive, lung embolism, 1288
CT arteriography effects on, diagnosis of pulmonary thromboembolism, 1437(ab)
low probability reading, clinical assessment of pulmonary embolism and, 1433(ab)
regional ratios, histogram distribution, in pulmonary embolism, 1438(ab)
technegas *versus* ^{81m}KR, suspected acute pulmonary embolism, 393
Ventilation studies, administered cumulated activity for, MIRD pamphlet No. 18, 520
Ventricular pacing, short- and long-term, effects on left ventricular function, Fourier-filtered volume curves, 755(ab)
Ventricular parameters, left and right, reproducibility of gated blood pool SPECT, 195(ab)
Ventricular volume, accuracy, gated myocardial SPECT, 1571
Ventriculography
contrast left, ECG-gated PET and, comparison of left ventricular ejection fraction, 734(ab)
left, ECG gated myocardial SPECT, 1747
planar radionuclide, algorithms for left ventricular ejection fraction, 705(ab)
Vesicoureteric reflux, role in urinary tract infection, children, 1426(ab)
Vigabatrin, chronic treatment, $GABA_A$ receptor binding and, children with epilepsy, 141(ab)

W

Warping registration
cerebral perfusion SPECT, errors caused by hypoperfusion and, 25(ab)
PET-CT, quantitative pulmonary imaging with, 36(ab)
Wavelet transforms
myocardial blood flow, PET, 194
noise reduction based on, myocardial perfusion in humans, 201
White blood cells
scanning, ^{99m}Tc ciprofloxacin (infection) comparison, in infection imaging, 567
^{99m}Tc ECD labeling of, 1111(ab)
Wilson's disease
hepatic function in, ^{99m}Tc mebrofenin imaging in rat model, 494(ab)
^{99m}Tc TRODAT-1 imaging in, 967(ab)
World Federation of Nuclear Medicine and Biology (WFNMB)
AMA PRA category 1 credit, 36N(5)
8th congress, 24N(4)

X

Xenon-133
comparison with ^{99m}Tc ECD SPECT, subacute cerebral infarction, 543
quantitative SPECT, normal population, T-score analysis, 998(ab)
regional pulmonary ventilation function, maximal inspiration and expiration, in lung cancer, 1435(ab)
SPECT, cerebral blood flow, 864
Xerophthalmia, Sicca syndrome after radioiodine therapy, 738
Xerostemia, Sicca syndrome after radioiodine therapy, 738

Y

Yttrium-86
anti-Lewis Y monoclonal antibodies, PET, nude mouse model, 1281
new method of purification, selective resin, 1084(ab)
Yttrium-86 DOTATOC, ^{111}In octreotide and, differences in biodistribution and dosimetry, in endocrine tumors, 84(ab)
Yttrium-90
intrahepatic microspheres, for hepatic carcinoma, 1587(le)
microspheres, treatment for hepatocellular carcinoma, 1317(ab)
monoclonal antibody RS7, human lung cancer xenograft, 967
treatment of hepatobiliary cancers, 32N(12)
urinary clearance, after Zevalin radioimmunotherapy of B-cell non-Hodgkin's lymphoma, 1124(ab)
Yttrium-90 antibody therapy, non-marrow targeting, dose estimate for prediction of myelotoxicity, 80(ab)
Yttrium-90 DOTA-biotin, A431 xenografted mice pretargeted with, radioimmunotherapy, 567(ab)
Yttrium-90 DOTA-J591, ^{177}Lu DOTA-J591 comparison, anti-tumor effects, LNCAP tumors, 566(ab)
Yttrium-90 DOTATOC, 200 mCi/m^2 and, treatment of advanced neuroendocrine tumors, 136(ab)
Yttrium-90 DOTA^0,Tyr^3 octreotide, tumor response after, rat tumor model, 1841
Yttrium-90-labeled RGD peptide, tumor targeting with, nude mouse tumor model, 474(ab)
Yttrium-90 octreotide
radionuclide therapy with, renal protection, 1037(ab)
receptor-mediated radiotherapy with, 134(ab)
Yttrium-90 peptides, targeting of prostate cancer, 1149(ab)

Z

Zinc, hepatoprotective role of, in protein deficiency and lead toxicity, clearance of ^{99m}Tc mebofenin and, 1050(ab)